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1. Introduction
1.1. HIV-1
Human immunodeficiency virus (HIV), identified in 1983, is the etiological agent of
the acquired immunodeficiency syndrome (AIDS) (Barre-Sinoussi et al., 1983; Coffin
et al., 1986; Gallo et al., 1983; Levy et al., 1984). Two types of HIV are known: the
most common HIV-1, which is responsible to the world-wide AIDS epidemic and the
immunologically distinct HIV-2 (Clavel et al., 1986), which is much less common and
less virulent (Ariyoshi et al., 2000; Ariyoshi et al., 1999), but produces clinical
findings similar to HIV-1 (Wilkins et al., 1993). The HIV-1 type itself includes three
groups M with subtypes A to K, and group O, which have different geographic
distributions but all produce similar clinical symptoms. The basic pathology in AIDS
is the loss of CD4+ lymphocytes and a variety of disorders in immune function,
leading to the onset of opportunistic infections like Pneumocystis Carinii pneumonia
and malignancies as Kaposi’s sarcoma or B-cell lymphomas (Levy, 1998).
HIV is a member of the lentivirus genus of the Retroviridae family. Like all
retroviruses, HIV virions contain two identical copies of a single stranded RNA
genome which are used as templates by the RNA-dependent DNA polymerase
[Reverse Transcriptase (RT)] for production of DNA. Retroviruses were traditionally
divided into three subfamilies, based primarily on pathogenicity rather than on
genome relationship (oncoviruses which cause neoplastic disorders, spumaviruses
which give cytopathic effect in tissue culture but apparently not associated with any
known disease and lentiviruses which induce slowly progressing inflammatory,
neurological and immunological diseases). Recently the international committee on
the taxonomy of viruses has recognized seven distinct genera in the Retroviridae
family (Table 1.1) (Fields and Knipe, 1996). Members belonging to the family of
Retroviridae are widespread in nature and have been detected in many vertebrate
species. Retroviruses show a great diversity in the interaction with their hosts. In fact,
infection with some retroviruses can result in fatal diseases like AIDS, malignancies,
neurological disorders and other pathological manifestations. Other retroviruses in
contrast induce only benign viremia without apparent effects and some can even
become established in the germ-line, where they persist as endogenous proviruses
(Fields and Knipe, 1996).
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Genus Example isolates Comments
Avian-leukosis-sarcoma (s) Rous sarcoma virus (RSV) exogenous, oncogene-containing
Rous associated virus 0 endogenous, benign
Rous associated virus 1 to 50 exogenous, cause B-lymphoma,
and other diseases
 Mammalian C-type (s) Feline leukemia virus exogenous, causes T-cell
lymphoma, immunodeficiency
and other diseases
Simian sarcoma virus exogenous, oncogene-containing
 B-Type viruses (s) Mouse mammary tumor virus endogenous and exogenous,
causes mostly mammary
carcinoma
 D-Type viruses (s) Mason-Pfizer monkey virus exogenous, unknown
pathogenicity
 HTLV-BLV viruses (c) Human T-cell leukemia virus exogenous, causes T-cell
lymphoma (HTLV)-1 and -2 and neurological disorders
 Lentiviruses (c) Equine infectious virus (EIAV) exogenous, causes autoimmune
hemolytic anemia
Visna/maedi virus causes encephalopathy and lung
disease in sheep
 Caprine arthritis-encephalitis virus causes encephalopathy and
(CAEV) immune deficiency
Bovine immunodeficiency virus (BIV) causes lymphadenopathy and
neurological disorders
Feline immunodeficiency virus (FIV) causes immune deficiency 
Simian immunodeficiency virus (SIV) causes immune deficiency
and encephalopathy
Human immunodeficiency virus causes immune deficiency
(HIV)-1 and -2  and encephalopathy
Spumaviruses (c) Simian foamy virus (SFV) exogenous, apparently benign
Human foamy virus exogenous, apparently benign
Table 1.1   Retroviruses Genera. (s) Indicate simple and (c) complex retroviruses.
The lentiviruses are exogenous, non-oncogenic retroviruses causing persistent
infections leading to chronic diseases with long incubation periods (lenti for slow).
They usually infect cells of the immune system (dendritic cells, macrophages, T
lymphocytes) and cause cytopathic effects in permissive cells, such as syncytia and
cell death by apoptosis and necrosis.
The prototype members of the lentivirus family were the slow visna virus, the equine
infectious anemia virus (EIAV) and the caprine arthritis-encephalitis virus (CAEV).
More recent isolates include the related human and simian immunodeficiency viruses
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(HIV and SIV) and the more distantly related feline and bovine immunodeficiency
viruses (FIV and BIV) (Table 1.1). Like the human T-cell leukemia virus (HTLV)
family of primate onco-retroviruses, lentiviruses are complex retroviruses (Cullen,
1991). The significant characteristic of the complex retroviruses is the ability to
regulate their own expression via virally encoded protein factors not found in other
retroviruses. This property has been proposed to be essential for the long-term
association of the complex retroviruses with the host and the generation of chronic
active infections. The lentiviral complexity is reflected in their replication cycle,
which reveals intricate regulatory pathways, unique mechanisms for viral persistence
(Tang et al., 1999) and the ability to infect non-dividing cells.
1.1.1. Genome and morphology of the mature virion
Like all other retroviruses, the proviral DNA of HIV-1 (~ 9.2 kb) has three coding
regions gag, pol, and env, two long terminal repeats (LTRs) with transcriptional
regulatory elements, and one primary transcript (Fig. 1.1 and 1.2) [for review see
(Frankel and Young, 1998; Turner and Summers, 1999)].
The RNA genome is flanked by two short redundant (R) sequences at both termini
with adjacent unique sequences, U5 and U3, found at the 5’ and 3’ ends, respectively.
The gag gene encodes the large precursor polyprotein p55 that is cleaved in four
proteins: the matrix p17 (MA), the "core" capsid p24 (CA), the nucleocapsid p7 (NC)
and the p6 (Freed, 1998).
The pol gene encodes the synthesis of three important enzymes that function at
different times during the replicative cycle. The reverse transcriptase/ribonuclease H
complex p51and p66 (RT) acts in the early steps of the virus replication to form a
double-stranded cDNA of the virus RNA. The integrase p32 (IN) mediates integration
of the viral cDNA into the host chromosomal DNA. The protease p10 (PR) is
responsible for the cleavage of the viral Gag and Gag-Pol polyproteins during the
maturation of the viral particle.
The env gene directs the production of an envelope precursor protein gp160, which
undergoes cellular proteolytic cleavage into the outer envelope glycoprotein gp120
(SU), responsible for binding to CD4+ receptors, and the transmembrane glycoprotein
gp41 (TM), which catalyzes the fusion of HIV to the target cell's membrane.
In addition, HIV-1 has at least six more genes encoding viral proteins with regulatory
functions (tat and rev) or accessory functions (nef, vif, vpr and vpu), for reviews see
(Cullen, 1998; Emerman and Malim, 1998; Frankel and Young, 1998; Kjems and
Askjaer, 2000; Piguet and Trono, 1999; Pollard and Malim, 1998; Trono, 1995).
Introduction  5
Fig. 1.1   HIV-1 genomic organization. Like all other retroviruses, HIV-1 has three
structural genes gag, pol and env  (heavily shaded), which are flanked by the long terminal
repeats (LTR’s). In addition it has six more genes, including two regulatory genes tat and rev
(stippled) and four accessory genes nef, vif, vpr and vpu  (white).
Fig. 1.2   HIV-1 mature virion structure. Modified from WebPath resource collection
(Klatt, 2000). Typical lentivirus particles are spherical, about 80-110 nm in diameter, and
consist of a lipid bilayer membrane surrounding a conical core. The two identical single-
stranded RNA (ssRNA) molecules, of about 9.2kB each, are associated with the nucleocapsid
proteins p7gag (NC). They are packed into the core along with virally encoded enzymes:
reverse transcriptase (RT), integrase (IN), and protease (PR). P24gag comprises the inner part
of the core, the capsid (CA). The p17gag protein constitutes the matrix (MA) which is located
between the nucleocapsid and the virion envelope. The viral envelope is produced by the
cellular plasma membrane and contains the protruding viral Env glycoproteins: gp120 surface
glycoprotein (SU) and gp41 transmembrane protein (TM). Among the accessory proteins
 ssRNA
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 gp41 TM
 p17 MA
 p24 CA
 p7 NC
 p66/51 RT
 p32 IN 
 p10 PR
 vpr
 p15 Vpr
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 tat
rev
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encoded by HIV-1, certainly Vpr and perhaps Nef and Vif are packaged into virions,
although the precise location have not yet been elucidated. Neither the other accessory
protein Vpu nor the regulatory proteins Tat and Rev have been detected in virion particles.
1.1.2. Replication cycle
General features of the HIV-1 replication cycle are shown in Fig. 1.3. The HIV-1
replication cycle begins with the recognition of the target cell by the mature virion.
The major targets for HIV-1 infection are cells bearing the HLA class II receptor,
CD4, on their cell surfaces. These include T-helper lymphocytes and cells of the
monocyte/macrophage lineage including microglia cells in the brain. The virus-CD4
binding occurs via specific interactions between the viral outer envelope glycoprotein
gp120 and the amino-terminal domain of CD4 (Dalgleish et al., 1984; Klatzmann et
al., 1984). These interactions are sufficient for binding but not for infection.
Subsequently the virus glycoprotein gp120 interacts with additional cell-surface
proteins to promote fusion of the viral and cellular membranes. These coreceptors
have recently been identified to be members of the chemokine receptor family and
include CXCR4 and CCR5 (Alkhatib et al., 1996; Deng et al., 1996; Doranz et al.,
1996; Moore, 1997). The initial binding of HIV to the CD4 receptor is mediated by
conformational changes in the gp120 subunit, followed by a conformational change in
the gp41 subunit, stimulated by the chemokine receptors, that allows fusion and
subsequent entry of HIV. Various strains of HIV differ in their use of chemokine
coreceptors. There are strains of HIV known as T-tropic strains, which selectively
interact with the CXCR4 chemokine coreceptor of lymphocytes, while M-tropic
strains of HIV interact with the CCR5 chemokine coreceptor of macrophages and dual
tropic HIV strains that infect both cell types (Littman, 1998; Moore, 1997). HIV-1
infection of CD4 negative cells, such as neural cells, has also been reported (Clapham
et al., 1989; Harouse et al., 1989; Kozlowski et al., 1991; Kunsch et al., 1989) but the
mechanisms of HIV entry are still unclear.
Membrane fusion is followed by a poorly understood uncoating event that allows the
intracellular reverse transcription.
The viral RNA is transcribed in the cytosol into double stranded DNA by the reverse
transcriptase RT (Hansen et al., 1987; Muesing et al., 1985). This enzyme possesses
three enzymatic activities: RNA-dependent DNA polymerase, DNA-dependent DNA
polymerase, and ribonuclease H (RNase H). The reverse transcription process takes
place within a large nucleic acid-protein complex known as the preintegration
complex (PIC) by the assistance of the accessory protein Vif (von Schwedler et al.,
1993) and the nucleocapsid protein NC (Darlix et al., 1993). Once synthesized, the
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viral DNA is transported to the nucleus of the infected cell as part of the PIC that
appears to include tightly condensed viral nucleic acids and the IN, MA, RT, and Vpr
proteins. In contrast to other retroviruses, that require cell division and concomitant
breakdown of the nuclear envelope to gain access to the nuclear compartment, the
lentiviral PIC is actively imported into the nucleus during the interphase (Bukrinsky et
al., 1992; Lewis and Emerman, 1994). Nuclear import of the PIC seems to be directed
by the accessory protein Vpr (Fouchier et al., 1997; Heinzinger et al., 1994), the Gag
matrix protein MA (Bukrinsky et al., 1993; von Schwedler et al., 1994) and the
integrase IN (Gallay et al., 1997). Vpr does not contain a conventional nuclear
localization signal (see later) but appears to function by connecting the PIC to the
cellular nuclear import machinery (Fouchier et al., 1998; Popov et al., 1998a; Popov et
al., 1998b). The role of the MA protein in nuclear translocation of PIC remains
controversial (Fouchier et al., 1997; Freed et al., 1995). The ability of lentiviruses
such as HIV-1 to utilize active transport mechanisms for translocation of the PIC into
the nucleus, allows these viruses to infect non-dividing cells such as differentiated
macrophages, quiescent T lymphocytes and possibly neurons.
In the nucleus, IN catalyzes covalent integration of the viral DNA into the host
genome, where it resides permanently as a provirus. An important modification as a
result of reverse transcription and integration is the duplication of the U5 and U3
sequences in the LTR, such that the provirus now is flanked by tandemly repeated
sequences U3-R-U5 with important regulatory functions.
The regulation of the HIV-1 transcription involves a complex interplay between cis-
acting DNA and RNA elements present within the chromatin-associated proviral
LTRs, cellular transcription factors and the viral regulatory protein Tat (transcriptional
transactivator). In an arrangement similar to that of several inducible cellular
promoters, the HIV-1 promoter, which is located in the U3 region of the 5’LTR,
contains a TATA box and binding sites for several cellular DNA-binding transcription
factors, such as NF-kB, Sp1 and TBP (Jones and Peterlin, 1994). It is highly inducible
and responds to the activation status of the infected cell. NF-kB is the major inducible
cellular activator. It is well established that many cells in the lymphoid tissue of
infected individuals are latently infected (Pantaleo et al., 1993), even though the viral
replication in the body is always active. In resting T-cells, the activity of the HIV-1
promoter is minimal, leading to viral quiescence in infected primary cells. Therefore,
viral activation is associated with cell activation.
The transcription of the provirus by the cellular RNA polymerase II results in a
primary transcript that may serve three distinct functions: 1) it constitutes genomic
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RNA that is incorporated into the virion; 2) it serves as template for translation (Gag
and Gag-Pol); 3) it functions as the precursor RNA for the production of diverse
subgenomic mRNAs (Fig 1.3).
As mentioned before, HIV-1 encodes two essential regulatory proteins Tat and Rev,
which increase viral gene expression at the transcriptional and post-transcriptional
levels, respectively. HIV-1 mRNA expression is biphasic and can be divided into
early (Rev-independent) and late (Rev-dependent) stages (Kim et al., 1989; Pomerantz
et al., 1990). First, shortly after the infection of cells, multiply spliced (~ 2kb) RNA
species are formed from the primary transcript and three proteins are produced: Tat,
Rev and Nef, therefore referred as early gene products (Schwartz et al., 1990). Tat [for
reviews see (Cullen, 1998; Emerman and Malim, 1998; Rubartelli et al., 1998)],
greatly increases transcription from the HIV promoter, by binding to a cis-acting
target sequence, the trans-activator response element (TAR), which is located at the 5’
end of the nascent viral RNA transcript (Berkhout et al., 1989; Dingwall et al., 1989;
Rosen et al., 1985). Tat recruits two cellular factors to this complex: cyclin T and
cyclin-dependent protein kinase-9 (Cdk9). Cyclin T is proposed to bind directly Tat
and to increase its affinity for the TAR RNA (Wei et al., 1998). Cdk9 phosphorylates
the RNA polymerase II transcription complex and thus stimulates transcriptional
elongation (Herrmann and Rice, 1995; Reines et al., 1996; Wei et al., 1998). Rev
(regulator of expression of the virion), which accumulates during the early phase of
expression, initiates late gene expression by binding a unique RNA element located in
the env coding region of HIV-1, the so called Rev-responsive element (RRE). This
interaction promotes the stability and transport of unspliced (~ 9 kb) and partially
spliced (~ 4 kb) HIV-1 mRNAs out of the nucleus. These mRNAs are responsible for
the production of the viral enzymes and structural proteins (Daly et al., 1989; Felber et
al., 1989; Hadzopoulou-Cladaras et al., 1989; Hammarskjold et al., 1989; Malim et
al., 1989c). Therefore Gag, Pol, Env, Vif, Vpr, and Vpu proteins are referred to as late
HIV-1 proteins.
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Fig. 1.3   Replication cycle of HIV-1. Modified from Ludwig (Ludwig, 1999). Each
fundamental step is presented in bold. Names in italic refer to viral gene products involved in
the specific steps. HIV-1 gene expression is stimulated by HIV-1 Tat and Rev, which act at
transcriptional and post-transcriptional levels, respectively, and can be divided into two
phases. The early phase is Rev-independent and the later phase is Rev-dependent (text in
gray). Rev stabilizes and mediates export of singly spliced and unspliced RNA transcripts out
of the nucleus into the cytoplasm.
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Controversial functions have been assigned to the Nef (negative factor) protein. First,
it was assumed to have an inhibitory function in the transcription of HIV-1 genes
(Ahmad and Venkatesan, 1988). However, recent studies have contradicted this
concept by showing that Nef is important for virus replication. Among its various
functions (Piguet and Trono, 1999), it enhances viral expression in quiescent cells and
mediates lymphocyte chemotaxis and activation at sites of virus replication (Kestler et
al., 1991; Kirchhoff et al., 1995; Koedel et al., 1999; Miller et al., 1994; Swingler et
al., 1999).
The Env precursor polyprotein (gp160) is synthesized in the endoplasmatic reticulum
(ER) where it is glycosylated and appears to oligomerize to a trimeric structure post-
translationally (Wyatt et al., 1998; Wyatt and Sodroski, 1998). Thereafter, it is cleaved
to produce the non-covalently associated (gp41 TM - gp120 SU)3 trimeric
glycoprotein complex, which is transported to the cell membrane for virus assembly.
Vpu is thought to enhance this process and inhibit a premature trapping of CD4 to Env
in the ER by binding CD4 molecules, which are also synthesized in the ER, and
directing them to the ubiquitin-proteasome degradation pathway (Margottin et al.,
1998; Schubert et al., 1998; Strebel et al., 1988; Willey et al., 1992a; Willey et al.,
1992b). Similarly, the accessory protein Nef facilitates the routing of CD4 from cell-
surface and Golgi apparatus to lysosomes, resulting in endosomal degradation and
preventing inappropriate interaction with Env (Aiken et al., 1994). In addition, both
Vpu and Nef can down-regulate expression of MHC class I molecules. The down-
regulation of CD4 and MHC class I molecules on the surface of infected cells also
helps infected cells to evade immune responses of the host, such as killing by
cytotoxic T lymphocytes (Collins et al., 1998; Kerkau et al., 1997).
During synthesis of the Gag polyprotein by ribosomes, a translational frameshift may
occur, resulting in generation of smaller amount of Gag-Pol precursor polyproteins,
which associate with the Gag polyprotein at the cellular membrane. The N-terminally
myristoylated MA domain of the Gag/GagPol polyproteins directs insertion of the
Gag precursors into the cellular membrane and interacts with the cytoplasmic tail of
gp41 resulting in the anchoring of Env to the viral particle (Dorfman et al., 1994).
Approximately 1200 to 2000 copies of Gag precursor bud to form an immature
particle, which encapsidates two copies of the unspliced viral RNA genome, by the
ability of NC to interact with nucleic acids. Vif and Vpu proteins have been reported
to play a role in packaging of the nucleoprotein core and in virion release, respectively
(Hoglund et al., 1994; Lamb and Pinto, 1997). Concomitantly or immediately
following the external budding, the cleavage of the Gag/Gag-Pol polyproteins by the
Introduction  11
virally encoded PR produces the structural proteins MA, CA, NC as well as the
independent enzymes PR, RT and IN. This final step primes new virus particles for
the next round of infection and is termed maturation.
1.2. Pathways of nuclear transport: a general overview
As mentioned above active nuclear translocation of HIV nucleic acids, as well as of
PIC, and Tat and Rev proteins is essential for HIV replication. Therefore, a general
overview of cellular nuclear import and export pathways will be given before
discussing the Rev protein in more detail.
Eukaryotic cells are characterized by distinct nuclear and cytoplasmic compartments,
which are separated by the nuclear envelope, a double membrane that is continuing in
the endoplasmatic reticulum. The genetic information is contained in the nucleus,
whereas protein synthesis occurs in the cytoplasm. This separation offers additional
opportunities to control gene expression, but requires a large amount of energy to
assure controlled bi-directional exchange of macromolecules between these two
compartments.
For example RNAs, synthesized in the nucleus, are almost all actively exported to the
cytoplasm. A large number of proteins with nuclear functions are actively transported
into the nucleus. In addition some RNA molecules, including many uridine-rich small
nuclear RNAs (UsnRNAs) are transported in both directions as a part of their
assembly into small nuclear ribonucleoproteins (snRNP).
Transport into and out of the eukaryotic cell nucleus occurs through nuclear pore
complexes (NPCs), large structures spanning the nuclear envelope and consisting of
~50-100 different proteins that are often commonly called nucleoporins. Many recent
reviews have considered NPC composition, their assembly, structure and function
(Davis, 1995; Doye and Hurt, 1997; Fabre and Hurt, 1994; Talcott and Moore, 1999).
Generally, proteins can enter and exit the nucleus through NPC, either by diffusion or
by active mechanisms, which are saturable, energy-dependent and which involve
specific signal-mediated transport. For recent reviews see (Gorlich, 1997; Gorlich and
Kutay, 1999; Kaffman and O'Shea, 1999; Mattaj and Englmeier, 1998; Nigg, 1997).
The structural constraints of the NPC dictate that proteins smaller than 40 kDa may
enter the nucleus by passive diffusion. However, RNAs and many small proteins, such
as histones or the 18 kDa Rev protein, are imported by a regulated signal-mediated
pathway. Generally, proteins require a targeting signal called nuclear localization
signal (NLS) for active transport into the nucleus. Export from the nucleus into the
cytoplasm requires a nuclear export signal (NES). RNA-substrates for nuclear export,
like messenger RNAs, ribosomal RNAs, small nuclear RNAs and transfer RNAs are
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probably exported from the nucleus as RNA-protein (RNP) complexes, rather than as
naked RNA (Izaurralde and Mattaj, 1995; Nakielny et al., 1997; Stutz and Rosbash,
1998). This indicates that RNA transport is mediated by specific signals provided by
the specific cellular factor with which each RNA is associated. Many proteins are
capable of both entering and exiting the nucleus. These are nucleocytoplasmic shuttle
proteins and they contain NLS and NES signals, which may be contained in separate
domains of the protein. However, nucleocytoplasmic shuttling can also be controlled
by a class of unique transport signals known as NSSs (nucleocytoplasmic shuttling
signals) or be indirectly mediated by interaction with proteins that are transported into
and out of the nucleus.
The first two NLSs characterized were the “bipartite” signal in nucleoplasmin
[KRPAATKKAGQAKKKK; (Dingwall et al., 1982)] and the “classical” signal in
Simian Virus 40 (SV40) large T antigen [PKKKRKV; (Kalderon et al., 1984a;
Kalderon et al., 1984b)]. A large number of other NLSs have been identified during
the last years, and the NLSs of most nuclear proteins were found to contain a basic
amino acid cluster in their primary amino acid sequences, even though there might be
no obvious consensus sequences. The classical monopartite NLS contains a lysine-
rich stretch of amino acids, whereas the bipartite NLS is composed of two lysine-rich
stretches separated by a short amino acid spacer. In contrast, the Rev and Tat NLS
signals [RRNRRRRWRER (Kubota et al., 1989; Perkins et al., 1989) and
RKKRRQRRR (Subramanian et al., 1990)] are strikingly arginine-rich.
Several years ago, the analysis of the nucleo-cytoplasmic shuttling pathways of Rev
and the cyclic AMP dependent protein kinase inhibitor (PKI), led to the identification
of two nuclear export signals, short leucine-rich amino acid sequences
[LQLPPLERLTLD (Fischer et al., 1995; Wen et al., 1995); LALKLAGLDI (Wen et
al., 1995)]. Since then, an increasing number of proteins have been shown to also
contain leucine-rich NES. By comparing all of these sequences, a consensus for
leucine-rich NESs has been defined (LX2-3LX2-3LXL), characterized by four
characteristically spaced hydrophobic residues (Kjems and Askjaer, 2000). Many of
these proteins are implicated in RNA metabolism: the viral HIV-1Rev, HTLV Rex
(Hakata et al., 1998), Herpesvirus ICP27 (Sandri-Goldin, 1998), Influenzavirus NS2
(O'Neill et al., 1998), Adenovirus E1-34 kDa (Dobbelstein et al., 1997); the cellular
TFIII (Fridell et al., 1996b), Gle1p (Murphy and Wente, 1996), FMR-1 (Fridell et al.,
1996a). Many other leucine-rich NES containing proteins are involved in the
regulation of other critical cellular functions: including PKI, Actin (Wada et al.,
1998), MAPKK (Fukuda et al., 1997), p53 (Stommel et al., 1999). The Rev NES is
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transferable to heterologous proteins, and mutations in this domain abolish the ability
of Rev to shuttle between the cytoplasm and the nucleus. In addition, Rev NES-
mutants exhibit a trans-dominant negative phenotype capable of repressing wild-type
Rev function as well as HIV replication (Malim et al., 1989b).
NSS consist of both, NLS and NES, directing both nuclear import and nuclear export
(Michael, 2000). The majority of proteins known to contain NSS interact with mRNA,
a fact that has stimulated speculations that NSS-proteins are involved in mRNA
nuclear export. The first NSS was found in the heterogeneous nuclear hnRNP A1
protein (Michael et al., 1995; Siomi and Dreyfuss, 1995), one of the major pre-
mRNA/mRNA binding proteins in eukaryotic cells. A protein, although one of the
most abundant in the nucleus, that shuttles continuously between the nucleus and the
cytoplasm, via its sequence termed as M9 (NQSSNFGPMKGGNFGGRSSGPYGGG
GQYFAKPRNQGGY), which has no similarity to any other NLS or NES, and
mediates the nuclear export of cellular mRNA.
Nucleocytoplasmic exchange is mediated by soluble transport receptors that are
thought to shuttle continuously between nucleus and cytoplasm. Many of these
receptors have now been identified. Interestingly, it emerged that both import and
export events are mediated by a related family of shuttling transport factors, which are
referred as importin β superfamily (Table 1.2). In humans, the importin β superfamily
consists of at least 21 members, which recognize various nuclear transport signals and
cargo molecules, comprising cellular (Gorlich and Kutay, 1999) and viral proteins
(Whittaker and Helenius, 1998).
Generally, the process of nuclear protein import can be divided into three steps: first,
an energy-independent docking to the cytoplasmic face of the NPC, second, an
energy-dependent translocation through the NPC, followed by the third step of nuclear
release of the cargo. Although proteins carrying different NLSs probably follow the
same overall pathway, interesting differences at the docking step exist according to
the different types of NLS [see reviews (Gorlich and Kutay, 1999; Kjems and Askjaer,
2000; Mattaj and Englmeier, 1998)].
The mechanism for import of lysine-rich NLS proteins and the arginine-rich NLS Rev
has been studied intensively.
A protein carrying the classical lysine-rich NLS, which is found in the majority of
nuclear proteins, is recognized by a cytoplasmic receptor that consists of the importin
α/importin β heterodimer. Importin α provides the NLS-binding site (Adam and
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Gerace, 1991; Weis et al., 1995) and serves as a bridge between substrate proteins
carrying the classical NLS and the actual import factor importin β.
  Transport receptors [alternative names] Function             References
Importin (Imp) β Import of ribosomal proteins, HIV Rev, HIV Tat, HTLV Rex 1-4
[Karyopherin β1]
Imp β/Imp α complexes Import of proteins containing the classical NLS 5-6
Imp β/Snurportin complexes Import of UsnRNPs 7
Transportin 1 Import of hnRNPs, Tap, ribosomal proteins, nucleolin C23   8-10
[Importin β2  Karyopherin β2]
Exportin 1 [Crm1] Export of proteins containing leucine-rich NESs, 11-14
UsnRNAs, Snurportin 1
CAS Export of Importin α 15
Exportin t Export of tRNA 16-17
Table 1.2   Human transport receptors of the importin  superfamily. Modified version
of Table 1 in (Gorlich and Kutay, 1999). References: 1 (Henderson and Percipalle,
1997); 2 (Jakel and Gorlich, 1998); 3 (Truant and Cullen, 1999); 4 (Palmeri and
Malim, 1999); 5 (Gorlich et al., 1995); 6 (Imamoto et al., 1995); 7 (Huber et al., 1998);
8 (Pollard et al., 1996); 9 (Truant et al., 1999); 10 (Yaseen and Blobel, 1997); 11
(Fornerod et al., 1997); 12 (Fukuda et al., 1997); 13 (Ossareh-Nazari et al., 1997); 14
(Paraskeva et al., 1999); 15 (Kutay et al., 1997); 16 (Arts et al., 1998); 17 (Kutay et al.,
1998).
Importin β, via a direct interaction with the nucleoporins of the NPC, drives the
translocation of the complex into the nucleus (Gorlich et al., 1995; Moroianu et al.,
1995). Once the import complex reaches the nuclear face of the NPC, the direct
binding of nuclear RanGTP (see later) to importin β finally terminates the
translocation and the dissociation of the importin heterodimer complex, releasing the
import substrate in the nucleoplasm.
In contrast, Rev, as well Tat and Rex, which all contain an arginine-rich NLS, have
been shown to interact directly with importin β, suggesting that importin α is not
essential for the import of these proteins (Henderson and Percipalle, 1997; Palmeri
and Malim, 1999; Truant and Cullen, 1999).
Another essential component and common regulator of the nucleocytoplasmic
transport is the previously mentioned small Ran-TC4 GTPase (Dahlberg and Lund,
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1998; Gorlich, 1997; Kutay et al., 1997; Mattaj and Englmeier, 1998; Melchior et al.,
1993). Like all G proteins, Ran switches between a GDP- and a GTP-bound state by
nucleotide exchange and GTP hydrolysis. It is proposed that Ran provides the energy
necessary for translocation through the pore via GTP hydrolysis and provides
directionality of the transport process by virtue of the asymmetry of
RanGTP/RanGDP, that exists across the nuclear membrane (Izaurralde et al., 1997).
In fact, Ran is mainly complexed with GDP in the cytoplasm and with GTP in the
nucleus. Transport receptors are RanGTP-binding proteins that respond to this
gradient by loading and unloading their substrates in the appropriate compartment.
Importins bind their cargoes in the cytoplasm, release them upon binding to RanGTP
in the nucleus and return to the cytoplasm without their cargo, as RanGTP complexes
(importin β) or exported by a specialized exportin, namely CAS (importin α,)
(Gorlich and Kutay, 1999; Izaurralde et al., 1997; Jakel and Gorlich, 1998; Kutay et
al., 1997). Unlike importins, which bind their substrates only in the absence of
RanGTP (i.e. in the cytoplasm), export receptors like Crm1(chromosome region
maintenance, also known as exportin 1) bind their cargoes preferentially in the
nucleus forming ternary complexes with their substrate and RanGTP but not RanGDP
(Fornerod et al., 1997; Gorlich and Kutay, 1999; Kutay et al., 1997; Kutay et al.,
1998). The trimeric complex is then rapidly transferred to the cytoplasm where it is
disassembled, and the free export receptors can re-enter the nucleus and bind the next
cargo molecule.
Unlike many substrates for protein import, which are individual proteins carrying a
NLS and thus are relatively small and simple, nuclear export substrates are often large
and complexes as RNA-protein particles. The molecular mechanism for Rev-mediated
nuclear export has been studied intensively and a great part of the knowledge on
general nucleocytoplasmic transport relies on analysis of Rev as a prototypic shuttling
protein. The presence of leucine-rich NES is a necessary prerequisite for Rev and the
other numerous proteins containing this signal, to be recognized by Crm1, a shuttling
export receptor related to importin β superfamily (Table 1.2)(Fornerod et al., 1997;
Fukuda et al., 1997; Neville et al., 1997; Ossareh-Nazari et al., 1997; Stade et al.,
1997).
1.3. The Rev protein
1.3.1. Rev function and features of Rev-responsive RNAs
The translation of messages containing introns is very unusual in eukaryotic cells.
Indeed, a mechanism which retains incompletely spliced RNAs in the nucleus until
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splicing is complete (Cullen, 1998), ensures that only the correct protein is expressed.
Retroviruses such as HIV employ a variety of different splicing events and
overlapping reading frames to express a large array of mRNAs (over 30) and proteins
(at least 15) from a single primary transcript. The HIV-1 RNA sequence contains at
least 4 different 5’ splice sites and 8 different 3’ splice sites, which are used
alternatively (Neumann et al., 1994; Purcell and Martin, 1993; Schwartz et al., 1990).
In the HIV-1 replication cycle, as mentioned before, the structural proteins are
produced from incompletely spliced and unspliced mRNAs. To bypass the cellular
nuclear retention of incompletely spliced viral transcripts, HIV-1 expresses the protein
Rev. This protein mediates the nuclear export of unspliced and singly spliced viral
mRNAs by binding to and multimerizing on a specific recognition element located
within the second intron on the viral RNA, the RRE (Emerman et al., 1989; Felber et
al., 1989; Hammarskjold et al., 1989; Malim et al., 1989c).
Rev regulated-expression of incompletely spliced mRNAs has a significant effect on
the temporal expression pattern of the individual HIV-1 genes. At the initial stage of
HIV-1 expression, the concentration of Rev is low, and incompletely spliced viral
mRNAs are subjected to nuclear retention. They are either spliced to completion or
subjected to degradation. The fully spliced mRNAs encoding Tat, Rev, and Nef are
not retained in the nucleus but are exported to the cytoplasm by the normal mRNA
export pathway and therefore are Rev-independent. Subsequently, Rev enters the
nucleus, binds to its target RNA, and at a certain threshold concentration, and through
interactions with cellular host factors, mediates cytoplasmic expression of unspliced
(gag, pol) and singly spliced (env, vif, vpr, vpu) viral messages. Therefore this phase
of HIV-expression is Rev-dependent. The temporal delay of expression of mRNA
encoding the structural proteins Gag and Env has been considered to play a role for
maintenance of viral latency and to prevent elimination of infected cells by the
immune system (Kjems and Askjaer, 2000; Levy, 1998).
Rev-like transactivator proteins have been identified in all known lentiviruses
(Kiyomasu et al., 1991; Malim et al., 1989a; Schoborg et al., 1994; Tiley et al., 1990)
and within human oncoretroviruses, the human T-cell leukemia viruses type-I and
type II (HTLV-I and -II) (Hanly et al., 1989; Hidaka et al., 1988). In HTLV-I and -II,
the protein is known as Rex and the cis-acting RNA target is termed Rex response
element (RXRE). In addition, a protein with Rev-like function has been identified in
the human endogenous provirus HERV-K (Lower et al., 1995; Yang et al., 1999).
In contrast, simple retroviruses lack a Rev equivalent protein and can bypass the
nuclear retention of intron-containing mRNAs by the action of a cis-acting structured
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RNA target, termed constitutive transport element (CTE), that together with cellular
host factors activates the transport of unspliced viral mRNA to the cytoplasm. The
CTE was initially discovered in the Mason-Pfizer monkey virus (Bray et al., 1994)
and similar elements have subsequently been found in other retroviruses (Ogert et al.,
1996; Tabernero et al., 1997; Zolotukhin et al., 1994). In the case of the Mason-Pfizer
monkey virus two host proteins, TAP (Gruter et al., 1998; Kang and Cullen, 1999)
and RNA Helicase A (Li et al., 1999; Tang et al., 1997), have been identified and
proposed for different roles in the CTE-RNA export. Interestingly, although the CTE
and Rev/RRE can functionally substitute for each other in mediating nuclear RNA
export, they appear to act via distinct pathways and different mechanisms (Kang and
Cullen, 1999; Pasquinelli et al., 1997; Saavedra et al., 1997).
Rev-responsive RNAs contain two distinct features required for regulation: first the
cis-acting sequence-specific target for Rev, RRE, and second, elements that ensure
nuclear retention of an accessible pool of RNA to serve as a substrate for Rev.
The RRE is a highly structured RNA element (351 nucleotides) that resides within the
env intron and is therefore present in all ~9kb and ~4kb mRNAs. The Rev-RRE
interaction has been studied extensively, both in vitro  and in vivo . The RRE contains
extensive secondary structure, including several stem loops. The initial and primary
specific sequences within the RRE that determine Rev responsiveness are located in
the second stem loop from the 5’ end, SLIIB, (Bartel et al., 1991; Battiste et al., 1996).
The RRE serves as the docking site for Rev on RNAs that are confined to the nucleus.
In fact the RRE is the only HIV-1 sequence that needs to be transferred to a
heterologous RNA for Rev-responsiveness to be acquired. Even though the RRE
harbours only a single high-affinity Rev-binding site, in vitro binding and footprinting
studies have clearly demonstrated that multiple Rev molecules bind to a single RNA,
forming complexes (Rev)n-RRE (Daly et al., 1989; Heaphy et al., 1990; Kjems et al.,
1991a). The observation that Rev function requires the sequential binding of multiple
Rev molecules to the RRE provides a biochemical explanation for the observed
threshold effect for Rev function in vivo.
The splice sites of HIV-1 are inefficiently used by the cellular splicing machinery, and
thus have been proposed to permit accumulation of a pool of unspliced RNAs in the
nucleus. The nuclear accumulation of precursor RNAs is not typical for cellular genes.
They are normally retained in the nucleus by the interaction of splicing factors until
they are either rapidly spliced to completion, and efficiently exported to the cytoplasm
as fully processed mRNAs, or they are degraded (Izaurralde and Mattaj, 1995;
Nakielny and Dreyfuss, 1997). It has also been proposed that the Rev-responsive
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RNAs are retained in the nucleus by the interaction of splicing factors and that Rev
itself could regulate a dissociation of splicing components and pre-mRNA (Chang and
Sharp, 1989; Lu et al., 1990; Stutz and Rosbash, 1994). This hypothesis is supported
by inhibition of splicing by Rev in in vitro experiments (Kjems et al., 1991b).
However, more recently, it has been shown that Rev is able to induce the export of
both spliceable and non-spliceable RRE-containing pre-mRNAs, regardless of the
location of the RRE within the RNA, suggesting that Rev can function independently
of splicing (Fischer et al., 1999).
Besides the inefficient splicing of primary transcripts, particular sequence elements
are proposed to be important for the control of Rev-responsive mRNAs processing.
They have been termed cis-acting repressive sequences (CRSs) and/or instability
sequences (INSs) (Cochrane et al., 1991; Maldarelli et al., 1991; Rosen et al., 1988;
Schneider et al., 1997; Schwartz et al., 1992a; Schwartz et al., 1992b). These
sequences are distributed throughout the regions of HIV-1 that form introns in gag,
pol and env, and function by promoting degradation of these transcripts. When
appended in cis to heterologous reporter genes they inhibited expression of those
genes.  This inhibition was counteracted only by the positive effect of the Rev-RRE
interaction. These elements did not contain any known HIV-1 splice sites and acted
independently of splicing. It was found that these sequences have an unusually high
adenine-uracil content, a common feature among cellular mRNAs with short half-
lives, such as those encoding a number of proto-oncogenes or cytokines (Chen and
Shyu, 1995; Jacobson and Peltz, 1996). However, unlike the HIV ~9kb and ~4kb
transcripts, these cellular mRNAs are degraded in the cytoplasm as fully processed
transcripts. Nevertheless, the identification of nuclear cellular factors which are able
to interact with the HIV-1 cis-acting repressive sequences raise the possibility that the
CRS elements could assist nuclear sequestration and nuclear degradation of RNA by
formation of RNA-protein complexes not accessible to nuclear export pathways
(Olsen et al., 1992).
Therefore, the mechanisms underlying the nuclear accumulation of HIV-1 precursor
mRNAs and their marked nuclear degradation in the absence of Rev still remain to be
clarified.
1.3.2. Domain structure of Rev
The HIV-1 Rev is an 18 kDa phosphoprotein containing 116 amino acids that, as
previously described, has a number of attributes essential for viral replication. It is
capable of being imported into the nucleus, where it binds specifically to incompletely
spliced mRNAs containing the RRE, forming multimers (Rev)n-RNA, and it drives
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nuclear export of these mRNAs. These numerous activities are directed by at least two
functional domains that have been delineated by extensive mutagenesis studies (Hope
et al., 1990; Malim et al., 1989b; Malim et al., 1991) (Fig. 1.4). The amino-terminal
domain contains a basic arginine-rich motif (aa 35-51: RQARRNRRRRWRERQRQ),
which mediates both RNA-binding (Bohnlein et al., 1991; Hope et al., 1990; Kjems et
al., 1992; Malim et al., 1990) and nuclear/nucleolar localization (Bohnlein et al.,
1991; Cochrane et al., 1990; Kubota et al., 1989; Perkins et al., 1989; Venkatesh et al.,
1990). This is, closely flanked on both sides by two sequences (aa 12-29 and aa 52-
60) that are responsible for the multimerization of Rev (Malim and Cullen, 1991;
Olsen et al., 1990; Szilvay et al., 1997; Thomas et al., 1998; Zapp et al., 1991). The
carboxy-terminal region contains a leucine-rich domain (aa 73-84: LQLPPLERLTLD)
originally coined the activation domain, because it was thought to bind necessary Rev-
interacting proteins (Hope et al., 1992; Malim et al., 1989b; Mermer et al., 1990) and
recently, discovered to function as a nuclear export signal (Fischer et al., 1995; Meyer
and Malim, 1994; Wen et al., 1995).
Fig.1.4  Structure of HIV-1 Rev protein. Rev is composed of several domains harboring
distinct functions. The N-terminal basic domain including residues 35-51 is involved in RRE
binding and in nuclear/nucleolar localization. Sequences flanking the basic domain (aa12-29
and aa 52-60) are essential for multimerization of Rev. The leucine-rich part in the C-
terminus (aa 73-84) acts as a nuclear export signal. Mutational analysis showed the presence
of amino acids (in bold) essential for Rev function (Hope et al., 1990; Kjems and Askjaer,
2000; Malim et al., 1989b; Thomas et al., 1998).
Activation domain
Nuclear export (NES)
RNA-binding domain & 
Nuclear/nucleolar localization 
(NLS/NOS)
RQARRNRRRRWRERQRQ
Arginine-rich domain Leucine-rich domain  
LQLPPLERLTLD
       Exon I
(26 amino acids)
       Exon II
(90 amino acids)
LIRTVRLIKFLYQSN PPP IHSISERRIL
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1.3.3. Cellular cofactors interacting with Rev and RRE
The observation that murine fibroblasts do not support Rev (Trono and Baltimore,
1990) and Tat functions (Winslow and Trono, 1993) was ascribed to lack of essential
human factors in murine cells. Both defects could be complemented by fusion with
human cells or addition of selected human chromosomes (Shukla et al., 1994; Shukla et
al., 1996; Trono and Baltimore, 1990; Winslow and Trono, 1993). Whereas human
cyclin T was identified as a candidate host-cell factor for Tat activity (Wei et al., 1998),
human host-cell factors capable of restoring Rev activity in rodent cells have not yet
been identified.
Many groups tried to isolate and characterize possible Rev-interacting cofactors
essential for the post-transcriptional regulation. Besides the recent identification of
importin β and Crm1, during the last ten years several other cellular proteins have been
reported to interact with Rev and different mechanisms have been proposed to activate
Rev function (Table 1.3). These include in chronological order B23, eIF-5A, the
splicing factor ASF/SF2-associated protein p32 and several nucleoporins including
Rip/Rab. However, although these factors are thought to be Rev-interacting stimulatory
cofactors, their actual role in Rev function and support of virus replication is still
unknown.
B23 was the first protein identified to interact with Rev, using affinity chromatography
(Fankhauser et al., 1991). B23 is one of the major nucleolar phosphoproteins and it may
be involved in the process of maturation of ribosomal structures. Rev often accumulates
in the nucleolus (Cochrane et al., 1990) and this may reflect the ability of Rev to bind
the nucleolar B23 protein. Although B23 was found to stimulate the import of Rev it
appears to be neither necessary nor sufficient for this, suggesting that B23 may act as a
molecular chaperone by preventing aggregation of proteins and assisting the nuclear
import of Rev (Szebeni and Olson, 1999).
The cellular protein eIF-5A, which is the only known protein containing the amino acid
hypusine, was shown to cross-link to the Rev/RRE complex in vitro (Ruhl et al., 1993).
A transdominant negative mutant of eIF-5A, which retained its ability to bind Rev,
caused a block of Rev nuclear export as well as HIV replication in lymphocytes (Bevec
et al., 1996). Interestingly, although eIF-5A was originally proposed to be a translation
initiator, the normal function of the protein is unknown. EIF-5A was shown to interact
also with the ribosomal protein L5, which is implicated in the 5S rRNA export pathway
(Schatz et al., 1998). Therefore, eIF-5A is one of the Rev-interacting factors that have
been suggested to support RNA export.
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A murine homologue (YL2) of a human ~32 kDa protein (p32), normally associated
with the cellular splicing factor SF2/ASF (Krainer et al., 1991), was identified as a Rev-
interacting factor by the yeast-two hybrid selection method (Luo et al., 1994). A
functional significance of this interaction was proposed by in vivo studies where a
transient over-expression of YL2 lead to a potentiation of Rev activity while antisense
YL2 transcripts reduced it. In addition, the p32-Rev binding was confirmed by in vitro
coprecipitation experiments and p32 modulated the inhibitory effect of Rev on in vitro
splicing (Tange et al., 1996). SF2/ASF itself has also been shown to interact with the
RRE in vitro in a Rev-dependent manner (Powell et al., 1997), raising the possibility
that the p32/SF2/ASF complex may bind co-operatively to the Rev/RRE complex.
Therefore, it has been proposed that the interaction of Rev with proteins involved in the
splicing process, such as p32, may participate in the removal of splicing factors from
intron-containing RNAs and that the arrested complex may subsequently function as a
substrate for Rev-mediated nuclear export.
An additional proposed cofactor engaged in the Rev transactivation pathway is the
RNA helicase A. It was originally identified as a protein binding to the CTE of type D
retroviruses (Tang et al., 1997), and subsequently observed also to bind RRE
independently of Rev in vivo (Li et al., 1999). In experiments with RRE-containing
reporter genes an over-expression of the RNA helicase A lead to increased Rev-
mediated expression, as well as HIV replication, suggesting a regulatory role of this
protein at the post-transcriptional level. RNA helicase has been implicated in the
release of mature mRNA from the spliceosomes (Ohno and Shimura, 1996) and
contains a bi-directional NSS, using a Crm1-independent export pathway (Tang et al.,
1999). Therefore, it was proposed that RNA helicase A acts at a step prior to nuclear
export in the Rev transactivation pathway, supporting the release of premature
unspliced or incompletely spliced viral mRNAs from the splicing machinery (Li et al.,
1999).
Although the involvement of Crm1 in nuclear export as a receptor for NES-bearing
proteins is now well documented, the mechanism of translocation of the RRE-Rev-
Crm1-Ran complex through the NPC is still unknown. As mentioned before, the NPC
consist of different nucleoporins, which are often characterized by domains that contain
numerous repeats of the di-peptide phenylalanine-glycine (FG-repeat domain) (Davis,
1995; Doye and Hurt, 1997). Many FG-repeat containing nucleoporins have been
shown to interact with Rev and have been proposed to support its nucleocytoplasmic
trafficking. The first nucleoporin identified interacting with the Rev NES was isolated
by two independent groups using the yeast two-hybrid screening; it was termed
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hRip/Rab (Rev interacting protein/Rev activation domain-binding protein (Bogerd et
al., 1995; Fritz et al., 1995). Rip/Rab has been shown to be an inessential protein in S.
cerevisiae, to exhibit nucleoplasmic as well as NPC localization and to modestly
enhance Rev function when over-expressed in transfected cells (Bogerd et al., 1995;
Fritz et al., 1995). In the beginning, Rip/Rab was proposed to be the export cofactor for
Rev NES. However, recent studies convincingly demonstrated that the export receptor
for the leucine-rich NES is Crm1, and that this protein probably mediates the
interaction observed between Rev with Rip/Rab and with other Rev-interacting
nucleoporins (Neville et al., 1997). Rev and/or Rev NES also interacted by two-hybrid
analysis with the FG-repeat regions of a number of additional distinct yeast and
vertebrate nucleoporins (Farjot et al., 1999; Fritz and Green, 1996; Stutz et al., 1996;
Stutz et al., 1995). Factors that interact with Rev are summarized in Table 1.3.
1.4. Aim of the work
As mentioned above, the binding of the Rev/RRE complex to cellular cofactors is
assumed to be essential for Rev function. Although several cellular proteins have been
reported to interact with Rev, their actual role in supporting Rev function and virus
replication is still unknown. Only recently, it started to become clear that importin β
and Crm1 are directly involved in the Rev nuclear transport.  However, several aspects
involved in the complexity of the multiple functions of Rev still have to be clarified.
For instance, it is interesting to note that the Rev protein may behave differently in
certain cell types. In fact, some studies, carried out in the group directed by Dr. Brack-
Werner, showed that astrocytes constitute the first example of a human cell type with
an impaired Rev-response (Brack-Werner, 1999; Ludwig, 1999; Ludwig et al., 1999;
Neumann et al., 1995). Astrocytes, well-known long-lived cells that perform crucial
functions in the central nervous system, are known to be target cells for non-
productive HIV persistence. The failure of the intracellular milieu of astrocytes to
support function of Rev, which may be a fundamental mechanism underlying the
astrocyte-specific restriction of virus production, could be due to either lack of
necessary positive cellular cofactors, or to the presence of negative cellular cofactors
capable of repressing Rev/RRE regulation.
This astrocyte behaviour strongly supports the idea that the function of Rev and,
consequently, the latent infection may be controlled by still unknown cellular
mechanisms.
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Based on these considerations, the aim of my work was to study the role of Rev-
interacting cellular proteins and signals in Rev in controlling the function of Rev in the
host cell. To this end, I pursued the following goals:
• Identification of new factors interacting with HIV-1 Rev protein by yeast two-
hybrid screening;
• analysis of their expression and intracellular localization in several human cells
including astrocytes;
• analysis of their role and influence on Rev function and virus production;
• analysis of the presence of possible new functional signals in the Rev sequence.
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2. Materials and Methods
2.1. List of abbreviations and Glossary
A Adenine, or adenosine or alanine
AA = aa Amino acid(s)
Ab Antibody
AB/AM antibiotic-antimycotic solution
Aqua bidest. Water double deionized filtered trough Millipore filters
Aqua dest. Water deionized
Ag Antigen
AIDS Acquired immunodeficiency syndrome
Ala = A Alanine
AMP Adenosine monophosphate
APS Ammonium peroxidisulfate
Arg = R Arginine
Asn = N Asparagine
Asp = D Aspartic acid
ATCC American Type Culture Collection
ATP Adenosine triphosphate
BBB Blood brain barrier
bp Base pair(s)
BSA Bovine serum albumine
B42 Bacterial transcription factor
C Cytosine, or Cytidine or cysteine
°C Degree Celsius
CAT Chloramphenicol acetyltransferase
CD Cluster of differentiation
cDNA Complementary DNA, synthetic DNA transcribed from a specific RNA through
the action of the reverse transcriptase
cfu Colony forming units
Ci Curie, radioactive unit
CM Complete minimal dropout medium for yeast
CMV Cytomegalovirus
CNS Central nervous system
cpm counts per minute
CTP Cytidine triphosphate
CX Cycloheximide
Cy 3/5 Fluorochrom-conjugate
Cys = C Cysteine
dATP Deoxyadenosine triphosphate
D Aspartic acid
DMEM Dulbecco’s Modified Eagle Medium
DMF Dimethylformamide
DMSO Dimethylsulfoxide
DNA Deoxyribonucleic acid
DNase Deoxyribonuclease
dCTP Deoxycytosine triphosphate
DEPC Diethyl pyrocarbonate
dGTP Deoxyguanosine triphosphate
DMSO Dimethyl sulfoxid
dNTP Deoxynucleotide triphosphate
DTAF Dichlorotriazinyl amino fluorescein
dTTP Deoxythymidine triphosphate
DTT Dithiothreitol
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E Glutamic acid
E.coli Escherichia coli
EDTA Ethylenediaminetetraacetic acid
EGY48 Yeast strain
ELISA Enzyme linked immunosorbent assay
ER Endoplasmatic reticulum
EtBr Ethidium bromide
EtOH Ethanol
FCS Fetal calf serum
g Gram
g Relative centrifugal acceleration
G Guanine, or guanosine or glycine
Gal Galactose
GAL1 Yeast promoter
Gal4 Yeast transcription factor
GFAP Glial fibrillary acidic protein
GFP Green fluorescent protein
Glc Glucose = dextrose
Gln = Q Glutamine
Glu = E Glutamic acid
Gly = G Glycine
GTP Guanosine triphosphate
h Hour(s)
HEPES N-(2-Hydroxyethyl)piperazine-N’-2-ethan sulphuric acid
His = H Histidine
HIV Human immunodeficiency virus
HTLV Human T-cell lymphotropic virus 
Ile = I Isoleucine
IN Integrase
Insert DNA fragment that has been inserted into a vector plasmid
IPTG Isopropyl-ß-D-thio-galactopyranoside
KAc Potassium acetate
kb Kilobase(s)
KCl Potassium chloride
kDa Kilodalton
KH2P04 Potassium dihydrogenphosphate
l Liter
LB Luria-Bertani bacterial medium
Leu = L Leucine
LexA Bacterial transcription factor
LMB Leptomycin B
LTR Long terminal repeat
Lys = K Lysine
M Molar
ml Milliliter
µl Microliter
Met = M Methionine
MgCl2 Magnesium chloride
MgS04 Magnesium sulfate
min Minute(s)
mix Mixture
MOPS 4-Morpholine-propanesulfonic acid
mRNA Messenger RNA
MW Molecular weight
N Asparagine
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NaAc Sodium acetate
NaH2P04 Sodium dihydrogenphosphate
Na2HP04 Disodium hydrogenphosphate
NES Nuclear export signal
(NH4)2S04 Ammonium sulfate
NLS Nuclear localization signal
NPC Nuclear pore complex
NSS Nucleocytoplasmic shuttling signal
Nt Nucleotide
OD Optical density
O/N Over night
ORF Open reading frame, section of DNA sequence that begins with a start codon and
ends with a stop codon
PAGE Polyacrylamide gel electrophoresis
PBS Phosphate buffered saline
PCR Polymerase chain reaction
PEG Polyethylene glycol
Pen/Strep Penicillin/Streptomycin
Phe = F Phenylalanine
PIC Preintegration complex
PR Protease
Pro = P Proline
R Arginine
Raff Raffinose
RFB Reilly-Finkel-Biskis murine leukemia virus
RISP Rev interacting shuttle protein
RNase Ribonuclease
RNA Ribonucleic acid
rRNA Ribosomal RNA
RRE Rev response element
RSV Rous sarcoma virus
RT Room temperature
RT Reverse transcription, or reverse transcriptase
RT-PCR Method for amplifying cDNA from an RNA template
SDS Sodium dodecyl sulfate
sec Second(s)
Ser = S Serine
SSC Saline-sodium citrate buffer
SSPE Saline sodium phosphate buffer
T Thymine, or thymidine or threonine
TAE Tris-acetate-EDTA buffer
Taq Thermus aquaticus (-Polymerase)
TE Tris-EDTA buffer
TEMED N,N,N’,N’-Tetramethylethylendiamine
Thr = T Threonine
TLC Thin layer chromatography
TNE Tris-NaCl-EDTA buffer
Trp = W Tryptophan
Tris Trishydroxyaminomethan
tRNA Transfer RNA
TTP Thymidine triphosphate
Tyr = Y Tyrosine
u Unit
U Uracil, or uridine
UV Ultraviolet light
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Val = V Valine
Vector Plasmid or phage chromosome used to carry cloned DNA segment
Vol Volume
v/v Volume:volume ratio
W Tryptophan
WB Western blot
wt Wild type
w/v Weight:volume ratio
X-gal 5-bromo-4-chloro-3-indolyl-ß-D-galactopyranoside
Y Tyrosine
YNB-AA/AS Yeast nitrogen base (without amino acids and ammonium sulfate)
YPD Yeast extract, peptone, dextrose
2.2 Materials
2.2.1. Chemicals, kits and materials
1-kb-DNA molecular weight marker Life Technologies, Eggenstein
Acetyl-CoA Roche Molecular Biochemicals, Mannheim
Acrylamide/Bis solution BioRad, Munich
Actinomycin D Sigma, Deisenhofen
Agar (Bacto-agar) Difco, Detroit MI, USA
Agarose (SeaKem) FMC Bio Products, Rockland USA
Amino acids (yeast two hybrid) Sigma, Deisenhofen
Ampicillin Sigma, Deisenhofen
Ampuwa® H20 Fresenius, Bad Homburg
Antibiotic-antimicotic solution Life Technologies, Eggenstein
α[32P]dCTP [#PB10205, 3000Ci/mmol] Amersham Buchler, Braunschweig
Aprotinine Sigma, Deisenhofen
Aqua bidest. Millipore, Eschborn
Alexa™ 488 protein labeling kit Molecular Probes, Oregon, USA
Alexa™ 568 protein labeling kit Molecular Probes, Oregon, USA
BCA Protein Assay Reagent Kit Pierce, Rockford, USA
Bio-Spin® chromatography columns BioRad, Munich
β−Mercaptoethanol Sigma, Deisenhofen
Bromophenol blue Merck, Darmstadt
Bovine serum albumine Sigma, Deisenhofen
Calf instestinal alkaline phosphatase Roche Molecular Biochemicals, Mannheim
CAT Elisa Roche Molecular Biochemicals, Mannheim
Cell count chamber MD Kova Raster 10 Madaus Diagnostik, Munich
Cell culture medium DMEM with Glutamax Life Technologies, Eggenstein
Cell culture medium MEM-D-Val Life Technologies, Eggenstein
Cycloheximide Sigma, Deisenhofen
Cellphect Transfection Kit Pharmacia Biotech, Freiburg
Coomassie-Brilliant-Blue R-250 Serva, Heidelberg
Chloroform Merck, Darmstadt
DEPC Sigma, Deisenhofen
Dextrose extra pure Sigma, Deisenhofen
DMSO Sigma, Deisenhofen
DNA (type III sodium salt form salmon testes) Sigma, Deisenhofen
DNA Ligase buffer 5X Life Technologies, Eggenstein
DNAse Sigma, Deisenhofen
dNTPs Pharmacia Biotech, Freiburg
DTT Sigma, Deisenhofen
Enhanced chemiluminescence (ECL) assay Amersham Buchler, Braunschweig
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EDTA Sigma, Deisenhofen
Electroporation cuvettes BioRad, Munich
Ethanol Merck, Darmstadt
Ethidium bromide Serva, Heidelberg
Ethyl acetate Merck, Darmstadt
ExpandTM High Fidelity PCR System Roche Molecular Biochemicals, Mannheim
Fast CAT® Green (deoxy) CAT kit Molecular Probes, Oregon, USA
Filter 0.22µm Nalgene, USA
Filterpaper, Whatman 3mm Whatman, Maidstone, GB
Filterpaper, extra tick 7.5x10cm BioRad, Munich
Fetal calf serum (FCS) Life Technologies, Eggenstein
  “ Seromed, Berlin
Formaldehyde 37% Sigma, Deisenhofen
Formamide Merck, Darmstadt
Fugene™ 6 Transfection reagent Roche Molecular Biochemicals, Mannheim
Galactose Sigma, Deisenhofen
Gentamycin Life Technologies, Eggenstein
Glass beads (425-600 µ #G8772) Sigma, Deisenhofen
Glutathione Sepharose™ 4B Pharmacia Biotech, Freiburg
Glycerol Merck, Darmstadt
Glyoxal Sigma, Deisenhofen
Kaleidoscope prestained standard BioRad, Munich
HIV-1 p24 Ag Assay Coulter Immunotech, Krefeld
Hoechst 33342 (Bisbenzimide) Molecular Probes, Oregon, USA
IPTG Roche Molecular Biochemicals, Mannheim
Isopropanol Merck, Darmstadt
Leptomycin B Provided by Dr. Mattaj, Heidelberg
Leupeptine Sigma, Deisenhofen
Lithium acetate Sigma, Deisenhofen
L-Glutamine (cell culture) Life Technologies, Eggenstein
Lysozyme Sigma, Deisenhofen
Luciferase Assay System Promega, Madison, USA
Methanol Merck, Darmstadt
Methylene blue Merck, Darmstadt
MOPS Merck, Darmstadt
Nitrocellulose membrane BioRad, Munich
Nylon filter (Hybond) Amersham
NucleoSpin PCR purification kit Macherey-Nagel, Oensingen, Schweiz
Paraformaldehyde Sigma, Deisenhofen
Pepstatine Sigma, Deisenhofen
Polyethylenglycol (PEG) 4000 Baker, USA, and Merck, Darmstadt
Pen/Strep Life Technologies, Eggenstein
Phenol Life Technologies, Eggenstein
Phenol/Chloroform Applied Biosystems, Weiterstadt
Plastic material for cell culture Greiner, Labortechnik, Frickenhausen
PMSF Sigma, Deisenhofen
Polaroid s/w Film 667 Polaroid, Offenbach
Proteinase K Roche Molecular Biochemicals, Mannheim
Qiagen® Plasmid Maxi Kit Qiagen, Hilden
Qiagen® RNEasy Mini Kit Qiagen, Hilden
Raffinose Difco, Detroit MI, USA
Rainbow-SDS-Protein standard Promega, Madison, USA
Rapid DNA Ligation Kit Life Technologies, Eggenstein
Rediprime™ II random prime labeling system Pharmacia Biotech, Freiburg
Restriction enzymes Roche Molecular Biochemicals, Mannheim
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  “ NewEngland Biolabs, Schwalbach
SDS Löwe Biochemika, Munich
  “ BioRad, Munich
SOC medium Life Technologies, Eggenstein
T4 DNA Ligase Life Technologies, Eggenstein
TEMED BioRad, Munich
Thiamine (vitamine B1) Sigma, Deisenhofen
TLC plastic sheets Silica gel 60 Merck, Darmstadt
Topo TA cloning® kit Invitrogen, De Shelp, Netherlands
Tris Löwe Biochemika, Munich
Triton® X-100 Sigma, Deisenhofen
Trypan blue Merck, Darmstadt
Trypsin-EDTA solution Biochrom, Berlin
Tween® 20 Sigma, Deisenhofen
UlTRAhyb™ Hybridization Solution Ambion, Austin, USA
Uracil Sigma, Deisenhofen
Yeast extract (Bacto-yeast extract) Difco, Detroit MI, USA
Yeast nitrogen base (YNB-AA/AS) Life Technologies, Eggenstein
X-gal Löwe Biochemika, Munich
Zetaprobe® GT Nylon membrane BioRad, Munich
2.2.2. Bacteria E.coli
• BL21 Pharmacia Biotech, Freiburg
• XL1-blue supercompetent cells Stratagene, Heidelberg
• KC8 Provided by Dr. W. Kolanus, Munich
• TOP10F’One Shot competent cells Invitrogen, De Shelp, Netherlands
2.2.3.  Yeast cells
• EGY48 (Gyuris et al., 1993) Provided by Dr. W. Kolanus, Munich
2.2.4.  Human cells
• HeLa:
Human cervical adenocarcinoma cell line with epithelial morphology [American Type
Culture Collection (ATCC) CRL-7923, Rockville, Maryland]
• HEK293:
Human embryonal kidney cell line (ATCC CRL-1573, Rockville, Maryland)
• Jurkat T cells:
T-cell line (Provided by Dr. W. Kolanus, Genzentrum, Munich)
• 85HG66: 
Human CD4-negative astrocytoma cell line described in (Brack-Werner et al., 1992;
Stavrou et al., 1987) 
• U87MG (U87): 
Human astrocytoma-/glioblastoma cell line (ATCC HTB-14, Rockville, Maryland)
• U138MG (U138): 
Human glioblastoma cell line (ATCC HTB-16, Rockville, Maryland)
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• Primary fetal astrocytes (H4/96):
Human astrocytes prepared from myelencephalon-mesencephalon of a 9-week-old fetus as
described in (Aloisi et al., 1992) provided by Dr. F. Aloisi, ISS, Rome, Italy.
2.2.5.  Antibodies
The following antibodies were used for indirect immunofluorescence and/or western
blot analysis:
• Mouse monoclonal anti-GST, IgG1 (Biozol)
• Mouse monoclonal anti-HIV-1Tat, IgG1a (Dr. J. Karn, MRC AIDS)
• Rabbit polyclonal anti-GFP serum (Dr. George Pavlakis, NCI, Maryland, USA)
• Rabbit polyclonal anti-HIV-1Tat, IgG (Dr. Barbara Ensoli, ISS, Rome, Italy)
• Rabbit polyclonal anti-HIV-1 Rev (#29994 T.B.I.) (Dr. George Pavlakis, NCI, Maryland,
USA)
• Rat monoclonal anti-Risp, IgG2a (5D3, 5D4, 8B6, 8B8) and IgG1 (6F11, 6F12, 7B4,
8A11) (Dr. Elisabeth Kremmer, GSF, Munich)
• Rat monoclonal anti-GST, IgG1 (Dr. Elisabeth Kremmer, GSF, Munich)
• Cy3-conjugated goat anti-human IgG (Dianova)
• Cy3-conjugated goat anti-rabbit IgG + IgM (Dianova)
• Fluorescein (DTAF)-conjugated goat anti-rat IgG + IgM (Dianova)
• Peroxidase-conjugated goat anti-mouse IgG + IgM (Dianova)
• Peroxidase-conjugated goat anti-rabbit IgG + IgM (Dianova)
• Peroxidase-conjugated goat anti-rat IgG + IgM (Dianova)
2.2.6.  Plasmids
The following mammalian expression plasmids were used for human cell transfections,
the yeast and E.coli shuttle plasmids were used in the yeast two hybrid search and
the prokaryotic pGEX-3X expression plasmid was used to produce GST-fusion
proteins (for an overview see Fig. 2.1). To check whether the insertion of the
interested gene was correct, all plasmids constructed for this work were sequenced
(Sequiserve, Munich).
2.2.6.1.   Mammalian expression plasmids:
2.2.6.1.1. HIV-1 regulatory gene-expression plasmids
• pBsRev
Bluescript vector pBSPL that expresses the HXB2- rev gene with synthetic exon 1
under the control of the HIV-1 LTR promoter (Neumann et al., 1995), (provided by Dr.
G. Pavlakis, NCI, Maryland, USA).
• pBsRevM10BL
Bluescript vector pBSPL that expresses the HXB2-synthetic rev gene containing the
M10 mutation in the activation domain at the amino acids position 78-79 LE—> DL
(Malim et al., 1989) and an additional mutation BL resulting in the addition of 4
amino acids EDLP between position 82-83 (Stauber et al., 1995), (provided by Dr. G.
Pavlakis, NCI, Maryland, USA).
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• pcRev
pBC12/CMV vector that expresses the HXB3-rev gene (Bogerd et al., 1995; Malim et
al., 1988), (provided by Dr. B. Cullen, Durham, USA).
• pcRevM5
pBC12/CMV vector that expresses the M5 mutation in the NLS/RNA-binding
domain of the HXB3-Rev at the amino acids position 38-39 RR—> DL (Malim et al.,
1989) (Thomas et al., 1998), (provided by Dr. B. Cullen, Durham, USA).
• pcRevM5-sg143
pFred143 vector (see 2.2.6.1.4.) that expresses the fusion protein RevM5-GFP under
the control of the CMV promoter. The RevM5-ORF starting from the second codon
of pcRevM5 was PCR amplified (5’ primer 23957 and 3’ primer 23958) and fused in
frame to an enhanced fluorescence mutant of GFP into the pFred143 vector (see
later). The revM5 gene was inserted into a unique NheI restriction site immediately
downstream of the ATG start codon of GFP. A Gly-Ala-Gly hinge region was inserted
between the last Rev-codon and the following GFP-ORF to allow correct folding of
both protein domains (F. Ceccherini-Silberstein, GSF, Neuherberg).
• pCsRev-sg143
pFred143 vector that expresses the fusion protein Rev-GFP under the control of the
CMV promoter. The Rev-ORF starting from the second codon of pBsRev was PCR
amplified and was inserted into the unique NheI restriction site immediately
downstream of the ATG start codon of GFP. A Gly-Ala-Gly hinge region was inserted
between the last Rev-codon and the following GFP-ORF to allow correct folding of
both protein domains (Ludwig et al., 1999), (Dr. M. Neumann, GSF, Neuherberg).
• pcTat
pBC12/CMV vector that expresses the HXB3-tat gene (Malim et al., 1988), (provided
by Dr. B. Cullen, Durham, USA).
• pcTat-Rev
pBC12/CMV vector that expresses a fusion protein consisting of the full length Tat
protein linked to the first amino acid of the Rev ORF (Tiley et al., 1992), (provided by
Dr. B. Cullen, Durham, USA).
Fig. 2 .1  Schematic overview of expression plasmids used for transient
transfection assays. The transcription of HIV-1 derived genes was directed either by the
HIV-LTR (U3/R region) or the immediate early CMV promoter. pB37RGag contains gag
encoding sequences (p17 and p24) and the complete RRE (330bp StyI  fragment) and lacks the
major splice donor site (mSD) of HIV-1, (hfs= human flanking sequences).
pHIV∆npsLTRCAT contains partial Nef sequences upstream of the LTR (nps = nef partial
sequence). The transcription of GFP and human-derived genes was directed by the CMV
promoter.  Transcription of the luciferase gene was directed either by the LTR of the Rous
Sarcoma virus (pRSVluc) or from the murine leukemia virus-related RFB-virus (pGL3-RFB).
Transcription of LexA- or B42AD-fusion genes was directed by the yeast ADH1 or the
inducible GAL1 promoter respectively.
Poly (A) signals (p(A)) for transcription termination were derived from SV40, bovine growth
hormone (BGH), ADH1, or insulin genes. For further details on plasmids including
references, see the text.
pBsRev
sRev SV40 p(A)
pBsRevM10BL
CMV   HXB-3-Tat Prepro Insulin p(A)
pcTat
pL3Tat
A. HIV-1 expression plasmids
(a) Rev- and Tat- expression plasmids
U3 R sTat SV40 p(A)
1 exon (72aa)
Nef-ORF
pcTat-Rev
CMV    Prepro Insulin p(A)Rev
pcRev
BGH p(A)
BLM10  
sRev
HXB-3-RevCMV   Prepro Insulin p(A)
B. Rev-interacting cellular factors expression plasmids
(a) Known cellular factors expression plasmids
pcTat-Rab
CMV Rab Prepro Insulin p(A)
pcRab
CMV Rab Prepro Insulin p(A)
U3 R
78DLRLEDLP85
pB37R 
U3 R U5 p24Gag RRE U3 R U5
 mSD Stop
hfs hfs
(b) Rev- and Tat-response plasmids
p17Gag
pSLIIBCAT
U3 R-SLIIB CAT SV40 p(A)
pHIV  npsLTRCAT
U3 R CAT SV40 p(A)
U3 R SV40 p(A)
pcRevM5
HXB-3-RevCMV   PreproInsulin p(A)
pcRevM5-sg143
CMV  GFPsg143HXB-3-Rev
pCsRev-sg143
CMV  GFPsg143sRev BGH p(A)
38DL39
M5
38DL39
M5
HXB-3-Tat
HXB-3-Tat
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pGEX-3X-Risp
(b) Risp related expression plasmids
pcRisp-sg143
Risp GFPsg143 BGH p(A)CMV
RispGST       XA
pcIg-Risp
CMV CH2-CH3 IgG Risp
(2-38 aa)Risp
pcIg-(2-38)-Risp 
(2-73 aa)Risp
pcIg-(2-73)-Risp 
(2-133 aa)Risp
pcIg-(2-133)-Risp 
(134-171 aa)Risp
pcIg-(134-171)-Risp 
(74-171 aa)Risp
pcIg-(74-171)-Risp 
(39-171 aa)Risp
pcIg-(39-171)-Risp 
CMV CH2-CH3 IgG
CMV CH2-CH3 IgG
CMV CH2-CH3 IgG
CMV CH2-CH3 IgG
CMV CH2-CH3 IgG
CMV CH2-CH3 IgG
pcCrm1-sg143
CMV Crm1 GFPsg143 BGH p(A)
tac 
D. Bacterial expression plasmids
pcPKI-sg143
CMV GFPsg143 BGH p(A)PKI
C. HIV-unrelated expression plasmids
pFred143 
CMV GFPsg143 BGH p(A)
pRSVluc
pGL3-RFB
ADH p(A)
RFB-LTR Luciferase SV40 p(A)
RSV-LTR Luciferase SV40 p(A)
pceIF-5A-sg143  
GFPsg143 BGH p(A)eIF-5ACMV
pc11.5.1-sg143  
GFPsg143 BGH p(A)11.5.1CMV
pcTat-Risp
CMV RispHXB-3-Tat Prepro Insulin p(A)
SV40 p(A)
SV40 p(A)
SV40 p(A)
SV40 p(A)
SV40 p(A)
SV40 p(A)
SV40 p(A)
pcIg 
CMV CH2-CH3 IgG SV40 p(A)
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pEG202-sRev
ADH sRevLexA BD
pEG202-Rev
ADH HXB-3-RevLexA BD
pEG202-RevM4 
pEG202-RevM5 
pEG202-RevSLT40
pEG202-RevM10BL
ADH HXB-3-RevLexA BD
SLT 40
59DD60
ADH sRevLexA BD
BLM10  
78DLRLEDLP85
ADH HXB-3-RevLexA BD
38DL39
M5
ADH HXB-3-RevLexA BD
23DQDL26
M4
E. Yeast two hybrid expression plasmids
(a) Bait-expression plasmids   
(b)  Prey-expression plasmids
GAL1 cDNA
pJG4-5-cDNA library 
B42 ADNLS
GAL1 Risp
pJG4-6-Risp 
B42 ADNLS
GAL1 (2-38 aa)Risp
pJG4-6-(2-38)-Risp 
B42 ADNLS
GAL1 (2-73 aa)Risp
pJG4-6-(2-73)-Risp 
B42 ADNLS
GAL1 (2-133 aa)Risp
pJG4-6-(2-133)-Risp 
B42 ADNLS
GAL1 (134-171 aa)Risp
pJG4-6-(134-171)-Risp 
B42 ADNLS
GAL1 (74-171 aa)Risp
pJG4-6-(74-171)-Risp 
B42 ADNLS
GAL1 (39-171 aa)Risp
pJG4-6-(39-171)-Risp 
B42 ADNLS
ADH p(A)
ADH p(A)
ADH p(A)
ADH p(A)
ADH p(A)
ADH p(A)
ADH p(A)
ADH p(A)
ADH p(A)
ADH p(A)
ADH p(A)
ADH p(A)
ADH p(A)
ADH p(A)
GAL1 sRev
pB42AD-sRev
B42 ADNLS ADH p(A)HA
HA
HA
HA
HA
HA
HA
HA
HA
pEG202-LexCD2   
ADH CD2LexA BD ADH p(A)
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• pL3Tat
pBR322 vector that expresses the HXB2-tat gene (1 exon) under the control of the
HIV-1 LTR promoter (Felber et al., 1990; Neumann et al., 1995), (provided by Dr. G.
Pavlakis, NCI, Maryland, USA)
2.2.6.1.2.  HIV-1 Rev- and Tat-response plasmids
• pB37R
Rev response plasmid that contains HXB2-Gag encoding sequences (p17 and p24)
and the complete RRE (330bp StyI fragment) and lacks the major splice donor site
(mSD) of HIV-1. The expression of the plasmid is under the control of the HIV-1 LTR
promoter (therefore it is Rev and Tat dependent) (Ludwig et al., 1999; Neumann et al.,
1995), (provided by Dr. G. Pavlakis, NCI, Maryland, USA).
• pHIV∆npsLTRCAT
Tat response plasmid that directs expression of the chloramphenicol acetyltransferase
(CAT) reporter gene from the HIV-1BRU LTR in a pBR322-derived vector (pSB1). Nef
sequences upstream of the LTR were deleted (nps = nef partial sequence) (Ludvigsen
et al., 1996), (Dr. A. Ludvigsen, GSF, Neuherberg).
• pSLIIBCAT
Tat-Rev response plasmid that directs expression of the CAT reporter gene from a
modified HIV-1 LTR. The TAR RNA stem-loop in HIV-1 LTR linked to CAT is
replaced with the RRE-derived stem loop IIB (SLIIB), the minimal RNA target
sequence for HIV-1 Rev (Bogerd et al., 1995; Tiley et al., 1992), (provided by Dr. B.
Cullen, Durham, USA).
2.2.6.1.3. Expression plasmids for Rev-interacting cellular factors
• pcRab
pBC12/CMV vector that expresses the human rab gene (Bogerd et al., 1995),
(provided by Dr. B. Cullen, Durham, USA).
• pcTat-Rab
pBC12/CMV vector that expresses a fusion protein consisting of the full length Tat
protein linked to the first amino acid of the Rab ORF (Bogerd et al., 1995).
The NcoI/HindIII fragment containing the full-lenght rev gene was replaced with a
NcoI/HindIII PCR product (5’ primer 17355 and 3’ primer 17356) containing the full-
lenght rab gene into the pcTat-Rev plasmid (F. Ceccherini-Silberstein, GSF,
Neuherberg).
• pcCrm1-sg143
pFred143 vector that expresses the human crm1 gene fused in frame to the enhanced
fluorescence mutant of GFP under the control of the CMV promoter (Dr. M.
Neumann, GSF, Neuherberg).
• pceIF-5A-sg143
pFred143 vector that expresses the human eIF-5A gene fused in frame to the
enhanced fluorescence mutant of GFP under the control of the CMV promoter (Dr.
M. Neumann, GSF, Neuherberg).
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• pc11.5.1-sg143
pFred143 vector that expresses the 11.5.1 cDNA (one of the two new yeast two
hybrid positive Rev-interacting clones isolated in this study)  fused in frame to the
enhanced fluorescence mutant of GFP under the control of the CMV promoter. The
11.5.1 -ORF starting from the second codon was PCR amplified from the pJG4-5-
11.5.1 plasmid (5’ primer 15759 and 3’ primer 15760) and was inserted into the
unique NheI restriction site. A Gly-Ala-Gly hinge region was inserted between the
last 11.5.1-codon and the following GFP-ORF to allow correct folding of both protein
domains (F. Ceccherini-Silberstein, GSF, Neuherberg).
2.2.6.1.3.1.  Risp (= 16.4.1 artificial protein) expression plasmids
• pcRisp-sg143
pFred143 vector that expresses the risp gene fused in frame to the enhanced
fluorescence mutant of GFP under the control of the CMV promoter. The risp gene
starting from the second codon was PCR amplified from the pJG4-5-16.4.1 plasmid
using (5’ primer 16552 and 3’ primer 15762). The Risp PCR product contains few
additional nucleotides to include the “missing N-terminal part” (8 amino acids) of the
EST 343275 5’ clone (Fig. 3.9). The Risp PCR product was inserted into the unique
NheI restriction site and a Gly-Ala-Gly hinge region was inserted between the last
Risp-codon and the following GFP-ORF to allow correct folding of both protein
domains (F. Ceccherini-Silberstein, GSF, Neuherberg).
• pcIg-Risp
pRK5/CMV derived vector containing the 78g78 multi cloning sites (Zeitlmann et al.,
1998) that expresses the risp gene fused in frame to the C-terminus of the CH2 and
CH3 heavy chain domains from human IgG1(see 2.2.6.1.4.). The Risp-ORF starting
from the second codon was PCR amplified from the pcRisp-sg143 plasmid (5’ primer
18733 and 3’ primer 18510) and was inserted into the pcIg-Sam68 plasmid (provided
by Dr. W. Kolanus, Genzentrum, Munich) using the MluI/NotI cloning site after the
removal of the MluI/NotI Sam68 insert (F. Ceccherini-Silberstein, GSF, Neuherberg).
• pcIg-(2-38)-Risp
pRK5/CMV derived vector that expresses the N-37 amino acids of Risp fused in
frame to the CH2 and CH3 IgG1 domains. A 121 nucleotide MluI/NotI fragment
containing a TAG stop codon was PCR amplified from the pcRisp-sg143 plasmid (5’
primer 18733 and 3’ primer 19538) and was inserted into the pcIg-Sam68 plasmid
using the MluI/NotI cloning site (F. Ceccherini-Silberstein, GSF, Neuherberg).
• pcIg-(2-73)-Risp
pRK5/CMV derived vector that expresses the N-72 amino acids of Risp fused in
frame to the CH2 and CH3 IgG1 domains. A 226 nucleotide MluI/NotI fragment
containing a TAG stop codon was PCR amplified from the pcRisp-sg143 plasmid (5’
primer 18733 and 3’ primer 19539) and was inserted into the pcIg-Sam68 plasmid
using the MluI/NotI cloning site (F. Ceccherini-Silberstein, GSF, Neuherberg).
• pcIg-(2-133)-Risp
pRK5/CMV derived vector that expresses the N-132 amino acids of Risp fused in
frame to the CH2 and CH3 IgG1 domains. A 406 nucleotide MluI/NotI fragment
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containing a TAG stop codon was PCR amplified from the pcRisp-sg143 plasmid (5’
primer 18733 and 3’ primer 19540) and was inserted into the pcIg-Sam68 plasmid
using the MluI/NotI cloning site (F. Ceccherini-Silberstein, GSF, Neuherberg).
• pcIg-(39-171)-Risp
pRK5/CMV derived vector that expresses the C-133 amino acids of Risp fused in
frame to the CH2 and CH3 IgG1 domains. A 409 nucleotide MluI/NotI fragment
containing a TAG stop codon was PCR amplified from the pcRisp-sg143 plasmid (5’
primer 20817 and 3’ primer 18510) and was inserted into the pcIg-Sam68 plasmid
using the MluI/NotI cloning site (F. Ceccherini-Silberstein, GSF, Neuherberg).
• pcIg-(74-171)-Risp
pRK5/CMV derived vector that expresses the C-98 amino acids of Risp fused in
frame to the CH2 and CH3 IgG1 domains. A 304 nucleotide MluI/NotI fragment
containing a TAG stop codon was PCR amplified from the pcRisp-sg143 plasmid (5’
primer 20818 and 3’ primer 18510) and was inserted into the pcIg-Sam68 plasmid
using the MluI/NotI cloning site (F. Ceccherini-Silberstein, GSF, Neuherberg).
• pcIg-(134-171)-Risp
pRK5/CMV derived vector that expresses the C-38 amino acids of Risp fused in
frame to the CH2 and CH3 IgG1 domains. A 124 nucleotide MluI/NotI fragment
containing a TAG stop codon was PCR amplified from the pcRisp-sg143 plasmid (5’
primer 20819 and 3’ primer 18510) and was inserted into the pcIg-Sam68 plasmid
using the MluI/NotI cloning site (F. Ceccherini-Silberstein, GSF, Neuherberg).
• pcTat-Risp
pBC12/CMV vector that expresses a fusion protein consisting of the full length Tat
protein linked to the first amino acid of the Risp ORF.
The NcoI/HindIII fragment containing the full-lenght rev gene was replaced with a
NcoI/HindIII PCR product (5’ primer 17357 and 3’ primer 17358) containing the full-
lenght risp gene into the pcTat-Rev plasmid (F. Ceccherini-Silberstein, GSF,
Neuherberg).
2.2.6.1.4.  HIV-unrelated expression plasmids
• pBSPL
Bluescript derived vector used as inert carrier plasmid to increase the quantity of
DNA for transfections with calcium phosphate procedure (Schwartz et al., 1990),
(provided by Dr. G. Pavlakis, NCI, Maryland, USA).
• pcIg
pRK5/CMV derived vector that expresses the constant CH2 and CH3 domain
segments (768 bp) from a human IgG1 (provided by Dr. W. Kolanus, Genzentrum,
Munich).
• pFred143 (KH1035)
Vector that directs the expression of an enhanced fluorescence mutant GFP under the
control of the CMV immediate early promoter (Stauber et al., 1998), (Dr. M. Neumann,
GSF, Neuherberg).
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• pcPKI-sg143
Vector that directs the expression the human cyclic AMP dependent protein kinase
inhibitor (PKI) gene (Wen et al., 1995) fused in frame to the enhanced fluorescence
mutant of GFP under the control of the CMV promoter (Dr. M. Neumann, GSF,
Neuherberg).
• pGL3-RFB
pGL3-basic vector that directs the expression of luciferase gene under the control of
the C-type murine leukemia virus-related RFB-virus LTR promoter (Frech et al., 1997)
(provided by Dr. T. Werner, AG BIODV, GSF, Neuherberg).
• pRSVluc
pBR322 vector that directs the expression of luciferase gene under the control of
the C-type Rous sarcoma virus (RSV) LTR promoter (de Wet et al., 1987), (provided
by Dr. G. Pavlakis, NCI, Maryland, USA).
2.2.6.2.  Prokaryotic expression plasmids
• pGEX-3X
pGEX vector for inducible, high-level intracellular expression of genes as fusion with
Schistosoma japonicum glutathione S-transferase (GST) under the control a tac
promoter (inducible with IPTG 1-5mM). The vector includes an internal lac Iq gene
for use in any E. coli host and a coding region for factor Xa protease recognition site
for cleaving the desired protein from the fusion protein (Pharmacia Biotech).
• pGEX-3X-Risp
pGEX-3X vector that directs the inducible expression of risp gene fused in frame to
GST-factor Xa. The Risp-ORF starting from the second codon was PCR amplified
from the pcRisp-sg143 plasmid (5’ primer 17746 and 3’ primer 17747) and was
inserted into the pGEX-3X vector using the BamHI/EcoRI cloning site (F. Ceccherini-
Silberstein, GSF, Neuherberg).
• pCR® 2.1-Topo
Vector supplied linearized with single 3‘ thymidine (T) overhangs for TA cloning. It
provides a highly efficient insertion of Taq polymerase-amplified PCR products with
3’ A overhangs. The cloning site is situated into a laczα fragment (571bp) and is
flanked by two EcoRI sites, which allow easy analysis of the plasmid by enzymatic
digestion. The presence of any insert interrupts the lacz gene and allow a blue/white
screening in the presence of X-gal (Invitrogen).
2.2.6.3. Yeast two hybrid expression plasmids
2.2.6.3.1. Bait-expression plasmids
• pEG202 LexA-fusion plasmid
Yeast and E.coli shuttle multicopy vector containing the yeast 2µm origin of
replication and the HIS3 selectable marker gene, the full-length coding region (amino
acids 1 to 202) of the bacterial DNA-binding protein LexA, flanked by the yeast
strong constitutive alcohol dehydrogenase ADH1 promoter and terminator as well as
a polylinker available for insertion of bait coding sequences. The plasmid contains
also the ampicillin resistance gene (AmpR) and the pBR origin (ori) of replication to
Materials and Methods 40
allow propagation in E.coli (Golemis et al., 1999) (provided by Dr. W. Kolanus,
Genzentrum, Munich).
• pEG202-sRev (sense and antisense)
TheHXB2-Rev-ORF starting from the second codon of pBsRev was PCR amplified
and inserted in frame with LexA into the unique restriction site EcoRI into the
pEG202 vector (in sense and antisense orientation), (Dr. A. Ludvigsen, GSF,
Neuherberg).
• pEG202-Rev (sense)
The HXB3-Rev-ORF starting from the second codon of pcRev was PCR amplified
(5’ primer 19777 and 3’ primer 19776) and inserted in frame with LexA into the
unique restriction site EcoRI into the pEG202 vector (F. Ceccherini-Silberstein, GSF,
Neuherberg).
• pEG202-RevM4 (sense and antisense)
Rev expression plasmid containing the M4 mutation in the I multimerization domain
at the amino acids position 23-25-26 YSN—> DDL (Malim et al., 1989). The RevM4-
ORF starting from the second codon of pcTat-RevM4 (Thomas et al., 1998) ((kindly
provided by Dr. J. Hauber, University of Erlangen) was PCR amplified (5’ primer
19777 and 3’ primer 19776) and inserted in frame with LexA into the unique
restriction site EcoRI into the pEG202 vector (in sense and antisense orientation), (F.
Ceccherini-Silberstein, GSF, Neuherberg).
• pEG202-RevM5 (sense)
Rev expression plasmid containing the M5 mutation in the NLS/RNA-binding
domain (Malim et al., 1989). The RevM5-ORF starting from the second codon of
pcRevM5 was PCR amplified (5’ primer 19777 and 3’ primer 19776) and inserted in
frame with LexA into the unique restriction site EcoRI into the pEG202 vector (in
sense orientation), (F. Ceccherini-Silberstein, GSF, Neuherberg).
• pEG202-RevSLT40 (sense)
Rev expression plasmid containing the SLT40 mutation in the II multimerization
domain at the amino acids position 59-60 IL—> DD (Thomas et al., 1998). The
RevSLT40-ORF starting from the second codon of pcRevSLT40 (kindly provided by
Dr. J. Hauber, University of Erlangen) was PCR amplified (5’ primer 19777 and 3’
primer 19776) and inserted in frame with LexA into the unique restriction site EcoRI
into the pEG202 vector (in sense orientation), (F. Ceccherini-Silberstein, GSF,
Neuherberg).
• pEG202-RevM10BL (sense and antisense)
Rev expression plasmid containing the M10BL mutant NES region of Rev. The
RevM10BL-ORF starting from the second codon of pCsRevM10BL-sg143 was PCR
amplified (5’ primer 19777 and 3’ primer 21116) and inserted in frame with LexA into
the unique restriction site EcoRI into the pEG202 vector (in sense and antisense
orientation) (F. Ceccherini-Silberstein and C. Bickel, GSF, Neuherberg).
• pEG202-LexCD2
Unspecific bait control plasmid expressing the cytoplasmic domain of CD2 fused in
frame to LexA (provided by Dr. W. Kolanus, Genzentrum, Munich).
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2.2.6.3.2. Prey-expression plasmids
• pJG4-5 library plasmid
Yeast and E.coli shuttle vector that contains a yeast expression cassette that includes
sequences that encode 106 amino acids fusion moiety, consisting of the SV40 virus
large T antigen NLS (PPKKKRKVA), the B42 transcription activation domain (88-
residues) and the hemagglutinin (HA) epitope tag (YPYDVPDYA). Expression of the
sequences is under the control of the GAL1 inducible yeast promoter and the
terminator sequences from the yeast ADH1 gene. The plasmid contains also the TRP1
selectable marker and the 2µm origin of replication to allow propagation in yeast, and
the ampicillin resistance gene (AmpR) and the pUC origin (ori) of replication to allow
propagation in E.coli (Golemis et al., 1999; Gyuris et al., 1993), (provided by Dr. W.
Kolanus, Genzentrum, Munich).
• pJG4-5-cDNA library
pJG4-5 vector that expresses a Jurkat T cell cDNA library inserted into the unique
EcoRI and XhoI sites so that encoded proteins are expressed fused in frame to the
B42 transcription activation domain at their amino terminus (Kolanus et al., 1996)
(provided by Dr. W. Kolanus, Genzentrum, Munich).
• pJG4-5-11.5.1
pJG4-5 vector that expresses the 11.5.1 Jurkat T cell cDNA encoded protein able to
interact in the yeast two hybrid system with the HIV-1 Rev protein.
• pJG4-5-16.4.1
pJG4-5 vector that expresses the 16.4.1 Jurkat T cell cDNA encoded protein able to
interact in the yeast two hybrid system with the HIV-1 Rev protein.
• pJG4-6  
 pJG4-5-derived vector with the original NotI restriction site removed and containing
an insert in the EcoRI/XhoI cloning site with a MluI and NotI restriction site at the 5’
and 3’ extremity respectively. Vector used to express encoded proteins fused in frame
to the B42 transcription activation domain at their amino terminus using the
MluI/NotI cloning site (provided by Dr. W. Kolanus, Genzentrum, Munich).
• pJG4-6-Risp
pJG4-6 vector that expresses the full lenght of Risp fused in frame to the B42
transcription activation domain. The Risp-ORF starting from the second codon of
pcRisp-sg143 plasmid was PCR amplified (5’ primer 18733 and 3’ primer 18510) and
inserted into the pJG4-6 vector using the MluI/NotI cloning site (F. Ceccherini-
Silberstein, GSF, Neuherberg).
• pJG4-6-(2-38)-Risp
pJG4-6 vector that expresses the N-37 amino acids of Risp fused in frame to the B42
transcription activation domain. A 121 nucleotide MluI/NotI fragment containing a
TAG stop codon was PCR amplified from the pcRisp-sg143 plasmid (5’ primer 18733
and 3’ primer 19538) and was inserted into the pJG4-6 vector using the MluI/NotI
cloning site (F. Ceccherini-Silberstein, GSF, Neuherberg).
• pJG4-6-(2-73)-Risp
pJG4-6 vector that expresses the N-72 amino acids of Risp fused in frame to the B42
transcription activation domain. A 226 nucleotide MluI/NotI fragment containing a
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TAG stop codon was PCR amplified from the pcRisp-sg143 plasmid (5’ primer 18733
and 3’ primer 19539) and was inserted into the pJG4-6 vector using the MluI/NotI
cloning site (F. Ceccherini-Silberstein, GSF, Neuherberg).
• pJG4-6-(2-133)-Risp
pJG4-6 vector that expresses the N-132 amino acids of Risp fused in frame to the B42
transcription activation domain. A 406 nucleotide MluI/NotI fragment containing a
TAG stop codon was PCR amplified from the pcRisp-sg143 plasmid (5’ primer 18733
and 3’ primer 19540) and was inserted into the pJG4-6 vector using the MluI/NotI
cloning site (F. Ceccherini-Silberstein, GSF, Neuherberg).
• pJG4-6-(39-171)-Risp
pJG4-6 vector that expresses the C-133 amino acids of Risp fused in frame to the B42
transcription activation domain. A 409 nucleotide MluI/NotI fragment containing a
TAG stop codon was PCR amplified from the pcRisp-sg143 plasmid (5’ primer 20817
and 3’ primer 18510) and was inserted into the pJG4-6 vector using the MluI/NotI
cloning site (F. Ceccherini-Silberstein, GSF, Neuherberg).
• pJG4-6-(74-171)-Risp
pJG4-6 vector that expresses the C-98 amino acids of Risp fused in frame to the B42
transcription activation domain. A 304 nucleotide MluI/NotI fragment containing a
TAG stop codon was PCR amplified from the pcRisp-sg143 plasmid (5’ primer 20818
and 3’ primer 18510) and was inserted into the pJG4-6 vector using the MluI/NotI
cloning site (F. Ceccherini-Silberstein, GSF, Neuherberg).
• pJG4-6-(134-171)-Risp
pJG4-6 vector that expresses the C-38 amino acids of Risp fused in frame to the B42
transcription activation domain. A 124 nucleotide MluI/NotI fragment containing a
TAG stop codon was PCR amplified from the pcRisp-sg143 plasmid (5’ primer 20819
and 3’ primer 18510) and was inserted into the pJG4-6 vector using the MluI/NotI
cloning site (F. Ceccherini-Silberstein, GSF, Neuherberg).
• pB42AD-sRev
The HXB2-Rev-ORF starting from the second codon of pBsRev was PCR amplified
(5’ primer 8726 and 3’ primer 9585) and fused in frame to the B42 transcription
activation domain using the unique restriction site EcoRI into the pB42AD vector
(pJG4-5 derivate-vector, Clontech), (F. Ceccherini-Silberstein, GSF, Neuherberg).
2.2.7. Primers
Oligonucleotides used for DNA amplification and sequence analysis (Table 2.1) were
designed using the software programs Gene Construction Kit™2 and OligoEdit and
were kindly synthesized in the institute AG BIODV (GSF, Neuherberg).
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2.2.8. Buffers and Solutions
All the solutions used for cell culture were sterilized (autoclaved or filtered with
0.22µm filters).
Actinomycin D stock
Actinomycin D 0.1%
Ampuwa H20
Sterilized by filtration. Aliquots 100 µl; stored -20°C
Ampicillin stock
Ampicillin 100mg/ml
Ampuwa H20
Aliquots 500 µl; stored -20°C
Breaking buffer (rapid isolation of plasmid DNA from yeast)
Triton-X-100 2%
SDS 1%
NaCl 100mM
Tris/HCl 10mM (stock 1M pH 8.0)
EDTA 1mM, (stock 0.5M pH 8.0)
Buffer A (CellPhect; Pharmacia Biotech)
CaCl2 0.5M
in HEPES 0.1M pH 7.0
Buffer B (CellPhect; Pharmacia Biotech)
NaCl  0.28M
NaH2PO4  0.75mM
Na2HPO4 0.75mM
in HEPES 0.05 M pH 7.0
Buffer P1 resuspension buffer (Qiagen)
Tris/HCl  50mM pH 8.0
EDTA 10mM
RNAse A 100 µg/ml
Buffer P2 lysis buffer (Qiagen)
NaOH 200mM
SDS 1%
Buffer P3 neutralisation buffer (Qiagen)
Potassium acetate 3M pH 5.5
Buffer QBT equilibration buffer (Qiagen)
NaCl 750mM
MOPS 50mM
EtOH 15%
Triton X-100  0.15%
Buffer QC wash buffer (Qiagen)
NaCl 1M
MOPS 50mM pH 7.0
EtOH 15%
Buffer QF elution buffer (Qiagen)
NaCl  1.25M
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Tris/HCl  50mM pH 8.5
EtOH 15%
Cellular lysis buffer for Western Blot (WB) 5X
Tris/HCl 250mM (stock 1M pH 6.8)
SDS 10%
Glycerin 7.5%
ß-Mercaptoethanol 2.5%
Bromophenol blue 0.1%
Cell culture lysis reagent 5X 30 ml (Luciferase, Promega)
Tris/H3PO4 125 mM pH 7.8
EDTA 10mM
DTT 10mM
Glycerol 50%
Triton X-100 5%
Cycloeximide stock
Cycloeximide 0.2%
Ampuwa H20
Sterilized by filtration. Aliquots 100 µl; stored -20°C
Denhardt’s solution 50X
BSA (fractionV) 1%
Ficoll (type 400) 1%
Polyvinylpyrrolidone 1%
Aqua bidest.
Sterilized by filtration (0.45µm). Stored -20°C
DNA loading buffer
Bromophenol blue 0.25%
Xylencyanol FF 0.25%
Ficoll in Aqua bidest. 15%
Ampuwa H20
Dithiothreitol (DTT)
DTT 1M
Sodium acetate 0.01M pH 5.2
Sterilized by filtration (0.22µm). Aliquots 1 ml; stored -20°C
Ethidium bromide stock
Ethidium bromide 1% (w/v)
Aqua bidest.
Formaldehyde 3.7%
Formaldehyde 3.7% (stock 37%)
in PBS
Glycerol solution
Glycerol 65% (v/v) sterile
MgSO4 0.1 M
Tris/HCl 25 mM pH 8.0
Ampuwa H20
Glyoxal-mixture for Northern Blot
Glyoxal 14.7% (stock 40%; aliquots 50 µl; stored -20°C)
Na2HPO4 10mM (stock 1M pH 7.2)
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DMSO 50%
Ampuwa H20
Hybridization solution for Southern Blot
SSPE 5X
Denhardt’s solution 10X
SDS 2%
Freshly denatured, sheared salmon sperm DNA 0.01%
Ampuwa H20
Sterilized by filtration (0.45µm)
IPTG
Isopropyl-ß-D-thio-galactopyranoside 0.2%
Ampuwa H20
Sterilized by filtration (0.2µm). Aliquots 1 ml; stored -20°C
Leptomycin B stock
Leptomycin B 40µM
Ampuwa H20
Sterilized by filtration. Aliquots 100 µl; stored -20°C
Lithium acetate stock solution 10X pH 7.5
Lithium acetate 1M
Acid acetic
Ampuwa H20
Sterilized by filtration
Luciferase assay reagent 7mg lyophilized (Promega)
When re-hydrated with 10 ml of luciferase assay buffer:
Coenzyme A (lithium salt) 270µM
Luciferin 470µM
ATP 530µM
stored –80°C
Luciferase assay buffer 10 ml (Promega)
Tricine 20mM
(MgCO3)4Mg(OH)2· 5H2O  1.07mM
MgSO4 2.67mM
EDTA 0.1mM
DTT 33.3mM
Na2HPO4  1M pH 7.2
Na2HPO4 1M
H3P04 85%
Ampuwa H20
Autoclaved
Paraformaldehyde 3.7%
Paraformaldehyde 3.7%
in PBS (dissolved at 60°C, filtered with paper filter)
50% PEG 4000
PEG 4000 (or 3350) 50%
Ampuwa H20
Phosphate buffer saline (PBS)  pH 7.4
NaCl 140mM
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KCl 5.4mM
Na2HPO4 x 2H2O 9.7mM
KH2PO4 2mM
Aqua bidest.
Reagent A (BCA kit, Pierce) 1000 ml
Na2CO3   1%
NaHCO3   1%
BCA-Na2  1%
Sodium tartrat   0.16%
in NaOH 0.2N
Reagent B (BCA kit, Pierce) 25 ml
CuSO4   4%
RNA hybridization buffer for glyoxal method
SDS 7%
Na2HPO4 0.5M (stock1M pH 7.2)
Ampuwa H20
RNA loading buffer for glyoxal method
Bromophenol blue 0.4%
Glycerol 50% (stock 50% in Ampuwa H20, autoclaved; aliquots 1 ml; stored -
20°C)
Na2HPO4 10mM (stock 1M pH 7.2)
Sodium dodecyl sulfate (SDS) 10%
Sodium dodecyl sulfate 10% (w/v)
Aqua bidest.
Autoclaved
SDS-electrophoresis running buffer 10X pH 8.3
Tris Base 250mM
Glycin 1.92M
SDS 1% (w/v)
Aqua bidest.
SDS-protein running gel 12% 10%
Tris/HCl (stock 1.5M pH 8.8) 2.5 ml 2.5 ml
Acrylamide + Bisacrylamide (stock 30%) 4 ml 3.33 ml
SDS (stock 10%) 0.1 ml 0.1 ml
Aqua bidest. 3.3 ml 4 ml
TEMED 5 µl 5 µl
APS (stock 10%) 0.1 ml      0.1 ml
SDS-protein stacking gel 4.4%
Tris/HCl (stock 1M pH 6.8) 3.5 ml
Acrylamide + Bisacrylamide (stock 30%) 0.75 ml
SDS (stock 10%) 0.05 ml
Aqua bidest. 3.5 ml
TEMED 5 µl
APS (stock 10%) 0.09 ml
Saline sodium citrate buffer (SSC) 20X
NaCl 3M
Sodium citrate 0.3M pH 7.0
DEPC-treated Aqua bidest.
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Autoclaved
Saline sodium phosphate buffer (SSPE) 20X pH 7.4
NaCl 3M
NaH2PO4 ·H2O  0.2M
EDTA 20mM
DEPC-treated Aqua bidest.
Autoclaved
Stripping buffer for WB
Tris/HCl 62.5mM (stock 1M pH 6.7)
SDS 2%
ß-Mercaptoethanol 100mM
Aqua bidest.
Stripping buffer for Northern Blot
SSC 0.1X
SDS 2%
TBS-T wash buffer 5X pH 7.5
Tris Base 250mM
NaCl 750mM
Tween 20 0.1% (1X)
Aqua bidest.
TE buffer
Tris/HCl 10mM (stock 1M pH 8.0)
EDTA 1mM
Aqua bidest.
TNE buffer pH7.4
Tris/HCl 40mM (stock 1M pH 7.4)
EDTA 1mM (stock 0.5M)
NaCl 150mM
Aqua bidest.
Transfer buffer pH 8.3
Tris Base 25mM
Methanol 20%
Glycine 1.44% (w/v)
Aqua bidest.
Tris acetate EDTA (TAE) buffer 50X pH 8.0
Tris-acetate 2M
NaCl  0.5M
EDTA 50mM (stock 0.5M pH 8.0)
Aqua bidest.
Triton X-100 cell lysis buffer
Triton X-100 0.5%
in PBS
Trypan blue solution
NaCl 0.9%
Trypan blue dyestuff 0.5%
Aqua bidest.
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X-gal
5-Bromo-4-chloro-3-indolyl-ß-D-galactopyranoside 2%
in 100% N,N-dimethylformamide
Wrapped in aluminium foil; stored -20°C
2.2.9.  Media
2.2.9.1.  Bacterial media
E.coli bacteria were grown in Luria Bertani (LB) medium. Transfected bacteria
containing the ampicillin resistance gene cells were grown in LB containing ampicillin
(Amp) at the concentration of 50-100µg/ml.
LB medium pH 7.5
Bacto-tryptone 1%
Bacto-yeast extract 0.5%
NaCl 0.5%
Aqua bidest.
Autoclaved
LB agar plates
LB medium 1000 ml
Bacto agar 15 g
Autoclaved
Amp 100 mg
SOC medium
Complete E.coli medium without selection (Stratagene or Life Technologies)
Glycerol freezing solution
80% Glycerol 2/3
10mM MgCl2
2.2.9.2. Yeast media
Ingredients for liquid or solid media were dissolved in deionized water, mixed until
completely dissolved and autoclaved in bottles (500-1000 ml). Amino acids (dropout
solutions) were prepared in water as stock solutions, filtered (filters 0.22µm) and each
added (8.3 ml/liter) as requested to the complete minimal (CM) media after have been
autoclaved.
Dropout solutions
  Amount in dropout powder (g) Final concentration (mg/ml) Stock (mg/100 ml)
Adenine (hemisulfate salt)  40 500 2.5 RT
L-arginine (HCl) 1.2 20 240 4°C
L-aspartic acid 6.0 100 1200 RT
L-glutamic acid 6.0 100 1200 RT
L-histidine 1.2 20 240 4°C
L-leucine 3.6 60 720 RT
L-lysine (mono-HCl) 1.8 30 360 4°C
L-methionine 1.2 20 240 4°C
L-phenylalanine 3.0 50 600 RT
L-serine 22.5 375 4500 4°C
L-threonine 12.0 200 2400 4°C
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L-tryptophan 2.4 40 480 4°C
L-tyrosine * 1.8 30 180 RT
L-valine 9.0 150 1800 4°C
Uracil 1.2 20 240 RT
*16.6 ml/liter of L-tyrosine was added.
Gal/Raff/CM liquid solid
YNB-AA/AS  0.17%
(NH4)2S04  0.5%
Galactose 2% + Agar 2%
Raffinose 1% + NaOH 0.01%
Autoclaved
Dropout solutions
Glc/CM liquid solid
YNB-AA/AS  0.17%
(NH4)2S04  0.5%
Dextrose 2% + Agar 2%
Autoclaved + NaOH 0.01%
Dropout solutions
Glc/CM  X-gal plates
YNB-AA/AS  0.17%
(NH4)2S04  0.5%
Dextrose 2%
Agar 2%
NaOH 0.01%
Autoclaved
Dropout solutions
KH2P04 0.07M pH 7.0 (Stock 0.7M)
X-gal 0.004% (stock 2% in N,N-dimethylformamide)
Gal/Raff/CM  X-gal plates
YNB-AA/AS  0.17%
(NH4)2S04  0.5%
Galactose 2%
Raffinose 1%
Agar 2%
NaOH 0.01%
Autoclaved
Dropout solutions
KH2P04 0.07M pH 7.0 (Stock 0.7M)
X-gal 0.004% (stock 2% in N,N-dimethylformamide)
YPD medium liquid solid
Yeast extract 1%
Peptone 2% + Agar 2%
Dextrose 2% + NaOH 0.01%
Medium-A 5X
(NH4)2S04  0.5%
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KH2P04 2.25%
K2HP04 5.25%
Sodium citrate x 2H20  0.25%
Autoclaved
Minimal vitamin B1, Trp- plates (1 liter)
Agar 2%
Aqua bidest up to 800 ml
Autoclaved
+ 200 ml Medium-A (stock 5X, autoclaved)
+ 1 ml MgS04 (stock 1M, autoclaved)
+ 10 ml Galactose (stock 20%, autoclaved)
+ 0.1 ml Vitamin B1 (stock 0.5%, filtered)
+ 16.6 ml L-uracil (240 mg/100 ml, filtered)
+ 16.6 ml L-histidine (240 mg/100 ml, filtered)
+ 5.5 ml L-leucine (720 mg/100 ml, filtered)
+ Amp 100 mg
2.2.9.3. Cell culture media
Dulbecco’s modified Eagle medium (DMEM)
with Glutamax I, w/o Na-Pyruvat, 4.5g/l Glucose (Life Technologies)
Complete DMEM
DMEM
Fetal calf serum 10% (heat-inactivated)
AB/AM solution 1% (= 100 units Penicillin, 100µg Streptomycin, und 0.25µg
Fungizone®/ml, Life Technologies)
DMSO freezing medium
Complete DMEM 45%
Fetal calf serum 45%
DMSO 10%
2.3. Molecular biology methods
Many of the molecular biology procedures were performed as described in (Ausubel
et al., 1999; Sambrook, 1989).
2.3.1. Plasmid DNA isolation from E.coli
2.3.1.1.  QIAGEN maxi preparation
The plasmids used in the transfection experiments were prepared with the Qiagen
maxiprep kit, according to the manufacturer’s instructions. Qiagen plasmid
purification protocols are based on a modified alkaline lysis procedure, followed by
binding of plasmid DNA to QIAGEN anion-exchange resin under appropriate salt and
pH conditions. RNA, proteins, dyes, and low molecular weight impurities are removed
by a medium salt wash. Plasmid DNA was eluted in a high salt buffer, concentrated
and desalted by isopropanol precipitation.
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Briefly, plasmids were prepared from E.coli XL-1 bacterial cultures grown in the
presence of a selective antibiotic, generally ampicillin.
A single colony (or 50 µl of a glycerol stock) was inoculated into 5 ml of standard LB
medium in the presence of ampicillin (50 µg/ml), and grown for 4-5 h at 37°C  with
vigorous shaking (260 rpm). The miniculture was diluted 1:100 into a larger volume
of selective medium and grown to saturation (O/N) at 37°C with gently shaking (100
rpm).
The bacterial cells were harvested and centrifuged at 4000 rpm for 20 min at 4°C in
Sorvall RC-5 with GS-3 rotor. The pellet was resuspended in 10 ml of Buffer P1
containing RNase (1 mg/10 ml) and transferred into non-glass tubes for rotor SS3H.
10 ml of Buffer P2 were added, mixed gently, and the mixture was incubated at room
temperature (RT) for 5 min maximum. 10 ml of ice-cold Buffer P3 were added, mixed
gently and the mixture incubated on ice for 20 min. The suspension was centrifuged
at 16000 rpm 30 min at 4°C and the supernatant was transferred into new tube and
recentrifuged at 16000 rpm 15 min at 4°C.  Qiagen column was equilibrated with 10
ml Buffer QBT. Subsequently, the supernatant from the cell lysate was applied to the
column. Plasmid DNA bound to QIAGEN anion-exchange resin was washed twice
with 30 ml Buffer QC and eluted with 15 ml Buffer QF, collecting it in a 50 ml Falcon
tube. The DNA was precipitated with 0.7 vol of RT isopropanol, incubated 5 min at
RT and centrifuged at 5000 rpm for 30 min. The DNA pellet was washed with 15 ml
of 70% ethanol, vortexed, centrifuged 15 min at 5000 rpm, dried for 5-30 min and
redissolved in 1 ml of sterile Ampuwa water. The DNA was stored at -20°C.
2.3.1.2.  QIAGEN mini preparation
This procedure, which isolates rapidly plasmid DNA from bacteria using the alkaline
lysis method followed by isopropanol precipitation, was used during the cloning
process to isolate small amount of DNA from a large number of clones.
Briefly, each single colony was inoculated into 3 ml of LB medium (plus 100µg/ml
Amp) in glass culture tubes and grown O/N at 37°C with vigorous shaking (260
rpm). The next day 1.5 ml of miniculture was transferred in Eppendorf tube and
bacterial cells were harvested centrifuging at 14000 rpm for 2 min.
The pellet was resuspended in 250 µl of ice-cold Buffer P1 containing RNase (1
mg/10 ml) and 250 µl of Buffer P2 were added, mixed gently, and the mixture was
incubated at RT for 2-3 min.  250 µl of ice-cold Buffer P3 were added and mixed
gently. The mixture was incubated on ice for 5-10 min and then centrifuged at 14000
rpm 10 min. The supernatant (~800 µl) was transferred in a new Eppendorf tube and
0.7 vol of isopropanol was added. The suspension was vortexed and recentrifuged at
14000 rpm 15 min. The pellet was washed with 500 µl of 70% ethanol, vortexed,
centrifuged 5 min at 14000 rpm, dried for 5-30 min and redissolved in 50 µl of sterile
Ampuwa water. The DNA was stored at -20°C.
2.3.2. Qualitative and quantitative DNA analysis
To determine the quality and yield, the DNA was measured in an UV
spectrophotometer (Pharmacia Biotech) at 260 and 280 nm, normally diluting 2 µl in
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100 µl of Ampuwa water. The DNA concentration was calculated by the
spectrophotometric conversion 1A260 unit of double-stranded DNA = 50µg/ ml
(Sambrook, 1989). In addition, the ratio A260/A280 was measured. Preparation with a
DNA concentration below of 0.2µg/ml and a ratio below of 1.5 was discarded.
To ensure the correct preparation of the DNA plasmids, the DNAs were analyzed by
one or more restriction enzyme digestions.
0.5-1 µg DNA (from maxiprep) or 5-10 µl DNA (from 50 µl miniprep) were digested
into 1.5 ml Eppendorf tube in 20 µl of total volume containing:
1 µl of enzyme (10U)
2 µl of buffer (10X)
x µl of Ampuwa water up to 20 µl
The mixture was spun down and incubated at 37°C (or recommended temperature)
for 2 h. 0.8-1.2% agarose gel in TAE 1X buffer with ethidium bromide (final
concentration 20 µg/100 ml) was prepared. 2 µl of DNA loading buffer (10X) was
added and mixed to each DNA sample and all content was loaded on the gel and run
for 1-2 h at 50-100 V. The 1-kb-DNA molecular weight marker (Life Technologies)
was used as a standard marker.
2.3.3. DNA transformation into bacteria cells
Two different protocols were used for bacterial transformation. The electroporation
procedure was performed to transform electrocompetent BL21 cells (see 2.3.3.1),
used to produce expression of GST fusion protein, and electrocompetent KC8 cells
(see 2.4.8.), used in the yeast two hybrid system. The heat shock protocol was
performed to transform chemically competent cells such as Epicurian coli XL1-blue
supercompetent cells (see 2.3.3.3) and TOP10F’ cells (see 2.3.4.2).
2.3.3.1. Preparation of electrocompetent cells
A single bacterial colony was inoculated in 10 ml of LB medium in a small glass tube
and incubated O/N at 37°C shaking. The next morning the O/N culture (10 ml) was
inoculated in 200 ml in 1l flask and cells were grown for 2 h to reach OD600 ~0.5.
Subsequently, (working always on ice) the cells were transferred into Beckman
centrifuge-tubes and centrifuged 15 min at 4000 xg in precooled GS-3 rotor at 4°C.
Each cell pellet was washed first in 100% vol with cold and sterile Ampuwa water,
then in 50% vol Ampuwa water and finally in 10 ml of cold 10% glycerol (filtered).
Cells were re-centrifuged 10 min at 4000 xg, resuspended in 600 µl of cold 10%
glycerol, aliquoted (45 µl / sterile Eppendorf tube), frozen in N2 and stored in -80°C
freezer.
2.3.3.2. Plasmid DNA transformation with electroporation
For electroporation, BL21 bacteria cells and the pGEX-3X-Risp plasmid DNA were
thawed on ice.
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1 µl of plasmid DNA (50-100ng) was added to thawed cells (45 µl) and mixed. The
cells were incubated on ice 30 sec and added to ice-cold electroporation cuvette. The
cells were shocked by 1 pulse of 1.8 kV in 3-4msec. After each pulse immediately 900
µl of RT SOC medium were added and the suspension was transferred back to the
original microtube, then incubated 50 min at 37°C shaking. After 1 min of
centrifugation at 2000 rpm, 800 µl of medium was removed, the rest was resuspended
and 100 µl of suspension was plated on prewarmed LB/Amp plates and incubated at
37°C O/N.
2.3.3.3. Plasmid DNA transformation in Epicurian coli XL1-blue supercompetent
cells
The transformation of Epicurian coli XL1-blue supercompetent cells (Stratagene) was
performed according to the manufacturer’s instructions. Briefly, cells were thawed on
ice (~ 15 min) and aliquots of 100 µl of cells, for each transformation (included one for
the vector religation control), were transferred into prechilled 15 ml Falcon 2059
polypropylene tubes. 1.7 µl of the provided β-mercaptoethanol was added to each
tube, mixed gently keeping the tube on ice and incubated for 10 minutes, mixing
occasionally. 1 ng of transforming plasmid DNA or 5 µl of a typical 10 µl ligation
mixture were added to the cells, mixed gently and incubated on ice for 30 min. The
cell/DNA mixtures for exactly 45 seconds were heat shocked at 42°C in a water bath.
Cells were transferred immediately on ice and incubated for 2 min. 900 µl of RT SOC
medium were added to each tube. The tubes were incubated at 37°C for 1 h with
shaking at 250 rpm. Cells were then concentrated by centrifuging at 1000 rpm for 5
min. The pellet was resuspended in 200 µl of SOC medium and 100 µl were spreaded
on prewarmed LB/Amp plates and incubated O/N at 37°C.
2.3.4. Cloning of PCR products
All the new plasmids generated in this work were prepared by subcloning into the
appropriate recipient vector the gene of interest amplified by PCR and containing the
compatible cloning restriction sites.
Briefly, the strategy followed was:
• Design and synthesize 5’and 3’-end PCR primers with the desired restriction sites
• Perform the PCR with the appropriate primers and DNA template
• Clone the PCR product into the pCR®-TOPO® vector
• Transformation of DNA into TOP10F’ cells
• Analysis of TOP10F’ transformants (blue/white selection)
• Plasmid DNA minipreps
• Identification of clones containing the correct DNA insert (restriction analysis)
• Insert DNA sequence analysis
• Preparation of the vector and the insert for cloning (preparative gel/DNA
purification)
• Ligation of plasmid vector and insert DNAs
• Transformation of DNA into E.coli XL1-blue supercompetent cells
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• Plasmid DNA minipreps
• Identification of clones containing the correct DNA insert (restriction analysis)
• Insert DNA sequence analysis
• Store the correct plasmid as DNA and bacteria glycerol stock at -80°C.
2.3.4.1. Amplification of DNA by polymerase chain reaction (PCR)
To amplify DNA the Expand™ High Fidelity PCR system (Roche Molecular
Biochemicals) was used. The system is composed of a unique enzyme mix containing
thermostable Taq DNA and Pwo DNA polymerases (Barnes et al., 1994). This
powerful polymerase mixture is designed to give PCR products with high yeld, high
fidelity and high specificity. The final product has blunt ends and 3’ single A
overhangs. The DNA amplification was performed according to the manufacturer’s
instructions. First, the cycle conditions in the Thermocycler (Perkin Elmer Cetus Gene
Amp 9600) have been adjusted. Generally the PCR reaction (used for PCR fragment
with length up to 1.5 kb) has been performed at the following conditions:
1. 94°C 2 min denaturation of template
2. 94°C 30 sec denaturation
3. 65°C 30 sec annealing        20 cycles
4. 72°C 1 min elongation
5. 72°C 10 min prolong elongation
6.   4°C ∞ reaction end
Subsequently, two master mixes were prepared (in a PCR room, on a laminar flow
cabinet) into sterile microfuge tubes on ice as follows:
•     Mix    1:
dNTPs (10mM) 8 µl
5’ Primer (20µM) 0.75 µl
3’ Primer (20µM) 0.75 µl
Sterile Ampuwa water               up to 49 µl
•     Mix    2:
10X Expand HF buffer (with 15mM MgCl2)          10 µl
Expand HF enzyme mix 0.75 µl
Sterile Ampuwa water                up to 50 µl
Outside the PCR room, working on ice, mix 1 and mix 2 were pipetted into a thin-
walled PCR tube, 1 µl of template DNA (100 ng) was added and immediately the
sample was placed in the thermocycler and the PCR performed. At the end of the
PCR, 5 µl for each sample was analyzed on a 0.8-1% agarose gel.
2.3.4.2. TOPO TA Cloning®
The TOPO TA cloning® (Invitrogen) provides a highly efficient, one-step cloning
strategy for the direct insertion of Taq polymerase-amplified PCR products into a
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plasmid vector. The kit provides a plasmid vector pCR2.1-TOPO supplied linearized
with single 3‘ thymidine (T) overhangs for TA cloning and Topoisomerase. Since
PCR products generated with Taq polymerase or Expand™ High Fidelity enzyme
mix are with blunt ends and 3’ single A overhangs, ligation of the pCR2.1-TOPO
vector with a PCR product is very efficient. The TOPO TA cloning® was performed
according to the manufacturer’s instructions.
Generally 1 µl of fresh PCR product, 1 µl of pCR2.1-TOPO vector and 3 µl of sterile
Ampuwa water were mixed and incubated at RT for 5 min. Subsequently the DNA
mixture was placed on ice and transformed into One Shot™ TOP10F’ cells thawed on
ice.
2 µl of 0.5M β-mercaptoethanol were added to each vial of competent cells and
mixed by stirring gently with the pipet tip.
2 µl of the TOPO cloning™ reaction were added to each vial of competent cells,
mixed gently and incubated on ice for 30 min. Cells were incubated at 42°C for 30
sec, transferred immediately to ice and incubated for 2 min.  250 µl of RT SOC
medium were added and the vials were put in bacterial culture glass tubes and
incubated at 37°C for 30 min with shaking at 250 rpm. 100 µl from each
transformation were spread on LB/Amp plates prewarmed and prespreaded with
IPTG (40 µl of 100mM) and X-gal (40 µl of 40mg/ml) and incubated O/N at 37°C.
The next morning ~12 white or light blue colonies were picked for DNA plasmid
miniprep analysis (digestion and subsequent sequence analysis). The plasmid
containing the correct DNA insert was stored as DNA miniprep or maxiprep at -20°C.
2.3.4.3. Vector and insert preparation
In this study DNA was purified from agarose gels using a modified “Freeze
Squeeze”method (Tautz and Renz, 1982).
Both vector (2-5 µg DNA) and pCR2.1-TOPO-PCRinsert (2-5 µg DNA or 10 µl DNA
miniprep) were digested with the compatible restriction enzymes in 20-40 µl for 3-4h.
If the ends of the prepared vector were identical (e.g., following a single digestion),
the vector DNA was treated for 30 min at RT with 1 µl of calf intestinal alkaline
phosphatase (Roche Molecular Biochemicals) to remove the phosphate groups from
the 5‘ends to prevent self-ligation of the vector.
Both linearized vector and insert were separated by agarose gel electrophoresis using
0.8% high-quality SeaKem agarose. The DNA fragments were then isolated by
cutting the smallest possible volume of gel slice.
2.3.4.3.1. DNA recovery form agarose gel using the freeze squeeze method
To isolate DNA from agarose gel a modified “Freeze Squeeze” method was
performed. Briefly, the gel slice of interest was incubated into 1.5 ml sterile Eppendorf
tube with 1 ml of sodium acetate buffer (NaAcetate 0.5M, EDTA 1mM, pH 5.2) at RT
for 30 min.  Subsequently, the gel slice was dried with a paper towel and transferred
to a perforated 0.5 ml autoclaved freeze squeeze Eppendorf tube containing
siliconized glasswool (Whatman GF/C, φ=2.5cm) and frozen in liquid N2 for 1-2 min.
The freeze squeeze tubes were placed into 1.5 ml sterile tubes without lid and were
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centrifuged at maximum speed, 14000 rpm for 10 min RT. The DNA flow-through was
transferred into a new sterile Eppendorf tube and DNA was precipitated with 2.5 vol
ethanol 100%. After 3 min of incubation at RT, samples were centrifuged at 14000
rpm 15 min, and DNA pellet was washed with ethanol 70%, dried and dissolved in 5-
30 µl of sterile Ampuwa water.
2.3.4.4. Ligation of plasmid vector and insert DNAs
After the vector and insert DNAs have been purified, the concentration of DNA was
estimated by agarose gel electrophoresis along with molecular weight standard (1 µl
sample). The ligation reaction was performed using the T4 DNA Ligase (Life
Technologies) according to the manufacturer’s instructions. The typical ligation
reaction was performed at RT for 2 h, with 50-200 ng of vector DNA (molar ratio of
vector to insert 1:3) in 10 µl of final volume:
1-2 µl of vector
3-5 µl of insert
2 µl of DNA Ligase buffer (5X)
1 µl of T4 DNA Ligase
x µl of Ampuwa water up to 10 µl
To monitor the efficiency of ligation of vector with insert, the linear vector was
subjected to ligation in the absence of the DNA insert.
At the end of the reaction, the mixture samples were placed on ice and 5 µl were
transformed into chemically competent cells (E.coli XL1-blue supercompetent cells).
2.3.5. Analysis of RNA by Northern hybridization
To analyze the size and the expression of the Risp RNA, Northern analysis was
performed. Total RNA was isolated by cellular lysates, run on an agarose gel,
transferred on nylon membrane and detected by hybridization with a radiolabeled
DNA-probe. To successfully isolate and analyze intact RNA some important
precautions were performed: effective disruption of cells, denaturation of
nucleoprotein complexes, inactivation of endogenous ribonuclease (RNase) activity
and purification of RNA away from contaminating DNA and protein (Sambrook,
1989). All disposable plasticware were sterile. Many solutions as well as
nondisposable plasticware were pretreated with diethyl pyrocarbonate (DEPC)
0.05% O/N before sterilization.
2.3.5.1. QIAGEN isolation of total RNA
The isolation and purification of RNA from cell lysates was performed using the
Qiagen RNEasy mini kit according to the manufacturer’s instructions. Briefly, cells
were washed with sterile PBS, trypsinized, diluted in the complete medium, counted
and centrifuged at 1000 rpm for 5 min. 10 µl of the provided β-mercaptoethanol were
added per 1 ml of RLT lysis buffer. Cell pellets were resuspended well with RLT
buffer (350 µl / for up to 5x10 6 cells or 600 µl / for up to 1x107 cells) and frozen at -
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80°C. Frozen lysates were thawed at 37°C for 10 min and were transferred directly
into QIAsheder columns sitting in 2 ml collection tubes and centrifuged at maximum
speed for 2 min. Samples were collected into new tubes and 1 vol of ethanol 70% was
added, creating conditions which promote selective binding of RNA to the RNEasy
membrane. 700 µl of sample were applied to RNEasy mini spin column sitting in 2 ml
collection tubes and centrifuged at 10000 rpm for 15 sec to allow absorption of RNA
to the membrane. If the volume of lysate cells was exceeding 700 µl, all the rest of
suspension was applied to the same RNEasy spin column, using the same collection
tube but discarding each time the flow-through.
The columns were washed with 700 µl of RW buffer and centrifuged at 10000 rpm
for 15 sec. After having transferred the RNEasy spin columns into 2 ml new collection
tubes, 500 µl of RPE buffer (containing ethanol) were added and centrifuged at
10000 rpm for 15 sec. Reusing the collection tubes and discarding the flow-through,
the columns were recentrifuged at maximum speed for 2 min to dry the RNEasy
membrane. The RNEasy spin columns were transferred into 1.5 ml collection tubes
and RNA was eluted with two centrifugation steps at 10000 rpm for 1 min with 40 µl
of sterile Ampuwa water and stored at -80°C.
After this step all procedures were performed keeping RNA samples on ice.
Yield and quality of RNA were analyzed by UV spectrophotometer. The concentra-
tion of RNA was determined by the spectrophotometric conversion 1A260 unit of
single-stranded RNA = 40 µg / ml. The absorbance ratio A260/A280 was determined and
good RNA preparations were considered exhibiting a ratio A260/A280 grater than 1.8
(Sambrook, 1989). RNA (1.5 µl) was also analyzed by agarose gel electrophoresis and
the 28S and 18S ribosomal RNA bands were observed.
2.3.5.2. Agarose gel electrophoresis (glyoxal method)
To perform Northern analysis, a modified glyoxal method (Ausubel et al., 1999;
Sambrook, 1989) was performed. Two hours before starting, the run chamber, combs
and tray were incubated with 0.5% SDS in TE + Proteinase K (10-20 mg/l) for 30-60
min and after washed with DEPC-treated millipore water.
20 µg of total RNA were dried in a speed vac and resuspended in 20 µl of Glyoxal-
mixture, mixed well by pipetting and incubated for 1 h in a water bath at 50°C
(mixing every 30 min for 30 sec).
• Glyoxal mixture for 10 samples:
64 µl Ampuwa H20
2 µl  Na2HPO4 1M pH 7.2
100 µl DMSO
34 µl Glyoxal (40%)
200 µl
After 1 h of incubation on ice, 6µl of RNA loading buffer were added and samples
were loaded into the previously prepared 1% agarose gel without EtBr (because it
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interferes with glyoxal). The gel was run for 4-5 h at 75-80V. The electrophoresis was
performed until the bromophenol blue has migrated 2/3 of the gel.
• Loading buffer
1 ml 50% Glycerol  (autoclaved, 1 ml aliquots stored at -20°C)
10 µl Na2HPO4 1M pH 7.2         
0.4 g Bromophenol blue
• Agarose gel
Agarose 1%     
Na2HPO4 10mM pH 7.2
Ampuwa H20
• Running buffer
Na2HPO4 10mM pH 7.2
2.3.5.3. Transfer of RNA to membrane
At the end of the electrophoresis, the gel was soaked in NaOH 0.05M for 5-15 min to
partially hydrolyze RNA. The gel was then rinsed in sterile DEPC-treated Millipore
water. In the meanwhile twelve pieces of Whatman 3MM paper and one piece of
nylon membrane (Zeta–Probe® GT blotting membrane, BioRad) were cut to the exact
size of the gel, soaked first in sterile DEPC-treated Millipore water and after in SSC
10X (prepared with DEPC-treated Millipore water and autoclaved). The transfer of
RNA to membrane was performed by capillar blotting O/N at RT (Sambrook, 1989).
To control the RNA on the filter, the membrane was first incubated for 10 min in a
solution of sodium acetate 0.3M pH 5.2 containing 0.02% methylen blue and after
washed in SSC 2X for 2-5 min. The filter was photographed, baked at 80°C for 1 h
and stored at RT.
2.3.5.4. Probe hybridization
Before the hybridization step, the filter was washed in SSC 0.2X and SDS 1% at RT
for 20-30 min, changing several times the buffer.
The filter was then placed in a heat sealable glass tube and pre-hybridized for 1 h in
rotation at 65°C in 10 ml of hybridization solution. The DNA probe was prepared,
denatured at 100°C for 5 min, quick chilled on ice and added in 7-10 ml of fresh
prepared and prewarmed hybridization solution at the final concentration of 106
cpm/ml. The filter was hybridized in continuous rotation O/N at 65°C. It was washed
twice with 50-100 ml of wash buffer I at 65°C for 20-30 min and twice with 50-100
ml of wash buffer II at 65°C for 20-30 min. The radioactive filter was wropped in
plastic (without allowing to dry) and normal autoradiography was performed. To
reprobe the filter, it was washed in a large volume of stripping buffer at 95°C for 20
min.
As a positive control for RNA levels, the filter was re-hybridized with a GAPDH
[α32P]-labeled probe, using a GAPDH insert of 1.3 kb (PstI-PstI) from a GAPDH
expression pBSPL-plasmid (kindly provided by Dr. M. Stuerzl, GSF).
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• Hybridization solution
Na2HPO4 0.5M pH 7.2
SDS 7%
• Stringency wash buffer I Stringency wash buffer II
Na2HPO4 40mM pH 7.2 Na2HPO4 40mM pH 7.2
SDS 5% SDS 1%
• Stripping wash buffer
SSC 0.1X
SDS 0.5%
To increase the sensitivity of blot hybridization UlTRAhyb™ Ultrasensitive
Hybridization Solution (Ambion) has been also tried once. This solution maximizes
the sensitivity by increasing hybridization signal without increasing background.
According to the manufacturer’s instructions, the UlTRAhyb™ was preheated at
68°C before use and 10 ml were used to prehybridize the filter for 30 min at 42°C.
The hybridization was performed at 42°C O/N and filters were washed at 42°C twice
with SSC 2X and SDS 0.1% for 5 min and twice with SSC 0.1X and SDS 0.1% for 15
min.
2.3.5.5. Radioactive labeling of DNA
2.3.5.5.1. Radioactive PCR
One of the methods performed to incorporate 32P in the DNA probe was a PCR
using α[32P] dCTP with standard cycle conditions (see 2.3.4.1). The PCR reaction
mixture was prepared by adding mix 1 to mix 2:
• Mix 1:
dATP (10mM) 1 µl
dGTP (10mM) 1 µl
dTTP (10mM) 1 µl
α[32P] dCTP (0.1mM) 7 µl
5’ Primer (20µM) 1 µl
3’ Primer (20µM) 1 µl
Sterile Ampuwa water                                   11 µl
DNA (10ng/µl) 1 µl
• Mix 2:
10X Expand HF buffer (with 15mM MgCl2)    4 µl
Expand HF enzyme mix 0.75 µl
Sterile Ampuwa water                                   10.25 µl
The PCR product was subsequently centrifuged and purified using NucleoSpin PCR
purification kit (Macherey-Nagel). 60 µl of TE buffer pH 8.0 and 400 µl of NT2 buffer
were added to the 40 µl of PCR and mixed. The sample loaded into a NucleoSpin
tube previously placed into a 2 ml centrifuge Eppendorf was centrifuged at 6000 xg
for 1 min. After discarding the flow-through, NucleoSpin tube was washed twice with
700 µl of NT3 buffer (containing ethanol) at maximum speed for 1 min. It was dried
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by centrifugation and DNA was eluted in 40-70 µl of NE buffer by centrifugation at
maximum speed for 1 min. 2 µl of probe were diluted in 10 ml of scintillation fluid and
the specific activity of the probe was measured in a liquid scintillation counter
(Kontron).
2.3.5.5.2. Rediprime™ II random prime labeling system
Alternatively, the system Rediprime™ II (Pharmacia), which uses random sequence
hexanucleotides to prime DNA synthesis on denatured template DNA at numerous
sites along its length, was used to radiolabel DNA. Using Klenow fragment of DNA
polymerase I, non-radioactive nucleotides were substituted with the radiolabeled
equivalent in the reaction mixture, and newly synthesized DNA was made
radioactive. According to the manufacturer’s instructions, 50 ng of DNA was diluted
in 45 µl of TE buffer pH 8.0 in a 1.5 ml sterile centrifuge tube, heat denatured at 95-
100°C for 5 min and snap cooled on ice for 5 min. After a brief spin down, all the
DNA denatured was added to the reaction Rediprime™ II tube. 5 µl of α[32P] dCTP
were added, mixed by pipetting up and down about 12 times, and the reaction
mixture was incubated at 37°C for 10 min. The reaction was stopped by adding 50 µl
of TE buffer and DNA was denatured by heating to 95-100°C for 5 min and snap
cooled on ice for 5 min. After a brief spin down, the radiolabeled DNA was purified
using Bio-Spin Chromatography columns (BioRad) according to the manufacturer’s
instructions.
2.3.6. Analysis of DNA by Southern hybridization
Risp DNA analysis was performed using positively charged nylon membrane
(Clontech’s ZOO-BLOT) containing EcoRI-digested genomic DNAs derived from 9
eukaryotic species: human, monkey (Rhesus), rat (Sprague-Dawley), mouse (Balb/c),
dog, cow, rabbit, chicken and yeast (Saccharomyces cerevisiae). The hybridization
was performed according to the manufacturer’s instructions. The hybridization
solution was first warmed at 50°C and used to prehybridize the filter for 6 h at 65˚C.
100µg/ml of freshly denatured, sheared salmon sperm DNA were added to the
prehybridization and hybridization solution. The hybridization was performed at
65˚C O/N with 1-2 x106 cpm/ml radioactively labeled DNA probe. The hybridized
filter was washed under non stringent conditions for detection of genomic sequences
with low homology. First it was washed with SSC 2X and SDS 0.05% for 40 min at
RT with several changes of wash solution and after for 40 min at 63˚C. The
radioactive filter was wropped in plastic and normal autoradiography was performed.
2.4. Yeast two hybrid system
2.4.1. Background
To identify new Rev-interacting factors the interaction trap/two-hybrid system has
been used (Fields and Song, 1989; Golemis et al., 1999; Gyuris et al., 1993). This
method is a useful sensitive approach to detect protein-protein interactions that uses
yeast as a test vehicle and transcriptional activation of a reporter system. The two-
hybrid approach takes advantage of the modular domain structure of eukaryotic
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transcription factors. This modular structure consist at least of two distinct functional
domains, one that directs binding to specific DNA sequences and one that activates
transcription. The DNA binding and activation domains need not to be covalently
attached to each other for activation; and they can be exchanged between
transcription factors and retaining the function. In this work the interaction trap
developed by Gyuris et al. has been used (Brent and Finley, 1997; Gyuris et al., 1993)
that consists of three critical components (Fig. 2.2):
1) The vector pEG202 (see 2.2.6.3.1.) that directs the expression of the HIV-1 Rev
bait protein fused to the DNA-binding domain of the bacterial LexA transcription
factor.
2) The pJG4-5 library plasmid (see 2.2.6.3.2.) that directs the conditional expression
of a Jurkat T cell cDNA library fused at their amino termini to a moiety containing
three domains: the SV40 nuclear localization signal, the activation domain of the
bacterial B42 transcription factor, and the hemagglutinin (HA) epitope tag. The
activation-tagged cDNA-encoded protein is expressed from the conditional yeast
GAL1 promoter, which is induced by galactose and repressed by glucose.
3) A trap that uses the EGY48 yeast strain expressing two reporter genes with
binding sites for the LexA DNA-binding domain in the promoter. One reporter is the
yeast LEU2 gene that has its normal upstream regulatory sequences replaced by three
high affinity LexA operators and integrated into the yeast chromosome. The yeast
growth is limited in the absence of leucine unless the LexAop-LEU2 gene is
transcribed. The other reporter gene is the bacterial LacZ, which can be expressed by
the plasmid pJK103 or by pSH18-34. These LacZ reporters contain part of GAL1
promoter plus various number of LexA operators, 1 in the PJK103 and 8 in the
pSH18-34 reporter gene plasmids. In addition to the mutation in the endogenous
LEU2 gene, EGY48 strain carries mutations in three other marker genes (his3, trp1,
and ura3) that are needed to allow selection of the plasmids used in the interaction
trap. The his3 mutation is complemented by the HIS3 gene on the pEG202-bait
expression vector. The trp1 and ura3 mutations are respectively complemented by
the TRP1 gene on the pJG4-5 library plasmid, and the URA3 gene on the lacZ
pJK103 or PSH18-34 reporter plasmid (Fig. 2.2).
The preparation and the characterization of the Rev-LexA expression plasmid as well
as part of the test screening was made by Dr. Alexandra Ludvigsen and Petra
Willnauer, members of IMV/GSF.
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Fig. 2.2 The principle of the interaction trap. In glucose medium the GAL1 promoter
is repressed and no cDNA-encoded protein is made. The expression of Rev (bait) protein fused
with the binding domain of LexA and the corresponding binding to LexA operators upstream of
the reporter genes LEU2 and LacZ are not enough to activate their transcription and the yeast
does not grow in the absence of leucine. When the yeast is grown on galactose medium,
activation-tagged cDNA-encoded proteins are expressed, and those that interact with Rev
activate transcription of the reporter genes LEU2 and LacZ, allowing the yeast to grow in
galactose medium lacking leucine and form blues colonies on galactose X-gal plates.
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Brielfly, the main steps of the interaction trap performed to identify new Rev-
interacting factors were:
• Construction of bait protein plasmids (pEG202-sRev sense, pEG202-sRev anti-sense,
pEG202-LexCD2)
• Transformation of yeast EGY48 cells with pSH18-34 or pJK103 reporter plasmid
• Transformation of EGY48/pSH18-34 and EGY48/pJK103 cells with pEG202-sRev sense
plasmid
• Characterization of bait protein expression and activity
• Large scale transformation of EGY48/pSH18-34/pEG202-sRev and EGY48/pJK103/
pEG202-sRev cells with pJG4-5 Jurkat-cDNA library plasmid
• Collection of primary transformants (8 x 24x24-plates), stored 25 aliquots 1-ml at -80°C
• Screening for Rev-interacting clones:
Thaw one aliquot and plated on 20 100-mm Gal/Raff U-, H-, W-, L- plates
Collection of clones after 2d, 3d, 4d
• Test for Gal-dependence:
Stop GAL1 promoter induction by plating clones in Glc/U-, H-, W- plates
Plated on Gal/Raff U-, H-, W-, L-; Gal/Raff U-, H-, W-, X-gal; Glc/ U-, H-, W-, L-; and
Glc/ U-, H-, W-, X-gal plates
Selection of clones by growth into Gal/Raff L- and blue in Gal/Raff X-gal plates
• Isolation of plasmid-DNA from yeast clones and transformation in KC8-bacteria
• Selection of pJG4-5 library plasmid:
Replica-plating on VitB/W- andVitB/W-, H- plates with KC8-bacteria
Selection of clones by growth into VitB/W- plates and no growth into VitB/W-, H- plates
• Isolation of plasmid-DNA by miniprep, restriction analysis
• Screening for specific Rev interacting proteins:
Transformation of cDNA library plasmids into yeast:
             EGY48 / pSH18-34 / Rev sense
        “                 “    / Rev as      
        “                 “   / LexCD2
Selection of transformants for each cDNA clone (growth in Glc/ U-, H-, W- plates)
Plated on Gal/Raff U-, H-, W-, L-; Gal/Raff U-, H-, W-, X-gal; Glc/ U-, H-, W-, L-; and
Glc/ U-, H-, W-, X-gal plates
Selection of clones by growth into Gal/Raff L- and blue in Gal/Raff X-gal plates
• DNA maxiprep of positive clones and sequence analysis
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2.4.2. Determination of yeast cell density
The density of cells in culture was determined spectrophotometrically by measuring
its optical density (OD) at 600 nm. For reliable measurements, cultures were diluted
such that the OD600 was <1. In this range, each 0.1 OD600 unit correspond to ~ 3x10
6
cells/ml.
2.4.3. DNA transformation into yeast cells using lithium acetate procedure
The lithium acetate method is based on the fact that alkali cations make yeast
competent to take up DNA and provides high transformation efficiency of 104 to 106
transformants/µg.
At least two days before the experiment a single EGY48 yeast colony was inoculated
in 5 ml of medium (YPD or CM dropout medium according to the yeast culture) and
grown O/N to saturation at 30°C. (Some times the saturated overnight culture was
stored for few days at 4°C and used <2 weeks).
The night before transformation an appropriate amount (5 to 25 µl) of the saturated
culture was inoculated into a 1 l sterile flask containing 50 ml medium and grown O/N
at 30°C to reach ~1x107 cells/ml (OD600 0.3 to 0.5). At this point cells were diluted to
2x106cells/ml (OD600 ~0.1) in fresh medium and grown for another 1 to 2 generations
(2 to 5 h).
After that procedure, the yeast cells were harvested by centrifuging 5 min at 5000
rpm in Sorvall GS rotor at RT, resuspended in 10 ml sterile Ampuwa water, transferred
to smaller centrifuge tubes and centrifuged again 5 min at 7000 rpm in SS-34 rotor at
RT.  Pellet cells were resuspended in 1.5 ml buffered lithium solution, freshly prepared
as follows:
1 vol 10X TE buffer, pH 7.5
1 vol 10X lithium acetate stock solution
8 vol Sterile Ampuwa water.
Cells were incubated for 1 h at 30°C and after were transformed. (Some times the
yeast cells were stored at 4°C in this solution and used <2 weeks).
For each transformation, 200 µg freshly denaturated high-molecular-weight carrier
DNA with 5 µg transforming DNA were mixed into a sterile 1.5 ml microcentrifuge
tube. Total volume of DNA was kept <20 µl. Immediately 200 µl of yeast suspension
and 1.2 ml PEG solution freshly prepared as follows, were added:
1 vol 10X TE buffer, pH 7.5
1 vol 10X lithium acetate stock solution
8 vol 50% PEG.
Cells were shaken 30 min at 30°C; heat shocked 15 min at 42°C and centrifuged 5
sec at RT. Finally, yeast cells were resuspended in 200 µl to 1 ml of 1X TE buffer
freshly prepared. 200 µl of yeast suspension were plated onto CM dropout plates,
incubated at 30°C until transformants were appearing (normally 2-5 days).
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2.4.3.1. Preparation of single-stranded high-molecular-weight carrier DNA
Addition of denatured (single-stranded) high-molecular-weight carrier DNA is critical
to achieve high transformation efficiency using the lithium acetate method.
1 g of DNA (type III sodium salt form salmon testes; Sigma D1626) was dissolved in
100 ml TE buffer (pH 8.0) and was stirred O/N at 4°C. The viscous solution of DNA
was subsequently sonicated several times at 75% power for 30 sec. An aliquot of
DNA was run on a 0.8% agarose gel to check the size distribution of sonicated
fragments. The sonification was considered complete when the fragments were
distributed in a range from 2 kb to 15 kb, with a mean size of ~7 kb.
The DNA was extracted firstly with 1:1 (vol/vol) phenol/chloroform and then with
chloroform alone. Afterwards the DNA was precipitated with 1/10 vol of 3M sodium
acetate (pH 5.2) and 2.5 vol of ice-cold 100% ethanol centrifuging 15 min at 12000
xg.
The DNA pellet was washed with 70% ethanol, centrifuged, dried and resuspended in
sterile TE buffer to a 10mg/ml final concentration.
The suspension was stirred O/N at 4°C and after a boiling-denaturation for 2-3 min
was transferred in ice-water bath. Finally, the DNA was aliquoted into sterile tubes
and stored at -20°C.
2.4.4. Preparation and test of the Rev bait protein
Firstly, pEG202 bait plasmids expressing wt Rev, in sense and antisense orientation,
and the cytoplasmic domain of CD2 were produced. In a second step, using the
lithium acetate procedure, the yeast strain EGY48/pJK103 containing the two LexA
operator-responsive reporters (leucine and LacZ) was transformed with the plasmids
pEG202-sRev sense, pEG202-sRev antisense and pEG202-LexCD2. In parallel,
EGY48 yeast cells were transformed with the pSH18-34 plasmid in presence and
absence of the bait plasmids pEG202-sRev sense, pEG202-sRev antisense and
pEG202-LexCD2. Since the lacZ reporter gene expression plasmids pSH18-34 and
pJK103 and the bait expression plasmid pEG202 harbor the URA3 and HIS3 genes
respectively (see 2.2.6.3.1.), transformants were selected by the growth in Glc/CM
Ura-, His-, dropout plates.
Series of control experiments were performed to establish that the bait protein is made
as stable protein in yeast and that it does not appreciably self-activate transcription of
the LexA operator-based reporter genes.
The test for self-activation was performed picking a colony of EGY48 yeast
containing pBait and pSH18-34/or pJK103 reporter plasmids into 500 µl sterile water.
100 µl of suspension were diluted into 1 ml sterile water and a series of 1/10 dilutions
were prepared in sterile water to cover a 1000-fold concentration range. 100 µl from
each tube (undiluted, 1/10, 1/100, 1/1000) were spreaded out on 100-mm Gal/Raff Ura-
, His- and Gal/Raff Ura-, His-, Leu- dropout plates and then incubated at 30°C. In
addition, background of LacZ expression in the selection strains was also tested. For
this selection 100 µl from each yeast suspension undiluted was plated on Glc/CM
Ura-, His-, X-gal plates. The growth of cells was monitored for several days. Yeast
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strains that grew well on plates with leucine and did not grow on plates lacking
leucine, and were white on plates containing X-gal were chosen for the further use.
To confirm expression of Rev protein each yeast strain harboring the bait plasmid was
analyzed by western blot. A single colony of EGY48 yeast containing pBait and
pSH18-34/or pJK103 reporter plasmids was grown in 5 ml of Glc/CM Ura-, His- liquid
dropout medium O/N at 30°C. 1/10 of the O/N culture was inoculated into a fresh 5ml
culture and incubated at 30°C for 5-6 h (OD600 = 0.5-1). After that 1.5 ml of yeast
culture was transferred into microcentrifuge tubes, the yeast were spun down and the
pellet dissolved in 50 µl of western blot lysis buffer.
2.4.5. Large scale cDNA library transformation
In order to obtain a high number of primary transformants expressing an individual
library plasmid, each yeast strain was transformed in large scale in 30 different sterile
tubes.
Each yeast selection strain EGY48/pSH18-34 and EGY48/pJK103 containing the
pEG202-sRev sense plasmid was grown in 20 ml of Glc/CM Ura-, His- liquid dropout
medium O/N at 30°C.
The next morning, the cultures were diluted into 1 l sterile flasks into 300 ml of
Glc/CM Ura-, His- liquid dropout medium to 2x106cells/ml (OD600 = 0.1) and incubated
at 30°C to reach 1x107 cells/ml (OD600 ~ 0.5).
After that step, the yeast cells were harvested by centrifuging 5 min at 1000-1500 xg
in a low-speed centrifuge at RT, resuspended in 30 ml sterile Ampuwa water,
transferred to 50 ml conical tubes and centrifuged again 5 min at 1000 xg at RT.
The cells were resuspended in 1.5 ml 0.1 M lithium acetate/TE buffer.
For each yeast selection strain transformation, 50 µg high-quality sheared salmon
sperm carrier DNA with 1 µg pJG4-5 library DNA plasmid were added in 30 sterile 1.5
ml microcentrifuge tubes (total volume of library and carrier DNA was kept <20 µl).
Immediately 50 µl of the resuspended yeast solution and 300 µl of sterile 40% PEG
4000 were added and after inverting the tubes, cells were shaken 30 min at 30°C.
40 µl of DMSO were added, the tubes were inverted and heat shocked 10 min at
42°C.
All the content of 28 tubes plus 360 µl from the other 2 tubes was mixed and plated
undiluted on 8 24x24-cm Glc/CM Ura-, His-, Trp- dropout plates (~1.2 ml/plate). The
remaining 40 µl of the 2 tubes were used to make a series of 1/10 dilutions in sterile
water (1/10, 1/100, 1/1000) and spreaded on 100-mm Glc/CM Ura-, His-, Trp- dropout
plates. All the plates were then incubated at 30°C for 2-3 days expecting colonies.
The dilution series were performed to calculate the transformation efficiency.
2.4.5.1. Preparation of sheared salmon sperm DNA (sssDNA)
200 mg of high-quality salmon sperm DNA (type III sodium salt form salmon testes;
Sigma D1626) were dissolved in 20 ml TE buffer (pH 7.5) and were stirred O/N at
4°C. The viscous solution of DNA was subsequently sheared by sonicating 2-3 times
at 75% power for 30 sec. A small aliquot of DNA was run on a 0.8% agarose gel to
check the size distribution of sonicated fragments. The sonification was considered
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complete when the fragments were distributed in a range from 2 kb to 15 kb, with a
mean size of ~7 kb.
The sssDNA was extracted by mixing with an equal volume of TE-saturated buffered
phenol in a 50 ml conical tube, shaking vigorously and centrifuged 5-10 min at 3000
xg. The extraction was repeated using 1:1 (vol/vol) buffered phenol/chloroform and
once with chloroform alone. Afterwards the DNA was transferred in tubes suitable for
high-speed centrifugation and precipitated with 1/10 vol of 3M sodium acetate (pH
5.2) and 2.5 vol of ice-cold 100% ethanol centrifuging 15 min at 12000 xg.
The DNA pellet was washed with 70% ethanol, centrifuged, dried and resuspended in
sterile TE buffer to 10mg/ml final concentration.
The resuspension was denatured for 20 min in a 100°C water bath then immediately
transferred in ice-water bath. Finally, the DNA was aliquoted in sterile tubes and
stored at -20°C.
2.4.5.2. Collection of primary transformants
The 8 24x24-cm Glc/CM Ura-, His-, Trp- dropout plates containing the primary
transformants from each strain were cooled for several hours at 4°C to harden the
agar. Wearing gloves and using sterile glass microscope slides, yeast cells were gently
scraped and collected in 50 ml conical tubes. The cells were washed twice with sterile
TE buffer and centrifuged 5 min at 1000-1500 xg RT. The pellet of cells was
resuspended in 1 vol glycerol solution and frozen in aliquots (1ml) at -70°C.
To determine the replating efficiency 200 µl of 1 ml aliquot of frozen transformed
yeast was diluted 1/10 in Gal/Raff/CM Ura-, His-, Trp- dropout medium and incubated
with shaking for few hours at 30°C to induce the GAL promoter on the library. Serial
dilutions of yeast cells were plated on 100-mm Gal/Raff/CM Ura-, His-, Trp- dropout
plates and incubated at 30°C until colonies were visible. Yeast colonies were
counted and the number of cfu per aliquot of transformed yeast was determined.
2.4.6. Screening for interacting proteins
To select for transcription of the LEU2 reporter gene, 200 µl of each transformed
yeast strain were incubated O/N in 300 ml of Gal/Raff/CM Ura-, His-, Trp- medium.
Cultures were plated on 20 100mm Gal/Raff/CM Ura-, His-, Trp-, Leu- dropout plates
and incubated 2-4 days at 30°C.
3 series of new Gal/Raff/CM Ura-, His-, Trp-, Leu- master dropout plates picking
colonies at day 2, 3 and 4 were prepared.
To test for Gal dependence of the Leu and LacZ phenotypes (to confirm that they are
attributable to expression of the library-encoded proteins) the GAL1 promoter was
turned off in the presence of glucose. For this purpose the Leu+ clones were replated
from the Gal/Raff/CM Ura-, His-, Trp-, Leu- dropout plates to 100-mm Glc/CM Ura-,
His-, Trp- dropout plates and incubated at 30°C until colonies were growing.
With all yeast clones replica plating was performed using different dropout selection
plates:
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Gal/Raff/CM Ura-, His-, Trp-, Leu-
Glc/CM Ura-, His-, Trp-, Leu-
Gal/Raff/X-gal/CM Ura-, His-, Trp-
Glc/X-gal/CM Ura-, His-, Trp-.
The colonies were considered positive if they were blue on Gal/Raff/X-gal/CM Ura-,
His-, Trp- but not on Glc/X-gal/CM Ura-, His-, Trp- dropout plates and if they grew on
Gal/Raff/CM Ura-, His-, Trp-, Leu- but not on Glc/CM Ura-, His-, Trp-, Leu- dropout
plates.
2.4.7. Rapid isolation of plasmid-DNA from yeast
Plasmid DNA is released from yeast transformants along with chromosomal DNA in a
rapid protocol by vortexing cells with glass beads in the presence of detergents,
phenol, chloroform, and isoamyl alcohol.
Each single yeast colony was inoculated into 2 ml of medium in sterile glass tubes.
The yeast cells were grown O/N at 30°C at 200 rpm.
From each of the O/N cultures 1.5 ml was transferred in a new microcentrifuge tube
and spun 5 sec at high speed RT. The supernatant was removed and the pellet was
briefly vortexed. Cells were resuspended in 200 µl of breaking buffer (see 2.2.8.). 0.3
g of glass beads (0.45-0.52 mm acid-washed, ~200 µl) and 200 µl of
phenol/chloroform/isoamyl alcohol (25:24:1) were added and vortexed for 2 min at
highest speed. The suspension was centrifuged 5 min at high speed at RT, and 50 µl
of the aqueous layer was transferred in a new microcentrifuge tube and stored at -
20°C.
2.4.8. Transformation of plasmid DNA in E.coli KC8 by electroporation
Firstly E.coli KC8 were made electrocompetent and aliquoted at -80°C (see 2.3.3.1).
To perform the electroporation with plasmid DNA, KC8 bacteria cells and DNA were
thawed on ice.
2 µl of plasmid DNA was added to thawed cells, mixed, and added to ice-cold
cuvettes. The cells were shocked by 1 pulse of 1.8 kV in 3-4msec. After each pulse
immediately 900 µl of SOC medium were added and the suspension was transferred
back to the original microtube, then incubated 1 hour at 37°C shaking. After 2 min of
centrifugation at 5000 rpm, 800 µl of medium was removed, the rest was resuspended
and 50 µl of suspension was spreaded in LB/Amp plates and incubated at 37°C O/N.
2.4.9. Selection of library plasmid in E.coli KC8 using vitamin B1 plates
The inability of E.coli KC8 to grow in absence of tryptophan was used to select
bacteria containing the library plasmid with the yeast TRP1 gene on the pJG4-5
library plasmid. Bacteria containing library plasmids were selected by growing on
minimal plates supplemented with vitamin B1, ampicillin, uracil, histidine, and leucine
and lacking tryptophan. Firstly 30-40 transformed bacteria by each LB/Amp plate
were transferred in a special scheme in a new LB/Amp master plate and incubated at
37°C O/N. Using sterile nylon filters replica plating was performed. The nylon filters
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were cautiously brought first in contact with clones on the masterplate and
subsequently put on minimal vitamin B1, Trp- plates and on minimal vitamin B1, Trp-,
His- plates.
Clones containing the pJG4-5 library plasmid were selected by the growth on plates
lacking tryptophan. Bacteria growing on plates in the absence also of histidine were
expressing the HIS3 gene by the bait pEG202 plasmid and were excluded.
Single bacteria clones containing the pJG4-5 library plasmid were picked from the
minimal vitamin B1, Trp- plates and transferred in new LB/Amp plates to isolate DNA
and analyzed by enzyme digestion.
2.4.10. Screening for specific interacting proteins
To select only specific Rev-interacting proteins the rescued library plasmid DNAs
were retransformed in the original yeast strains containing the bait plasmids
(expressing Rev in sense and antisense orientation and the unspecific bait CD2).
DNAs were separately transformed using the lithium acetate procedure in:
EGY48/pSH18-34/pEG202-sRev sense
  pEG202-sRev antisense
           pEG202-LexCD2
or in:
  EGY48/pJK103/  pEG202-sRev sense
         pEG202-sRev antisense
                     pEG202-LexCD2.
Each transformation was plated on Glc/CM Ura-, His-, Trp- dropout plates and
incubated at 30°C for 2-3 days until colony growth was detected. Four to six
independent colonies from each transformation plate were replated on Glc/CM Ura-,
His-, Trp- master dropout plates and incubated O/N at 30°C. With the same series of
yeast clones replica plating was performed using the following different selection
plates:
Gal/Raff/CM Ura-, His-, Trp-, Leu-
Glc/CM Ura-, His-, Trp-, Leu-
Gal/Raff/X-gal/CM Ura-, His-, Trp-
Glc/X-gal/CM Ura-, His-, Trp-.
Clones were considered positive when growing without Leu and showing X-gal
conversion only in the presence of galactose and not of glucose.
2.4.11.  Sensitive and semi-quantitative Lac Z dot-blot assay
For some clones LacZ activity was also/only analyzed using a sensitive and semi-
quantitative dot-blot assay (Essers and Kunze, 1996).
After the transformation, yeast cells were resuspended in 600 µl of 1x TE buffer
freshly prepared. 200 µl were inoculated in 5 ml of Glc/CM Ura-, His-, Trp- dropout
medium and incubated at 30°C 1-3 days until the OD600  >1. Yeast cells that grew
more rapidly were kept at 4°C.  Once each yeast clone was with the OD600  >1, 500 µl
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of each were added in 5 ml of fresh dropout medium Glc/CM Ura-, His-, Trp-, Gal/Raff
Ura-, His-, Trp- and Gal/Raff/CM Ura-, His-, Trp-, Leu-. The cultures were then
incubated for few (3-5) hours until they reached the same OD600  ~ 0.8 to obtain
equal cell densities. Aliquots of 25 µl, 100 µl and 500 µl were transferred onto nylon
filter by vacuum filtration in a standard dot-blot chamber. The 25 and 100 µl
suspension volumes were diluted with sterile water to achieve a more even
distribution of cells within the dot area. The nylon filters were submerged in liquid
nitrogen for 10 sec to crack the cells and then placed onto X-gal plates (100mM
Na2PO4 pH 7.0, 10mM KCl, 1mM MgSO4, 1mM DTT, 14 g/l agar, 40-200 mg/l X-gal).
The filters on the plates were incubated at 37°C until the blue colour was clearly
visible (O/N - 24 h).
2.5. Biochemical methods
2.5.1. Cell culture  
Cells were maintained under standard cell culture conditions in Dulbecco’s modified
Eagle medium, with Glutamax-I, without Na-Pyruvat, and with 4.5 g/l of Glucose.
Media were supplemented with 10% fetal calf serum, 1% antibiotic-antimycotic
solution (100 units of penicillin, 100µg streptomycin and 0.25µg fungizone/ml). Cells
were kept in culture for serial passages (maximum 50), and were expanded 1:5 – 1:10
twice weekly by trypsinization. Primary fetal astrocytes (H4/96 passages 3-4) (kindly
provided by Dr F. Aloisi, ISS, Rome) were maintained under standard cell culture
conditions in Minimal essential medium D-valine (Life Technologies) containing 10%
fetal calf serum, Glutamine 2mM and Gentamicin 1% (Aloisi et al., 1992).
2.5.1.1.  Plasmid-DNA transfection of adherent cells
Cells were transfected either by calcium phosphate (CaPO4) coprecipitation method
with a commercially available kit (CellPhect; Pharmacia,) or using FuGENE™ 6
transfection reagent (Roche Molecular Biochemicals) according to the
manufacturer’s instructions. One day before transfection, cells were seeded at
densities between 4-8x105 cells per 60-mm diameter dish or at densities between 1-
4x105 cells per 35-mm diameter dish depending on the cell line. Plasmids were purified
with Qiagen DNA purification columns according to the manufacturer’s instructions.
2.5.1.1.1.  Calcium phosphate method
Using the CaPO4 coprecipitation the correct amount of DNA was mixed with CaCl2
and dropped onto a phosphate buffer containing Hepes solution. At the correct pH of
7.1 a CaPO4 precipitate is formed. Part of the phosphate backbone of the DNA takes
part in this process leading to a coprecipitation of the DNA.
DNA was always filled up with pBSPL bluescript vector to total amount of 17 µg/60-
mm diameter dish or 8.5µg/35-mm diameter dish. In each experiment, the same plasmid
mixture was added to at least two dishes of cells.
After warming up all reagents to RT, in a laminar flow cabinet the DNA mixtures were
prepared. In sterile tubes the DNA plasmids (17µg total/plate) were added and diluted
in Ampuwa water (120 µl/plate). After a short spinning down, to the same Eppendorf
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tubes the appropriate amount of buffer A (120 µl/plate) was added. The mixture was
incubated at RT for 10 min, in the same time, in 50 ml Falcon tubes the appropriate
amount of buffer B (240 µl/plate) was added. The DNA mixture was added slowly
and dropwise to buffer B, which was subjected to constant air stream with a pipet
aid. The mixture was incubated at RT for 15 min and subsequently dropwise to cells.
Cells were incubated with DNA precipitates for 4 h, after a short check at the
microscope, cells were washed twice with prewarmed DMEM w/o serum and refed
with complete medium. Cells were harvested 48 h after the washing step.
• Rev response assays were typically performed with
Gag reporter plasmid pB37R 5µg
Tat and/or Rev expression plasmids 1µg
Luciferase expression plasmid 1µg
Bluescript vector up to 17µg
• Tat response assays were typically performed with
CAT reporter plasmid pHIV∆nps-LTR-CAT2µg
Tat expression plasmids 1µg
Luciferase expression plasmid 1µg
Bluescript vector up to 17µg
• Tat-Rev response assays were typically performed with
CAT reporter plasmid pSLIIB-CAT 2µg
Tat and Rev/or Tat-Rev expression plasmids 1µg
Luciferase expression plasmid 1µg
Bluescript vector up to 17µg
To assay Rev response (Ludwig, 1999; Ludwig et al., 1999), 48 h after transfection,
cells were washed twice with PBS, incubated 10 min at 37°C in TNE 1X 1 ml / plate
and harvested. 200 µl of the cell suspension were transferred in 1.5 ml sterile
Eppendorf tubes and used to measure luciferase activity: the cells were centrifuged
15 min at 35000 xg, resuspended in 100 µl of 1X ”Cell culture lysis buffer”
(Luciferase Assay System, Promega) and stored at -20°C.  The remaining cells were
transferred in other 1.5 ml sterile Eppendorf tubes and used to measure the total
protein content (BCA kit, Pierce) and the p24Gag production (p24ELISA, Coulter).
Cells were centrifuged 15 min at 35000 xg, lysed by three freeze-thaw cycles (-80°C
- 37°C) in 400 µl 0.5% Triton X-100/PBS, cleared by centrifugation 10min at 35000
xg and stored at -20°C.
For analysis of Tat or Tat-Rev response (Ludwig, 1999; van Empel, 2000), CAT
reporter gene expression was quantified either on the protein level by ELISA (Roche
Molecular Biochemicals) or by a functional CAT assay (Molecular Probes). The CAT
ELISA was performed with cell lysates prepared as described above.
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2.5.1.1.2.  FuGENE method
For localization analysis, cells were seeded into glass-bottomed dishes (35-mm
diameter) and transfected using FuGENE™ 6 transfection reagent.
Generally, the transfection mixture consisted in 0.5-2.0 µg of effector plasmid with 3
times more (in µl) of FuGENE in 100 µl/60-mm diameter or 50 µl/35-mm diameter
dishes.
In sterile Eppendorf tubes, serum-free DMEM was added to dilute FuGENE to 100 µl.
The necessary amount of FuGENE was added directly into the medium without
touching the plastic of the tube and incubated for 5 min at RT. After that, the
FuGENE/medium mix was dropped in other sterile Eppendorf tubes containing
already the plasmids and after a gentle mix by tipping the tubes, incubated for 15 min
at RT. The mix was added to the cells drop by drop and 24-48 h later the cells were
examined.
In some experiments, cells were incubated with several drugs:
• with the dye Hoechst 3342 (2µg/ml) for 10 min to allow easy identification of
nuclei
• with cycloheximide (25µg/ml) for 2h to block new protein synthesis
• with actinomycin D (5µg/ml) for 2h to block RNA synthesis
• with leptomycin B (10nM) for 2h to block Crm1-dependent nuclear export.
2.5.2. Indirect immunofluorescence
Indirect immunofluorescence was essentially performed as described elsewhere
(Ludwig et al., 1999). Briefly, cells were washed with PBS and fixed for 10 min at RT
with paraformaldehyde (or formaldehyde) 3.7%. After two washes with PBS, cells
were permeabilized for 10 min with PBS/Triton-X100 0.5%.
Primary antibodies were diluted in PBS in concentrations ranging between 1:20-
1:100 and secondary antibodies were diluted in PBS 1:50-1:200. Cells were
incubated with the respective antibodies at RT for 30 min. After each antibody-
incubation, cells were carefully washed several times with PBS. Finally cells were
protected with few drops of slow fade light mounting mix (Molecular Probes) and
observed in an inverted research fluorescence microscope (Axiovert 135TV Zeiss,
Germany). Negative control plates were treated identically except that they were not
incubated with the first antibody. The excitation wavelength 493 nm was used for
GFP, DTAF and Alexa-green analysis, whereas wavelength 580 nm was used for
cyanine 3 and Texas red detection and wavelength 357 nm for Hoechst 33342.   
2.5.3. Fluorescence microscopy and imaging of living cells
Microscopy of fixed and living cells expressing GFP-fusion proteins was performed
as described extensively in (Lee et al., 1999; Neumann et al., 2001). For GFP-analysis
in living cells, cells were seeded into glass bottom petri dishes (Mattek Corp.,
Ashland, MA), transfected as described above and observed 24-48 hours later.
Medium was exchanged against complete medium without phenolred and dishes put
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on an inverted fluorescence microscope with a mounted environmental chamber.
Images were taken at 10x, 20x, 32x or 40x magnification using a cooled 12 bit CCD-
camera (Quantix, Photometrics, AZ). Images were taken at subsaturating conditions
(i.e., pixel intensity < 4095). Filters, shutters and camera were controlled by a
Macintosh PowerPC computer using IPLab Spektrum 3.2 software. Care was taken
to ensure that images used for comparative purposes were taken under identical
lighting conditions, exposure and gain settings. Images were manipulated with IPLab
Spectrum 3.2, Adobe Photoshop 5.0 and Adobe Illustrator 8.0.
2.5.4. Cellular quantification of GFP fluorescence
The procedure for the quantification of GFP fluorescence in cells expressing GFP
fusion proteins was performed using IPLab spectrum as described in (Lee et al., 1999;
Neumann et al., 2001). Briefly, images were taken under non-saturating conditions of
the CCD detector. For each cell to be quantified the total fluorescence signal of the
entire cell and of its nuclear compartment were measured. Transferring cellular and
nuclear outlines from phase and Hoechst 33342 images respectively to GFP
fluorescent images assisted the delineation of cellular boundaries. Background
fluorescence was determined by measuring a signal of an extra area GFP-negative
and by calculation of mean background signal per pixel. Total fluorescent signal
measured for each cell segment was corrected for background fluorescence and for
its area. The corrected signal value of the entire cell segment was set to 100% and
proportions of nuclear and cytoplasmic signals calculated.
2.5.5. Western Blot
To analyze protein expression a SDS polyacrylamide gel electrophoresis (SDS-PAGE)
followed by immunoblotting procedure has been performed.
2.5.5.1. SDS polyacrylamide-gel electrophoresis (SDS-PAGE)
First cellular protein extracts were prepared. Cell cultures were washed with cold
sterile PBS, trypsinized, diluted in PBS, centrifuged at 1000 rpm for 5 min, rewashed in
PBS, counted, centrifuged and resuspended in cellular lysis buffer WB 1X (see 2.2.8.)
100 µl/1.5x106 cells.
After 5 min of denaturation at 100°C and a brief spin down, 20 µl of samples and 10
µl of standard molecular weight marker were loaded in home-made or ready (BioRad)
SDS gels and run into a gel-electrophoresis chamber (BioRad) in the presence of SDS
electrophoresis running buffer 1X pH 8.3 (see 2.2.8.). The running conditions were
fixed at 120V/20mA for the first 20-30 min and after at 150V/50mA for 40-60 min.
Different gels were used to separate proteins with molecular weight:
• < of 50 kDa, resolving gels with 12% of acrylamide/bisacrylamide,
• > of 50 kDa, resolving gels with 10% of acrylamide/bisacrylamide,
• > of 20 and <  of 250 kDa, resolving Tris-HCl ready gels 4-15%.
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2.5.5.2. Immunoblotting
Proteins separated on SDS-PAGE were transferred to nitrocellulose membranes
(BioRad) using a Semi-dry-Electroblotter (Sartorius). Gels were soaked first in sterile
Millipore water and after in transfer buffer pH 8.3 1X for 30 min. Six pieces of
Whatman 3MM paper and one piece of nitrocellulose membrane were cutted to the
exact size of the gel, soaked first in water and after wards in transfer buffer. The
transfer occurred in 1h 30 min at ~ 50V/200mA (mA= cm2 membrane x 0.8). Filters
were blocked in the dark in the presence of BSA 1% in TBS-T wash buffer pH 7.5 1X
(see 2.2.8.) at 4°C O/N.  Filters were then incubated with the respective antibodies
diluted in BSA 1% in TBS-T wash buffer (1:50 – 1:5000) at RT for 1h in continuous
agitation, washed with TBS-T wash buffer once for 15 min and twice for 5 min in
continuous agitation. Filters were stained with the secondary anti-mouse, anti-rabbit
or anti-rat antibodies horseradish peroxidase-conjugate (1:100 – 1:2000) and finally
stained proteins were detected by the enhanced chemiluminescence (ECL) assay
(Amersham).
2.5.6. Total protein determination (BCA test)
The determination of protein amount in the cellular lysates was performed using the
bicinchoninic acid (BCA) kit from Pierce according to the manufacturer’s
instructions. This system combines the well-known biuret reaction (proteins reducing
Cu2+ in an alkaline medium to produce Cu1+) with the higly selective detection
reagent BCA. BCA in fact, is in the form of its water-soluble solution salt, as sensitive,
stable and highly specific reagent for the cuprous ion (Cu1+) and forms a complex
BCA- Cu1+-BCA exhibiting a strong absorbance at 562 nm.
Briefly, dilutions in water 1:2 for a series of 8 calibration standards (2000–15.8 µg/ml)
from a stock of BSA (2mg/ml) were prepared. In a microtiter plate, per well, in
duplicate were added 10 µl of protein standards, water (blank) or cell lysate samples.
200 µl of a mixture of working reagents (50 parts of reagent A with 1 part of reagent
B) were added per well and the plate was incubated at 37°C for 30 min. The
absorbance was measured using a microelisa reader plate (BioRad) at 570 nm. A
standard curve was prepared by plotting the absorbance values obtained on the x-
axis against the specific standard protein concentrations on the y-axis, performing
linear regression analysis with the computer programs CA-Cricket Graph III or
Microsoft Excel 5.0. Using the standard curve, the protein concentration for each
unknown protein sample was determined using Microsoft Excel 5.0.
2.5.7. HIV-1 p24 antigen capture ELISA
The quantitative production of HIV-1 Gag in the cell lysates was determined by a
commercial HIV-1 p24-antigen ELISA kit from Coulter according to the
manufacturer’s instructions. Briefly, dilutions 1:2 for a series of 6 calibration standards
(125–3.9 pg/ml) from a purified HIV-1 p24 antigen reagent (625 pg/ml) were
prepared. 200 µl of p24 standards, 0.5% Triton X-100 in PBS (blank), cell lysate
samples (undiluted and/or diluted 1:10, 1:100 and 1:1000) were added to the
designated wells, prebound to the surface with a murine monoclonal antibody anti-
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HIV-1 p24 antigen. The plate was incubated at 37°C for 1 h. Following a wash step,
200 µl of reconstituted biotinylated human anti-HIV-1 IgG reagent were added to
each well and the plate was incubated at 37°C for 1 h.  Following another wash step,
200 µl of reconstituted streptavidin-horseradish peroxidase were added and the plate
was incubated at 37°C for 30 min. Following a wash step, 200 µl of a substrate
reagent containing tetramethylbenzidine (TMB) were added and the plate was
incubated at RT in the dark for 30 min. In the presence of peroxidase and hydrogen
peroxide, TMB is complexed to form a blue color. Finally, the reaction was stopped
adding 50 µl of H2S04 4N. Using a microelisa plate reader the absorbance was
measured at 450 nm with reference wavelenght at 570. A standard curve was
prepared by plotting the absorbance values obtained on the x-axis against the p24
standard concentrations on the y-axis, performing linear regression analysis with the
computer softwares CA-Cricket Graph III or Microsoft Excel 5.0. Using the standard
curve, the concentration of HIV-1 p24 antigen for each sample was determined using
Microsoft Excel 5.0 software. Samples with absorbance values higher than the
highest point on the standard curve (125 pg/ml) were retested more diluted. The
levels of Gag were standardized to 100 µg of total protein.
2.5.8. Luciferase Assay
As control for transfection efficiency, the production of the luciferase reporter gene
was measured using a luciferase assay provided from Promega. The principle of the
assay is based on the activity of the luciferase enzyme, derived from the coding
sequence of the luc gene cloned from the firely Photinus pyralis (De Wet 1985
PNAS). The enzyme catalyzes a reaction using D-luciferin and ATP in the presence of
oxygen and Mg2+ resulting in light emission.
First, the luciferase assay reagent was reconstituted adding 10 ml of luciferase assay
buffer to the vial containing the lyophilized luciferase assay substrate and brought at
RT. Once re-hydrated the luciferase assay reagent was stored at -80°C. 10 µl of RT
cell extract was transferred in 5 ml clear polystyrol tubes (Sarstedt) and transferred in
an automated injection luminometer (AutoLumat LB 953, Berthold) setted to inject
100 µl of luciferase assay reagent substrate to each tube. The light intensity was
measured for 10 sec after 6 sec of interval after each substrate-injection and is
proportional to luciferase concentration. The light units from each sample were
standardized to 100µg of total protein.
2.5.9. CAT ELISA
The quantitative determination of the chloramphenicol acetyltransferase (CAT) in
transfected cells was performed using a commercial CAT ELISA kit from Roche
Molecular Biochemicals, according to the manufacturer’s instructions. Briefly, the
CAT enzyme stock solution was reconstituted adding 0.5 ml of Ampuwa water. A
series of 7 dilutions 1:2 to produce CAT enzyme standards (1000-15 pg/ml) were
freshly prepared adding 40 µl of CAT stock solution in 3.96 ml sample buffer (PBS
containing blocking reagents). 200 µl of CAT standards, sample buffer, or cell lysate
samples (undiluted and/or diluted 1:2, 1:10 and 1:100) were added to the designated
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wells precoated with a goat polyclonal antibody anti-CAT. The plate was incubated
at 37°C for 1h. Following a wash step, 200 µl of a reconstituted and freshly diluted
antibody anti-CAT conjugated to digoxigenin were added per well and the plate was
incubated at 37°C for 1h. Following a wash step, 200 µl of reconstituted and freshly
diluted antibody anti-digoxigenin conjugated to peroxidase were added per well. The
plate was incubated at 37°C for another 1 h. Following the final wash step, 200 µl of
a peroxidase substrate containing ABTS were added, and incubated at RT for 30-40
min until color development (green color). Using a microelisa plate reader the
absorbance of the samples was measured at 405 nm with reference wavelenght at
490. A standard curve was prepared by plotting the absorbance values obtained on
the x-axis against the CAT standard concentrations on the y-axis, performing linear
regression analysis with the computer softwares CA-Cricket Graph III or Microsoft
Excel 5.0. Using the standard curve, the CAT concentration for each sample was
determined using Microsoft Excel 5.0 software. The levels of CAT were standardized
to 100µg of total protein.
2.5.10.  CAT Assay
To determine the CAT-activity a fluorescent CAT assay (Fast CAT® Green kit,
Molecular Probes) has been used according to the manufacturer’s instructions.
Briefly, 48 h after transfection, cells were washed twice with PBS, incubated 10 min
at 37°C in TNE 1X 1 ml/plate, transferred in 1.5 ml sterile Eppendorf tubes and
centrifuged 5 min at 10000 xg. The cells were resuspended in 100-300 µl Tris/HCl
0.25M pH 7.4, lysed by 3 freeze-thaw cycles (-80°C/37°C), cleared by centrifugation
at 4°C at 35000 xg and stored at -80°C. The total protein content and luciferase
activity were determined. Depending on the luciferase values, 10-30 µg of total
protein was transferred in new 1.5 ml sterile Eppendorf tubes and diluted to a final
volume of 65 µl with Tris/HCl 0.25M pH 7.4. Cell lysates were then incubated at
37°C in a thermo block with 5 µl fluorescence-labeled chloramphenicol substrate
(freshly rehydrated with 1 ml of methanol). Subsequently, 10 µl of acetyl-CoA
solution (9mM final concentration) were added and the probes were incubated 2h-
O/N at 37°C in the dark. The reaction was stopped adding 1 ml of cold (4°C) ethyl
acetate. After a brief vortex (20 sec) to mix both phases, the samples were centrifuged
2 min at 35000 xg to achieve a good phase separation. The organic phase (~ 950 µl)
containing the chloramphenicol was transferred in new Eppendorf tubes. The green
substrate was evaporated to dryness using a speed-vacuum and resuspended in 10 µl
of ethyl acetate. Each sample was dropped onto a silica gel TLC plate and dry. The
TLC plates were placed in a chromatography tank pre-equilibrated with 200 ml of
chloroform:methanol (85:15) and subjected to thin-layer-chromatography for 35-45
min. Acetylated and non-acetylated chloramphenicol forms were separated and
quantified using a STORM™ fluorescence scanner (Molecular Dynamics, Germany)
using a Molecular Dynamics-Software (Image Quant v1.2).
Inductions reflect the ratio of CAT-levels or conversion-rates, respectively,
standardized to total protein amount in the presence or absence of Tat-expression
plasmid.
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2.5.11. Preparation and purification of Risp-GST protein
To prepare and purify Risp-GST fusion protein it has been cloned the risp gene in the
pGEX-3X vector (see 2.2.6.2), and electrocompetent E.coli BL21 cells were
transformed (see 2.3.3.2) with the constructed plasmid pGEX-3X-Risp. Transformant
cells were selected in LB/Amp plate and two clones were picked and diluted into 50
ml of LB/Amp medium and incubated O/N at 37°C.  The next day 50 ml of culture
were diluted 1:10 in 500 ml of LB/Amp medium and incubated at 37°C for 1-2 h
(OD600 ~0.8). The expression of the fusion protein was induced by incubation of cells
with IPTG (1mM) for other 3-4 h. Cells were centrifuged at 4000 rpm at 4°C for 15
min and the pellet stored at -20°C. Cells were then resuspended in a freshly prepared
lysis buffer, vortexed, incubated on ice for 15 min and lysed by mild sonification.
• Lysis Buffer:
10 ml PBS containing 10 µl Leupeptin (1mg/m H20)
10 µl Pepstatin (5mg/ml DMSO)
10 µl Aprotinin (1mg/ml H20)
10 µl DNase (1mg/ml 50% glycerol)
20 µl PMSF (0.2M in isopropanol)
26 µl MnCl2 (1M)
260 µl MgCl 2 (1M)
0.01% Lysozyme
After the sonification, 1 ml of NaCl 5M and 500 µl of Triton X-100 20% were added
and the mixture was vortexed and incubated on ice for 10 min to facilitate the
solubilization of the proteins. The suspension mixture was centrifuged at 14000 rpm
at 4°C for 20 min and the supernatant transferred in 50 ml Falcon tube. The
purification of the GST fusion protein was performed with glutathione Sepharose 4B
(Pharmacia) according to the manufacturer’s instructions. Bacterial lysate was
incubated with glutathione Sepharose 4B (500 µl / 50 ml lysate) and the Risp-GST
protein was eluted using glutathione 15 mM. The integrity of the purified protein was
examined in SDS 12% PAGE and Coomassie blue staining. The best fraction of the
eluted protein was extensively dialyzed against cold PBS (O/N), quantified using the
BCA protein determination assay (see 2.5.6.) and stored at -80°C.
2.5.12. BSA labeling and peptides conjugation
Synthetic peptides were obtained from commercial sources (Sigma-Genosys, Ltd,
Pampisford, UK) and were conjugated with BSA previously labeled with the
fluorescent Alexa fluor 488 reactive dye (Molecular Probes) according to the
manufacturer’s instructions.
The following peptides were synthesized:
• CGG-LQLPPLERLTLD amino acids 73-84 of HIV-1 Rev wild-type,
• CGG-LQLPPDLRLTLD amino acid positions 73-84 of HIV-1 RevM10 mutant,
• CG-LQLPPLEALTLD amino acid positions 73-84 of HIV-1 Rev-A mutant,
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• CG-LQLPPDLALTLD amino acid positions 73-84 of HIV-1 RevM10-A mutant,
• CG-LESNLFDDNIDIFADL amino acids 86-105 of Risp,
• CG-KPKEKSKKKVEAK amino acids 106-118 of Risp.
2.5.13. Cellular microinjection
One day before microinjections, 1-3x105 cells were seeded into glass-bottomed dishes
(35-mm diameter). BSA-Alexa Fluor 488 labeled-conjugate peptides (~1mg/ml) or
purified Risp-GST protein (~1mg/ml) were microinjected into cytoplasm or nuclei of
cells using a manual injector system (Eppendorf). As internal injection control,
peptides or purified protein were comicroinjected in the presence of unconjugate
BSA-Alexa Fluor 568 labeled (~1mg/ml). After two hours of incubation at 37°C, cells
were fixed and analyzed in an inverted fluorescence microscope.
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2.6. Computer programs
Program Origin Application
Adobe Illustator®8   (Mac) Adobe Systems, USA Graphic images
Adobe PhotoShop®5.02
(Mac)
Adobe Systems, USA Conversion of scanned files
Ca Cricket Graph II and III
(Mac)
Cricket Software, USA Linear regression analysis,
diagrams
ClarisWorks 4.0 and 5.0
(Mac)
Claris Corporation, USA Table calculations, graphic
images
Claris Draw 1.0v4  (Mac) Claris Corporation, USA Graphic images
DIALIGN (PC) AG BIODV, GSF Multiple sequence alignment
DNA-Strider   (Mac) C. Marck, France DNA and protein sequence
analysis
EndNote 3.1 (Mac) Niles Software, USA Bibliography organizer
GCG (PC) AG BIODV, GSF Find patterns
Gene Construction Kit ™2
(Mac)
Textco Corp. USA DNA and plasmid sequence
presentation
GraphPad PRISM 2.0
(Mac)
GraphPad Software, USA Statistical analysis
(Mann-Whitney-U test)
IPLab Spectrum 3.2.4
(Mac)
Scanalytics, USA Microscope fluorescence
images analysis
Microsoft Word 98  (Mac) Microsoft Corporation, USA Text processing
Microsoft Excel 98  (Mac) Microsoft Corporation, USA Linear regression analysis,
table calculations, diagrams
Microsoft Internet Explorer
4.5 (Mac)
Microsoft Corporation, USA Internet search
OligoEd (Mac) AG BIODV, GSF Primers analysis
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Analysis on
Internet
WWW Address Application
BEAUTY (BLAST
Enhanced
Alignment Utility)
http://dot.imgen.bcm.tmc.edu:
9331/seq-search/protein-
search.html
DNA or protein sequence homology
search
BLAST search http://www.ncbi.nlm.nih.gov/
BLAST/
DNA or protein sequence homology
search
BLOCKS search http://dot.imgen.bcm.tmc.edu:
9331/seq-search/protein-
search.html
Motif blocks search
GeneStream align http://www2.igh.cnrs.fr/bin/al
ign-guess.cgi
Alignment and local
alignment of two sequences
PATTIMPROT
search
http://pbil.ibcp.fr/cgi-
bin/npsa_automat.pl?page=np
sa_pattern.html
Pattern search
PROSITE pattern
search
http://www2.ebi.ac.uk/ppsear
ch/
Protein motifs search
PSORT II search http://psort.nibb.ac.jp/form2.h
tml
Prediction of protein sorting signals
and subcellular localization
sites
PubMed http://www.ncbi.nlm.nih.gov/
entrez/query.fcgi?db=PubMed
National library of medicine’s search
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3. Results
3.1. Identification of two HIV-1 Rev-interacting proteins by yeast two-hybrid
selection
To identify new HIV-1 Rev-interacting proteins we performed a yeast two-hybrid
protein interaction assay. The Rev protein served as a bait and a Jurkat T-cell cDNA
library encoding possible Rev-interacting factors supplied the prey (Fig. 3.1).
3.1.1. Preparation and test of Rev as a bait protein
With standard subcloning techniques, rev cDNA was inserted into the polylinker of
the pEG202 plasmid (see 2.2.6.3.1.) to produce an in frame LexA-Rev fusion protein.
Briefly, the HXB2- rev-ORF in pBsRev was amplified beginning at the second codon
by PCR and inserted in frame with LexA into the unique EcoRI restriction site of the
pEG202 vector in sense and antisense orientation. The cytoplasmic domain of CD2
fused to LexA was used as an unspecific bait control (pEG202-LexCD2, see
2.2.6.3.1.).
Using the lithium acetate procedure the yeast strain EGY48/pJK103, containing the
two LexA operator-responsive reporters (leucine and LacZ), was transformed with
the plasmids pEG202-sRev sense, pEG202-sRev antisense and pEG202-LexCD2. In
parallel, EGY48 yeast cells were transformed with the pSH18-34 plasmid in presence
and absence of the bait plasmids pEG202-sRev sense, pEG202-sRev antisense and
pEG202-LexCD2. Since the lacZ reporter gene expression plasmids pSH18-34 and
pJK103 and the bait expression plasmid pEG202 harbor the URA3 and HIS3 genes
respectively (see 2.2.6.3.1. and 2.4.1) transformants were selected which grow in
glucose medium lacking uracil and histidine. To investigate whether Rev as a bait
protein activates transcription of the reporter genes in the absence of the “prey”
protein, each yeast transformant was diluted 100 and 1000-fold in sterile water and
plated on Gal/Raff Ura-, His- and Gal/Raff Ura-, His-, Leu- plates. In this test galactose
medium was used because the following screening of the cDNA library was carried
out on galactose plates to induce expression of the activation-tagged cDNA protein.
The growth of cells was monitored for several days. All yeast clones grew well to a
similar density on the Gal/Raff Ura-, His- plates. However, in the absence of leucine
some yeast clones did not grow at all and some showed weak growth. In addition
background LacZ expression in the selection strains was tested. Therefore each yeast
transformant was plated on Glc/CM Ura-, His-, X-gal plates. The absence of blue
colonies confirmed that the lacZ gene was inactive in the presence of glucose.
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Fig. 3.1 Flow diagrams for the identification of two Rev-interacting cDNA-
encoded proteins.
Transformation of yeast EGY48 with pSH18-34 (U), pEG202-sRev sense (H) and pJG4-5 Jurkat-cDNA library plasmid (W)
                         
25 aliquots 1-ml -80°C  (transformation efficiency 3.7x10  )
200 µl in 300 ml Gal/Raff U-, H-, W- medium
56  clones (1.1, 2.1, etc.)
 43  DNAs electroporated into KC8 bacteria
several transformants for each yeast clone DNA (1.1.1, 5.2.1, 5.2.2, etc) 
replica-plating on VitB/W- plates with 660 transformants 
84 transformants/33  yeast DNA 
43   clones  (1.1, 5.1, 5.2, etc.)
Selection 1 of  pJG4-5 library plasmid
 52 DNA/33  cDNA library plasmids transformed into yeast
           EGY48 + pSH18-34+ Rev sense
      “                 “   + Rev as       
      “                 “  + Lex cd2       
growth in Gal/Raff L-;  blue in Gal/Raff  X-gal plates
6 clones sequenced (harboring a clear cDNA insert)  
133 transformants/33  yeast DNA (5.2.1, 5.2.2, 5.2.3, 6.2.1, etc)
Test for specificity of Rev-binding:
 4  positive clones: specific binding to Rev sense (specific growth in Gal/Raff L- and  blue in Gal/Raff X-gal plates)
  2 putative clones: binding to Rev sense and weak to Rev antisense (very weak blue in Gal/Raff X-gal plates)
  3 putative clones: binding to Rev sense and weak background (very weak blue in Glc/ X-gal plates) 
  4 negative clones: no binding to Rev sense (no growth in Gal/Raff L- and no blue in Gal/Raff X-gal plates) 
20 negative clones: unspecific binding to Rev sense (unspecific growth in Gal/Raff L- and  blue in Gal/Raff  X-gal plates)
several transformants for each cDNA clone (growth in Glc/ U-, H-, W- plates) 
plated on Gal/Raff U-, H-, W-, L- , Gal/Raff U-, H-, W-, X-gal plates
             Glc/ U-, H-, W-, L-  and Glc/ U-, H-, W-, X-gal  plates
2 positive clones: specific Rev binding (11.5.1 and 16.4.1)
Stop GAL1 promoter induction
plated in Glc/U-, H-, W- plates
Selection test 2: 
growth in Gal/Raff L-; blue in Gal/Raff  X-gal plates
plated on Gal/Raff U-, H-, W-, L- , Gal/Raff U-, H-, W-, X-gal plates
             Glc/ U-, H-, W-, L-  and Glc/ U-, H-, W-, X-gal plates
4 negative clones: common Y2H false positives 
plated on 20 100-mm Gal/Raff U-, H-, W-,L- plates
Selection test 1: 
growth in Gal/Raff  L-  plates
A  
no growth on  VitB/W-, H- plates
Selection 2 of  pJG4-5 library plasmid
growth on  VitB/W- plates
43   yeast DNA minipreps  
84  DNA minipreps and restriction analysis
5
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Transformation of yeast EGY48 with pJK103 (U), pEG202-sRev sense (H) and pJG4-5 Jurkat-cDNA library plasmid (W)
                         
25 aliquots 1-ml -80°C (transformation efficiency 1.5-3.2x106; replating efficiency 7x107 )
7  clones (1, 2, etc.)
 7  DNAs electroporated into KC8 bacteria
several transformants for each yeast clone DNA (1.1, 1.2, 1.3,  etc) 
15 transformants/6  yeast DNA 
 7   clones  (1, 2, 3, etc.)
 14 DNA/6  cDNA library plasmids transformed into yeast
           EGY48 + pJK103 + Rev sense
      “                 “   + Rev as       
      “                 “  + Lex cd2       
growth in Gal/Raff L-;  blue in Gal/Raff X-gal plates
23 transformants/6  yeast DNA (1.13, 2.1, 2.6, 2.10, etc)
Test for specificity of Rev-binding
6 negative clones: unspecific binding to Rev sense and/or weak background (unspecific growth in Gal/Raff L- 
       and in Glc/ L- plates and unspecific blue in Glc/ X-gal plates) 
several transformants for each cDNA clone (growth in Glc/ U-, H-, W- plates) 
plated on Gal/Raff U-, H-, W-, L- , Gal/Raff U-, H-, W-, X-gal plates
     Glc/ U-, H-, W-, L-  and Glc/ U-, H-, W-, X-gal  plates
Stop GAL1 promoter induction
growth in Glc/U-, H-, W-
Selection test 2: 
growth in Gal/Raff L-;  blue in Gal/Raff X-gal plates
plated on Gal/Raff U-, H-, W-, L- , Gal/Raff U-, H-, W-, X-gal plates
             Glc/ U-, H-, W-, L-  and Glc/ U-, H-, W-, X-gal  plates
200 µl in 300 ml Gal/Raff U-, H-, W- medium
plated on 20 100-mm Gal/Raff U-, H-, W-,L- plates
Selection test 1: 
growth in Gal/Raff  L-  plates
B
replica-plating on VitB/W- plates with 128 transformants 
Selection 1 of  pJG4-5 library plasmid
no growth on  VitB/W-, H- plates
Selection 2 of  pJG4-5 library plasmid
growth on  VitB/W- plates
7   yeast DNA minipreps  
15 DNA minipreps and restriction analysis
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These results showed that the corresponding binding of Rev-LexA fusion protein to
the LexA operators upstream of the reporter genes LEU2 and lacZ was not enough
to activate their transcription. Therefore, it was concluded that the Rev protein is
suitable as a bait protein for the yeast two-hybrid assay. One of the Rev sense, Rev
antisense and LexCD2 expressing yeast clones, which didn’t show any background
activity, was chosen for further use.
 Yeast strain LacZ reporter Bait plasmids
EGY48 pSH18-34 pEG202-sRev sense
“ “ pEG202-sRev antisense
“ “ pEG202-LexCD2
“ pJK103 pEG202-sRev sense
“ “ pEG202-sRev antisense
“ “ pEG202-LexCD2
Table 3 .1   Various transformants of EGY48 yeast strain were created to
identify new HIV-1 Rev-interacting factors.
To confirm expression of Rev protein each yeast strain harboring the bait plasmid was
analyzed in a western blot. Therefore protein extracts of the yeast clones were
separated on a SDS polyacrylamide gel. The gel was blotted and filter-bound protein
detected with a polyclonal Rev-specific antibody (see 2.2.5. and 2.5.5.). As a control
extracts from HeLa cells transfected with a Rev expression plasmid (pBsRev) were
used.
Only yeast clones harboring Rev in sense orientation showed a clear band around
42 kDa corresponding to the Rev-LexA fusion protein.
3.1.2. Selection of Rev-interactors from library transformants
The interactor hunt was performed in two consecutive large plating steps. First, the
pJG4-5 plasmid containing the human Jurkat T-cell cDNA library fused to the B42
activation domain (kindly provided by Dr. W. Kolanus) was introduced into both
yeast selection strains EGY48/pSH18-34 and EGY48/pJK103 containing the
pEG202-sRev sense plasmid. In order to obtain a high number of primary
transformants expressing an individual library plasmid, each yeast strain was
transformed in large scale in 30 different sterile tubes (see 2.4.5.). To check the
transformation efficiency 2 times 40 µl of both yeast strains were used as described in
2.4.5.2. The transformation efficiency expressed as colony forming units (cfu) was
3.7x105 for EGY48/pSH18-34 and 1.5-3.2x106 for EGY48/pJK103. The remaining
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content of the 30 tubes was pooled, plated undiluted on eight 24x24-cm Glc/CM
Ura-, His-, Trp- dropout plates and incubated at 30˚C for 2-3 days until colony
growth could be detected.  In this first plating step, glucose was used as a sugar
source to allow growth of all yeast clones harboring the pJG4-5 plasmid. In the
presence of glucose the inducible yeast GAL1 promoter that directs expression of
cDNA-encoded proteins fused to the B42 activation domain is not activated. This
allows amplification of all transformants with heterologous cDNAs. Therefore, cDNAs
encoding proteins possibly toxic to the pJG4-5-containing yeast cells were not lost
for the following interactor hunt. Primary transformants from each strain were
collected in 25 ml sterile TE buffer, washed and resuspended in 1 vol glycerol solution
and frozen in 1 ml aliquots at -70˚C (see 2.4.5.2.). Replating efficiency was
determined. The cfu was 7x107.  In this second step the presence of galactose induces
expression of activation-tagged cDNA proteins. To select for transcription of the
LEU2 reporter gene, 200 µl of each transformed yeast strain were incubated O/N in
300 ml of Gal/Raff/CM Ura-, His-, Trp- medium. Cultures were plated on twenty
100mm Gal/Raff/CM Ura-, His-, Trp-, Leu- dropout plates and incubated at 30˚C.
After four days 7 clones from the EGY48/pJK103 strain and 56 clones from the
EGY48/pSH18-34 strain were detected. These clones were collected on
Gal/Raff/CM Ura-, His-, Trp-, Leu- master plates. Each clone was identified by a
number (e.g. clone 1.1 = clone number 1 on plate number 1).
1.1 1.2 2.1 4.1 5.1 5.2 6.1 6.2 6.3 6.4
6.5 8.1 9.1 9.2 10.1 10.2 10.3 11.1 11.2 11.3
11.4 11.5 11.6 12.1 12.2 13.1 13.2 14.1 14.2 14.3
14.4 14.5 14.6 14.7 15.1 15.2 15.3 16.1 16.2 16.3
16.4 16.5 16.6 17.1 17.2 17.3 17.4 18.1 18.2 18.3
19.1 19.2 19.3 19.4 20.1 20.2
Table 3.2   56 positive clones from the first and second selection test (EGY48
/pSH18-34 strain). Clones that grew in Gal/Raff/CM Ura-, His-, Trp-, Leu- and not in
Glc/CM Ura-, His-, Trp-, Leu- plates and were blue on Gal/Raff/X-gal/CM Ura-, His-, Trp-
and not on Glc/X-gal/CM Ura-, His-, Trp- plates are expressed in bold.
To confirm that the growth of these clones in the absence of leucine was actually due
to expression of the activation-tagged cDNA proteins, a second test for galactose
dependence was done. The GAL1 promoter was turned off by adding glucose to the
medium and leucine selection eliminated before reinduction. For this purpose the
Leu+ clones were replated from the Gal/Raff/CM Ura-, His-, Trp-, Leu- dropout plates
to 100-mm Glc/CM Ura-, His-, Trp- dropout plates and incubated at 30˚C until
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colonies were growing. With all yeast clones replica plating was performed using
different selection plates to investigate for LacZ expression and galactose
dependence.
At this juncture 7 out of 7 and 43 out of 56 clones grew in the absence of leucine
and showed X-gal conversion (=blue colonies) only in presence of galactose and
not glucose as sugar source. The 43 positive clones are shown in bold in the Table
3.2.
3.1.3. Specificity test
Detection of galactose-dependent Leu+ and LacZ+ yeast cells demonstrated that the
reporter genes were activated by expression of the activation-tagged cDNA-encoded
protein. The next step was to examine that activation of the reporters was due to
specific interaction of this cDNA-encoded protein with Rev, and not due to a non-
specific interaction with LexA operators in the promoters, or with some part of the
transcription machinery. To verify that the cDNA-encoded proteins were interacting
specifically with Rev, library plasmids were isolated from the Leu+ LacZ+ yeast clones
and selected in KC8 bacteria. The plasmids were reintroduced into the original
selection strains EGY48/pSH18-34 and EGY48/pJK103 expressing Rev sense, Rev
antisense as well as the unrelated bait LexCD2 to perform the final specificity test.
3.1.3.1. Isolation and classification of library plasmids
From each of the 7 (EGY48/pSH18-34) and 43 (EGY48/pJK103) positive yeast
clones library plasmids were isolated by performing a rapid yeast plasmid preparation
and the isolated DNA was transformed into competent KC8 bacteria by
electroporation. KC8 is an E.coli strain that contains a mutation in the trpC gene
(trpC-9830 mutation). The inability of these bacteria to grow in absence of
tryptophan was used to select bacteria containing the library plasmid with the yeast
TRP1 gene on the PJG4-5 plasmid. Transformed bacteria were isolated by plating on
LB/Amp plates and incubated at 37˚C O/N.
Thirty-five of 43 yeast DNAs were successfully transformed, while 8 were not
expressed in KC8 bacteria. Bacteria containing library plasmids were selected by
growing on minimal plates supplemented with vitamin B, ampicillin, uracil, histidine,
and leucine and lacking tryptophan. Out of 660 individual KC8 transformants plated
on the selection plates lacking Trp, 133 transformants with 33 yeast (EGY48/pSH18-
34 strain) plasmids grew on the plates. In order to obtain pJG4-5 library plasmid DNA
in the absence of the pEG202-sRev sense plasmid a second selection test was
performed. The 133 KC8+ bacteria were replica plated on vitamin B plates lacking
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tryptophan and histidine. Bacteria growing on plates in the absence also of histidine
were expressing the HIS3 gene by the bait pEG202 plasmid and were excluded.
Eighty-four KC8 bacterial clones were selected by their disability to grow in absence
of histidine. DNA was isolated and then analyzed by restriction with different
enzymes. Each DNA clone was identified by a number (e.g. clone 5.2.2 = clone
number 2 of original yeast clone number 5.2). Examples of the 84 KC8+ clones are
shown in the Table 3.3.
From the 7 yeast (EGY48/pJK103 strain) DNAs that were successfully transformed in
KC8 bacteria, 128 individual transformants were analyzed in order to obtain pJG4-5
library plasmid DNAs. 23 KC8 transformants with 6 yeast DNAs grew on vitamin B,
Amp, Ura, His, Leu, Trp-, and 15 KC8 bacteria were selected by not growing in plates
lacking histidine. From these bacteria DNA was isolated, and analyzed by restriction
enzyme digestion.
Growth in KC8
Yeast+
clones Transformants
      LB/amp
Master plate
LB/amp VitB/Trp- VitB/Trp-, His-
KC8+ clones
5.2 22 17 3 /17 1 /3 5.2.2
6.1  5              5 0 0 0
6.2 50 16 3 /16 3 /3 6.2.1, 6.2.2, 6.2.3
6.5 110 30 10 /30 7 /10 6.5.1, 6.5.2, 6.5.3,6.5.5, 6.5.6, 6.5.7, 6.5.8
10.2 7 7 0 0 0
11.1 20 20 0 0 0
11.2 117 37 3 /37 3 /3 11.2.1, 11.2.2, 11.2.3
Table 3 .3   Isolation of cDNA library plasmids. A set of DNA isolated from
EGY48/pSH18-34/pEG202-sRev sense/pJG4-5-Jurkat-T-cDNA library yeast strain was
transformed in KC8 bacteria. From each transformation group several KC8 transformants were
obtained. A variable number of bacteria was tested by selection growth on plates lacking
tryptophan and/or histidine to isolate the pJG4-5 cDNA-library plasmids. Examples of KC8+
clones containing library plasmid are shown.
Each bacterial miniprep DNA was digested with EcoRI and XhoI enzymes to control
the insert size of the library plasmids and to exclude possible identical cDNA inserts.
Not every DNA preparations showed clear restriction fragments. However each yeast
cDNA (33 from EGY48/pSH18-34 and 6 from EGY48/pJK103 strains) was
represented by at least one KC8 DNA. DNAs that were used for the consecutive
screening experiments are shown in the Table 3.4.
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A
5.2.2 6.2.1 6.2.2 6.5.1 6.5.2 6.5.3 6.5.6 11.2.1 11.2.2
11.3.1 11.3.2 11.4.1 11.4.2 11.4.12 11.5.1 11.5.2 11.6.1 11.6.4
12.1.1 12.1.2 13.1.1 13.1.2 13.2.8 13.2.12 14.1.1 14.3.2 14.5.1
14.5.2 14.7.1 15.1.1 15.1.2 15.2.2 15.3.1 16.2.1 16.3.10 16.3.15
16.4.1 16.6.3 17.1.3 17.2.2 17.4.3 17.4.4 18.1.2 18.2.1 19.1.2
19.1.3 19.2.3 19.3.2 19.4.20 19.4.21 20.1.2 20.2.3
B
1.13 2.1 2.6 2.10 3.6 3.7 4.1 4.2 4.3
5.3 5.10 5.17 7.12 7.14
Table 3 .4   DNA used to test specificity of Rev-binding. A) 52 KC8 clones
harboring 33 cDNA library plasmids  (EGY48/pSH18-34 strain); B) 14 KC8 clones harboring
6 cDNA library plasmids (EGY48/pJK103 strain).
3.1.3.2.  Selection of positive yeast clones in the Rev-binding test
Spurious background was already removed by the previously described series of
controls. In order to eliminate other classes of false positives the rescued library
plasmid DNAs were retransformed in the original yeast strains containing the bait
plasmids.
The 52 purified DNAs (Table 3.4 A) were separately transformed in:
EGY48/pSH18-34/pEG202-sRev sense
  pEG202-sRev antisense
         pEG202-LexCD2.
The 14 purified DNAs (Table 3.4 B) were separately transformed in:
  EGY48/pJK103/  pEG202-sRev sense
     pEG202-sRev antisense
                        pEG202-LexCD2.
Each transformation was plated on Glc/CM Ura-, His-, Trp- dropout plates and
incubated at 30˚C for 2-3 days until colony growth was detected. Four to six
independent colonies from each transformation plate were replated on Glc/CM Ura-,
His-, Trp- master dropout plates and incubated O/N at 30˚C. With the same series of
yeast clones replica plating was performed using the following different selection
plates:
Gal/Raff/CM Ura-, His-, Trp-, Leu-
Glc/CM Ura-, His-, Trp-, Leu-
Gal/Raff/X-gal/CM Ura-, His-, Trp-
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Glc/X-gal/CM Ura-, His-, Trp- plates.
For some clones LacZ activity was also/only analyzed using a sensitive and semi-
quantitative dot-blot assay (see Mat and Meth.).
Clones were considered positive when growing without Leu and showing X-gal
conversion only in the presence of galactose and not of glucose.
None of the 6 tested cDNA-encoded proteins expressed in the EGY48-pJK103
strains showed specific binding to Rev.
Some yeast clones showed growth or blue colonies also in the presence of the
unspecific bait or with the Rev antisense bait. Other yeast showed a weak
background on plates containing glucose.  
Among the 33 cDNA encoded proteins expressed in EGY48-pSH18-34, 5 clones
(two of which represented a same cDNA library plasmid) have been identified to
bind specifically to Rev and 5 clones showed “putative” specific binding to Rev
(Table 3.5).
The 5 positive clones grew in the absence of leucine and were blue only in plates
containing galactose and in the presence of Rev in sense orientation.  The 5
“putative” positive clones showed either very weak blue background on Glc/X-gal
plates or very weak blue background in yeast expressing Rev in antisense on
Gal/Raff/X-gal plates. As mentioned before, one or two DNAs for each cDNA library
plasmid was used for the screening experiments. However, with the exception of the
pair clones 11.5.1 and 11.5.2, the other pairs of KC8 DNAs representing the same
cDNA encoded protein gave different results (Table 3.5).
Other 20 clones were considered as false positives by growing in the absence of
leucine and showing blue color also in plates containing glucose and not only in
the presence of Rev in sense orientation. The remaining 4 clones were considered
as negative because in both specificity tests they were clearly negative.
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Positive clones Interaction with Rev cDNA EcoRI/XhoI insert
6.2.1 putative/unspecific ~ 400 bp + 300 bp inserts
6.2.2 negative ND
11.2.1 putative/unspecific ~ 1200 bp insert
11.5.1 clear/specific ~ 500 bp insert
11.5.2 clear/specific  ND
11.6.1 putative/unspecific no insert
11.6.4 unspecific ND
12.1.1 negative ND
12.1.2 clear/specific no insert
13.1.1 clear/specific no insert
13.1.2 unspecific ND
15.2.2 putative/unspecific ~ 300 bp + 100 bp inserts
16.3.15 putative/unspecific ~ 1400 bp insert
16.3.10 unspecific ND
16.4.1 clear/specific ~ 800 bp insert
Table 3.5   Positive clones in the test for specificity of Rev-binding. In bold are
shown clones that grew without leucine and showing X-gal conversion only in the presence of
galactose.  Only from the clear and putative positive clones DNA was isolated and then analyzed
by restriction enzyme analysis.
Restriction analysis was performed with the DNA of 4 positive clones (the clone
11.5.2 was not analyzed, because considered identical to 11.5.1) and the 5
“putative” positive clones. Maxiprep DNA of each KC8 bacteria clone was digested
with EcoRI/XhoI and AluI enzymes to analyze the insert size.  After separation of
EcoRI/XhoI digested DNA on a 2% agarose gel 2 out of the 4 positive clones and 1
out of the 5 “putative” positive clones did not show any insert (Table 3.5).
In summary, 6 yeast clones were isolated in the test for specificity of Rev-binding.
Each contained an EcoRI/XhoI cDNA library insert encoding protein able to bind
specifically (2 clones) and not clear specifically (4 “putative” clones) the HIV-1
Rev protein.
3.1.3.3.  Sequence analysis of positive yeast clones
The 6 clones harboring a EcoRI/XhoI insert in the library plasmid were sent to a
company (Medigene) to perform sequence analysis using the primers 20634 (Table
2.1).  NCBI's BLAST search (see 2.6.) of available sequence databases suggested that
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the “putative” positive clones could be considered as unspecific Rev-binding clones
(Table. 3.6). In fact, their sequences were very similar to sequences of proteins
generally indicated as common false positive in the yeast two-hybrid assay (Hengen,
1997). The clone 11.5.1 was identified to contain the cDNA for a previously reported
nuclear single-strand DNA binding protein dbpB (Sakura et al., 1988). Regarding
the clone 16.4.1, computer analysis using the non-redundant database of GenBank
EST division revealed initially a 92% sequence identity with Soares fetal heart
NbHH19W Homo sapiens cDNA 343275 5’ clone. Subsequently, BLAST search
revealed a high identity (99%) with the C-terminal part of a human large brain cDNA
clone for KIAA0592 protein (Nagase et al., 1998) and two other human cDNA clones
for hypothetical proteins (accession number CAB45765 and CAB43380, submitted
1999). However, BLAST search failed to identify any proteins with known function
with significant or partial homology to the predicted 16.4.1 protein sequence. Figure
3.2 shows the final comparison of 16.4.1 clone with previously reported genes.
Figures 3.3 A and B show the alignment results of the two clones 11.5.1 and 16.4.1
with the corresponding database clones.
Clone Interaction with Rev cDNA bp Sequence identity with
6.2.1 putative/unspecific   680 ribosomal protein s7 100%
11.2.1 putative/unspecific 1260 heat shock protein  99.8%
11.5.1 clear/specific   935 h DNA binding protein dbpB  99.9%
15.2.2 putative/unspecific   420 zinc finger proteins   85%
16.3.15 putative/unspecific 1570 HLA-DR associated protein 100%
phosphatase 2A inhibitor I2PP2a 100%
h Set gene  99.3%
16.4.1 clear/specific   696 h Soares fetal heart clone 343275 5’ 92%  
h male brain 3’end cDNA clone for  99%
KIAA0592 protein
Table 3.6   Summary of BLAST search with the sequences of the positive
clones interacting with Rev. The ribosomal proteins, zinc finger containing proteins, heat
shock proteins are common false positives in the yeast two-hybrid system (Hengen, 1997).
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In summary, using the yeast two-hybrid system, the screening of a Jurkat T-cell
cDNA library led to the identification of two Rev-interacting cDNAs encoding
proteins. Computer analysis of available sequence databases revealed a high
percentage of identity (99.9%) with the C-terminal part of a previously reported
human nuclear single-strand DNA binding protein dbpB to the clone 11.5.1
(Sakura et al., 1988).
Clone 16.4.1 showed high sequence identity (99%) with the C-terminal part of a
human large brain cDNA clone for KIAA0592 protein (Nagase et al., 1998) and
with additional sequences representing subsections of KIAA0592 isolated from
fetal heart (clone 343275 5’), adult testes (CAB45765) and from fetal kidney
(CAB43380) tissues (Fig. 3.2). In addition, no other known proteins with
significant or partial homology were identified.
Fig. 3 .2  Comparison of 16 .4 .1  clone with previously isolated genes with
unknown function. Risp represents the 16.4.1 cDNA-encoded protein plus 8 amino acids
missing from the N-terminal part of the Soares fetal heart clone. The single letters on front of
each cDNA-encoded protein bar indicate the first coding amino acid. Dark gray shading
represent the location of Risp fragment.
KIAAO592 (1353 aa)
Soares fetal heart clone 343275 5’ (200 aa)
16.4.1 (163 aa)
Risp (171 aa)
Hypothetical protein CAB45765 (491 aa)  
Hypothetical protein CAB43380 (283 aa) 
 ORF
V
M
M
M
S
A
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>_ 11.5.1 cDNA                                      935 nt vs.
>_ h DNA binding protein cDNA                      1452 nt
scoring matrix: , gap penalties: -12/-2
58.4% identity; Global alignment score: 2196                               
                                                               30  
11.5.1 ---------------------------------------------------------CAA
                                                                :::
_      .... TAACCATTATAGACGCTATCCACGTCGTAGGGGTCCTCCACGCAATTACCAGCAA
              550       560       570       580       590       600
             40        50        60        70        80        90  
11.5.1 AATTACCAGAATAGTGAGAGTGGGGAAAAGAACGAGGGATCGGAGAGTGCTCCCGAAGGC
       ::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::
_      AATTACCAGAATAGTGAGAGTGGGGAAAAGAACGAGGGATCGGAGAGTGCTCCCGAAGGC
              610       620       630       640       650       660
            100       110       120       130       140       150  
11.5.1 CAGGCCCAACAACGCCGGCCCTACCGCAGGCGAAGGTTCCCACCTTACTACATGCGGAGA
       ::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::
_      CAGGCCCAACAACGCCGGCCCTACCGCAGGCGAAGGTTCCCACCTTACTACATGCGGAGA
              670       680       690       700       710       720
            160       170       180       190       200       210  
11.5.1 CCCTATGGGCGTCGACCACAGTATTCCAACCCTCCTGTGCAGGGAGAAGTGATGGAGGGT
       ::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::
_      CCCTATGGGCGTCGACCACAGTATTCCAACCCTCCTGTGCAGGGAGAAGTGATGGAGGGT
              730       740       750       760       770       780
            220       230       240       250       260       270  
11.5.1 GCTGACAACCAGGGTGCAGGAGAACAAGGTAGACCAGTGAGGCAGAATATGTATCGGGGA
       ::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::
_      GCTGACAACCAGGGTGCAGGAGAACAAGGTAGACCAGTGAGGCAGAATATGTATCGGGGA
              790       800       810       820       830       840
            280       290       300       310       320       330  
11.5.1 TATAGACCACGATTCCGCAGGGGCCCTCCTCGCCAAAGACAGCCTAGAGAGGACGGCAAT
       ::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::
_      TATAGACCACGATTCCGCAGGGGCCCTCCTCGCCAAAGACAGCCTAGAGAGGACGGCAAT
              850       860       870       880       890       900
            340       350       360       370       380       390  
11.5.1 GAAGAAGATAAAGAAAATCAAGGAGATGAGACCCAAGGTCAGCAGCCACCTCAACGTCGG
       ::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::
_      GAAGAAGATAAAGAAAATCAAGGAGATGAGACCCAAGGTCAGCAGCCACCTCAACGTCGG
              910       920       930       940       950       960
            400       410       420       430       440       450  
11.5.1 TACCGCCGCAACTTCAATTACCGACGCAGACGCCCAGAAAACCCTAAACCACAAGATGGC
       ::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::
_      TACCGCCGCAACTTCAATTACCGACGCAGACGCCCAGAAAACCCTAAACCACAAGATGGC
              970       980       990      1000      1010      1020
            460       470       480       490       500       510  
11.5.1 AAAGAGACAAAAGCAGCCGATCCACCAGCTGAGAATTCGTCCGCTCCCGAGGCTGAGCAG
       ::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::
_      AAAGAGACAAAAGCAGCCGATCCACCAGCTGAGAATTCGTCCGCTCCCGAGGCTGAGCAG
             1030      1040      1050      1060      1070      1080
            520       530       540       550       560       570  
11.5.1 GGCGGGGCTGAGTAAATGCCGGCTTACCATCTCTACCATCATCCGGTTTAGTCATCCAAC
       ::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::
_      GGCGGGGCTGAGTAAATGCCGGCTTACCATCTCTACCATCATCCGGTTTAGTCATCCAAC
             1090      1100      1110      1120      1130      1140
            580       590       600       610       620       630  
11.5.1 AAGAAGAAATATGAAATTCCAGCAATAAGAAATGAACAAAAGATTGGAGCTGAAGACCTA
       ::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::
_      AAGAAGAAATATGAAATTCCAGCAATAAGAAATGAACAAAAGATTGGAGCTGAAGACCTA
             1150      1160      1170      1180      1190      1200
            640       650       660       670       680       690  
11.5.1 AAGTGCTTGCTTTTTGCCCGTTGACCAGATAAATAGAACTATCTGCATTATCTATGCAGC
       ::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::
_      AAGTGCTTGCTTTTTGCCCGTTGACCAGATAAATAGAACTATCTGCATTATCTATGCAGC
             1210      1220      1230      1240      1250      1260
            700       710       720       730       740       750  
11.5.1 ATGGGGTTTTTATTATTTTTACCTAAAGACGTCTCTTTTTGGTAATAACAAACGTGTTTT
       ::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::
_      ATGGGGTTTTTATTATTTTTACCTAAAGACGTCTCTTTTTGGTAATAACAAACGTGTTTT
             1270      1280      1290      1300      1310      1320
            760       770       780       790       800         935  
11.5.1 TTAAAAAAGCCTGGTTTTTCTCAATACGCCTTTAAAGGTTTTTAAATTGTTTCATAT…..
       ::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::
_      TTAAAAAAGCCTGGTTTTTCTCAATACGCCTTTAAAGGTTTTTAAATTGTTTCATAT…..
             1330      1340      1350      1360      1370      1452
F i g .  3 . 3  A   Alignment between 11.5 .1  and a section of the gene encoding
human binding protein B. The stop codon is shown in green.
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>_ 16.4.1 cDNA                                     696 nt vs.
>_ fetal heart clone 343275 5’cDNA                 670 nt
scoring matrix: , gap penalties: -12/-2
72.3% identity;         Global alignment score: 1635
16.4.1 --------------------------AGCAGTGATGATGATCTCTTTCAGTCTGCTAAAC
                                 ::::::::::::::::::::::::::::::::::
_      ..ATGTTTCCTGCTCTAGGCGAGGCCAGCAGTGATGATGATCTCTTTCAGTCTGCTAAAC
               70        80        90       100       110       120
           40        50        60        70        80        90
16.4.1 CAAAACCAGCAAAGAAAACAAATCCCTTTCCTCTCCTGGAAGATGAGGATGACCTCTTTA
       ::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::
_      CAAAACCAGCAAAGAAAACAAATCCCTTTCCTCTCCTGGAAGATGAGGATGACCTCTTTA
              130       140       150       160       170       180
          100       110       120       130       140       150
16.4.1 CAGATCAGAAAGTCAAGAAGAATGAGACAAAATCCAATAGTCAGCAGGATGTCATATTAA
       :::::::::::::::::::::::::::::::::::: :::::::::::::::::::::::
_      CAGATCAGAAAGTCAAGAAGAATGAGACAAAATCCAGTAGTCAGCAGGATGTCATATTAA
              190       200       210       220       230       240
          160       170       180       190       200       210
16.4.1 CAACACAAGATATTTTTGAGGATGATATATTTGCTACGGAAGCAATTAAACCCTCTCAGA
       ::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::
_      CAACACAAGATATTTTTGAGGATGATATATTTGCTACGGAAGCAATTAAACCCTCTCAGA
              250       260       270       280       290       300
          220       230       240       250       260       270
16.4.1 AAACCAGAGAGAAGGAGAAAACATTGGAATCTAATTTATTTGATGATAACATTGATATCT
       ::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::
_      AAACCAGAGAGAAGGAGAAAACATTGGAATCTAATTTATTTGATGATAACATTGATATCT
              310       320       330       340       350       360
          280       290       300       310       320       330
16.4.1 TTGCTGACTTAACTGTAAAACCAAAAGAAAAGTCCAAAAAGAAAGTGGAAGCCAAGTCTA
       ::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::
_      TTGCTGACTTAACTGTAAAACCAAAAGAAAAGTCCAAAAAGAAAGTGGAAGCCAAGTCTA
              370       380       390       400       410       420
          340       350       360       370       380       390
16.4.1 TATTTGATGATGATATGGATGACATCTTCTCCTCTGGTATCCAGGCTAAGACAACCAAAC
       :::::::::::::::::::::::::::::::: :::::::::::::::::::::::::::
_      TATTTGATGATGATATGGATGACATCTTCTCCACTGGTATCCAGGCTAAGACAACCAAAC
              430       440       450       460       470       480
          400       410       420       430       440       450
16.4.1 CAAAAAGCCGATCTGCACAGGCCGCACCTGAACCAAGATTTGAACACAAGGTGTCCAACA
       ::::::::::::::::::::::::::::::::::::::::::::::::::::::::: ::
_      CAAAAAGCCGATCTGCACAGGCCGCACCTGAACCAAGATTTGAACACAAGGTGTCCACCA
              490       500       510       520       530       540
          460       470       480       490       500       510
16.4.1 TCTTTGATGATCCCCTGAATGCCTTTGGAGGCCAGTAGAGCACACAGGGTATCCACATGT
       :::::::::::.:: ::::::::::::: ::::::::::. ::::::::: ::: :::::
_      TCTTTGATGATNCC-TGAATGCCTTTGG-GGCCAGTAGAN-ACACAGGGT-TCC-CATGT
              550        560        570        580        590
          520       530       540       550       560       570
16.4.1 TACCCTGCAGCTACATTGTTGAGTTAGTGATGATGTTGTATATGCTGATGGTCTTAACTG
       :.:: :: :: ::::: :::::::. :::   :::.:     :::   ::: :::::: :
_      TNCC-TGAAG-TACAT-GTTGAGTN-GTGTGTATGNT-----TGCC--TGG-CTTAACGG
          600         610        620            630          640
          580       590       600       610       620       630
16.4.1 GATTACAAAAAGCAAATACTAGAACAGCTAGCTCATCGTTCACCCAATGTACTTGGTATT
       :  : ::::.           ::
_      G--TCCAAAN-----------GA-------------------------------------
             650
          640       650       660       670       680       690
16.4.1 TTTCTGCACTGGTTTAATCATGCTTAATACTACAAAACAAAAATAAATATTTCACAGTGG
         :::::: ::                  :  :                ::::
_      --TCTGCAGTG------------------CCCC----------------TTTC-------
             660                                         670
Fig. 3.3 B  Alignment between 16.4.1 and 343275 5’ clones. The different codons
of the two clones are pointed out in bold letters and by boxes. The start and the stop codons are
shown in red and green respectively.
3.2. Computer sequence data analysis of the 11.5.1 and 16.4.1 clones
After identification of the 4 “putative” unspecific Rev binding cDNAs as false
positive clones, the 11.5.1 and the 16.4.1 cDNA sequences were analyzed in more
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detail employing several computer programs. At the beginning of this analysis the
cDNA clone for KIAA0592 protein had not yet been reported. Using FASTA and
BLAST search it was difficult to identify any significant homology of the 16.4.1 clone
with known proteins. However a very weak and partial homology appeared with
some RNA-/DNA- binding proteins as shown in the table 3.7.
                          Protein             Similarity with 16.4.1 clone
Name(source) Size (aa) Function Location (aa)    %Identity       Score
RNA Helicase a 671    RNA binding 2-78 32.5%/77aaa     91
Cylicin h 598 spermatogenesis 4-119 24.6%/118aa 86
MECpGB-2 h 486 DNA binding 122-147 42.3%/26aa 76
Chitin synthase 3 n 960 glycosyltransferase 145-161 66.7%/18aa 74
MAP1.2 m 2464 microtubule binding 86-146 26.2%/61aa 74
U1 snRNP A y 298    RNA binding 34-158 20.5%/127aa 67
Nucleolin C23 r 713 DNA/RNA binding 8-53 28.3%/46aa 65
Nopp140 r 734 nucleolus shuttle 63-143 24.7%/81aa 66
Histone H5 x 196  DNA binding 68-134 22.9%/70aa 49
Fibrillarin h 321 RNA binding 16-27 54.5%/11aa 45
Table 3.7    Similarity of 16.4.1 clone to protein with known function. Initial
letters were used to indicate the species source as (a) Arabidopsis Thaliana, (h) human, (m)
mouse, (n) neurospora crassa, (r) rabbit, (y) yeast Saccharomyces cerevisiae, (x) Xenopus
laevis. The similarity analysis was performed using local alignment program. Location indicates
the corresponding region in 16.4.1 sequence. Score indicate the highest score obtained for each
query protein and is correlated with the location and % identity. aaa indicates the number of
amino acids overlapping.
3.2.1. BCM search launcher program
3.2.1.1. BEAUTY search results
One of the preferred programs was BEAUTY (BLAST Enhanced Alignment Utility) in
the BCM search launcher. This program is an enhanced version of the NCBI's
BLAST database search tool. It integrates multiple biological information resources
into sequence similarity search results, offering detection of weak, but functionally
significant, matches in BLAST database searches.
One of the databases used in the search was the CRSeqAnnot database. This
database (78,469 sequences) contains full-length protein sequences with family and
conserved region information. Other full-length sequences that contain at least one
annotated domain/site are also listed.
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Performing the query with the 11.5.1 cDNA-encoded protein, a considerable
number of DNA-binding proteins with high scores were represented as shown in
the Table 3.8.
However performing the query with the 16.4.1 cDNA-encoded protein, different
proteins appeared on the resulting list. Unfortunately none of them was
represented with high scores (max score was 61). Nevertheless the list contained
shuttle proteins (nop140=nucleolus-cytoplasm shuttle phosphoprotein, nucleolin
c23) and RNA-/DNA-binding proteins (u1 small nuclear ribonucleoprotein A,
methyl-CPG-binding protein 2, etc) as shown in the Table 3.9.
Sequences producing High-scoring Segment Pairs: Score    Smallest Sum Probability
Similar to dbpB/YB-1 of mouse       191  1.1e-38   
CCAAT-binding transcription factor I subunit A - mouse 312 3.5e-36
DNA-binding protein B 312   5.0e-36   
transcription factor YB-1 - Mouse               304  4.4e-35   
Y box binding protein-1 (y-box transcription binding factor I) 296  5.7e-34   
DNA-binding protein                             251  8.4e-28   
Nuclease sensitive element binding protein-1    251  8.5e-28   
…etc…..
Table 3.8   Beauty search results of 11.5.1 clone. Among the proteins proposed to
share some similar function with the 11.5.1 clone it was shown with high score the DNA
binding protein dbpB (written in bold).
Sequences producing High-scoring Segment Pairs: Score    Smallest Sum Probability
M-phase inducer phosphatase (mitosis initiation)   49  0.045     
Microtubule-associated protein 1B               40  0.87      
Nopp140 protein A – rat nucleolus-cytoplasm shuttle phosphoprotein 50  0.95      
Cylicin.                                        61  0.97      
Methyl-CPG-binding protein 2 (MECP-2 protein)  54  0.999997  
U1 small nuclear ribonucleoprotein A 37  0.999999  
Minor capsid protein                            56  1.000000  
Initiation factor eIF-2 beta chain - rabbit     49  1.000000  
Elongation factor 1 gamma, EF-1 gamma    55  1.000000
RNA-directed RNA polymerase (EC 2.7.7.48)/coat fusion protein   44  1.000000  
Chitin synthase 2 (chitin-UDP acetyl-glucosaminyl transferase  54  1.000000  
Nucleolin (protein C23).                   51  1.000000  
Histone H2B                                     41  1.000000  
…etc…..
Table 3.9    Beauty search results of 16.4.1 clone.
3.2.1.2. BLOCKS search results
A BLOCKS search (see 2.6.) with the sequence of the 11.5.1 and 16.4.1 clones was
performed to receive more information on which family of proteins they could belong
to.
However performing the query with both 11.5.1 and 16.4.1 cDNA-encoded
proteins, few member of family proteins appeared on the resulting list and only
with low scores, suggesting low significance of these results.
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Using the program at different times, first in September 1997 and the second time in
March 2000, different results were obtained. Probably this is due to a different
number and subgroups of sequences representing the blocks, to a new version of the
program and as well to the low scores obtained in both searches with both clones.
Within the first search performed in 1997 the query was compared to 4754 block
databases. Within the second search performed in the 2000 the query was compared
to 10532 block databases.
10 possible hits reported                          
Alkylbase DNA glycosidases
Floricaula / Leafy protein   
HIV Tat domain signature **
HIV Rev protein     ***   
Mas20 protein import receptor signature
Ribosomal protein L2 proteins     
Phosphatidylinositol transfer proteins
Polysaccharide deacetylase
Protamine P1 proteins
Synapsins proteins                
**   
TAT_HV1RH   50      KKRRQRRGPPQGSQTHQ
                          | |||||   |
11.5.1      88      yRpRfRRGPPrQRQPRE
    ----------------------------------------------------
***   
REV_HV1A2|P04623   26      NPPPSPEGTRQARRNRRRRWRERQRQIR
                                |||  | ||  |||        |
11.5.1             14      gsesaPEGqAQQRRpyRRRRfppyymrR
Table 3.10  BLOCKS search results of 11.5.1 clone. List of hits founded in both
searches (1997 and 2000).
7 possible hits reported                          
p53 tumor antigen proteins.      
Plasmid replication protein      
Flavivirus glycoprotein          
Methyl-CpG binding domain        
Heat shock hsp90 proteins family
General diffusion Gram-negative  
AAA-protein family proteins.     
Table 3.11   BLOCKS search results of 16.4.1 clone. List of hits founded in both
searches (1997 and 2000).
Interestingly, among the hits proposed for the clone 11.5.1 appeared the NLS block
of both HIV-1 Rev and Tat. Suggesting that the cDNA-encoded protein 11.5.1
contain an arginine-rich region with weak similarity with the NLS of both HIV-1
Rev and Tat proteins (Table 3.10).
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Among the hits proposed for the clone 16.4.1 (Table 3.11), several proteins with
DNA-binding function were listed. Confirming in some way the results already
obtained by the BEAUTY search, which were suggesting weak similarity with some
RNA-/DNA-binding proteins.
3.2.1.3. PROSITE pattern search results
To define the possible presence of already known motifs in 11.5.1 and 16.4.1
sequences a PROSITE pattern search using the 1994 EMBL Data Library based on
the MacPattern program was performed.
Regarding the 171 aa in the 11.5.1 clone 5 hits were obtained (Table 3.12 A),
suggesting one glycosylation, one amidation and three phosphorylation sites.
Regarding the 163 aa in the 16.4.1 clone 11 hits in the sequence were obtained
(Table 3.12  B), suggesting one glycosylation, and ten phosphorylation sites.
A
1 match ASN-glycosylation 159:
NSSA
1 match PKC-phospho-site 4:
TRR
2 matches CK2-phospho-site 23: 161:  
SAPE SAPE
1 match Amidation 49:
YGRR.
B
1 match ASN-glycosylation 39:
NETK
5 matches PKC-phospho-site 9: 70: 96: 103: 129:
                       SAK   SQK TVK SKK TTK
5 matches CK2-phospho-site 1:  2: 45:  52: 111:
                           SSDD  SDDD SQQD TTQD SIFD
Table 3.12  PROSITE search results of 11.5.1 (A) and 16.4.1 (B) clones.
3.2.2. Alignment of 16.4.1 with already known NLSs and NESs
The results of the sequence analyses indicated that the 16.4.1 protein could be a
member of a new family of nucleus-cytoplasm shuttle proteins involved in RNA-
/DNA-binding. Active nuclear import and export of proteins are generally known to
be mediated by signal-mediated transport. An increasing number of NLSs and NESs
have been identified in the last years (see 1.2.). To identify the presence or possible
similarities to one of these signals in the 16.4.1 cDNA-encoded protein, PSORT II
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program search (see 2.6.) as well a direct alignment or local alignment with the more
known NLS and NES was performed. PSORT II in fact is a web program that predicts
sorting signals and localization sites (as cleavage sites, trans-membrane segments and
nuclear localization signals) of proteins from their amino acid sequences.
Parts of the results are shown in Fig. 3.4 A and Fig.3.5 and suggest that the 16.4.1
sequence does not contain the “classical” signals known for mediating nucleus-
cytoplasm transport. However the presence of a lysine-rich cluster KPKEKSKKKVEAK
at 98 aa position that could possibly function as NLS or nucleolus localization
signal (NOS) was detected.
A
NUCDISC: discrimination of nuclear localization signals NLS Score: -0.22
 PKEKSKK (3) at  99
PROSITE DNA binding and ribosomal protein motifs:  none
NNCN: Reinhardt's method for Cytoplasmic/Nuclear discrimination
Results of the k-NN Prediction k = 9/23
 60.9 %: nuclear
 21.7 %: cytoplasmic
  8.7 %: cytoskeletal
  4.3 %: mitochondrial
  4.3 %: plasma membrane
>> prediction for QUERY is nuc (k=23)
B
NUCDISC: discrimination of nuclear localization signals NLS Score:  1.87
 RRRR (5) at   30 and 129
 RRRP (4) at  130
 PYRRRRF (5) at   28
 PRFRRGP (5) at   84
 PPQRRYR (3) at  117
 PQRRYRR (4) at  118
PROSITE DNA binding and ribosomal protein motifs:  none
NNCN: Reinhardt's method for Cytoplasmic/Nuclear discrimination
Results of the k-NN Prediction   k = 9/23
 65.2 %: nuclear
 13.0 %: cytoskeletal
  8.7 %: cytoplasmic
  4.3 %: Golgi
  4.3 %: plasma membrane
  4.3 %: vesicles of secretory system
>> prediction for QUERY is nuc (k=23)
Fig. 3.4     PSORTII search results of 11.5.1 (A) and 16.4.1 (B) clones.
Performing the PSORTII search with the amino acid sequence of 11.5.1 clone
several arginine-rich signals were suggested on the resulting list (Fig. 3.4B).
Confirming the results already obtained by the BLOCKS search, which were
suggesting that the cDNA-encoded protein 11.5.1 contain an arginine-rich region
with weak similarity with the NLS of both HIV-1 Rev and Tat proteins.
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Results from Lalign  GeneStream              
using matrix file : blosum50 , gap penalties: -14/-4
16.4.1 compared to classical basic NLSs
• SV40 T antigen pkkkrkv (monopartite NLS) max score: 28
66.7 % identity in 6 aa overlap      score: 28
    99
16.4.1 PKEKSK
    ::.: :
SV40   PKKKRK
66.7 % identity in 6 aa overlap score: 26     
   102
16.4.1  KSKKKV
  :.:.::
SV40   KKKRKV
• Nucleoplasmin krpaatkkagqakkkk  (bipartite NLS) max score: 14  
• c-myc        paakrvkld max score: 14
• Rev nrrrrwre        max score: 17
• Tat             rkkrrqrrr max score: 22
16.4.1 compared to NESs (leucine-rich)             
• PKI lalklagldi max score: 14
• Rev lpplerltld max score: 19
• TFIIIA   slvldklti            max score: 18    
• IkBa qqlgqltlenl max score: 18
• p53 mfrelnealel max score: 22
16.4.1 compared to other signals important for NLS and/or NES
• Importin α   rmrkfknkgkdtaelrrrrvevsvelrkakkdeqilkrrnv
import signal (= Importin β-binding domain) max score: 27        
38.5 % identity in 13 aa overlap score: 25
        98
16.4.1   KPKEKSKKKVEAK
    : :.:.:  .: .
Importin α     KFKNKGKDTAELR
  4
• hnRNP protein A1 nqssnfgpmkggnfggrssgpyggggqyfakprnqggy
import signal = export signal (M9) max score: 29
23.5% identity in 17 aa overlap  score: 29
       128    
16.4.1   KTTKPKSRSAQAAPEPR
         ... : . ..:   .::
M9    RSSGPYGGGGQYFAKPR
                    17  
Fig. 3.5 Lalign GeneStream results of 16.4.1 clone. Bold letters label residues that
have been shown to be particularly important for signal function. 16.4.1 contains a lysine-rich
sequence.
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3.2.3.  Identification of a common motif with other Rev-interacting factors
3.2.3.1. Alignment of 16.4.1 with already known Rev-interacting factors
Additionally, possible similarities between the sequences of 16.4.1 and 11.5.1 cDNA-
encoded proteins and sequences of already known Rev-interacting factors (Table
1.3) have been investigated using alignment programs.
A thorough analysis of the results showed that the 16.4.1 sequence exhibits a high
percentage of identity with many other Rev-interacting factors in the same N-
terminal region. Data are shown below.
Results from Lalign  GeneStream              
using matrix file: blosum50 , gap penalties: -14/-4
• 16.4.1 compared to hCrm1 (1071 aa)  max score: 40
      14     
16.4.1 PAKKTNPFPLLE
       : ..:: : ::. 50% identity in 12 aa overlap score: 36
Crm1   PEHRTNFFLLLQ
     842
• 16.4.1 compared to heIF-5A (154 aa)  max score: 37
    14  
16.4.1 PAKKTNPFPLLEDEDDLFT
       :  : : : :.  .:  .. 31.6% identity in 19 aa overlap score: 35
eIF-5A PNIKRNDFQLIGIQDGYLS
      82
• 16.4.1 compared to hp32 (278 aa)  max score: 45
       8    
16.4.1 QSAKPKPAKKTNPFPLL
       :  .: :   : :: :: 47.1% identity in 17 aa overlap score: 45
p32    QLLQPAPRLCTRPFGLL
    26  
• 16.4.1 compared to hRab/Rip (562 aa)  max score: 72
       2    
16.4.1 SDDDLFQSAKPKPAKKTNPF
       :....  .: :. :..::::   40% identity in 20 aa overlap score: 52
Rab    STNPFVAAAGPSVASSTNPF
     432   
• 16.4.1 compared to yNup42=yRip1p (430 aa)  max score: 49
       1
16.4.1 SSDDDLFQSAKPKPAKKTNPFPLLE
       .:... : .:.  :   :.::  :.   32% identity in 25 aa overlap
Rip1p  NSNNSAFGAASNTPLTTTSPFGSLQ score: 49
     164        
Fig. 3.6  Lalign GeneStream results of 16.4.1 clone. Bold letters label residues in
the 16.4.1 sequence that are highly conserved in the alignment with other Rev-interacting
proteins.
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3.2.3.2. Definition of a new specific motif shared between several Rev-interacting
factors
Based on these results two consensus motifs for the Rev-interacting factors (Crm1,
eIF-5A, hRab/Rip, p32, yRip1p and 16.4.1) have been designed (Fig. 3.7). The
common motif consists of 12 amino acids and includes 4 highly conserved residues.
The consensus motif 2 was designed for maximal conservation. Even allowing one
amino acid mismatch to each protein it appears stricter than motif 1 (Fig. 3.7). To
analyze the specificity of the motif for the Rev-interacting factors, the two motifs
were scanned against all available sequence databanks using two different programs:
Find patterns available in GCG program and PATTINPROT search available in
Network Protein Sequence (NPS) web site.
Identical results were obtained using both programs. Of all sequences analyzed
(SwissProtPlus + PIR + SPTrembl = 514652 sequences), the only proteins
identified as containing the motifs 1 and 2 were the known Rev-interacting factors
plus the hypothetical proteins containing the 16.4.1 sequence (Table 3.13 and
Table 3.14).
Pattern    mismatches
(PV)(AELNR)(KHILST)(KCRST)(TR)(NRS)(PDF)F(PGLQ)(LST)(LIN)(EAGQS)     0
Sequence databank n˚ proteins matches sequence
SwissProtPlus (209668 seq.)  7:
1 h Crm1 PEHRTNFFLLLQ
3 h,c,r eIF-5A PNIRRNDFQLIG
1 h Rab VASSTNPFQTNA
1 h Rip VASSTNPFQTNA
1 y Nup42/yRip1p PLTTTSPFGSLQ
PIR (107076 seq.)  7:
3 h,c,r eIF-5A PNIRRNDFQLIG
1 h p32 PRLCTRPFGLLS
1 h Rab VASSTNPFQTNA
1 h Rip VASSTNPFQTNA
1 y Nup42/yRip1p PLTTTSPFGSLQ
Table 3.13 RESULTS using Find patterns in GCG program with pattern
consensus motif 1.  For some proteins more than one match was proposed for the same
protein indicating different species source as human (h), chicken (c), rabbit (r), yeast (y).
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     Detection of a common 12 amino acids motif in the Rev-interacting proteins
h16.4.1  163 aa  14P A K K T    N    P F P L L E25
hCrm1   1071 aa 842P E H R T    N    F F L L L Q853
heIF-5A  154 aa  82P N I K R    N    D F Q L I G93
hp32     278 aa   32P R L C T    R    P F G L L S43
hRab/Rip 562 aa 444V A S S T    N    P F Q T N A455
yRip1p   430 aa 177P L T T T    S    P F G S L Q188
Consensus motif 1   [PV][AELNR][KHILST][KCRST][TR][NRS][PDF]   F  [PGLQ] [LST] [LIN] [EAGQS]
Consensus motif 2     P [AELNR][KHILST][KCRST] T N   [PD] F   [GLQ] [LST] [LIN] [EAGQS]
Fig. 3.7    Primary sequence of the minimal motif domain of selected Rev-interacting factors. The common motif consists
of 12 amino acids and includes 4 highly conserved residues (shown in bold). Consensus motif 1 is based on the presence of all
amino acids included in each protein domain. Consensus motif 2 allows one mismatch in each protein sequence. The amino
acids corresponding to the mismatches are underlined.
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Pattern    mismatches
 P (AELNR)(KHILST)(KCRST) T N (PD) F (GLQ)(LST)(LIN)(EAGQS)    1
Sequence databank n˚proteins matches sequence
SwissProtPlus/
SPTrembl (407576 seq.) 7 Rev-interacting proteins +
3 proteins containing 16.4.1 sequence:
1 h Crm1 PEHRTNfFLLLQ
3 h,c,r eIF-5A PNIRrNDFQLIG
1 h Rab vASSTNPFQTNA
1 y Nup42/yRip1p PLTTTsPFGSLQ
1 h p32 PRLCTrPFGLLS
1 h       * KIAA0592 prot. PAKKTNPFpLLE
1 h       * Hypothet.30.5kDa PAKKTNPFpLLE
1 h       * Hypothet.53.3kDa PAKKTNPFpLLE
Table 3.14  RESULTS using PATTINPROT with pattern consensus motif 2 .
For some proteins more than one match was proposed, indicating different species source as
human (h), chicken (c), rabbit (r), yeast (y). The amino acids corresponding to the mismatches
are expressed in small letters and in bold. The three matches with * are proteins containing the
16.4.1 sequence (Fig.3.2).
Query patterns containing partial modifications of one or more amino acids in the
consensus sequence led to isolate the Rev-interacting proteins plus a variable
increasing number of different proteins (Table 3.15).
Nevertheless, among all the Rev-interacting proteins, importin β , B23 and the two
recently identified Rev-interacting nucleoporins Nup98 and NLP-1 were not present
in this consensus motif. With the exception of Nup98, these proteins did not show a
high percentage of identity with the motif sequence of the N-terminal region of
16.4.1. Therefore, the similarities of the 16.4.1 sequence (PAKKTNPFPLLE) with the
importin β , B23, and NLP-1 protein sequences have been investigated with local
alignment program. Each sequence showing the highest similarity with 16.4.1 motif
has been used to create new motifs allowing the alignment of the additional proteins
(Fig. 3.8). Moreover, since Rev itself is a Rev-binding protein, Rev similarity with the
16.4.1 sequence (PAKKTNPFPLLE) has been investigated and a Rev-modified motif
has been created. Moreover, a modification of the consensus motif allowing the
alignment of other proteins Rev-related such as Sam68 (Reddy et al., 1999) (see
paragraph 3.6.), or 16.4.1-related such as Nopp140 or fibrillarin protein has also been
investigated. The subsequent screening analysis among all the sequences available in
the database, using the Nup98- or Rev-modified motif led to identify the already
previously selected Rev-interacting proteins plus the Nup98 protein or Rev itself.
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Rev-interacting motif P [AELNR][KHILST][KCRST]T N   [PD] F   [GLQ] [LST] [LIN] [EAGQS]  Score
hNup98       920 aa 894P A S q T t P l Q m a l905   39
HIV-1Rev     116 aa  21f L y q s N P p p n p E32   27
hImportinβ   876 aa 306P p e h T s k F y a k G317   23
hNLP1        423 aa  95f g L S e N P F a S L S106   26
hSam68       443 aa  68P p S a T g P d a T v G79   37
rNopp140     703 aa 278P L K K T a P k k q v v289   52
hB23         294 aa  85P t v S l g g F e i t p96   22
hFibrillarin 321 aa 204a k K R T N i i p v I E215   45
Motif Nup98-modified P [AELNR][KHILST][KCqRST] T Nt  [PD] F  [GLQ] [LmST][LaIN][EAGlQS]  a+0
Motif Rev-modified Pf[AELNR][KHILSTy][KCqRST]Ts N   [PD]   F  [GLpQ][LnST][LINp][EAGQS]   +0
Motif Imp. -modified P[AELNpR][KeHILST][KChRST]T N   [PDk] F  [GLQy][LaST][LkIN][EAGQS]   +1#
Motif NLP1-modified Pf [AEgLNR][KHILST][KCRST]T N   [PD] F  [GaLQ] [LST][LIN] [EAGQS]   +1*
Motif Sam68-modified P [AELpNR][KHILST][KaCRST]T Ng  [PD] F  [GaLQ] [LST][LINv][EAGQS]   +2*”
Motif Nopp140-modified P [AELNR][KHILST][KCRST] T Na  [PD] F  [GkLQ][LSTq][LINv][EAGQSv]   +2
Motif B23-modified P [AELNRt][KHILSTv][KCRST]T Ng  [PDg] F  [GeLQ][LiST][LINt][EAGpQS]   +3”
Motif Fibr.-modified P [AEkLNR][KHILST][KCRST] T N  [PDi] Fi [GLpQ][LSTv][LIN] [EAGQS]   +4
Fig. 3.8    Modification of the Rev-interacting motif allowing the presence of additional Rev-interacting and non-related
proteins. For each protein the region with highest similarity with the 16.4.1 motif sequence PAKKTNPFPLLE was selected. Score
regards the alignment of the sequence with 16.4.1 full-length or PAKKTNPFPLLE sequence. The amino acids conserved in the motif
are shown in bold, while in small letters are shown the additional amino acids. In each protein sequence one mismatch is allowed. The
amino acids corresponding to the mismatches are underlined. a indicates the number of unrelated proteins selected in addition to the
Rev-interacting proteins and the query protein using the Pattinprot search among the Swissprot and Sptrembl 456338 sequences.
#= Hypothetical 31.3 kDa protein (NPSA sptr||Q9X6Z7). * = Putative lipoprotein periplasmic GNA2132. ” = Adenyl cyclase.
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Pattern   mismatches  n˚proteins   matches sequence
P(AELNR)(KHILST)(KCRST)T N(PD)F(GLQ)(LST)(LIN)(EAGQS)  2    35: 10 Rev-interacting proteins (RIPs)
            +
     25 different proteins:
 Rab-R protein PLpSTNPFQpNG
 Capsid protein VP1 gLTSiNDFGTLA
 Adenyl cyclase PESSTgDtLTNS
…etc.
P   X      X       X  T N(PD) F(GLQ)(LST)(LIN)(EAGQS)  1    25: 10 RIPs + 15 different proteins:
CTD-binding SR-like prot.RA8 PPNVTNPaGLLG
TDC operon trans. activator PCDMTsPFGSN
…etc.
P   X      X       X  T N(PD) F(GLQ)(LST)(LIN)  -    1    65: 10 RIPs + 45 different proteins:
RNA binding protein PARSTtPFLLN
RNA polymerase PTSLlNDFLSI
RNA replicase polyprotein PKGKrNPFLTL
ATP-binding cassette transp. PYSHTNDFLSs
Gag polyprotein PANKnNPFQSL
DNA mismatch repair prot.MSH2 PQGPqNPFGSN
…etc.
-    X      X      X   T N(PD)F(GLQ)(LST)(LIN)(EAGQS)  1   334: 10 RIPs + 324 different proteins:
-(AELNR)(KHILST)(KCRST)T N(PD)F(GLQ)(LST)(LIN)(EAGQS)  1    19: 10 RIPs + 9 different proteins
P(AELNR)(KHILST)(KCRST)X N(PD)F(GLQ)(LST)(LIN)(EAGQS)  1    15: 10 RIPs + 5 different proteins
P(AELNR)(KHILST)(KCRST)T X(PD)F(GLQ)(LST)(LIN)(EAGQS)  1    16: 10 RIPs + 6 different proteins
P(AELNR)(KHILST)(KCRST)T N(PD)X(GLQ)(LST)(LIN)(EAGQS)  1    19: 10 RIPs + 9 different proteins
-(AELNR)(KHILST)(KCRST)X X(PD)X(GLQ)(LST)(LIN)(EAGQS)  0   983
-(AELNR)(KHILST)(KCRST)X X(PD)X(GLQ)(LST)(LIN)(EAGQS)  1    >5000
Table 3.15 Results  using PATTIMPROT.  Different query pattern with one or more amino acids modified in the consensus motif
2 was used for each search. 0, 1 or 2 mismatches were allowed. The amino acids modified in the query are expressed by a wild card
bold and underlined. The amino acids corresponding to the mismatches are expressed in small letters and in bold.
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The screening among the database of the importin β - or NLP-1-modified motif led to
identify the Rev-interacting proteins, comprising importin β or NLP-1 and the
addition of only 1 protein (Fig. 3.8). On the contrary, the screening of B23-, Sam68-,
Nopp140-, or fibrillarin-modified motif led to select in addition to the Rev-interacting
proteins a variable number (2-4) of other proteins (Fig. 3.8). As a control, Rev-
unrelated proteins such as glial fibrillary acid protein (GFAP) or fibronectin were also
tested in the motif alignment. The screening of GFAP- or fibronectin-modified motif
led to select in addition to the Rev-interacting proteins and GFAP or fibronectin, 5
and 13 additional proteins respectively (data not shown).
In summary, computer sequence analysis of 11.5.1 clone suggested that the 11.5.1
cDNA-encoded protein could belong to a transcription factors family, probably as
C-terminal part of the DNA binding protein dbpB. In addition, the presence of four
separated arginine-rich regions, some of which have a weak similarity with the
HIV-1 Rev and Tat NLS, suggested the presence in the 11.5.1 clone of arginine-rich
NLS.
Computer sequence analysis of the 16.4.1 cDNA encoded protein showed weak and
partial homology with some RNA-/DNA-binding proteins, some of which show a
nucleocytoplasmic activity. The presence of several serines and threonine residues
suggested ten hypothetical phosphorylation sites. Although no known signals for
mediating the nucleus-cytoplasm transport were recognized, the presence of a
lysine-rich cluster, with hypothetical NLS or NOS function was observed.
Moreover, several Rev-interacting proteins, such as Crm1, eIF5-A, hRab/Rip,
yRip1p and p32, showed a high homology with the N-terminal region of 16.4.1.
Based on these results a consensus motif consisting of 12 amino acids and 4 highly
conserved residues was proposed. This motif has been shown to be highly specific.
Scanning it against all available sequence databanks (407576 sequences
analyzed), the only proteins identified to contain that motif were the above
mentioned Rev-interacting proteins (and Rev itself).
3.3. 16.4.1 expression analysis  
The initial results indicated that only the clone 16.4.1 (and not the 11.5.1) shared a
common motif with other already known Rev-interacting factors. Moreover, the
16.4.1 cDNA encodes a protein with an unknown function, so that further studies
were concentrated on this clone. As described above, at the beginning the highest
similarity of the sequence of 16.4.1 cDNA was identified in the non-redundant
database of GenBank EST division with the Soares fetal heart NbHH19W Homo
sapiens cDNA clone 343275 5’. Differences between the two sequences were found
in both C- and N-terminal regions. The cDNA-translated sequence of the clone
343275 5’ contains 8 amino acids more in the N-terminal region and several amino
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acids more in the C-terminal region than the cDNA-translated from the 16.4.1
sequence (Fig. 3.9). Alignment of the two cDNA sequences (Fig. 3.3) showed that
only few bases were different and that two nucleotides were missing in the EST-clone.
The absence of these two nucleotides led to a frame shift in the 343275 5’-ORF,
eliminating the stop codon present in the sequence of 16.4.1 at position 490 bp. The
16.4.1 clone was thought to be part of the full-length cDNA expressed by the 343275
5’ clone in the EST database. It is known that often the sequences present in the
GenBank EST division are not very precise especially at the 3’ end.
Therefore a new version of 16.4.1 DNA was created to encode a new protein (Fig.
3.9) containing the “missing N-terminal part” (8 amino acids) of the Soares fetal
heart cDNA-encoded protein and terminating with the C-terminal part of 16.4.1. To
investigate the expression of this new Rev-interacting protein in the cell, analysis of
the gene, and expression on RNA and protein level were performed.
-    Soares   fetal    heart     NbHH19W     Homo    sapiens    clone    343275    5 '  200 aa
-    16 .4 .1   163 aa
- MFPALGEASSDDDLFQSAKPKPAKKTNPFPLLEDEDDLFTDQKVKKNETKSSSQQDVILTTQDI
- -------SSDDDLFQSAKPKPAKKTNPFPLLEDEDDLFTDQKVKKNETKSNSQQDVILTTQDI
- FEDDIFATEAIKPSQKTREKEKTLESNLFDDNIDIFADLTVKPKEKSKKKVEAKSIFDDDMDD
- FEDDIFATEAIKPSQKTREKEKTLESNLFDDNIDIFADLTVKPKEKSKKKVEAKSIFDDDMDD
- IFSTGIQAKTTKPKSRSAQAAPEPRFEHKVSTIFDDPECLWGQZNTGFPCSZSTCZVCVCCLAZRVQ
- IFSSGIQAKTTKPKSRSAQAAPEPRFEHKVSNIFDDPLNAFGGQ*
- RSAVPL
-    16 .4 .1     artificial    protein    =    Risp   171 aa
MFPALGEASSDDDLFQSAKPKPAKKTNPFPLLEDEDDLFTDQKVKKNETKSNSQQDVILTTQDIFE
DDIFATEAIKPSQKTREKEKTLESNLFDDNIDIFADLTVKPKEKSKKKVEAKSIFDDDMDDIFSS
GIQAKTTKPKSRSAQAAPEPRFEHKVSNIFDDPLNAFGGQ*
Fig. 3.9  Sequences of 16.4.1 and its correlates.  Identical amino acids presents in
16.4.1 and clone 343275 5’ of the EST database are indicated in bold. * indicates the stop
codon. As described in 3.5.4., 16.4.1 artificial protein fused to GFP is a nucleo-cytoplasmic
shuttle protein. Therefore it was termed Risp (=Rev-interacting shuttle protein).
3.3.1. Analysis of the 16.4.1 gene across species
A 16.4.1 DNA was used to probe a positively charged nylon membrane (Clontech´s
ZOO-BLOT) containing EcoRI-digested genomic DNAs derived from 9 eukaryotic
species: human, monkey (Rhesus), rat (Sprague-Dawley), mouse (Balb/c), dog, cow,
rabbit, chicken and yeast (Saccharomyces cerevisiae) (see 2.3.7.). The 16.4.1 DNA
probe was amplified by PCR from pcRisp-sg143 using the primers 17746 and 17747
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(Table 2.1), purified and [α32P]-labeled with [α32P]-dCTP using the random prime
labeling system of Pharmacia (see 2.3.6.5.2.). After O/N hybridization at 65˚C the
hybridized filter was washed under non-stringent conditions for detection of genomic
sequences with low homology. Three days exposure in the Fuji cassette at RT led to
detection of several bands. Although some bands were stronger (mouse, dog), others
weak (rat, cow) and some missing (rabbit, yeast), we concluded however 16.4.1 gene
is conserved across different species (Fig. 3.10 A). Moreover, since several large
EcoRI-fragments are shown in the filter, this suggests that the 16.4.1 sequence could
be part of a larger gene.  
3.3.2. Gene expression in human cells
To analyze 16.4.1 expression RNA from different human cells was prepared (see
2.3.6.1.). The following tumor cell lines were used: Jurkat T-cells (the source of the
yeast two-hybrid cDNA library), HeLa, HEK 293, U87, U138 and 85HG66. In
addition, primary human astrocytes and microvascular endothelial cells were used.
Ten µg of total RNA were transferred by Northern blot to Zeta-probe GT nylon
membranes (see 2.3.6.3). A 16.4.1 DNA amplified by PCR with primers 17357 and
17358 (see Table 2.1) and purified was [α32P]-labeled. The filter was hybridized O/N
at 65˚C and then was washed (as described in 2.3.6.4.). In every sample a weak
unique band a little bit lower than the 28S rRNA was observed, after 5 hours of
exposure at RT suggesting a size for the cDNA around 4.6-5 kb (Fig. 3.10 B). The
same weak band was observed after 7 days exposure with a x-ray film at – 80˚C.
In addition as a positive control for RNA levels, the filter was stripped (see 2.3.6.4.)
and re-hybridized with a probe for a housekeeping gene (GAPDH [α32P]-labeled
probe freshly prepared). After O/N exposure at RT a strong unique band lower than
the 18S rRNA around 1.6 kb was observed in every RNA sample.
Based on these results, it appeared that the mRNA expressed in the cells and
recognized by 16.4.1 probe was larger than the 343275  cDNA sequence in the EST-
database. In fact a more recent BLAST search showed that 16.4.1 cDNA could be the
C-terminal part of the KIAA0592 clone (4623 bp). This clone lacks a methionine
codon at the 5’end (Fig. 3.11) indicating that the sequence is incomplete. Therefore
the results indicated that 16.4.1 is expressed in the context of an mRNA 4.6-5 kb in
length. Moreover, the weak signals of mRNA recognized by the probe leads to the
suggestion that the constitutive expression of this 16.4.1/unknown gene is not very
high in cells growing under normal conditions.  
GAPDH 1.6 kb
RISP < 5 kb
 mRNA
 DNA
 A
 B
 mRNA
 C
RISP < 5 kb
Fig. 3.10    Analysis of 16.4.1 gene expression.  (A) Southern Blot analysis of genomic DNAs extracted
from the indicated species (Zoo-Blot from Clontech). (B and C) Northern Blot analysis of total RNA
extracted from the indicated human cells. For both analysis a 16.4.1 [α32P]-labeled probe was used.
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KIAA0592 1353 aa
VTPRAAWLGLGFRGSAVLGLCWQPRSPPSRAAGMMNRTTPDQELVPASEPVWERPWSVEEIRR  S
S  QSWSLAADAGLLQFLQEFSQQTISRTHEIKKQVDGLIRETKATDCRLHNVFNDFLMLSNTQFI
ENRVYDEEVEEPVLKAEAEKTEQEKTREQKEVDLIPKVQEAVNYGLQVLDSAFEQLDIKAGNSD
SEEDDANGRVELILEPKDLYIDRPLPYLIGSKLFMEQEDVGLGEL  SS EEGSVGSDRGSIVDTEE
EKEEEESDEDFAHHSDNEQNQHTTQMSDEEEDDDGCDLFADSEKEEEDIEDIEENTRPKRSRPT
SFADELAARIKGDAMGRVDEEPTTLPSGEAKPRKTLKEKKERRTPSDDEEDNLFAPPKLTDEDF
SPFGSGGGLFSGGKGLFDDEDEESDLFTEASQDRQAGASVKEE  SSSS  KPGKKIPAGAVSVFLGD
TQVFGAASVPSLKEPQKPEQPTPRKSPYGPPPTGLFDDDDGDDDDDFFSAPHSKPSKTRKVQST
ADIFGDEEGDLFKEKAVASPEATVSQTDENKARAEKKVTL  SSS  KNLKP  SS ETKTQKGLFSDEED
SEDLF  S  SQSASNLKGASLLPGKLPTSVSLFDDEDEEDNLFGGTAAKKQTLSLQAQREEKAKASE
LSKKKASALLF  S  SDEEDQWNIPASQTHLASDSRSKGEPRDSGTLQSQEAKAVKKTSLFEEDKED
DLFAIAKDSQKKTQRVSLLFEDDVDSGGSLFGSPPTSVPPATKKKETVSEAPPLLFSDEEEKEA
QLGVKSVDKKVESAKESLKFGRTDVAESEKEGLLTRSAQETVKHSDLF  S  SSS  PWDKGTKPRTKT
VLSLFDEEEDKMEDQNIIQAPQKEVGKGCDPDAHPKSTGVFQDEELLFSHKLQKDNDPDVDLFA
GTKKTKLLEPSVGSLFGDDEDDDLF  S  SAKSQPLVQEKKRVVKKDHSVNSFKNQKHPESIQGSKE
KGIWKPETPQANLAINPAALLPTAASQISEVKPVLPELAFP  SS EHRRSHGLESVPVLPGSGEAG
VSFDLPAQADTLHSANKSRVKMRGKRRPQTRAARRLAAQE  SS EAEDMSIPRGPIAQWADGAISP
NGHRPQLRAASGEDSTEEALAAAAAPWEGGPVPGVDTSPFAKSLGHSRGEADLFDSGDIFSTGT
GSQSVERTKPKAKIAENPANPPVGGKAKSPMFPALGEA  SS DDDLFQSAKPKPAKKTNPFP
LLEDEDDLFTDQKVKKNETK  S  S  SQQDVILTTQDIFEDDIFATEAIKPSQKTREKEK
TLESNLFDDNIDIFADLTVKPKEKSKKKVEAKSIFDDDMDDIF  S  SGIQAKTTKPKS
RSAQAAPEPRFEHKVSNIFDDPLNAFGGQ
Fig. 3.11   Sequences of KIAA0592. The amino acids present also in Risp are shown in
bold. Phenylalanine residues expressed as dipeptide motif FG (8) and FS (13), as well as runs
of serine are indicated (14).
To analyze a possible effect of Rev on the mRNA expression of this unknown gene,
RNA was extracted from HeLa and the astrocytoma cells 85HG66 non transfected
and transfected with pcRev. The RNA was blotted and analyzed as described above.
After 5 days of exposure in the Fuji cassette in every sample, a weak band a little bit
lower than the 28S rRNA was detected and no quantitative differences were
observed between transfected and non-transfected cells (Fig. 3.10 C). Since similar
levels of 28S rRNA expression were detected for each RNA preparation, an
additional positive control for RNA levels was not used. However a second
hybridization with a different 16.4.1 DNA probe and different washing conditions
showed the presence of two additional strong bands in the Rev-transfected cells
around the 18S rRNA and one larger than the 28S rRNA (data not shown).
For the analysis of protein production, several rat monoclonal antibodies against Risp
were prepared. To achieve this, the risp gene was cloned into the pGEX-3X vector to
allow expression and purification of Risp-GST protein (see 2.2.6.2.). The risp gene
was amplified by PCR from pcRisp-sg143 using the primers 17746 and 17747 (see
Table 2.1) and inserted into a BamHI/EcoRI restriction site. Four pGEX-3X-Risp
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plasmid clone preparations were sequenced and all contained the Risp insert in the
right correct frame with the GST gene. Two plasmids (4.1 and 4.2) were transformed
into E.coli (BLB21) by electroporation. Expression and purification of Risp-GST was
performed as described in 2.5.11. Both Risp-GST preparations were successful:
1.53mg/ml of fusion protein was obtained with the clone 4.1 and 1.77 mg/ml with the
clone 4.2.  One mg of Risp-GST protein from the 4.1 clone was sent to Dr. Elisabeth
Kremmer (GSF) to immunize rats. After several weeks, nine different rat monoclonal
antibodies were obtained (Table 3.16). Four out of nine antibodies recognized
exogenous expression of Risp protein by immunofluorescence procedure (see 2.5.2.)
in cells transfected with a Risp expression plasmid. However, with the same anti-Risp
antibodies and the same immunofluorescence protocol in HeLa and in U87 cells non-
transfected a weak unspecific fluorescence signal was observed.
Different dilutions (1:200, 1:500, 1:1000, 1:2000, 1:5000) of three monoclonal
antibodies against Risp (8A11, 8B6 and 5D3), which tested positive in
immunofluorescence staining, were also assessed by western blot analysis using cell
lysates from HeLa and U87 cells (Table 3. 16). All three antibodies were able to
recognize exogenous expression of Risp fusion proteins (Risp-GFP and Risp-IgG ~
60 kDa, Tat-Risp ~ 42 kDa). An additional weak band around 220 kDa was observed
in some, but not all cell lysates (Fig. 3.12). In addition, Michael Krappmann tested all
antibodies by western blot analysis using the recombinant Risp-GST protein. Seven
out of nine antibodies recognized the fusion recombinant protein and some of them
showed also a unspecific band around 220 kDa (Table 3. 16).
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Immunofluorescence Western Blot
Antibodies Dilutions Risp-IgG Dilutions Risp-GFP Tat-Risp *Risp-
GST
~ 220 KD
3E10 (?) 1:2
1:20
1:100
-
-
-
1:200 N.D. N.D. ++
5D3 (R2a)
= #7
1:50 + 1:200
1:500
1:1000
++++
+++
++
+++
-
-
+++ +
-
-
5D4 (R2a) 1:50 - 1:200 N.D. N.D. +++ -
6F11 (G1) 1:2
1:20
1:100
-
-
-
1:200 N.D. N.D. - -
6F12 (G1) 1:50 - 1:200 N.D. N.D. - -
7B4 (G1) 1:50 - 1:200 N.D. N.D. ++ ((+))
8A11 (G1)
= #4
1:50 + 1:200
1:500
1:1000
++
+
+
+
+
-
+++ -
(+)?
(+)?
8B6 (R2a)
= #1
1:50 + 1:200
1:500 **
1:2000
+++
+++
+++
-
-
+
+++ +
+
-?
8B8 (R2a) 1:50 + 1:200 N.D. N.D. +++ +++
Table 3.16  Summary of results obtained using several anti-Risp rat
monoclonal antibodies. Nine different anti-Risp antibodies were tested using U87 cells
transfected and non-transfected with pcIG-Risp plasmid (1µg) after fixation and
permeabilization by immunofluorescence technique. As positive control a Cy3-conjugated goat
anti-hIgG was used. Anti-Risp antibodies were also tested by western blot analysis to recognize
Risp fusion protein in cellular extracts or * using 10µg/ml of recombinant Risp-GST protein.
Proteins extracted from U87 and HeLa** cells (0.8x105 cells/60 mm plate) non- transfected and
transfected with 1µg of pcRisp-sg143 (Risp-GFP), pcIG-Risp (Risp-IgG) or pcTat-Risp (Tat-
Risp) plasmid were separated by gradient SDS-PAGE. The gel was blotted and protein detected
with the indicated rat monoclonal anti-Risp antibodies at different dilutions followed by a
second peroxidase-conjugated antibody (1:2000). (+) indicates weak signal. R2a indicates rat
IgG2a, and G1 IgG1.
M	1 	2 	3 	4 	5 	6 	7 	8 	9
220 KDa -
  66KDa -
  46KDa -
- Risp-GFP
M  Marker
1   HeLa
2   HeLa/pcRisp-sg143
3   HeLa/pcTat-Risp
4   HeLa/pcIG-Risp   
5   HeLa/pcRev-sg143
6   mouse cells
7   U87/pcRisp-sg143
8   U87
9   U87/pcRev
- ?
Fig.  3.12  Western Blot analysis of Risp.    Proteins extracted from HeLa, U87 or mouse
cells (0.8 x105 cells/60 mm plate) non transfected or transfected with 1µg of the indicated 
plasmids were separated by gradient SDS-PAGE. The gel was blotted and protein detected 
with the 8B-6 rat monoclonal anti-Risp antibody at dilution 1:500.
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In summary, to investigate the cellular expression of Risp, analysis on the DNA-,
RNA- and protein level was performed. 
The Southern blot analysis using a commercial blot, which contains genomic DNAs
derived  from  9 eukaryotic species indicated that  the risp gene  is common among 
different species. The Northern blot analysis showed a main, however weak, mRNA 
band around the size of 4.6-5 kb, indicating that  the risp probe recognized a larger
mRNA than the expected risp of 513 bp.  This  supports the  hypothesis  that Risp 
could  be  part of a larger protein such as  the predicted KIAA0592 (4623 bp; 
1353 aa) (Nagase et al., 1998). 
Analysis of Risp protein expression was performed with immunofluorescence and 
western blot analysis. Several tested monoclonal anti-Risp antibodies were able 
to recognize only exogenous expression of Risp fusion proteins (IgG-Risp, Risp-GFP
or Tat-Risp). No specific staining was observed in untransfected cells, suggesting 
that the available monoclonal Risp antibodies are not sensitive enough to recognize
the constitutive expression of the protein. 
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3.4. Characterization of domains responsible for Rev-Risp binding
3.4.1. In vivo Rev-binding assay in yeast cells
To define the regions involved in the interaction of Risp with Rev and vice versa, the
yeast two-hybrid approach was used again. Several segments of Risp were cloned
into the yeast pJG4-6 vector to encode acid blob B42 activation domain fusion
proteins (see Fig. 2.1E). In addition, a set of previously described Rev mutants within
different domains of Rev protein was cloned into the yeast pEG202 expression
plasmid to encode LexA fusion proteins (see Fig. 2.1E). The plasmids were
transformed into the yeast selection strains EGY48/pSH18-34 and EGY48/pJK103
and the Rev-binding specificity test was performed.
3.4.1.1. Preparation of several prey plasmids containing different regions of Risp
To locate the domain of Risp involved in the Rev-binding using the yeast two-hybrid
system, full-length or parts of the risp cDNA were fused to the B42 activation domain
of pJG4-6 expression plasmid. As described in 2.2.6.3.2. section, this vector is very
similar to the previously used pJG4-5; the only difference is, that in the pJG4-6
expression plasmid the cloning site is represented by the restriction enzymes
MluI/NotI instead of EcoRI/XhoI in the pJG4-5. Several cDNAs encoding N-terminal
or C-terminal peptides or the full-length Risp protein were generated by PCR
amplification using Risp-GFP as DNA template. Each 5’ primer contained a MluI
restriction site and each 3’ primer a NotI site (see Table 2.1). Seven constructs
generated with standard subcloning techniques were sequenced and each confirmed
correct plasmid was kept for further use (Fig. 3.13).
3.4.1.2. Determination of Risp region interacting with Rev
In order to identify which region of Risp is involved in the Rev-binding, three
independent experiments were performed. In each experiment EGY48/pSH18-34 and
EGY48/pJK103 yeast cells expressing the bait proteins were transformed with all the
different Risp-prey expression plasmids. Rev protein in sense orientation was used as
a bait whereas Rev antisense and the cytoplasmic domain of CD2 were used as
unspecific bait controls.
Each transformation mix was plated on Glc/CM Ura-, His-, Trp- dropout plates and
incubated at 30˚C for 2-3 days. The growth in these plates allowed selection of only
successfully transformed yeasts harboring both bait and prey expression plasmids. To
perform the Rev-binding specific test, six independent colonies from each
transformation plate were mixed in 1ml of sterile water, diluted 100 and/or 1000-fold
and plated on Gal/Raff/CM Ura-, His-, Trp-, Leu- and Glc/CM Ura-, His-, Trp-, Leu-
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plates. The growth of cells was monitored for several days. Clones were considered
positive when the number of yeast clones growing in Gal/Raff/CM Ura-, His-, Trp-,
Leu- plates was higher than 100 and when no significant growth was observed in
Glc/CM Ura-, His-, Trp-, Leu- plates. After 4-5 days of incubation at 30˚C none or
maximal up to 5 transformants grew in the absence of leucine in glucose plates. A
limited number (< 10) of yeast clones encoding the first or the last 38 aa of Risp
[transfected with pJG4-6-(2-38) or pJG4-6-(134-171)]  was able to grow on galactose
plates lacking leucine regardless of which bait protein was co-expressed. However a
high number (200-2000) of yeast clones expressing Risp or 16.4.1 cDNA encoded
protein or the other segments of Risp were able to grow in galactose plates lacking
leucine in presence of Rev sense as bait protein. In presence of the unspecific bait
only a limited number (< 31) of yeast clones grew in absence of leucine. Results of
one individual experiment are shown Table 3.17.
Figure 3.13 shows Risp regions that interact with Rev and represents the summary
of all three experiments. It is not clear, which is the minimal sequence part of Risp
required for the Rev-interaction. Nevertheless, we can assume that the binding
domain is located in the middle of the Risp protein between amino acids 39-133. In
addition it was shown that the N-terminal region of Risp harboring the motif
(PAKKTNPFPLLE, 22-33aa) common to Risp and to other Rev-interacting factors
is not essential for the Rev-binding.
 Fig. 3.13 Risp regions interacting with Rev. Summary of three experiments.
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38
73
133
39
74
134
  Binding to Rev
++
-
++
+
++
+
-
pJG4-6-Risp
pJG4-6-(2-38)
pJG4-6-(2-73)
pJG4-6-(2-133)
pJG4-6-(39-171)
pJG4-6-(74-171)
pJG4-6-(134-171)
  Prey plasmids
  Rev binding region
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  Yeast strains       Plasmids        Transformants on Glc/CM   Glc/CM Gal/Raff
           Ura-, His-, Trp-      Leu-    Leu-
  
pJG4-5-16.4.1   15 0   300 +
pJG4-6-Risp 648 1 1040 ++
pJG4-6-(2-38) 320 0       2 -
pJG4-6-(2-73)   31 0   200 +
EGY48/pSH18-34/
pEG202-sRev sense
pJG4-6-(2-133)   74 0   704 ++
pJG4-5-16.4.1   12 0     24 -
pJG4-6-Risp   94 0     31 -
pJG4-6-(2-38) 160 0       6 -
pJG4-6-(2-73)     5 0       3 -
EGY48/pSH18-34/
pEG202-LexCD2
pJG4-6-(2-133)     3 0       3 -
pJG4-5-16.4.1     1 0       0 -
pJG4-6-Risp   34 0   800 ++
pJG4-6-(2-38) 248 1       0 -
pJG4-6-(2-73)    9 0   368 +
EGY48/pJK103/
pEG202-sRev sense
pJG4-6-(2-133)   23 0 1360 ++
pJG4-5-16.4.1   19 0       2 -
pJG4-6-Risp 252 0     30* -
pJG4-6-(2-38) 164 0       1 -
pJG4-6-(2-73)   46 0       6 -
EGY48/pJK103/
pEG202-sRev
antisense
pJG4-6-(2-133)   34 0       0 -
pJG4-5-16.4.1 136 0         0 -
pJG4-6-Risp 200 0         1 -
pJG4-6-(2-38) 224 0         0 -
pJG4-6-(2-73)   82 0         0 -
EGY48/pJK103/
pEG202-LexCD2
pJG4-6-(2-133) 104 0         0 -
Table 3.17  Selective yeast growth in absence of leucine. Results of one
experiment. +/++/- indicate yeast growth and therefore strength of binding: + = binding, ++ =
stronger binding, - = no binding. * indicate growth of yeast cells very small.
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3.4.1.3. Preparation of several bait plasmids containing different Rev mutants
Several mutants of Rev (RevM4, RevM5, RevSLT40, Rev M10BL; see Fig. 2.1E)
were cloned in the pEG202 bait expression plasmid. As described in 2.2.6.3.1. each
Rev mutant was generated by PCR amplification of a cDNA template with the
respective mutation. Both 5’and 3’ primers used contained an EcoRI restriction site
to allow insertion in frame with LexA into the unique EcoRI restriction site of the
pEG202 vector (Table 2.1) in sense and antisense orientation. Seven Rev-bait
plasmids generated with standard subcloning techniques were sequenced and each
correct plasmid was kept for further use (see Fig. 3.15).
The plasmids containing the RevM10BL mutation were prepared at a later time point
and analyzed by Christian Bickel. Using the lithium acetate procedure both yeast
strains EGY48/pSH18-34 and EGY48/pJK103 were transformed with the different
bait expression plasmids. All transformants were selected for growth in Glc/CM Ura-,
His- plates.  Although the pEG202 bait plasmid is very big (~ 10 kb) and the
efficiency of transformation was not very high as is shown in the Table 3.18, it was
possible to isolate at least one yeast strain harboring a Rev mutant for each bait
construct.
Yeast strains Bait plasmids Transformants
EGY48/pSH18-34 pEG202-Rev sense   4
EGY48/pSH18-34 pEG202-RevM4 sense   0
EGY48/pSH18-34 pEG202-RevM4 antisense   1
EGY48/pSH18-34 pEG202-RevM5 sense 10
EGY48/pSH18-34 pEG202-RevSLT40 sense   6
EGY48/pJK103 pEG202-Rev sense   2
EGY48/pJK103 pEG202-RevM4 sense   6
EGY48/pJK103 pEG202-RevM4 antisense   1
EGY48/pJK103 pEG202-RevM5 sense 31
EGY48/pJK103 pEG202-RevSLT40 sense   6
Table 3.18  Yeast transformants with different Rev-bait expression plasmids.
To investigate whether these Rev proteins do not activate transcription of the
reporter genes without the prey constructs by themselves, the leucine- and X-gal-bait
test were performed. One clone of each yeast transformant was incubated O/N in
Glc/CM Ura-, His- medium. Half ml of the yeast suspension culture was diluted 100
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and 1000-fold in sterile water and plated in parallel on Glc/CM Ura-, His-, Leu-,
Gal/Raff Ura-, His-, Leu- and Gal/Raff Ura-, His-, X-gal plates. The growth of cells was
monitored for several days. All yeast clones on the Gal/Raff Ura-, His-, X-gal plates
grew well and were white, without showing any transcription activity of the lacZ
gene. In addition in the absence of leucine in both glucose and galactose plates no
yeast transformants grew. Only in the case of yeast EGY48/pJK103 expressing the
plasmid pEG202-RevM4 sense a very low background (4 clones) of growth in
Gal/Raff Ura-, His-, Leu- plates was detected.
To demonstrate, that the Rev mutants are expressed as full-length proteins, each of
these LexA-Rev fusion proteins were analyzed by western blot using a polyclonal
Rev-specific antibody. Only yeast clones containing Rev in sense orientation showed
a band around 42 kDa with similar intensity as the Rev-LexA fusion protein (Fig.
3.14).
Fig .  3 .14    Yeast expressing the Rev-LexA fusion proteins. Same amount of
proteins extracted from EGY48 yeast cells transformed with the indicated Rev-bait expression
plasmids were separated by 12% SDS-PAGE, transferred to nitrocellulose, and then subjected
to western blot analysis using a rabbit anti-Rev specific antibody (1:1000).
3.4.1.4. Determination of a region in the N-terminal part of Rev interacting with
Risp
In order to identify the region in Rev responsible for binding to Risp the plasmids
pJG4-6-Risp and pJG4-6-(39-171) were transformed into the yeast strains containing
the bait plasmids shown below:
M  Marker
1   pSH18-34/pEG202-Rev
2   pSH18-34/pEG202-RevM4
3   pSH18-34/pEG202-RevM5
4   pSH18-34/pEG202-RevSLT40
5   pJK103/pEG202-Rev
6   pJK103/pEG202-RevM4
7   pJK103/pEG202-RevM4 antisense
8   pJK103/pEG202-RevM5
9   pJK103/pEG202-RevSLT40
 M    1       2      3      4      5       6       7       8       9
 85KDa -
 42KDa -
 14KDa -   - Rev-LexA
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    EGY48/pSH18-34/pEG202-Rev sense
 pEG202-RevM4 antisense
pEG202-RevM5 sense
pEG202-RevSLT40 sense
pEG202-RevM10BL sense
      EGY48/pJK103/pEG202-Rev sense
pEG202-RevM4 sense
pEG202-RevM4 antisense
         pEG202-RevM5 sense
         pEG202-RevSLT40 sense
         pEG202-RevM10BL sense
Each transformation mix was plated on Glc/CM Ura-, His-, Trp- dropout plates and
incubated at 30˚C for 2-3 days until colony growth was detected.  To perform the
leucine test, six independent colonies from each transformation plate were mixed in
1ml of sterile water, diluted 100 and 1000-fold and plated on Gal/Raff/CM Ura-, His-,
Trp-, Leu- and Glc/CM Ura-, His-, Trp-, Leu- plates.
The growth of cells was monitored for several days. After 4 days of incubation at
30˚C none of the yeast transformants grew in the absence of leucine in plates
containing glucose. However in plates containing galactose the expression of
activation-tagged-Risp protein was induced and yeast clones containing Rev wild
type, RevM4 and RevM10BL in sense orientation grew very well in absence of
leucine. Yeast clones containing the other Rev mutants as bait proteins were all
negative.
Figure 3.15 shows Rev mutants that interact with Risp analyzed in three
independent experiments.
It is not clear, which is the minimal portion of Rev protein required for the Risp-
binding. Nevertheless, it can be assumed that Risp is a cellular cofactor that
interacts with Rev in a region that overlaps the two domains of RNA binding/NLS
(34-50aa) and the second multimerization region (52-60aa). In fact two Rev
mutants, that affect the RNA binding region and the NLS (RevM5) and the second
multimerization region (RevSLT40), were unable to interact with the Risp fusion
protein. On the contrary, two Rev mutants affecting the first multimerization region
(RevM4) and the effector domain (RevM10BL) were able to bind Risp.
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Fig.3.15  Rev mutants interacting with Risp. Summary of three individual
experiments.
3.4.2. In vivo Rev-binding assay in mammalian cells
To assess interaction of Rev and Risp in human cells, we performed a mono-hybrid
assay developed by B.R. Cullen and his collaborators (Bogerd et al., 1995; Tiley
et al., 1992). This mammalian in vivo assay uses the HIV-1 tat-RNA sequence-
specific transcriptional activator to provide an indirect measure of the assembly of a
protein complex on a RNA target sequence. pSLIIBCAT was used as indicator
construct and pcTat-Rab or pcTat-Risp in presence of pcRev were used as activator
plasmids (see Fig. 2.1). Tat activates gene expression from the HIV-1 LTR after
binding the cis-acting RNA target sequence TAR. In the pSLIIBCAT plasmid the
TAR RNA stem-loop in HIV-1 LTR linked to CAT is replaced with the RRE-derived
stem loop IIB (SLIIB), the minimal RNA target sequence for HIV-1 Rev. Trans-
activation of the HIV-1 LTR in pSLIIBCAT is mediated by a Tat-Rev fusion protein
(Fig. 3.16). Rev is required to direct binding to the specific SLIIB RNA target and Tat
to activate the transcription. Therefore, in this assay Rev is provided in its wild-type
form while Tat is fused to a Rev-binding cellular protein (Rab or Risp). Interaction of
Rev with the cellular proteins fused with Tat recruits Tat to the HIV-1 LTR promoter
element and activates expression of CAT.
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Fig .  3 .16  In v ivo  mono-hybrid assay for Rev-binding: SLIIB-CAT. Cells are
transfected with the Tat/Rev-response plasmid pSLIIBCAT in presence of the activator
plasmids pcRev and pcTat-Risp. Stimulation of CAT expression is directed by recruitment of
Tat-Risp to the LTR by the interaction of Risp with Rev. Binding of the ternary complex to the
LTR is mediated by binding of Rev to SLIIB.
3.4.2.1. Preparation of pcTat-Risp plasmid
pSLIIBCAT, pcTat-Rev and pcRev expression plasmids were kindly provided by Dr.
B.R. Cullen. PcTat-Risp plasmid as well as pcTat-Rab, used as positive control, were
generated by substituting the rev gene in the pcTat-Rev expression plasmid by risp
and rab. The rev gene was removed by cleavage with NcoI/Hind III and replaced
with a PCR-generated cDNA sequence of risp and rab. For both DNAs primers
containing a unique NcoI site at the 5' end and a unique Hind III site at the 3' end
(see Table 2.1) were used. The constructs generated with standard subcloning
techniques were sequenced and each correct plasmid was kept for further use. To
demonstrate expression of the fusion proteins Tat-Risp and Tat-Rab, HEK293 and
HeLa cells were independently transfected with the respective expression plasmids
(1µg DNA/60mm plate/0.8x105cells) and cellular protein extracts were analyzed by
western blot analysis. As a control cells non transfected or transfected with 1µg DNA
of pL3Tat, pcTat-Rev and pcTat-sg25 were used. Therefore cellular protein extracts
were separated on a gradient SDS polyacrylamide gel and protein expression was
detected with anti-Tat specific antibodies. Three different anti-Tat antibodies (a rabbit
polyclonal (ABT10) kindly provided by Dr. G. Sutter, a rabbit polyclonal kindly
pSLIIBCAT
Expression of reporter gene
HIV-1 LTR with SLIIB  CAT-gene
 SLIIB
 Rev
Tat Risp
 Rev-binding to SLIIB
  Risp-Rev binding
pcTat-Risp
+ 
pcRev
+ 
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provided by Dr. B. Ensoli and a mouse monoclonal (MRC) kindly provided by Dr. G.
Levi) were used in three different western blot experiments. Cell lysates transfected
with expression plasmids for Tat fusion proteins and Tat alone displayed several
bands around 13-16 kDa and no differences were observed. However using rat
monoclonal anti-Risp antibodies a strong band around 42 kDa corresponding to the
Tat-Risp fusion protein was observed (Fig. 3.17) only in cells transfected with the
pcTat-Risp plasmid. In addition, the fusion protein Tat-Risp was recognized also by
immunofluorescence using anti-Risp antibodies.
  M    1      2       3      4
Fig. 3.17   Western Blot analysis of Tat-Risp. U87 cells were transfected with 1µg of
the indicated expression plasmids and collected 48h posttransfection. Proteins extracted from
the indicated cells were separated by gradient SDS-PAGE, transferred to nitrocellulose, and
then subjected to western blot analysis using the rat monoclonal IgG1 anti-Risp antibody 8B6
(dilution 1:1500).
3.4.2.2. Tat transactivation assay with Tat-Risp expression plasmid
Before testing the Rev-binding capacity of Risp and Rab expressed as Tat fusion
proteins, the functionality of the Tat moiety of the fusion protein was analyzed. HeLa
cells were transfected with a Tat-response plasmid pHIV∆npsLTRCAT (see Fig. 2.1)
alone and in combination with pcTat, pcTat-Risp or pcTat-Rab expression plasmid.
All transfection reaction mixtures included the HIV-independent expression plasmid
M  Marker
1   U87/pcRisp-sg143
2   U87/pcTat-Risp
3   NIH3T3 
4   85HG-66
   
   85 kDA -
   
41.8 kDA -
- Risp-GFP
- Tat-GFP
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pGL3-RFB containing the luciferase gene under the control of a C-type retroviral
RFB-LTR (see Fig. 2.1). Activation of HIV-LTR-dependent CAT expression was
determined measuring CAT-activity with a fluorescent dye labeled chloramphenicol
substrate provided by a FAST-CAT Kit (see 2.5.10.). Briefly, cells were harvested 48h
after transfection and lysed by 3 freeze-thaw cycles. Total protein content and
luciferase activity were determined. Five to 10 µg of total protein was incubated
overnight with fluorescent dye labeled chloramphenicol and acetyl-CoA. Reaction
was stopped by ethylacetate and a thin-layer-chromatography was performed.
Acetylated and non-acetylated chloramphenicol was quantified using a STORM™
fluorescence scanner and the conversion-rates were determined. Results from two
separate experiments are shown in the Fig. 3.18. Similar levels of luciferase values
were obtained in each experiment indicating the same range of transfection
efficiency.
With the different Tat expression plasmids the same range of induction of CAT
expression were observed.
Fig. 3.18  Transactivation of HIV-1 Tat. Tat-response was assayed by determining the
effect of Tat on expression of the reporter gene CAT under the control of the HIV-1 LTR.
Results from two separate experiments are shown. HeLa cells were transfected with Tat-
response plasmid pHIV∆npsLTRCAT (2µg) alone and in combination with a Tat expression
plasmid (1µg): pcTat and pcTat-Risp in one experiment and pcTat and pcTat-Rab in another
experiment. All transfection mixtures included pGL3-RFB (1µg) as control for transfection
efficiency. Both luciferase and CAT expression were normalized to protein levels. Dots show
values for CAT activity in single transfection experiments performed in duplicate; bars show the
average values. CAT activity was determined as percentage of CAT converted to an acetylated
form.
+Tat-Rab
+Tat
+Tat-Risp
HIV-1 LTR-CAT
 CAT activity    
6050403020100
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3.4.2.3. SLIIB-binding assay with Tat-Risp
After demonstrating that Tat-Risp and Tat-Rab efficiently activate HIV-1 LTR
transcription, the SLIIB-binding assay was performed. HeLa cells were transfected
with pSLIIBCAT indicator plasmid (2µg) in combination with a Tat expression
plasmid (1µg). PcTat alone was used as a background control, pcTat-Rev as a positive
control and pcTat-Risp or pcTat-Rab were tested in presence and absence of pcRev
(1µg). All transfection mixtures were co-transfected with the plasmid pGL3-RFB
(1µg) as a control for heterologous gene expression. Forty-eight hours after
transfection cells were harvested and lysed. Total protein content and luciferase
activity were determined (see 2.5.6. and 2.5.8.).  CAT expression was measured by a
specific ELISA (see 2.5.9.) or by the functional FAST-CAT assay (see 2.5.10.).
Results from a representative experiment are presented in Fig. 3.19. Since luciferase
expression varied 2-5 fold between cells transfected with different plasmid mixtures,
CAT induction levels were normalized also to luciferase activity as it is shown in the
figure.
Neither Tat, Tat and Rev, Tat-Rab nor Tat-Risp alone were able to increase CAT
expression over to basal levels seen in cells transfected with the pSLIIBCAT
indicator plasmid in the presence of the Tat protein alone. Only the simultaneous
expression of both Rev and Tat-Rab in cells induced a detectable ~ 16-fold induction
of CAT expression. The simultaneous expression of Rev and Tat-Risp induced only a
slight increase of induction of CAT expression compared to that with Tat alone.
In summary, although it is not yet clear which is the minimal sequence part of Risp
or Rev required for the Risp-Rev interaction, we can assume that the binding
domain in Risp is located in the middle of the protein between amino acids 39-133.
It can be assumed that Risp interacts with Rev in a region that overlaps the two
domains of RNA binding/NLS (34-50aa) and the second multimerization region
(52-60aa). In addition, independently from the two different sources of plasmid
pBsRev or pcRev used to express the Rev protein in the yeast cells, no difference in
the ability of Risp to bind Rev was observed. In fact the Rev sequence of the two
plasmids even if they rather differ at the DNA level, show higher identity at amino
acid level and no differences in the known functional domains are present.
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Fig.  3.19   Tat-Risp is not able to induce efficient SLIIB-CAT activation. HeLa
cells were transfected with the Tat/Rev-response plasmid pSLIIBCAT (2µg) in combination
with a Tat expression plasmid (1µg) in presence or absence of pcRev (1µg). All transfection
mixtures included pGL3-RFB (1µg) as a control for transfection efficiency. Results from a
representative experiment performed in duplicate are shown. Dots represent luciferase activity
(RLU = relative light units) normalized to protein levels and divided by 1x104.  The expression
of CAT was quantified by the CAT-ELISA. The induction is the activation of CAT expression
referred to that obtained in the presence of Tat alone (set to 1) and normalized to protein and
luciferase levels.
3.5. Functional study of Risp
3.5.1. Competition of Tat-Rev binding to SLIIB RNA by Risp-GFP
There are several possible explanations for the inability of Tat-Risp to activate the
SLIIB-CAT expression in the presence of Rev. One is that the Risp-protein could
bind to the RNA binding domain of Rev and therefore prevent the binding of the
Rev protein to its SLIIB RNA target.  To test this hypothesis a Rev-SLIIB-binding
assay was performed in the presence of a Risp expression plasmid at different
concentrations.
First, risp gene was amplified by PCR from the pJG4-5-16.4.1 plasmid using the
primers 16552 and 15762 (Table 2.1) and inserted into the unique NheI restriction site
in pFred143 vector (see 2.2.6.1.). After several restriction analyses a pcRisp-sg143
plasmid preparation was sequenced. Sequence analysis confirmed the presence of the
CAT pg/100µg protein
Luciferase RLU/100µg protein/104
pg/100µg protein 
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Tat + Rev
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intact risp insert in sense and in frame with the GFP gene; therefore it was used for
the further experiments.
Cells were transfected with the pSLIIBCAT reporter plasmid (2µg) in combination of
pcTat (1µg) or with pcTat-Rev (1µg) in presence and absence of variable amounts
(0.01-5µg) of pcRisp-sg143. All transfection mixtures included pGL3-RFB or pRSV-
luc plasmids (1µg) as a control for luciferase gene expression In five independent
experiments HeLa cells were transfected using the FuGENE or calcium phosphate
transfection method (see 2.5.1.1.). Since the Rab protein is known to bind to the Rev-
protein in its activation domain, the pcRab plasmid (1-5µg) was used in three
experiments as a negative competitor control. Moreover, since Risp is expressed as a
GFP-fusion-protein, the GFP alone was also analyzed in four experiments using
pFred143 plasmid (0.5-5µg). A molar excess of RevM10 protein was used as a
positive competitor control using pBsRevM10BL plasmid (3µg). 48h after
transfection cells were harvested and lysed; total protein content and luciferase
activity were determined. CAT expression was measured by ELISA or by the FAST-
CAT assay. Different results for the CAT induction were obtained in the five
experiments. A summary of the results is shown in Table 3.19. One experiment was
not included in the table because the CAT expression induced by Tat-Rev in the
presence of any other plasmids was highly and unspecifically reduced.
       Plasmids µg          Stimulation of CAT expression (fold-induction)      % Induction
Experiments:     1a   2  3  4  Average b                Mean c
pSLIIBCAT 2
“ + pcTat-Rev 1  187 73.8 20.1 15.1 74 100
“ + “+ pcRisp-sg143 0.5   ND   ND 18.8 11.3 15.1 84.2
1 25.6 12.7 19.6   7.5 16.3 44.3
2   ND   9.6   8.4 13.2 10.4 47.4
5   0.3 15.1   ND   ND   7.7 10.3
“ + “+ pFred143 0.5   ND   ND 13.7   9.3 11.5 64.7
1   ND 52.3 15.5   4.0 23.9 58.2
2   ND 59.3   6.6   4.0 23.3 49
5   ND 11.7   ND   ND 11.7 15.8
“ + “+ pcRab 1  104.7 72.3   ND   ND 88.5 76.9
5   ND 55.7   ND   ND 55.7 75.4
“ + “+ pBsRevM10BL 3    0.9   2.3   ND   ND   1.6   1.85
Table 3.19  Reduction of SLIIB-CAT activation by expression of the Risp-GFP
protein. HeLa cells were co-transfected with the Tat/Rev-response plasmid pSLIIBCAT (2µg)
and pcTat or pcTat-Rev expression plasmid (1µg). PGL3-RFB or pRSV-luc plasmid (1µg)
were used as a control for transfection efficiency. PcRisp-sg143, pFred143, pcRab and
pBsRevM10BL plasmids were added at different concentrations. Results from four experiments
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performed in duplicate are shown. The induction is the activation of CAT expression in the
presence of Tat-Rev. a) indicates the use of the FuGENE transfection method while in the other
experiments the calcium phosphate transfection method was employed. b) represents the average
of the CAT induction values of all experiments. c) represents the average of the inductions
calculated in each experiment where the induction with Tat-Rev is set to the 100%.
In cells transfected with the pSLIIBCAT indicator plasmid, high levels of CAT
activation were obtained in the presence of the fusion protein Tat-Rev compared to
the basal levels observed in the presence of the Tat protein alone. Nevertheless, a
wide variation of CAT activation levels between the different experiments was
observed. The induction levels in fact varied between a minimum of 15-fold to a
maximum of 187-fold (see Table 3.19). Also luciferase expression varied between
cells transfected with different plasmid mixtures (2-10 fold) and between the
different experiments (2-20 fold).
However, luciferase activity was very high in each experiment, suggesting a variation
in transfection efficiency. A clear correlation between low values of CAT and low
luciferase expression was not found. Therefore CAT inductions were normalized only
to protein levels and not to luciferase activity.
The results obtained with these four experiments suggest still probably unspecific
inhibition of Rev-SLIIB binding in the presence of Risp.
In fact the presence of the Rab protein as well as the GFP alone, that both in principle
should not compete in the Rev-SLIIB binding, inhibited the Tat-Rev induced CAT
activation in some experiments. The presence of increasing amounts of Risp-GFP
expression plasmid in the first two experiments showed a higher and specific
reduction of the Tat-Rev induced CAT activation in comparison with the Rab/GFP
controls. Nevertheless, in the other two experiments, where Tat-Rev inductions were
not very high, a limited and similar reduction of CAT activation in the presence of
Risp-GFP and of GFP alone was observed.
The effect of the Risp-GFP-, GFP- and Rab-protein after transfection of 1 µg of DNA
of expression plasmid on the CAT activation is shown in Fig.3.19. The CAT
activation by Tat-Rev is set to 100%. Although the addition of all these proteins
partially inhibited the Tat-Rev-induced CAT activation, the highest level of reduction
was observed with the Risp-GFP protein. A major reduction effect of Risp-GFP
compared to the other two proteins was observed when the fold-activation was
expressed by the median value of all values obtained in every experiment (Fig. 3.20).
The median and mean values of CAT activation in the presence of Risp-GFP was 33
and 44%, in the presence of GFP 71 and 58% and in the presence of Rab 77 and
77%.
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Unfortunately, the limited number of experiments excludes the possibility of a
statistical analysis of the present data. More experiments have to be performed to
statistically confirm the observed slight but specific reduction of the binding of Rev
to its RNA target SLIIB by the Risp protein.
Fig.  3.20   Reduction of SLIIB-CAT activation by Risp-GFP. HeLa cells were co-
transfected with the Tat/Rev-response plasmid pSLIIBCAT (2µg) and pcTat or pcTat-Rev
expression plasmid (1µg) in presence and absence of pcRisp-sg143, pFred143 or pcRab
plasmids (1µg). PGL3-RFB or pRSV-Luc plasmid (1µg) were used as a control for
transfection efficiency. CAT activation by Tat-Rev is set to 100 %. Dots show single
transfection experiments performed in duplicate; red bars show the average values and blue bars
show the median values of all the experiments.
3.5.2. Effect of Risp-GFP on LTR transactivation
Since the Risp-GFP- and the GFP-protein, although to a low extent, were able to
inhibit CAT activation in the Rev-SLIIB binding assay as previously shown, the
effect of these proteins on HIV-1 LTR driven CAT expression was also analyzed.
HeLa cells were transfected with the Tat-response plasmid pHIV∆npsLTRCAT (2µg)
alone and in combination with pcTat (1µg) in presence and absence of pcRisp-sg143
or pFred143 plasmid (0.5, 1 and 2µg). PGL3-RFB plasmid (1µg) was used as a control
for transfection efficiency. After 48h of transfection cells were harvested and lysed;
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total protein content and luciferase activity were determined. CAT expression was
measured by the FAST-CAT assay. Results obtained from one experiment are shown
in the Fig. 3.21.
Fig .  3 .21   HIV-1 LTR-CAT activation. HeLa cells were transfected with the Tat-
response plasmid pHIV∆npsLTRCAT (2µg) alone and in combination with a Tat expression
plasmid (1µg): pcTat or pcTat-Risp. PcRisp-sg143 and pFred143 plasmids were added at
different concentrations as shown in the figure. PGL3-RFB plasmid (1µg) was used as a
control for transfection efficiency. Both luciferase and CAT expression were normalized to
protein levels. Results from a representative experiment performed in duplicate are shown. Dots
represent luciferase activity divided by 100. The inductions represent the x-fold activation of
CAT expression compared to the basal expression obtained in the absence of Tat. All values are
normalized to protein and luciferase levels.
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Since luciferase expression varied 2-4 fold between cells transfected with different
plasmid mixtures, CAT induction levels were normalized also to the luciferase activity
as shown in the figure.
The presence of up to 1µg plasmid DNA for Risp-GFP did not markedly influence
Tat-dependent transactivation of the HIV-1 LTR. 0.5µg Risp-GFP DNA led to 23%
and 1µg Risp-GFP DNA to 11% reduction of CAT activity. However the presence of
GFP expression plasmid also reduced Tat-mediated induction of CAT activity
(>50% of reduction).    
3.5.3. Influence on HIV-1 Gag production by overexpression of Risp-GFP
The previously described preliminary experiments showed that the binding of Risp to
Rev in its RNA binding domain partially prevented the binding of Rev protein to its
SLIIB RNA target. Additional experiments to test Rev function and therefore the
production of Rev-dependent viral proteins in the presence of Risp-GFP expression
plasmid were performed.
Using transient transfection, Rev function has been determined by assaying the
expression of Rev-dependent gag genes with and without Risp-GFP. HeLa cells were
transfected using the FuGENE or calcium phosphate coprecipitation with the HIV-1
subgenomic Gag-expression plasmid pB37R (see Fig. plasmids; 5µg) with and
without of pcRev expression plasmid (1µg) and Risp-GFP expression plasmid (1-2µg).
In all transfection mixtures, the pRSV-luc plasmid (1µg) was included as a control for
luciferase gene expression. Moreover, pFred143, pcRab and pcCrm-1-sg143 plasmids
(1-2µg) were also used as controls. Forty-eight hours after transfection cells were
harvested and lysed. Levels of total protein, luciferase activity and Gag antigen were
measured (see 2.5.6-2.5.8.). Low levels of Gag synthesis were obtained without Rev,
which of course increased in the presence of Rev. The media of the Rev-inductions
obtained in the three experiments was 252 fold.
Results from three independent experiments are presented in Fig. 3.22. The Rev-
inductions are set to 100% and normalized also to luciferase activity. The
overexpression of Risp-GFP reduced the induction of Gag production by Rev from
30% (1µg plasmid) to 70% (2µg plasmid), whereas the overexpression of GFP or Rab
proteins had only a very marginal effect (up to 10%). On the contrary, the
overexpression of Crm1-GFP increased Rev-inductions up to 70% (2µg plasmid). The
limited number of experiments excludes the possibility of a statistical analysis of the
present data. Therefore, more experiments have to be performed to statistically
confirm the observed slight and specific reduction of production of the Rev-
dependent viral proteins in the presence of Risp.
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Fig. 3 .22   Diminished Rev-dependent stimulation of Gag production in the
presence of Risp-GFP. HeLa cells were co-transfected with the Rev-response plasmid
pB37R (5µg) without or in combination with Rev-expression plasmid pcRev (1µg) in presence
or absence of pcRisp-sg143, pcCrm1-sg143, pcRab or pFred143 plasmid (1µg). Transfection
mixtures also included a control plasmid for heterologous gene expression (pRSVluc; 1µg).
Gag protein levels were measured in transfected cells by ELISA and the ratio of Gag produced
with and without Rev determined (inductions). The Rev-inductions are set to 100%. Dots show
single transfection experiments performed in duplicate; blue bars show the average values. All
values were normalized to protein and luciferase levels.
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3.5.4. Shuttling properties of Risp
3.5.4.1. Localization of Risp-GFP in HeLa cells
To examine the intracellular localization of Risp, cells were transfected with the
plasmid containing the risp gene fused to GFP-encoding sequences (pcRisp-sg143,
see 2.1B). The Risp-GFP localization was compared to the intracellular localization of
Rev-GFP and GFP alone using the pCsRev-sg143 or the pFred143 expression
plasmid respectively (see 2.2.6.1.). Both Rev- and Risp-GFP open reading frames in
the fusion constructs do not contain an internal translation initiation site downstream
of the rev- risp-sequences to rule out a possible synthesis of unfused GFP.
Expression of a single Risp-GFP fusion protein was confirmed by western blot
analysis of lysates of HeLa, U87 or HEK293 cells transfected with pcRisp-sg143
plasmid using antibodies against GFP or Risp (Fig. 3.17, Fig. 3.24).
A comparison of intracellular localization of Risp-GFP, Rev-GFP and GFP 24h after
transfection in HeLa cells is shown in Fig. 3.23 A.
As expected, HeLa cells transfected with pCsRev-sg143 plasmid showed a
predominantly nuclear/nucleolar distribution of Rev-GFP, whereas after
transfection with the pFred143 plasmid the GFP-protein was distributed in both
cytoplasmic and nuclear compartments as already known.
On the contrary, cells expressing the Risp-GFP-protein revealed a strong
cytoplasmic fluorescence, indicating that Risp sequesters GFP in the cytoplasm.
The cytoplasmic accumulation of Risp-GFP similar to that observed previously with
proteins with a strong NES, like PKI (Wen et al., 1995), suggests that Risp itself could
contain an NES or may interact with a protein containing a NES. Localization of the
PKI-GFP fusion protein in HeLa cells transfected with pcPKI-sg143 expression
plasmid (see 2.2.6.1.4.) is shown in Fig. 3.23A. The accumulation of Risp-GFP in the
cytoplasm of HeLa cells was also observed in stable pcRisp-sg143-transfected cells
(Fig. 3.23B).
To obtain information of the intracellular distribution of Risp-GFP, a quantification of
Risp-GFP fluorescence in nuclear and cytoplasmic compartments of living cells was
performed. As described in 2.5.4. total and nuclear fluorescence intensities were
quantified for single cells, corrected for background fluorescence and the proportion
of cytoplasmic fluorescence calculated. In addition, intracellular distribution of Rev-
GFP, PKI-GFP and GFP for nuclear and cytoplasmic control proteins was quantified.
Fig. 3.23 C shows the percentage of cytoplasmic fluorescence obtained with the
different GFP-tagged proteins for 9-20 HeLa cells.
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Fig.  3.23    Localization of Risp-GFP . (A) HeLa cells were transfected with 1µg of
pcRisp-sg143, pCsRev-sg143 or pFred143 and pcPKI-sg143 expression plasmids. Images of
living cells were taken 24h after transfection as described in Mat and Meth. Phase indicates
phase-contrast image. (B) Risp-GFP localization in HeLa cells stable transfected. (C)
Quantification of the proportion of cytoplasmic fluorescence in HeLa cells expressing Risp-
GFP, Rev-GFP, GFP and PKI-GFP 24h posttransfection. Symbols indicate values for single
cells and bars mean values for each protein.
Approximately 77% of Risp-GFP was contained into the cytoplasm, whereas 18%
of Rev-GFP, 65% of GFP and 74% of PKI-GFP were cytoplasmic. The difference
between Risp-GFP and the other proteins is highly significant with the exception
of the comparison with PKI-GFP (p < 0.0001 (Risp-GFP/Rev-GFP); p = 0.0002
(Risp-GFP/GFP); p = 0.1272 (Risp-GFP/PKI-GFP); Mann-Whitney t-test for non-
parametrically distributed values).
To analyze the intracellular distribution of Risp-GFP with an additional method, HEK
293 cells were transfected with 1µg of pcRisp-sg143 plasmid. Nuclear and
cytoplasmic cellular protein fractions were extracted and then subjected to western
blot analysis. The protein extracts were separated on a SDS polyacrylamide gel and
protein expression was detected with an anti-GFP antibody.
The nuclear and the predominantly cytoplasmic localization of the Risp-GFP-
protein were confirmed (data not shown). However, since protein quantification
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for the nuclear and cytoplasmic extracts was not performed, these results could
confirm only a qualitative nuclear presence of Risp-GFP.
3.5.4.2. Nuclear accumulation of Risp-GFP in the presence of leptomycin B
Several proteins containing leucine-rich NES sequences have been shown to bind to
Crm1, a cellular protein involved in nuclear export (see 1.2.) (Fornerod et al.,
1997). To assess, whether the cytoplasmic accumulation of Risp-GFP was associated
with the presence of NES-Crm1 dependent, the intracellular distribution of Risp-GFP
in the presence of leptomycin B was analyzed. Leptomycin B, a Streptomyces
product, is a potent inhibitor of Crm1, and it is commonly used to block Crm1-
mediated nuclear export of proteins (Bogerd et al., 1998; Kudo et al., 1998; Wolff et
al., 1997).
Two hours treatment of pcRisp-sg143-transfected cells with 10 nM leptomycin B
led to an increase in nuclear fluorescence approximately of the 15%, indicating a
clear visible shift of Risp-GFP localization (Fig. 3.24). This difference is highly
significant (p < 0.0001).
This experiment demonstrated that Risp-GFP is a shuttling protein that can enter
and exit the nucleus. Blockage of the nuclear export leads to a nuclear
accumulation of Risp-GFP. In addition, these results indicate that this new cellular
protein depends on Crm1 as export receptor.
As a control, pcPKI-sg143- and pFred143-transfected cells were also treated with
10nM leptomycin B for 2h and the corresponding fluorescence distribution was
quantified (Figs. 3.24 and 3.25).
Fig.  3.24   Localization of Risp-GFP after treatment with leptomycin B. HeLa
cells were transfected with 1µg of pcRisp-sg143 or pcPKI-sg143 expression plasmids.
Leptomycin B (LMB) was added at the concentration of 10nM 24h after transfection, and
images of living cells were taken 2h later.
Fig.  3.25   Quantitative analysis of the localization of GFP fusion proteins in
the presence of leptomycin B.  Quantification of the proportion of cytoplasmic
fluorescence in HeLa cells expressing Risp-GFP, GFP and PKI-GFP before and after LMB
treatment. Symbols indicate values for single cells and bars mean values for each protein.
Significance between data sets determined by calculating two-tail P values, using the Mann-
Whitney U test is also shown.
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To examine the intracellular distribution of other Rev-interacting proteins, cells were
transfected with pcCrm1-sg143, pceIF-5A-sg143 and pc11.5.1-sg143 expression
plasmids (see Fig. 2.1B). A comparison of intracellular localization of Crm1-GFP, eIF-
5A-GFP and 11.5.1-GFP in HeLa cells 24h after transfection, in presence and absence
of leptomycin B is shown in Fig. 3.26.
HeLa cells showed a nuclear and cytoplasmic localization of Crm1-GFP, eIF-5A-
GFP and 11.5.1-GFP with a predominant nuclear accumulation. No differences in
the cellular distribution of all of these proteins were observed after treatment with
leptomycin B.
Fig.  3.26  Localization of cellular Rev interacting proteins. (A) HeLa cells were
transfected with 1µg of pcCrm1-sg143, pceIF-5A-sg143 and pc11.5.1-sg143 expression
plasmids. Leptomycin B (LMB) was added at the concentration of 10nM 24h after transfection,
and images of living cells were taken 2h later.
3.5.4.3. Influence of protein and RNA synthesis on nuclear import and export of
Risp
To analyze whether the blocking of new protein-synthesis could influence the
nuclear import or export of Risp-GFP, the translation inhibitor cycloheximide was
used. Approximately 24h after transfection with pcRisp-sg143 or pcPKI-sg143
plasmid (1µg), HeLa cells were incubated for 2h in medium supplemented with
cycloheximide alone (25µg/ml), or with leptomycin B (10nM) after a 30 min
pretreatment with cycloheximide (25µg/ml). The results are shown in the Fig. 3.27.
Blocking new protein synthesis by cycloheximide had no effect on the cytoplasmic
localization and the nuclear import of Risp-GFP or PKI-GFP. In fact, the
combination of leptomycin B and cycloheximide induced the same nuclear
accumulation of Risp-GFP as observed in the absence of cycloheximide.
Fig. 3.27 Localization of Risp-GFP in the presence of cycloheximide. HeLa cells
were transfected with 1µg of pcRisp-sg143 or pcPKI-sg143 expression plasmids.
Cycloheximide (25µg/ml) and leptomycin B (LMB, 10nM) were added in the culture medium
24h after transfection.
It is known that the treatment of Rev-expressing cells with transcription inhibitors
leads to an accumulation of Rev in the cytoplasm (Meyer and Malim, 1994).
The effect of transcription inhibitors on the localization and shuttling property of
Risp was therefore evaluated.
Approximately 24h after transfection with pcRisp-sg143 or pCsRev-sg143 (used as a
control), HeLa cells were incubated for 2h in medium supplemented with the
transcription inhibitor actinomycin D (5µg/ml), which at this concentration is known
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to inhibit all three RNA polymerases. Additionally, to exclude new synthesis of Risp
or Rev proteins, the translation inhibitor cycloheximide was added to the cell cultures
30 min prior to the inhibition of transcription and was maintained in the medium
together with actinomycin D.
As previously noted treatment with actynomycin D and cycloheximide resulted in a
significant accumulation of Rev in the cytoplasm, which was not observed by
treatment of cells with cycloheximide alone (data not shown).
On the contrary, treatment with actynomycin D and cycloheximide did not alter the
cytoplasmic localization of Risp-GFP (Fig. 3.28).
Moreover, to analyze the effect of transcription inhibition on the shuttling properties
of Risp-GFP and Rev-GFP, the export-inhibiting drug leptomycin B (10nM) was
added to the cells previously treated for 2h with actinomycin D.
In the presence of actinomycin D and leptomycin B, Risp-GFP and Rev-GFP
accumulated in the nuclei, indicating that the inhibition of transcription did not
alter the nuclear import of both proteins (Fig. 3.28).
Fig. 3.28 Localization of Risp-GFP in the presence of actinomycin D. HeLa cells
were transfected with 1µg of pCsRev-sg143 or pcRisp-sg143 expression plasmid respectively.
Actinomycin  D (AD, 5µg/ml) was added 24h after transfection to cells pre-treated for 30’ with
cycloheximide (CX, 25µg/ml). Two hours later, leptomycin B (LMB, 10nM) was added in the
culture medium for 1h.
3.5.4.4. Nuclear transport signals in Risp: Identification of regions containing a
NES and a nucleolus localization signal  (NOS)
Nuclear localization and nuclear export signals are important to mediate nuclear
import and export pathways. Because it could be shown that Risp-GFP can shuttle
between the nucleus and the cytoplasm using Crm1 as an export receptor, the
identification of NLS and NES sequences in Risp was attempted.
3.5.4.4.1. Localization of several pcIg-plasmids containing different regions of
Risp
To localize the domains of Risp involved in the nuclear import and export of the
protein, full-length or parts of the risp cDNA were fused to the C-terminus of a fusion
protein cassette, containing the constant domains CH2 and CH3 of the human
immunoglobulin G1 (IgG), into the pcIg vector (see Fig. 2.1).
The seven cDNAs (5’MluI/3’NotI) encoding Risp protein and its N-terminal or C-
terminal peptides formerly inserted into the yeast two hybrid vector pJG4-6 were
recloned into the unique cloning sites MluI/NotI of the pcIg vector.
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After confirmation by sequence analysis, each correct plasmid was kept for further
use (Fig. 3.31).
First, HeLa cells were transfected with the pcIg-Risp and the pcIg expression
plasmids (1µg). Twenty-four hours post-transfection, the localization of IgG alone or
fused to Risp protein was analyzed by indirect immunofluorescence using a Cy3-
conjugated goat anti-human IgG antibody.
As previously observed in cells transfected with pcRisp-sg143, the predominantly
cytoplasmic distribution of Risp-GFP was observed also in steady-state
localization of Risp fused to the constant region CH2-CH3 of the human IgG
(cytoplasmic fluorescence 84%). Moreover, in one experiment, the addition of
leptomycin B to cells transfected with pcIg-Risp, led to an increase the nuclear
fluorescence of IgG-Risp (cytoplasmic fluorescence 63%) (Fig.3.29).
Fig. 3.29 Localization of IgG-Risp. HeLa cells were transfected with 1µg of pcIg-Risp
expression plasmid. Leptomycin B (LMB) was added at the concentration of 10nM 24h after
transfection. Cells were fixed, permeabilized and analyzed by indirect immunofluorescence
microscopy using a Cy3-conjugated goat anti-human IgG (1:200). (B) Quantification of the
proportion of cytoplasmic fluorescence in HeLa cells expressing IgG-Risp before and after
LMB treatment. Symbols indicate values for single cells and bars mean values for each protein.
To identify a NLS or a NES in Risp protein responsible for its shuttling properties,
HeLa cells were transfected with the different expression plasmids pcIg-(2-38), pcIg-
(2-73), pcIg-(2-133), pcIg-(39-171), pcIg-(74-171) or pcIg-(134-171) (1µg). Twenty-
four hours post-transfection, the localization of the different N-terminal and C-
terminal segments of Risp protein was analyzed by indirect immunofluorescence
using anti-human IgG or anti-Risp.
As shown in Fig. 3.30, HeLa cells expressing segments of Risp up to residue 73 or
from residues 134-171 showed fluorescence in both nucleus and cytoplasm
compartments, as observed for IgG alone. On the contrary, peptides containing the
region of Risp between amino acids 74-133 showed a high accumulation in the
cytoplasm.
These data suggest that the region between 74 and 133 of Risp is required for
nuclear export of Risp, while the region responsible for nuclear localization signal
has not been identified yet.
Moreover, although the antibodies anti-Risp #1, #4 and #7 recognized Risp in
different regions in the 3´part of the protein, similar results were obtained using
the anti-Risp and the anti-IgG antibodies .
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Fig. 3.30 Localization of several IgG-segments of Risp protein. HeLa cells were
transfected with 1µg of pcIg or pcIg-Risp expression plasmid respectively [pcIg-(2-38), pcIg-
(2-73), pcIg-(2-133), pcIg-(39-171), pcIg-(74-171) or pcIg-(134-171)]. Twenty-four hours
post-transfection, cells were fixed, permeabilized and analyzed by indirect immunofluorescence
microscopy using a Cy3-conjugated goat anti-human IgG (1:200) or the rat monoclonal anti-
Risp #1, #4 and #7 antibodies (1:100), followed by a FITC-conjugated goat anti-rat IgG
(1:50).
Fig. 3.31 Schematic diagram of the constructed IgG-segments of Risp protein
and summary of localization analysis.
3.5.4.4.2. Cellular microinjection of Risp peptides
The analysis of Risp primary amino acid sequence suggested that Risp sequence does
not contain “classical” signals known to mediate nucleo-cytoplasmic transport.
However, the intracellular localization analysis of different segments of Risp
suggested the presence of a NES in the region comprising the amino acids 73-133. A
more thorough analysis of this sequence showed at position 88 a short cluster
(LESNLFDDNIDIFADL) richer of leucine and isoleucine residues. Therefore, to
investigate whether this sequence could function as NES, a peptide consisting of the
residues 86-105 was synthesized and cross-linked to Alexa fluor 488-labeled BSA
(see 2.5.12. and Fig. 3.32). At 68 kDa, BSA is too large to passively diffuse through
the nuclear pores. Therefore, BSA is a heterologous protein commonly used as a
linker to peptides, with candidate nuclear transport signals. Linkage of peptide with
NLS or NES has been shown to mediate the nuclear import or export of the chimera
fusion protein (Fischer et al., 1995).
In addition, the presence of a lysine-rich cluster (KPKEKSKKKVEAK) at position 106
that could possibly function as NLS was previously detected. Therefore, a second
peptide consisting of the residues 106-118 was synthesized and cross-linked to Alexa
fluor 488-labeled BSA (Fig. 3.32).
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Fig. 3.32 Schematic description of the structure of Risp peptides conjugates to
BSA used in this study . BSA-Risp peptide #1 consists of Alexa fluor 488-BSA cross-
linked to peptides encompassing the residues 86-105 of Risp protein with suspected NES.
BSA-Risp peptide #2 consists of Alexa fluor 488-BSA cross-linked to peptides encompassing
the residues 106-118 of Risp protein with suspected NLS. One glycine residue was additionally
used as hinge region to allow correct folding of both protein and peptides.
To follow the intracellular trafficking of the Risp peptides, each purified Alexa fluor
488-labeled BSA conjugate (~1 mg/ml) was microinjected into the nuclei or into the
cytoplasm of HeLa cells along with Alexa fluor 568-labeled BSA (~1 mg/ml).
First, the nuclear export ability of the Risp peptide #1 was tested.
Two hours after nuclear microinjection of a mixture of BSA-Risp peptide #1 and
BSA, unconjugated BSA remained exclusively in the nucleus and the conjugated
BSA-Risp #1 was exported out of the nucleus into the cytoplasm (Fig. 3.33). On the
contrary, 2h after cytoplasmic microinjection of a mixture of BSA-Risp #1 and
BSA, both compounds stayed in the cytoplasm.
Therefore this experiment indicated the presence of a NES in the Risp protein
between amino acids 86 and 105, which is able to mediate nuclear export of a
BSA-conjugate.
To investigate whether the Risp peptide #2 could induce nuclear import of the BSA-
conjugate via an active pathway, cytoplasmic and nuclear microinjections of a
mixture of BSA-Risp peptide #2 and unconjugated BSA were performed.
Two hours after cytoplasmic microinjection, both unconjugated BSA and BSA-Risp
peptide #2 stayed in the cytoplasm (Fig. 3.33), indicating that in the Risp region
contained in BSA-Risp #2 peptide does not contain a NLS. On the contrary, the
fluorescent-labeled BSA-Risp #2 conjugate was imported into the nucleoli (Fig.
3.33) when microinjected into the nucleus. Interestingly when the mixture of BSA-
Risp #2 and BSA was microinjected in the same cell in both nuclear and
cytoplasmic compartments, only the BSA-Risp #2 conjugate entered the nucleus
and accumulated in the nucleoli, indicating the presence of a nucleolar
localization signal (NOS) in Risp not associated with a NLS.
Fig. 3.33 Nuclear import and export of fluorescent dye labeled BSA conjugate
to Risp peptides. HeLa cells were co-microinjected into the nucleus or into the cytoplasm
with the indicated Alexa fluor 488-BSA-Risp peptides (BSA-Risp peptide #1 or BSA-Risp
peptide #2) and the unconjugated Alexa fluor 568-BSA (BSA, injection control). To allow
sufficient time for import, cells were incubated for 2h at 37 C, fixed and analyzed by
fluorescence microscopy.
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3.5.4.4.3. Cellular microinjection of Risp-GST protein
To confirm the indications that Risp is a shuttle protein, also two microinjection
experiments using the purified Risp-GST protein were performed. To follow the
intracellular trafficking of this fusion protein, HeLa cells were microinjected in the
nuclei and in the cytoplasm with a mixture of Risp-GST (~ 1mg/ml) along with Alexa
fluor 568-labeled BSA (~1 mg/ml). After 2h the cells were fixed and stained with an
antibody against GST or Risp, followed by a FITC-conjugated second antibody.
Two hours after nuclear microinjection Risp-GST was exported out from the
nuclear injection site into the cytoplasm, while the unconjugated BSA remained in
the nucleus,  (Fig. 3.34).
On the contrary, 2h after cytoplasmic microinjection of a mixture of Risp-GST and
BSA, both compounds stayed in the cytoplasm.
Moreover, to test the ability of Risp-GST to be imported into the nucleus, cytoplasmic
microinjections of cells pre-treated with leptomycin B (10nM, 2h) were performed in a
preliminary experiment. Unfortunately, the experiment did not work, because also
BSA as the negative control diffused in and out of the nuclei, indicating that the cells
were damaged. Therefore additional experiments should be performed.
Fig. 3 .34 Nuclear export of Risp-GST fusion protein. HeLa cells were co-
microinjected into the nucleus or into the cytoplasm with the purified Risp-GST protein and the
unconjugated Alexa fluor 568-BSA (BSA, injection control). Cells were incubated for 2h at
37˚C, fixed and permeabilized. The injected Risp-GST fusion protein was visualized by
immunostaining using a rat monoclonal antibody anti-GST (1:100) or a rat monoclonal antibody
anti-Risp #4 (1:100), followed by a DTAF-conjugated goat anti-rat IgG (1:50).
3.5.4.5. Influence of the presence of Rev on Risp localization
To investigate whether the presence of Rev could induce a change in the localization
of Risp-GFP and vice versa, HeLa cells were transfected with the pcRisp-sg143 in the
absence or presence of pBsRev or pcRev expression plasmid. As control the plasmids
pL3Tat (see plasmids) and pcPKI-sg143 were used.
The intracellular localization of Risp-GFP alone and in the presence of the Rev-
and/or Tat- expression plasmid was observed and quantified. In addition, the
localization of PKI-GFP was compared with and without Rev. Statistical analysis of
differences between data sets was determined by calculating two-tail P values using
the Mann-Whitney U test.
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The presence of Rev protein, independently of which expression plasmid was used,
induced a statistical significant increase in nuclear fluorescence of Risp-GFP 5%
with pcRev and 15% with pBsRev in comparison to Risp-GFP alone. On the
contrary, the presence of Tat did not induce any significant change in the typical
cytoplasmic fluorescence of Risp-GFP, and the cytoplasmic localization of PKI-
GFP did not significantly change by the presence of Rev (Fig. 3.35).
To confirm that the increased nuclear localization of Risp-GFP was really due to the
presence of Rev protein in the cell, immunofluorescence was performed using rabbit
antibodies against Rev. Since with the anti-Rev used distinguishing between Rev
protein and coexpressed Risp-GFP was not observed, a clear result was not obtained.
Fig.  3.35    Localization of Risp-GFP in the presence of Rev. (A) HeLa cells were
transfected with pcRisp-sg143 or pcPKI-sg143 plasmid (1µg) in presence of pcRev, pBsRev
and pL3Tat or pL3Tat expression plasmid (1µg). (C) Quantification of the proportion of
cytoplasmic fluorescence was performed. Symbols indicate values for single cells and
horizontal bars indicate mean values. Statistical significance of differences between Risp-
GFP/PKI-GFP cytoplasmic data sets and the Risp-GFP/PKI-GFP cytoplasmic data sets
obtained in the presence of Rev or Tat determined by calculating two-tail P values using the
Mann-Whitney U test are shown.
3.5.4.6. Localization of Risp-GFP in astrocytes
Rev has been described to be a nuclear shuttle protein that accumulates
predominantly in the nucleoli of Rev-expressing cells. Nevertheless in a recent study,
carried out in the group directed by Dr. Brack-Werner, an unusual and strong
cytoplasmic localization of Rev-GFP was shown associated with a diminished
function of Rev in various human astrocytoma/glioblastoma cell lines and in primary
human fetal astrocytes (Ludwig et al., 1999). Astrocytes constitute the first
example of a human cell type with an impaired Rev-response and a strong steady-
state cytoplasmic accumulation of Rev. Since Risp is a Rev-interacting protein, I also
compared intracellular distribution of Risp in astrocytes and Rev-permissive control
cells (HeLa). Fig. 3.36 shows a comparison of intracellular localization of Risp-GFP
24h after transfection in two astrocytoma cell lines (85HG66 and U138), in primary
astrocytes (H4/96) and in HeLa cells.
HeLa cells transfected with pcsRisp-sg143 plasmid showed a predominantly
cytoplasmic distribution of Risp-GFP, whereas astrocytoma cell lines and primary
astrocytes showed a non-homogeneous cellular localization of the fusion protein.
Depending on the cellular confluence on the plate, a variable number of astrocyte
cells (10-60%) showed accumulation of Risp-GFP in both cytoplasmic and nuclear
compartments.
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Fig.  3.36    Localization of Risp-GFP in astrocytes. (A) HeLa, 85HG66, U138 and
primary astrocyte cells (H4/96) were transfected with pcRisp-sg143 or pcPKI-sg143 plasmid
(1µg). (C) Quantification of nuclear fluorescence intensity was performed. Symbols indicate
values for single cells and bars indicate mean values.
In summary, the results of four experiments showed that Risp-GFP was able to
inhibit the SLIIB-CAT expression induced by Tat-Rev at different levels according
to its concentration (Fig. 3.20). Risp was able to reduce the SLIIB-CAT activation,
presumably by competition to the binding of Rev with its RNA target, however an
inconsistent inhibition not related to Risp was also observed. In addition, despite
the overexpression of GFP or Rab proteins, which did not influence the HIV-1 Gag
production, cells expressing Risp-GFP showed distinctly diminished Rev-
dependent stimulation of Gag production. To confirm the specificity of the
reduction of Rev-SLIIB binding and HIV-1Gag production by Risp, more
experiments have to be performed to allow a statistical analysis of the data.
Qualitative and quantitative analysis of the intracellular localization of Risp in
HeLa cells showed that Risp-GFP is a shuttle protein that can enter and exit the
nucleus and accumulates in the cytoplasm, indicating the presence of a strong
nuclear export signal (NES). The identification of Risp NES was confirmed by
localization analysis of different transfected segments of Risp and by cytoplasmic
accumulation of nuclear microinjected BSA-fusion protein containing a peptide
from the C-terminal part of Risp. The inhibition of the Crm1-mediated nuclear
export, induced by the presence of leptomycin B, showed that the nuclear export of
Risp is Crm1-dependent.
A different cellular distribution of Risp-GFP in astrocytes with respect to the
typical cytoplasmic accumulation in HeLa cells was observed.  Depending on the
cellular confluence on the plate, a variable number of astrocyte cells (10-60%)
showed accumulation of Risp-GFP in both cytoplasmic and nuclear compartments.
3.6. Identification of an additional potential NLS in Rev
An increasing number of NLSs and NESs have been identified in the last years.
Recently it has been shown that a cellular RNA-binding protein, Sam68 (Src-
associated protein in mitosis), represents a functional homologue of the HIV-1 Rev
protein (Reddy et al., 1999). In addition, it was published that Sam68 contains a
NLS with non-apparent homology to any other known nuclear localization signal
(Ishidate et al., 1997). However, the sequence responsible for the nuclear
localization was found to contain a motif, PPXXR, which is conserved in various
RNA-binding proteins.
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To determine whether Risp or Rev contains a similar PPXXR motif, the amino acid
sequence of Risp and Rev were examined. This new motif could not be found in the
Risp sequence.
On the contrary, analysis of the HIV-1 Rev amino acid sequence revealed that this
viral homologue of Sam68 contains the PPXXR motif inside its activation domain
(LQLPPLERLTLD). Therefore, the possibility that Rev could contain an additional
potential NLS in the activation domain was investigated.
3.6.1. Localization of RevM5 and RevM5-GFP in HeLa cells
First, the intracellular localization of RevM5, a mutant of Rev in the arginine-rich NLS
(Malim et al., 1989), was analyzed.
For this purpose, a new construct linking the GFP to RevM5 was created (pcRevM5-
sg143, see plasmids). RevM5 gene was amplified by PCR from the pcRevM5 plasmid
(see plasmids) using the primers 23957 and 23958 (see Table 2.1), and inserted into
the unique NheI restriction site in the pFred143 vector. After sequence analysis, the
confirmed correct plasmid containing the revM5 insert in sense and in frame with the
GFP gene was kept for the further experiments.
HeLa cells were transfected with the pcRevM5 or pcRevM5-sg143 plasmids (1µg)
and as a control with wt pcRev and pCsRev-sg143 (1µg). Twenty four hours post-
transfection, the localization of the proteins was analyzed by indirect
immunofluorescence using antibodies against Rev, or in living cells by the direct
fluorescence of the GFP fusion proteins. The intracellular distribution of the proteins
was measured by quantifying the fluorescence in nuclear and cytoplasmic
compartments. Statistical significance of observed differences were analyzed by
using the Mann-Whitney U test.
As previously described for RevM5 (Malim et al., 1989), RevM5 (cytoplasmic
fluorescence 70%) and RevM5-GFP ((cytoplasmic fluorescence 81%) accumulated
to a higher extent in the cytoplasm than wt Rev (cytoplasmic fluorescence 26%)
and Rev-GFP (cytoplasmic fluorescence 16%)  (Fig. 3.37).
Moreover, to analyze the ability of RevM5/RevM5-GFP to enter the nucleus, the
export-inhibiting drug leptomycin B (10nM) was added for 2h to the cells previously
transfected (24h) with the pcRevM5 or pcRevM5-sg143 plasmid.
As shown in Fig. 3.37, RevM5 and RevM5-GFP, although containing a mutation in
the NLS region, were able to enter the nucleus and accumulate there in the
presence of leptomycin B (cytoplasmic fluorescence 55% and 53% respectively).
Therefore, the presence of an additional and functional NLS in Rev would be
possible.
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Fig. 3.37 Localization of RevM5 and RevM5-GFP. HeLa cells were transfected with
1µg of pcRev, pCsRev-sg143, pcRevM5 or pcRevM5-sg143 expression plasmid respectively.
Leptomycin B (LMB) was added at the concentration of 10nM 24h after transfection. Cells
were fixed and permeabilized. Cells transfected with pcRev and pcRevM5 plasmid were
analyzed by indirect immunofluorescence microscopy using a rabbit polyclonal anti-Rev
antibody (1:100), followed by Cy3-conjugated goat anti-rabbit IgG. Phase indicates phase-
contrast image. (B) Quantification of the proportion of cytoplasmic fluorescence in HeLa cells
before and after LMB treatment. Symbols indicate values for single cells and bars mean values
for each protein.
3.6.2. Cellular microinjection of Rev activation domain peptides
To analyze whether the activation domain of Rev, containing the signal PPXXR,
could also function as a nuclear localization signal, several peptides consisting of the
Rev NES (residues 73-84) were generated and cross-linked to Alexa fluor 488-
labeled BSA. Two fusion-peptides containing the activation domain of the wt Rev
and of the export-deficient mutant RevM10 (Malim et al., 1989) were generated (BSA-
RevNES and BSA-RevM10NES, Fig. 3.38). In addition, it has been published that in
the Sam68 motif PPXXR replacement of the arginine by alanine diminished the
nuclear accumulation activity of Sam68 (Ishidate et al., 1997). Therefore, two
additional peptides with a specific mutation (R->A) in the activation domain of the wt
Rev and of the mutant RevM10 were generated (BSA-RevNES-A and BSA-
RevM10NES-A, Fig. 3.38).
To follow the intracellular trafficking of the Rev NES peptides, each purified
conjugate (~1 mg/ml) was microinjected into the nuclei or into the cytoplasm of HeLa
cells along with Alexa fluor 568-labeled BSA (~1 mg/ml). The co-microinjection of
unconjugated fluorescent labeled BSA was used to assess the site of injection and
the post-injection integrity of the nucleus.
Fig. 3 .38 Schematic description of the structure of Rev NES peptides
conjugates to BSA used in this study. BSA-RevNES and BSA-RevM10NES consist of
BSA cross-linked to peptides encompassing the activation domain of wt Rev and of export-
deficient mutant RevM10 (78LE->DL)(Malim et al., 1989). The peptides of BSA-
RevNES-A and BSA-RevM10NES-A harbor a single amino acid substitution (80R->A). The
BSA  -CGG-LQLPPLERLTLD BSA-RevNES
BSA  -CG-LQLPPLEALTLD BSA-RevNES-A
BSA  -CGG-LQLPPDLRLTLD BSA-RevM10NES
BSA  -CG-LQLPPDLALTLD BSA-RevM10NES-A
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mutated amino acids are expressed in bold. The BSA conjugated to the peptides was previously
labeled with Alexa fluor 488. One or two glycine residues were additionally used as hinge
region to allow correct folding of both protein and peptides.
First, the nuclear export ability of the intact activation domain of Rev was tested.
As expected, 2h after nuclear microinjection of a mixture of BSA-RevNES and BSA,
unconjugated BSA remained exclusively in the nucleus and the conjugated BSA-
RevNES was exported out of the nucleus into the cytoplasm (Fig. 3.39). On the
other hand, 2h after nuclear microinjection of a mixture of BSA-RevM10NES and
BSA, both unconjugated BSA and the export-deficient mutant NES conjugated to
BSA stayed in the nucleus.
To investigate whether the nuclear export of our BSA-RevNES conjugate could be
inhibited by leptomycin B, cells were pretreated with (10nM) 2h before nuclear
microinjection.
As expected, leptomycin B completely abolished the nuclear export of the wt
activation domain of Rev-BSA conjugate (Fig. 3.39).
To investigate whether the Rev NES could induce a nuclear import of BSA-
conjugate via an active pathway, microinjections of BSA-RevNES peptides into the
cytoplasm were performed.
Two hours after cytoplasmic microinjection of a mixture of BSA-RevNES and BSA
in cells pretreated with leptomycin B (10nM) for 2h, BSA alone stayed in the
cytoplasm whereas the BSA-RevNES conjugate was imported into the nucleus (Fig.
3.40). Not all conjugated BSA-RevNES entered the nucleus and did not enter the
nucleoli, indicating that the signal and the mechanism of entry of this additional
Rev NLS is different from the Rev arginine-rich NLS, which has been shown to
mediate also nucleolar localization (Cochrane et al., 1990).
Similar results were obtained by the cytoplasmic microinjection of the export-
deficient mutant RevM10 NES, indicating the presence of a nuclear import signal
in the activation domain of Rev. Two hours after cytoplasmic microinjection of a
mixture of BSA-RevM10NES and BSA, unconjugated BSA remained exclusively in
the cytoplasm and the conjugated BSA-RevM10NES passed through the nuclear
membrane, and accumulated in the nucleus (Fig. 3.40).
Finally, to investigate whether the exchange of the arginine against alanine in the
activation domain of wt Rev and of RevM10 could induce a change in nuclear
export or import of BSA-NES-conjugates, nuclear and cytoplasmic microinjections of
BSA-RevNES-A and BSA-RevM10NES-A peptides were performed.
BSA-RevNES-A
BSA-RevM10NES-A
BSA-RevM10 NES
Fig. 3.39
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After nuclear microinjection, BSA-RevM10NES-A conjugate was not exported from
the nucleus into the cytoplasm, as observed with the BSA-RevM10NES conjugate
and BSA-RevNES-A was exported out of the nucleus like BSA-RevNES (Fig. 3.39).
This indicates that the single alanine exchange did not alter the nuclear export
ability of the Rev NES.
As it is shown in Fig. 3.40 both activation domains of wt Rev and of export-
deficient mutant RevM10 harboring the alanine mutation kept the nuclear entry
ability when injected in the cytoplasm. Nevertheless, a minor nuclear
accumulation of the BSA-RevM10NES-A conjugate in comparison to the BSA-
RevM10NES was observed, indicating that the alanine mutation could alter the
nuclear import ability of the Rev NES especially if mutated in its nuclear export
function.
Although many cells microinjected with RevM10 NES-A peptides showed a minor
nuclear accumulation as observed with the RevM10 NES peptides, higher number of
microinjection experiments are required. In fact, a kinetic analysis, as well as a
quantification and a statistical analysis should be performed.
Fig. 3.39 Nuclear export of fluorescent labeled BSA conjugate to Rev NES
peptides. Untreated or LMB pre-treated (2h) HeLa or 85HG66 (*) cells were co-microinjected
into the nucleus with the indicated Alexa fluor 488-BSA-RevNES peptides (BSA-RevNES,
BSA-RevM10NES, BSA-RevNES-A, BSA-RevM10NES-A) and the unconjugated Alexa fluor
568-BSA (BSA, injection control). To allow sufficient time for export, cells were incubated for
2h at 37 C, fixed and analyzed by fluorescence microscopy.
Fig. 3.40 Nuclear import of fluorescent labeled BSA conjugate to Rev NES
peptides. Untreated or LMB pre-treated (2h) HeLa cells were co-microinjected into the
cytoplasm with the indicated Alexa fluor 488-BSA-RevNES peptides (BSA-RevNES, BSA-
RevM10NES, BSA-RevNES-A, BSA-RevM10NES-A) and the unconjugated Alexa fluor 568-
BSA (BSA, injection control). To allow sufficient time for import, cells ells were incubated for
2h at 37 C, fixed and analyzed by fluorescence microscopy.
In summary, in this part of the study it has also been shown that a sequence in the
activation domain of the Rev protein can function as an additional nuclear
localization signal. The sequence is characterized by a motif PPXXR, that was
already described being important for nuclear accumulation of Sam-68, a nuclear
protein proposed to be the corresponding human cellular factor for the HIV-1 Rev
protein.
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4. Discussion
4.1. Identification of new HIV-1 Rev-interacting proteins by yeast two-hybrid
selection
The screening of a Jurkat T cell cDNA library, using the yeast two-hybrid selection
and HIV-1Rev as a bait protein, led to the isolation of two new Rev-interacting
cDNA-encoded proteins (11.5.1 and 16.4.1). The computer analysis of available
sequence databases revealed a 100% identity of the 11.5.1 cDNA with the C-terminal
part of a previously reported human nuclear single strand DNA binding protein
(Sakura et al., 1988). A partial sequence identity of 16.4.1 cDNA was observed with
two previously identified human genes with unknown function: a cDNA clone from
the EST database (ref) and the 3’end of a large brain-derived cDNA clone (Nagase et
al., 1998).
The subsequent study of the 16.4.1 clone led to the characterization of one fragment
of a larger protein, consisting of 171 amino acids that interacted specifically with Rev.
Because of its ability to shuttle between the nucleus and the cytoplasm it was termed
Risp (Rev-interacting shuttle protein).
The yeast two-hybrid system has revealed a number of useful applications (Allen et
al., 1995), including the capacity to isolate novel genes encoding proteins that
associate with a known protein of interest. Previous studies have already successfully
used Rev or its activation domain in the yeast two-hybrid selection to identify Rev-
interacting proteins (table 2.3) (Bogerd et al., 1995; Farjot et al., 1999; Fritz and Green,
1996; Fritz et al., 1995; Luo et al., 1994; Neville et al., 1997; Stutz et al., 1995). The
two-hybrid system is able to detect in vivo binding that is often undetectable in vitro
by methods such as immunoprecipitation. In fact, the two-hybrid system gives very
sensitive results. First of all, the hybrid-proteins are generally over-expressed by
strong promoters present in high-copy-number plasmids, which favor a complex
formation. In addition, the stability of the hybrid-protein complex is probably
enhanced by the interaction of the activation domain with proteins from the
transcriptional initiation complex, which also associate with the promoter DNA.
Therefore, the overall stability of the complex on DNA further increases the sensitivity
of detection of the bait-prey protein interaction.
However, the two main obstacles preventing the success of the yeast two-hybrid
system are the activation of transcription of the reporter gene by the bait protein itself
and the failure to express the bait properly. In our case, the Rev protein could be
proven to be a suitable bait, since it was not able to activate the transcription of the
reporter genes LEU2 and lacZ without the presence of the B42 activation domain.
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Moreover, the expression of the Rev protein fused to the binding domain LexA was
demonstrated by western blot analysis using a Rev-specific antibody.
Another major problem of the yeast two-hybrid system is the risk to detect “false
positive” interactors. In fact, some proteins contain regions that have low affinities for
many different proteins and therefore may form stable complexes with several bait
proteins, which result in an unspecific detection.
To limit the number of “false positive” interactions, a dual screen selection based on
the use of two distinct reporter genes, lacZ and LEU2 was performed. Moreover, for
additional controls the screening was performed in presence of the testing bait (Rev
sense) and two unspecific baits (Rev antisense and Lexcd2). While the lacZ
expression provided a detectable blue color phenotype on plates containing Xgal, the
LEU2 expression allowed a nutritional selection on plates lacking leucine. It is known
that the requirement for the expression of two reporter genes driven by different
promoters significantly reduces the number of false-positive signals, since separate
transcriptional events must be maintained at distinct chromosomal loci.
The screening of a Jurkat T cell cDNA library led us to sequence 6 yeast clones: two
were assumed to be clear Rev-interacting (11.5.1 and 16.4.1) and 4 “putative” Rev-
interacting clones (6.2.1, 11.2.1, 15.2.2 and 16.3.15) (see tables 3.5 and 3.6).
The sequence analysis and the subsequent BLAST search with available sequence
databases suggested that 3 out of the 4 “putative” clones were “false positive”. In
fact they were very similar (85%) or 100% identical to proteins generally known as
common false positive in the yeast two-hybrid system (i.e. ribosomal proteins, zinc
finger containing proteins or heat shock proteins) (Hengen, 1997). The “putative”
clone 16.3.15 was 100% identical with a HLA-DR associated protein (924bp) and the
phosphatase 2A inhibitor I2PP2a (833 bp).
I2PP2a is a truncated form of SET, a largely nuclear protein that is fused to
nucleoporin Nup214 in acute non-lymphocytic myeloid leukemia (Li et al., 1996).
However, even though this clone could be of certain interest - Nup214 is one of the
nucleoporins known to interact with Rev (Zolotukhin and Felber, 1999)- in this work
the other two Rev-interacting clones were further characterized for several reasons.
First, the yeast clone 16.3.10 (representing the same cDNA-encoded protein of
16.3.15) showed clearly unspecific binding to Rev. Second, the two clones 11.5.1 and
16.4.1 showed a certain specific binding to Rev. Third, the absence of homology of
the clone 16.4.1 to any proteins with known function.
It is worth noting that in our screen none of the known Rev-interacting proteins were
detected, maybe because of the insufficient number of analyzed clones.
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4.2. Computer sequence analysis and proposal for Risp cellular function
The DNA and the amino acid sequences of the clones 11.5.1 and 16.4.1 were
analyzed in detail with several computer programs. Regardless which program was
used, FASTA, BLAST or BEAUTY, the 11.5.1 cDNA-encoded protein was always
related to DNA binding proteins, and was reported to be 100% identical to the human
nuclear single strand DNA binding protein dbpB (Sakura et al., 1988). On the
contrary, from the beginning of the study until now, the sequence of the 16.4.1 clone
did not show any significant percentage of identity to proteins with known function.
Partial identity (92%) was first observed with Soares fetal heart NbHH19W cDNA
clone (EST database; Fig. 3.9). Subsequently, high identity (99%) was observed with
the C-terminal part of a large brain cDNA clone for the KIAA0592 protein (PRI
database, (Nagase et al., 1998)) and of two other human cDNA clones related to the
Nagase protein (accession number CAB45765 and CAB43380, PRI database,
submitted 1999) (Fig. 3.2). However, a minor degree of homology appeared with
some RNA-/DNA-binding proteins, such as the human fibrillarin protein, methyl-CPG-
binding protein 2, histone H2B, the Xenopus Laevis histone H5, the Arabidopsis
Thaliana RNA Helicase and the Saccharomyces Cerevisiae U1 small nuclear
ribonucleoprotein A.  In addition, partial homology was observed with two rat shuttle
proteins such as Nopp140 and nucleolin C23, and with other unrelated proteins, such
as the human structural protein cylicin and the mouse microtubule associated protein
1B (Table 3.9).
Among the group of the RNA-/DNA-binding proteins similar to the clone 16.4.1,
fibrillarin is a component of a nucleolar small nuclear ribonucleoprotein particle and is
thought to participate in the first steps of pre-ribosomal RNA processing. It is
associated with the U3, U8 and U13 small nuclear rRNAs (Jansen et al., 1991). The
nuclear methyl-CPG-binding protein 2 (MECP-2 protein) is proposed to be involved
in the regulation of transcription and alteration of chromatin structure. Histones are
chromosomal proteins remarkably conserved across the gamut of eukaryotic
organisms. They form the unit around which DNA is coiled in the nucleosomes.
Nucleosomes contain always an octamer-complex of two units, consisting in histones
H2A, H2B, H3 and H4. The histone H5 has the same function as H1, being necessary
for the condensation and stabilization of nucleosome chains into higher order
structures, and it replaces histone H1 in certain cells. Nucleolin C23 is the major
nucleolar protein of growing eukaryotic cells that shuttles between the nucleolus and
the cytoplasm (Borer et al., 1989). It is associated with intranucleolar chromatin and
pre-ribosomal particles. It induces chromatin decondensation by binding to histone
H1 and is thought to play a role in pre-rRNA transcription and ribosome assembly
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(Bourbon et al., 1988; Medina et al., 1995). Recently it was proposed to play also a
role in poliovirus genome amplification, since it appeared to strongly interact with the
poliovirus 3’ noncoding region (Waggoner and Sarnow, 1998), a nucleotide region
involved in the synthesis of viral negative-stranded RNA (Johnson, 1995). The
principal role of the U1 small nuclear ribonucleoprotein A is to support to fold or
maintain U1 RNA in an active configuration. It is the first sn-RNP to interact with pre-
mRNA (Liao et al., 1993).
The sequence similarity of Risp to each of the previously mentioned proteins is very
minimal and therefore suggests low significance. However, a more general analysis of
the proteins could include Risp protein - or the larger protein containing Risp - as
member of a family of proteins with RNA-/DNA-binding function.
Therefore it is possible to assume that Risp itself - or the larger protein containing
Risp - could actively be involved in one of the processes regarding the chromatine
metabolism or/and the pre-RNA processing.
In addition, some of these proteins, such as Nopp140 and nucleolin C23, proposed to
be similar to Risp, are nucleocytoplasmic shuttling proteins and accumulate in the
nucleoli. In this study it could be proved that also Risp is a shuttle protein, however, it
accumulates in the cytoplasm, and when present in the nucleus, it never accumulates
in the nucleoli, although Risp contains a stretch of basic amino acids with nucleolar
import activity (Fig. 3.33). It will be very important to clarify whether Risp is a part of
a larger protein and subsequently analyze its intracellular localization and its cellular
function.
A PROSITE pattern search was performed - this program is able to recognize known
functional motifs in the query sequence. The results suggested several possible post-
translational modifications in both the cDNA-derived protein sequences of 11.5.1 and
Risp. The analysis of the 11.5.1 clone sequence suggested consensus sequences
targeting one N-glycosylation, one amidation and three phosphorylation sites.
Regarding the Risp protein, one N-glycosylation and ten phosphorylation sites were
proposed. However, these results are only computer predictions and they need
experimental confirmations.
Nevertheless, it is interesting to note that among the 14 seryl residues in the Risp
sequence, 5 matched with the consensus sequence for casein kinase II (CK-II), a
kinase involved in the phosphorylation of HIV-1 Rev and rat Nopp140. In fact, CK-II
together with the mitogen-activated protein kinase (MAPK) has been suggested to be
potential candidate for Rev phosphorylation in vivo, based on their capacity to
phosphorylate Rev in vitro (Critchfield et al., 1997; Ohtsuki et al., 1998; Yang and
Gabuzda, 1999). The nucleolar phosphoprotein Nopp140, a shuttle protein proposed
 Discussion 168
to possess a weak homology to Risp, is characterized by the presence of a 10-fold
repeated motif of highly conserved acidic serine clusters containing an abundance of
phosphorylation consensus sites for CK-II (Meier and Blobel, 1992). Therefore, it
would be important to determine using phosphorylation experiments if also the Risp
protein - or the larger protein containing Risp - is phosphorylated in vivo and if CK-II
is involved in this process. Moreover, the relevance of the phosphorylation with
respect to the protein function should be also established. For instance it is known
that Rev is phosphorylated in vivo at different serine residues (Cochrane et al., 1989;
Hauber et al., 1988; Meggio et al., 1996). However, the mutation of some of those
serines did not change Rev trans-activation in transfection experiments, suggesting
that the phosphorylation may not be essential for Rev function (Cochrane et al.,
1989; Malim et al., 1989). To predict additional sorting and localization signals in the
amino acid sequences of 11.5.1 and Risp proteins, a PSORT II search was performed.
Using this program the presence of putative cleavage sites, transmembrane segments
and nuclear localization signals was investigated. Performing the search on the amino
acid sequence of 11.5.1 clone, the presence of three arginine-rich consensus NLS with
a very high NLS score (1.87) was detected. These results confirmed those obtained by
the BLOCKS search, which suggested the presence of an arginine-rich region,
bearing weak similarity with the NLS of both HIV-1 Rev and Tat, in the 11.5.1 clone.
On the contrary, the analysis of the Risp sequence indicated the absence of any
classical signal but suggested the presence of a low score lysine-rich cluster with
potential NLS function. However, the results achieved by these programs should be
taken with the appropriate precautions, considering the limited number of signal
sequences available in the database. Furthermore, these programs cannot provide all
the information on the functionality of a protein. When the PSORT II search was
performed on the Rev protein as a control, its arginine NLS signal was sorted,
although the NLS score was negative (-0.16) and no RNA-binding motif was
identified (data not shown).
4.2.1. Identification of a new specific motif common to cellular Rev-interacting
factors
Possible similarities of the sequences of the new Rev-interacting factors 11.5.1 and
Risp with the sequences of already known Rev-interacting factors were investigated
with local alignment and DIALIGN, programs able to identify similar regions within
large unrelated sequences. Interestingly, each Rev-interacting protein, previously
proposed to support Rev function in the nucleus, such as Crm1, eIF5-A, hRab/Rip,
yRip1p and p32, showed a high percentage of identity with a same N-terminal region
of Risp. Based on these results a consensus motif consisting of 12 amino acids was
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proposed for these Rev-interacting factors (Fig. 3.7): P (AELNR) (KHILST) (KCRST)
T N (PD) F (GLQ) (LST) (LIN) (EAGQS). The consensus motif is based on occurrence
of all indicated amino acids in each protein domain with one mismatch allowed
(brackets indicate the less conserved residues).
This motif by computer analysis seems to be highly specific. Scanning it against all
available sequence databanks (with a total number of 407576 sequences analyzed),
the only proteins identified to contain that motif were the above mentioned Rev-
interacting proteins plus any hypothetical protein containing the Risp sequence.
Moreover, query patterns containing random modifications of one or more amino
acids in the consensus sequence led to the sort of the Rev-interacting proteins plus a
variable number of different proteins, with a minimum of 5 Rev-unrelated factors
(Table 3.15).
Nevertheless, among all the Rev-interacting proteins, the cytoplasmic import receptor
importin β , the nucleolar protein B23, the two recently identified Rev-interacting
nucleoporins Nup98 and NLP-1, and Rev itself were not present in this consensus
motif. Therefore, from each of these proteins the sequence with highest similarity with
the 16.4.1 motif sequence (PAKKTNPFPLLE) has been used to generate new motifs
allowing alignment of each one of these additional proteins (Fig. 3.8). The
subsequent screening analysis among all the sequences available in the database,
using the Nup98- or Rev-modified motif led to the identification of the Rev-
interacting proteins only. In contrast, the screening among the database of the
importin β -, NLP-1- or B23-modified motif led to the identification of the Rev-
interacting proteins and the addition of one unrelated protein (importin β , NLP-1) and
three unrelated proteins (B23)(Fig. 3.8).
Therefore, these results provide for the first time the description of a specific and
common motif shared between Rev-interacting factors. Further, only Risp, and not
the 11.5.1 cDNA-encoded protein, shares this specific motif. Finally, among all the
Rev-interacting factors two subgroups could be distinguished which share the motif
with different degree of specificity (Fig. 4.1). Although in every Rev-interacting
factor a region containing a sequence, which could be associated to the consensus
motif, was identified, a particular group of cellular proteins, mostly involved in the
Rev/RRE nuclear export, showed to be highly specific with respect to the motif. In
fact, applying the shared motif to the subsequent screening analysis among all the
sequences available in the database led to the identification of only those Rev-
interacting proteins. In contrast, the screening analysis using modified motifs related
to the second group of proteins led to the identification of a few additional (1-3)
unrelated proteins beside the Rev-interacting proteins (Fig. 3.8).
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Experimental data are currently missing to propose a functional significance of the
Rev-interacting proteins-motif; in fact, this was generated based on amino acid
sequence similarity and computer analysis. Moreover, a limit of the computer analysis
is the difficult interpretation of the different degrees of specificity. To investigate,
whether a specificity window for the Rev-interacting proteins-motif may exist, Rev-
unrelated proteins such as GFAP or fibronectin were also tested in the motif
alignment. The subsequent screening of those modified motifs led to a selection of 5
and 13 additional proteins respectively in addition to the Rev-interacting proteins
and GFAP or fibronectin (data not shown). This suggests that the threshold for non
specificity could start with a number of additional proteins larger than 4. Even if the
discovered motif shared between all the Rev-interacting proteins might be highly
specific for those proteins, the significance of the few (1-3) additional proteins
selected, using the modified motif from the second group of the Rev-interacting
proteins, remains to be interpreted.
Presently, it is unknown whether the hypothetical 31.3 kDa protein (NPSA
sptr||Q9X6Z7) and/or the putative lipoprotein periplasmic GNA2132 (appeared as
additional proteins in the Importin-β and NLP-1 modified motifs respectively) are non
Rev-related proteins or on the contrary potential new Rev-interacting factors. In
addition, it is worth to note that among the proteins sharing the Rev-interacting
proteins-motif Sam68 is included in the group of proteins with lower specificity.
Sam68 represents a cellular functional homologous of HIV-1 Rev (Reddy et al., 1999).
It can specifically bind to RRE in vitro and in vivo and can partially substitute for as
well as synergize with Rev in RRE-mediated gene expression and virus replication,
although a direct binding of Rev-Sam68 was not shown. Screening among the
database of the Sam-68-modified motif led to the identification of additional unrelated
proteins like the aforementioned putative lipoprotein periplasmic GNA2132 and the
adenyl cyclase. Therefore, it would be very interesting to investigate whether Rev
binds to one of these “additional” proteins.
However, until experimental data regarding the significance of the Rev-interacting
motif are available, a possible role in mediating the Rev function is speculative.
It is difficult to attribute a direct Rev-binding function to the motif domain. Although
the motif sequence in the proteins hRab/Rip, yRip1p or in Rev is part of the Rev-
binding region (in Rev is contained in the first multimerization domain), this was not
the case in proteins such as p32 (Tange et al., 1996) and Risp itself. In fact, the use of
several segments of Risp showed that its N-terminal region, containing the motif
sequence (22-33aa) was not essential for the Rev-binding in the yeast two-hybrid
system. Yeast transformed with the plasmid PJG4-6-(38-171), harboring a mutant of
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Risp missing that region, bound Rev as well as the wt Risp. In addition, the location
of the Rev-binding region in factors such as eIF-5A, Crm1, importin β or Nup98 is not
yet identified and therefore, it is impossible to determine whether the motif sequence
is included in the region of these proteins responsible for the Rev-binding.
Transcription factors and many other proteins including Rev itself contain one
binding and one activation domain both essential for the function of the protein.
There is a certain possibility that also the Rev-interacting proteins contain besides a
Rev-binding domain a Rev-modulatory domain that harbors that consensus motif. In
some proteins such as the nucleoporin Rab/Rip or Rev itself the binding and the
modulatory domains are very proximal to each other, whereas in other proteins such
as Risp or p32 the two functional domains are located in different regions.
It is interesting to note that among the Rev-interacting proteins shown to be highly
specific with respect to the motif (Fig. 4.1), with the exception of p32, which it is not
known to bind Crm1, all the others, including Risp, use the Crm1 export receptor for
their nuclear export. Therefore, it cannot be ruled out that this motif is related to the
Rev/RRE nuclear translocation and to Crm1 function. In fact, proteins such as
importin β and Sam68 that are proposed to use distinct nuclear export pathways
belong to the group of the Rev-interacting proteins that share this motif with less
specificity.
Therefore, the role and the relevance of the consensus motif present in Risp and in the
other Rev-interacting factors should be addressed in detail in future studies.
Mutational analysis and deletions of the domain in Risp and/or Crm1 and in Rev itself,
will be established to analyze whether the function of Rev could be modified.
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Fig. 4.1 Detection of a common 12 amino acids motif in the Rev-interacting
proteins. The location of each domain of the Rev-interacting proteins that showed high
percentage of identity with the Risp sequence PAKKTNPFPLLE is represented in yellow. A
consensus motif for those Rev-interacting factors was designed and showed high specificity.
The location of a domain of other Rev-interacting or Rev-related proteins (Sam68) that showed
a less high percentage of identity with the Risp sequence PAKKTNPFPLLE is represented in
gray. Modifications of the motif allowing the presence of one of these additional proteins
created less specific motifs.
4.3. Risp expression
Since this common and specific motif was found in several known host Rev-
interacting proteins and the newly isolated Risp, further studies on the
characterization of this protein have been undertaken.
An important issue to investigate was the cellular expression of Risp, therefore an
analysis on the DNA-, RNA- and protein level was performed.
The Southern Blot analysis using a commercial blot, which contains genomic DNAs
derived from 9 eukaryotic species indicated that the Risp gene is very common
among different species (Fig. 3.10). However, the different size of the bands observed
indicated that homologous genes with sequence divergence may occur in different
species.
hCrm1
heIF-5A
hp32
hRab/Rip
hRisp
yRip1p
 1071 aa
 154 aa
 278 aa
 562 aa
 171 aa
 430 aa
hNup98  920 aa
hImportin β  876 aa
hNLP-1  423 aa
hSam68  443 aa
high score ; specific
low score ; less specific
HIV-1 Rev  116 aa
hB23  294 aa
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Two northern blot experiments showed a main, however weak, mRNA band around
the size of 4.6-5 kb, indicating that the risp probe recognized a larger mRNA than the
expected risp of 513 bp. This supports the hypothesis that Risp could be part of a
larger protein as the predicted for KIAA0592 (4623 bp; 1353 aa) (Nagase et al.,
1998). However, in one experiment, where different conditions were used to probe
and wash the RNA-filter, an additional band slightly lower than the 18S rRNA (~1600
bp) was observed. This band was present only in the RNA obtained from cells
transfected with Rev and not from non-transfected cells. Since this is a result from
only one experiment, it has to be confirmed by further experiments. It is possible that,
as suggested from the submitters of the sequence of the clone CAB43380 in the
database, an mRNA splice variant encoding a smaller protein in addition to the
protein KIAA0592 might exist. Interestingly, it is also possible that the expression of
this splice variant could be upregulated by the presence of Rev.
An analysis of the Risp protein expression was performed with immunofluorescence
and western blot analysis using HeLa and some astrocytoma cell lines. Several tested
monoclonal anti-Risp antibodies were able to recognize only exogenous expression
of Risp fusion proteins (IgG-Risp, Risp-GFP or Tat-Risp). No specific staining was
observed in untransfected cells, suggesting that the available monoclonal anti-Risp
antibodies are not sensitive to recognize the constitutive expression of the protein.
Possible explanations for this are that the protein itself is expressed at very low levels
and/or the sensitivity of the antibodies is not adequate, or the epitope recognized by
the anti-Risp antibody is masked in the full-length protein. Moreover, as mentioned
above in the paragraph 3.3.3 a weak band around 220 kDa was observed in some
cell lysates. This weak signal was initially interpreted as being the larger protein
KIAA0592 constitutively expressed. However, in other western blot experiments, the
same anti-Risp antibodies recognized similar bands around 220 kDa in several
samples containing the purified GST-Risp protein diluted in buffer (Michael
Krappmann, (Table 3.16), suggesting that this large band could represent also only
unspecific antibody background.
Therefore, the production and use of additional new specific anti-KIAA0592
antibodies or antibodies against the full length protein will be necessary to analyze
the intracellular expression and localization of the endogenous protein and to
determine its exact size.
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4.4. Characterization of the domains responsible for Rev-Risp binding
One of the advantages that the two-hybrid system offers is that the residues required
for the physical interaction of a given pair of proteins can be easily mapped by
generating deletion hybrid constructs in one or both of the genes of interest. This
approach was utilized to delineate the regions responsible for the Risp-Rev
interaction. Several segments of Risp and several mutants of Rev were generated,
fused to the corresponding yeast vectors and then used in the interaction trap.
The data suggest that the binding domain in Risp is located between amino acids 39-
133, although, the minimal sequence of Risp or Rev required for the Risp-Rev
interaction has not been defined. As already mentioned, the N-terminal region of Risp
harboring the motif common for the Rev-interacting factors (22-33aa) is neither
essential nor sufficient for the Rev-binding (Fig. 3.13). Concerning the Risp-binding
region of Rev the results presented here suggest that it is situated in a region
overlapping the domain of RNA binding/NLS (34-50aa) and the second
multimerization region (52-60aa) (Fig. 2.4; Fig. 3.15). Two Rev mutants, the RevM5,
that affects the RNA binding region and the NLS, and the RevSLT40, that affects the
second multimerization region, were unable to interact with the Risp fusion protein.
On the contrary, two Rev mutants affecting the first multimerization region (RevM4)
and the effector domain (RevM10BL) were able to bind Risp (Fig. 3.15). When Rev
itself was used as control in the binding assay with wt Rev and all the Rev mutants, it
was able to bind to wt Rev, RevM4 and RevM10BL. On the contrary, like Risp, wt
Rev was not able to bind to the mutants RevM5 and RevSLT40 (data not shown,
Ceccherini-Silberstein and Chris Bickel). The fact that in the two-hybrid system Rev
was not able to bind to RevSLT40, a mutant in one of the two multimerization
domains, but it was able to bind to RevM10BL, a mutant that does not affect the Rev
multimerization, is not surprising. The fact that Rev was able to bind RevM4 mutant is
very interesting and will therefore be discussed below in more detail.
An important and often neglected aspect of the biological Rev functions is its ability
to form multimers. It has been suggested that this multimerization event is responsible
for a certain threshold level of intracellular Rev proteins, which must be overcome in
order to establish a productive HIV-1 infection, thereby regulating viral latency
(Malim and Cullen, 1991; Pomerantz et al., 1990). Rev has been reported to form
homomultimeric complexes in vivo and in vitro even in the absence of RRE RNA
(Kjems and Askjaer, 2000). The Rev sequences involved in the multimerization
process have been mapped using different assays and random mutational analysis of
the rev gene and often yielded opposing results. It is generally agreed that the
residues flanking the basic domain, which is responsible for RNA binding, and the
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NLS are controlling the Rev-Rev interactions (Fig. 2.4). Nevertheless, some reports
show that mutations in the NES also influence multimerization of Rev in vivo
(Bogerd and Greene, 1993; Madore et al., 1994). Little is known on the precise
localization of the domains responsible for the interactions and how many Rev
molecules form a biologically active complex on the RRE since as many as 12 Rev
molecules have been shown to bind to the RRE in vitro (Kjems and Askjaer, 2000).
Originally RevM4 was proposed to be a prototype multimerization-deficient Rev
mutant because of its failure to multimerize in an in vitro RNA gel retardation analysis
(Malim and Cullen, 1991). However subsequent studies showed that RevM4 was
able to multimerize about 40% as effectively as wild-type Rev in two in vivo assays,
while RevSLT40 appeared to be completely unable to form functional multimeric
complexes (Madore et al., 1994; Thomas et al., 1998). In agreement with these
previous in vivo assays, using the yeast two-hybrid system we were able to confirm
that the mutant RevM4, unlike the RevSLT40, is able to bind the Rev protein. One
explanation for the discrepancy often observed between the in vitro and in vivo
assays could be that the interaction and multimerization of mutant proteins is
quantitative in the in vitro assay, while the in vivo assay reflects the ability of a
mutant protein to interact with its wt protein in the cellular context.
Therefore, it is possible, that RevM4-Rev binding would occur in the yeast-two-
hybrid system, however RevM4 could not multimerize efficiently as its wt protein.
The minimal amount of interaction would allow to recruit the B42 activation domain
and the LexA binding domain on the transcription machinery and activate the
transcription of the yeast reporters. On the contrary, in previous data as well as data
presented here, the mutant RevSLT40 appears to be inactive in binding Rev and
unable to form functional multimeric complexes. Therefore, it can be considered as a
real prototype multimerization-deficient Rev mutant.
Moreover, we have shown that the mutant RevSLT40 was also unable to bind the
Risp protein. Therefore, it is possible that either a crucial Rev-/Risp-binding site is
located in the region harboring the SLT40 mutation (59-60aa), or that the mutation in
this region perturbs the overall structure of Rev thus resulting unfavorable the
binding to Rev and Risp proteins.
On the other hand, the fact, that we observed no binding of RevM5 to Risp and Rev,
points to the limitations of this system
Other investigators have shown that RevM5, a mutant in the RNA-binding and NLS
domain, could bind and multimerize efficiently in vivo with wt Rev when fused to Tat
(Madore et al., 1994; Thomas et al., 1998). In our system, the yeast pEG202 plasmid
(see 2.2.6.3.1.), used for the bait expression, does not contain an additional NLS like
in the Tat-fusion plasmid. Therefore, the absence of the strong functional NLS in
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RevM5 protein could be responsible for limiting the nuclear concentration of RevM5,
which is required for the binding with the Rev prey protein. It is also possible that
Risp was not able to bind the RevM5 mutant, not necessarily because the Risp-
binding region in Rev could be located in the RNA-binding/NLS domain, but because
not sufficient RevM5 protein was available for Rev binding in the nucleus. It will be
interesting to increase the nuclear expression of the bait RevM5 protein and to clarify
if Risp could bind Rev in its RNA binding domain. Therefore, the pJK202 plasmid,
which contains LexA fused to the SV40 NLS, will be used in repeating experiments
employing the yeast-binding selection.
To confirm the functional significance of the interaction between Risp and Rev
observed in yeast in human cells, an in vivo mammalian-binding assay was performed.
Because of the unknown location of the Risp-binding site in the Rev protein the
Rev-SLIIB-binding assay was performed as described in Fig. 3.16. This assay has
been already successfully used to prove the binding between the cellular cofactor
Rab (fused to Tat) and Rev (Bogerd et al., 1995) and the multimerization between
RevM5 (fused to Tat) and several Rev mutants (Thomas et al., 1998). In addition,
both the original RNA binding assay (Tiley et al., 1992) and the multimerization assay
(Madore et al., 1994; Thomas et al., 1998) were already established in this laboratory
(van Empel, 2000) and many plasmids were available. In light of the results obtained
with the Rev mutants in the yeast two-hybrid, this assay turned out to be not the best
suited one. In fact, the binding of Rev protein to a Rev-interacting cofactor fused to
Tat in this assay, depends also on the binding of Rev to the SLIIB RNA. Therefore, in
the context of proteins interacting with Rev at its RNA-binding domain, a binding
competition could occur that would limit the reliability of the assay.
In the case of Risp protein, Tat-Risp did not activate the SLIIB-CAT expression in the
presence of Rev like Tat-Rab did. Two possible explanations have been initially
considered: 1) Risp could bind to Rev in its RNA binding domain. Therefore, Risp
prevents the binding of the Rev protein to its SLIIB RNA target and the recruitment
of Tat-Risp on the HIV-1 LTR promoter element thus limiting the CAT expression.
2) In this cellular context Risp is not able to bind the Rev protein, and does not
activate the expression of SLIIB-CAT. Hence, the possibility that Risp could have
represented an artifact of the yeast two-hybrid system was considered. Nevertheless,
the identification of a common motif shared between several Rev-interacting factors
in Risp protein supports the idea that Risp could represent a specific new Rev-
interacting protein. To confirm, that Risp is in fact a Rev-binding protein, and that it
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could bind to the RNA binding domain of Rev, a Tat-Rev/SLIIB-binding inhibition
assay was performed in presence of a Risp expression plasmid.
The results of four experiments showed that Risp-GFP was able to inhibit the SLIIB-
CAT expression induced by Tat-Rev at different levels according to its concentration
(Fig. 3.20). The overexpression of two control proteins, which should not compete in
the Rev-SLIIB binding (such as Rab, which binds Rev in its activation domain, or
GFP, which is not a Rev-binding protein) inhibited the Tat-Rev induced CAT
activations in some experiments, even though at lower levels than Risp. Risp was able
to reduce the SLIIB-CAT activation, presumably by competing against the binding of
Rev with its RNA target. However, an inconsistent inhibition not related to Risp was
observed as well. This unspecific reduction effect was observed using larger amounts
of plasmid DNAs, especially with the GFP constructs. In addition, it is worth to note
that when the fold-activations are expressed by the median values instead of the
average values, the Risp inhibition is highly specific (Fig. 3.20). The overexpression
of Risp-GFP reduced the CAT activation for about 67%, the overexpression of GFP
for 29% and the overexpression of Rab for 23%.
A part of the unspecific reduction could be caused by a competition between the
different promoters with each other. In fact, the plasmids contained different
promoters (CMV promoter directed the expression of Risp-GFP, Rab, GFP and Tat-
Rev; HIV-LTR promoter directed the expression of the CAT reporter and murine
leukemia virus-related RFB-LTR the luciferase gene). It was impossible to use always
the same DNA-plasmid preparations for all the transfections. The different quality of
the plasmids could have interfered in some experiments with the efficiency of the
transfection itself. In support of this idea, it should be considered, that among the
different experiments, in cells transfected with the pSLIIBCAT indicator plasmid and
in absence of the inhibitors, a wide variation of CAT activation levels induced by Tat-
Rev was observed. The induction levels varied between 15-fold and 187-fold (see
Table 3.19). The luciferase expression also varied between the cells transfected with
different plasmid mixtures (2-10 fold) and between the different experiments (2-20
fold).
Therefore, due to the possible competition of the promoters and/or the different
transfection efficiencies, it could not be excluded that in some experiments the
expression of some proteins did not reach optimal levels and functions. This
consideration would suggest, that the inhibitory effects observed are not only caused
by protein interactions and may also explain the inhibitory effect by the GFP on the
HIV-1 LTR driven CAT expression seen in one single experiment (Fig. 3.21). In fact,
the presence of GFP, also at low levels of the expression plasmid (0.5µg), reduced the
Tat-dependent trans-activation of the HIV-1 LTR for more than  50%, whereas the
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presence of Risp-GFP (until 1µg of plasmid) reduced the LTR-CAT activation by Tat
for around 11%. Even if these data are obtained by a single experiment, nevertheless
it strongly supports the presence of a highly unspecific reduction independent of the
protein interactions.
Unfortunately, the limited number of the experiments excludes a statistical analysis of
the available data. On one hand more experiments should be performed to firmly
establish whether the observed reduction of the SLIIB-CAT inductions by Risp-GFP
is caused by the Rev-Risp protein interaction (i.e. is specific). On the other hand,
these results show that in binding-competition experiments, where the intracellular
concentration of the ligand and the competitor should be essentially precise and
controlled, a transfection system complex as the one used in this study is not well
suited.
Moreover, Risp-GFP should be fused to a strong NLS, such as the SV40 NLS, to
increase the nuclear concentration of Risp-GFP. In fact, another possible explanation
of the low reduction observed in the SLIIB-CAT inhibition by Risp, could be that the
levels of Risp-GFP in the nucleus are too limited to ensure a successful binding to
Rev. Even if Risp-GFP could shuttle between the cytoplasmic and the nuclear
compartments, its main location is in the cytoplasm, due to its strong NES.
Presumably a different method should be used to confirm that the Risp-Rev
interaction is real. In addition, the clarification of the region involved in this
interaction could be helpful. Currently, Chris Bickel, in the group of Dr. Brack-
Werner, is trying to set up a mammalian two hybrid system, already successfully used
to confirm the binding of Rev to Rab and to NLP-1 (Bogerd et al., 1995; Farjot et al.,
1999). A further possibility, within the use of the two hybrid technology (mammalian
or yeast), could be to test the ability of hybrid proteins to associate, when the bait
protein (Rev) is switched to the activation domain and the library-derived protein
(Risp) is fused to the DNA-binding domain. In fact, observed interaction between
reciprocal hybrids is generally considered as a strong indication of true physical
association. An alternative approach could be to use in vitro detection by
biochemical methods such as co-immunoprecipitation or in vitro binding. However,
this may cause a problem of sensitivity. Physical methods, such as the above-
mentioned, generally rely on a low rate of dissociation since complexes must survive
several washing steps, which decrease the signal, but are necessary to prove
specificity. In addition, protein-protein interactions may require other proteins for
stability, therefore it is not always possible to prove in vivo binding of proteins with
in vitro assays.
Finally, another potential protein-hybrid technology that could be applied to
intracellular events, could be the applying of the autofluorescent GFP reporter
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protein. A potential use of this reporter is based on fluorescence resonance energy
transfer (FRET), which can be detected, when two fluorochromes are brought into
close proximity. FRET is measured in real time to measure distances up to 100Å
(Pollok and Heim, 1999). GFP has been already modified to produce fluorochromes
with different absorption and excitation spectra. Therefore, it may be possible to
generate a fusion of Risp and Rev to GFP-modified fluorochromes and Risp-Rev
interaction could either be detected by cell sorting or observed microscopically in
living cells.
4.5. Influence on HIV-1 Gag production in the presence of Risp-GFP
Additional experiments to test Rev function in the presence of Risp-GFP were
performed by analysis of the production of the Rev-dependent structural viral
proteins. Results from three independent experiments are presented in Fig. 3.22.
Despite the overexpression of GFP or Rab proteins, which did not influence the HIV-
1 Gag production, cells expressing Risp-GFP showed a distinctly diminished Rev-
dependent stimulation of Gag production. The overexpression of Risp-GFP reduced
the Rev-inductions by 30% (1µg plasmid) up to 70% (2µg plasmid). However, the
limited number of experiments excludes the possibility of a statistical analysis of the
present data. Therefore, further experiments should be warranted.
Nevertheless, these preliminary data suggest that Risp, as a Rev-interacting protein, is
able to inhibit the Rev-trans-activation while Risp did not interfere with Tat in a Tat-
trans-activation assay  (Fig. 3.21)
It is possible to speculate that the diminished stimulation of Gag synthesis in the
presence of Risp is caused by an inhibitory effect of this protein in the function of
Rev. Even if it is not yet possible to conclude, that Risp binds Rev in its RNA-binding
domain, the binding in its II multimerization domain could be sufficient to explain the
inhibitory effect of Risp to Rev function.
The ability of HIV-1 to persist, even when attacked with multiple drugs, imposes to
continue the search for novel strategies in HIV therapy. Several anti-Rev strategies
have been proposed and tested (Gilboa and Smith, 1994; Lee et al., 1994; Pomerantz
and Trono, 1995). The development of effector molecules that could interfere with the
Rev-RRE interaction and/or Rev multimerization (Kjems and Askjaer, 2000) is
considered at this moment as a promising approach, regarding Rev targeted therapy.
It might be worth to employ a mutational analysis of the Rev-binding region in the
Risp protein, in an attempt to isolate more potent Rev-inhibitory mutants of Risp
which act by interfering with the RRE- and/or Rev-Rev interactions. Moreover, the
fact that the constitutive overexpression of Risp in HeLa and U87 astrocyte cells is
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not toxic, is promising. The mutation in the Rev-binding region should not change
the toxicity of the protein.
4.6. Nucleocytoplasmic shuttling properties of Risp: identification of a region
containing a NES
Qualitative and quantitative analysis of the intracellular localization of Risp showed
that Risp-GFP is a shuttling protein that can enter and exit the nucleus and
accumulates in the cytoplasm. The cytoplasmic accumulation at steady-state is similar
to that observed previously with proteins subjected to nuclear export, like PKI (Wen
et al., 1995), suggesting that Risp itself could contain a strong NES or may interact
with a protein containing a NES. In addition, Risp accumulated in the nucleus in the
presence of the Crm1 inhibitor leptomycin B, indicating that the nuclear export of
Risp-GFP is Crm1-dependent.
The identification of Risp NES was confirmed by localization analysis of different
transfected segments of Risp (Fig. 3.30 and 3.31) and by cytoplasmic accumulation of
nuclear microinjected BSA-fusion protein, containing a peptide from the C-terminal
part of Risp (residues 86-105, BSA-Risp peptide #2) (Fig. 3.33). Previous studies used
cellular microinjection of fusion proteins into the nucleus or cytoplasm as
experimental approach to identify signals or regions mediating protein nuclear export
or import. Fischer and coworkers demonstrated, using nuclear microinjection of
peptides comprising the activation domain of Rev cross-linked to BSA, that the Rev
activation domain constitutes a nuclear export signal that directs RRE-containing
viral RNAs export pathway (Fischer et al., 1995). Wen and coworkers also could
demonstrate that the activation domain of Rev has an intrinsic export capacity, in that
it mediates export of nuclear injected GST-Rev activation domain conjugate (Wen et
al., 1995).
The export receptor Crm1 is reported to mediate export of several viral and cellular
proteins involved in different biological functions (Fornerod et al., 1997; Gorlich and
Kutay, 1999; Kjems and Askjaer, 2000). Generally, these proteins are characterized by
different NES structures, although each contains a leucine-rich cluster. Using
sequence alignment and in vivo selection studies, a leucine-rich NES consensus
sequence was generated containing four characteristically spaced hydrophobic
residues “L X 2-3 L X 2-3 L X L” (where X denotes any residue) (Bogerd et al., 1996;
Kjems and Askjaer, 2000). Although leucine residues are most common, other
hydrophobic residues (such as F, I or M) are found, suggesting that this consensus is
not highly stringent.
Interestingly, an analysis of Risp primary amino acid sequence with the available
computer programs suggested that Risp sequence does not contain “classical”
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signals known to mediate nucleo-cytoplasmic transport. However, a more thorough
analysis of the sequence showed at position 88 a short cluster richer of leucine and
isoleucine residues (LESNLFDDNIDIFADL), motivating the choice of using these
residues to synthesize a Risp peptide and to test it for nuclear export (BSA-Risp
peptide #2).
The discovery of a new Crm1-dependent NES in Risp with no obvious relation to
other leucine-rich NESs, strongly support the necessity to get more detailed
information on how Crm1 recognizes the apparently different NES structures. One
possibility is that different adapters could be involved in recognition of those NESs.
Recently the existence of different specific nuclear export pathways for leucine-rich
NES-containing proteins was suggested, one represented by the nuclear export of the
viral RNA export factors Rev and Rex, and one by the export pathway accessed by
PKI (Elfgang et al., 1999). In the proposed model, Crm1 is a general export receptor
that mediates together with RanGTP the translocation of all nuclear export cargoes
containing leucine-rich NESs through the NPC, whereas eIF-5A is specifically
required for the nuclear export of the retroviral Rev and Rex RNA transport factors.
EIF-5A  was shown previously to interact functionally with the Rev- and Rex- NES
(Katahira et al., 1995; Ruhl et al., 1993), and distinct mutants have been described to
inhibit the nuclear export of Rev protein and thereby HIV-1 replication (Bevec et al.,
1996; Junker et al., 1996). Elfgang et al confirmed that the inhibition of eIF-5A by
antibodies, blocked the nuclear export of Rev and Rex, whereas the
nucleocytoplasmic translocation of the PKI NES was unaffected (Elfgang et al.,
1999). Regarding the Risp protein, it could be assumed, that its NES also belongs to
the classical leucine-rich NESs (with a little modification of the consensus “L X 2-3 L
X 2-4 I/L X I/L”). In any case it will be essential to determine, whether the leucine or
isoleucine positions are crucial for the nuclear export of Risp as it was performed for
the identification of amino acids in the Rev NES which direct its export activity.
The study of the export activity of Risp NES mutant peptides and Risp mutant
protein with alterations in one or more of the leucine or isoleucine hydrophobic
positions is necessary.
Moreover, analyses should be performed to understand whether these mutants may
also affect the nuclear export of the Rev protein. The cellular function of Risp and the
significance of the binding to Rev are still undefined. It cannot be excluded that since
both proteins are using the same export receptor Crm1, they also could compete at the
level of the nucleocytoplasmic translocation. Alternatively, Risp might be an
additional Rev-interacting protein, involved in the Rev nuclear export. However, in
both cases it will be interesting to analyze whether eIF-5A may play a role in the
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nuclear export of Risp. Hence, tests using anti-eIF5A antibodies should demonstrate
whether the inhibition of eIF-5A could also block the nucleocytoplasmic
translocation of Risp NES peptides or Risp protein.
Proposing Risp as a new nucleocytoplasmic shuttling protein implies, that in addition
to its identified Crm1-dependent NES, also a NLS should be present in the protein to
mediate its nuclear entry. The presence of a lysine-rich cluster (KPKEKSKKKVEAK)
in Risp at position 106, with low score of identity with the classical SV40 NLS, that
could possibly act as NLS, motivated  to test this region in microinjection experiments
as BSA-Risp peptide conjugate  (BSA-Risp peptide #2). However, a nuclear entry of
cytoplasmic injected BSA-Risp peptide #2 was not observed, while when
microinjected into the nucleus, it was imported into the nucleoli (Fig. 3.33).
Interestingly, when the mixture of BSA-Risp peptide #2 and BSA was microinjected
in the same cell in both nuclear and cytoplasmic compartments, only the BSA-Risp
peptide #2 conjugate entered the nucleus and accumulated in the nucleoli, indicating
the presence of a nucleolar localization signal in that basic region of Risp.
According to the result, that this region was not sufficient to mediate the nuclear
import of the BSA conjugate, it cannot be excluded that a larger sequence containing
the lysine-rich cluster would be necessary to trigger nuclear import of Risp.
Moreover, the proximity of the NES and the putative NLS (Fig. 4.2) allow the
speculation that Risp could be one of the proteins containing nucleocytoplasmic
shuttling signals (NSSs), which are transport signals that can direct nuclear import as
well as nuclear export (Michael, 2000). Therefore, further experiments with Risp
mutants in its NES and/or putative NLS could help to clarify the importance of this
region in the function of Risp.
It should be taken into account that Risp is most probably only a part of a larger
protein. One or more functional NLSs could be also located in another part of the
larger protein.   In support of this idea a PSORT II analysis with the clone K1AA0592
identified, with a total score of 1.92, 6 different possible NLSs in the sequence, which
all contain lysine and some also arginine residues (Fig. 4.2). Therefore, the possibility,
that the nuclear accumulation of Risp-GFP or IgG-Risp in the presence of leptomycin
B might be rather caused by passive diffusion than by active transport, has to be
considered.
Recently a study of Rev-trafficking in astrocytes indicated the presence of an
inhibitory activity in the cytoplasm of astrocytes, which prevented efficient nuclear
uptake of Rev during its nucleocytoplasmic shuttling (Neumann et al., 2001). These
results support the hypothesis of the existence of factor(s), that inhibit Rev function
in astrocytes. Since a different cellular distribution of Risp-GFP in astrocytes with
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respect to HeLa cells was observed, it remains very interesting to analyze the
constitutive expression of Risp (or the larger protein containing it) in astrocytes. May
be that Risp in these cells could interfere with the Rev function in a different way
than HIV-1 permissive cells.
Fig.  4 .2  K1AA0592 and Risp protein structure proposal. The location of Risp
within the larger protein KIAA0592 is represented in light blue. The 6 KIAA0592 putative
NLSs proposed with the PSORT II analysis are shown with the question marks. Regarding
Risp (171 aa), the domain containing the Rev-interacting proteins (RIP)-motif is shown in the
N-terminus. In the C-terminus the proximal leucine-isoleucine-rich stretch constituting the NES
and the basic region with NOS and possibly NLS function are represented. The minimal
sequence for the Rev-binding is not yet identified, however we assume that the Rev-binding
domain is located between amino acids 39-133 (1221-1315). Moreover, the consensus
sequences, recognized by the PROSITE pattern search, targeting 1 Asn-glycosylation (NETK),
5 phosphorylation sites for casein kinase II (S/T.K) and 5 phosphorylation sites for protein
kinase C (S/T..D) are shown as possible post-translational modifications in Risp.
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4.7. Nucleocytoplasmic shuttling properties of Rev: identification of a new
additional NLS in the Rev protein
Although Rev has been described to be a nuclear protein that accumulates
predominantly in the nucleoli of Rev-expressing cells, a part of the Rev molecules
continuously shuttles between the nucleus and the cytoplasm (Meyer and Malim,
1994). Generally, small proteins with sizes below 40-60kDa can enter the nucleus by
passive diffusion. However, in spite of Rev being significantly smaller than this limit
(18 kDa), nucleocytoplasmic traffic of Rev appears to be actively controlled.
In this study, the identification of a new region with intrinsic nuclear import activity
in the Rev protein has also been shown. Interestingly, analysis of the HIV-1 Rev
amino acid sequence revealed the presence of a particular motif, the PPXXR motif,
inside its activation domain (LQLPPLERLTLD). This motif is conserved in various
RNA-binding proteins and was proposed to be important to mediate nuclear
translocation of the cellular functional homologous of HIV-1 Rev Sam68 (Ishidate et
al., 1997). The possibility, that the Rev activation domain harboring this motif could
be important in mediating nuclear import of Rev and that it could represent an
additional NLS, has been hypothesized and investigated.
First, the intracellular localization of RevM5, a mutant of Rev in the arginine-rich NLS
(Malim et al., 1989), was analyzed. It is known that the arginine-rich region of the
Rev protein (aa 38-46), located within the core of the RNA binding domain, mediates
both the Rev nuclear import and nucleolar targeting (Cochrane et al., 1990; Kubota et
al., 1989; Malim et al., 1989; Perkins et al., 1989). As it was previously described for
RevM5 (Malim et al., 1989), HeLa cells transfected with the pcRevM5 or pcRevM5-
sg143 plasmids showed much higher levels of cytoplasmic accumulation of the Rev
mutant protein (cytoplasmic fluorescence > 70%) than wt Rev or Rev-GFP
(cytoplasmic fluorescence < 26%) (Fig. 3.37). However, in this study it has been
shown, that in the presence of the export-inhibiting drug leptomycin B RevM5 and
RevM5-GFP were able to enter the nucleus and accumulate there, suggesting that,
even if mutated in its arginine-rich NLS, Rev is able to shuttle between the cytoplasm
and the nucleus. The possibility, that the nuclear translocation of RevM5 was caused
by an active transport and not by passive diffusion, was confirmed by the
observation that the nuclear accumulation was energy dependent. In fact, recent
results from our group (Severine Demart, data not shown) indicated that in the
presence of leptomycin B RevM5-GFP only accumulated in the nuclei of cells
incubated at 37°C (nuclear fluorescence 48%). At 4°C only weak nuclear
translocation could be observed probably caused by passive diffusion (nuclear
fluorescence 35%).
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These results indicate that Rev may contain other signals mediating nuclear import in
addition to its arginine-rich NLS. To analyze, whether the activation domain of Rev,
containing the signal PPXXR, could act also as a nuclear localization signal and
mediate the nuclear import of Rev independently from the arginine-rich NLS, several
peptides consisting of the Rev activation domain (residues 73-84) were cross-linked
to fluorescence labeled BSA (Fig. 3.38). In this work different BSA-Rev NES
peptides, with either wt Rev or export-deficient mutant RevM10 activation domain
were used to investigate the nuclear export. The peptides were also microinjected
into the cytoplasm and their nuclear import activity was investigated.
Nuclear accumulation of cytoplasmic microinjected BSA-Rev NES peptides in cells
pretreated with the export-inhibiting drug leptomycin B clearly showed the ability of
the activation domain to induce nuclear import of BSA-conjugate (Fig. 3.40).
These results suggest that the leucine-rich domain of Rev harbors signals able to
mediate shuttling between the nuclear and cytoplasmic compartments, rather than
exclusively conferring nuclear export. This impression is supported by another recent
study, which showed nuclear entry in vivo and nuclear accumulation in vitro of beta-
galactosidase fusion protein containing the Rev NES, when microinjected in the
cytoplasm (Efthymiadis et al., 1998). However, Efthymiadis et al. observed, that NESs
of both Rev and PKI drove nuclear entry of the large heterologous protein β-
galactosidase. The absence of the motif PPXXR in the PKI NES lets suppose, that if
this motif is important for nuclear import activity of the Rev NES, a different signal
should be responsible for import activity of the PKI NES.
A point mutation changing the arginine in the PPXXR motif to alanine was described
to diminish the nuclear accumulation activity of a Sam68 NLS peptide, suggesting the
importance of this residue in nuclear translocation. Hence it was investigated,
whether the exchange of the arginine by an alanine in the activation domain of Rev
could also induce a change in its intrinsic nuclear import activity. As expected, the
alanine exchange did not alter the nuclear export ability of the Rev NES.
As it is shown in Fig. 3.40 both activation domains of wt Rev and of export-deficient
mutant RevM10 harboring the alanine mutation kept the nuclear entry ability when
injected into the cytoplasm. Nevertheless, at the same time post-injection a minor
nuclear accumulation of the BSA-RevM10NES-A conjugate in comparison to the
BSA-RevM10NES was observed. This indicates that the alanine mutation could alter
the nuclear import ability of the Rev activation domain if already mutated in its
nuclear export function.
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Although the PPXXR motif in Sam68 is thought to be important in mediating nuclear
entry, an additional mutational analysis of the Rev NES should be performed to
address the significance of the PPXXR motif in nuclear import of Rev.
The activation domain of Rev has been mapped to amino acids 73-83 on the basis of
mutational analyses (Kjems and Askjaer, 2000). Mutation of any of the three leucines
(Leu 78, Leu 81 or Leu 83) in this element not only abolished Rev function by
blocking its nuclear export, but also inhibited the activity of co-expressed wild type
Rev protein, a phenomenon known as trans-dominant inhibition.
In this study, we showed that the mutations of Leu 78 and Glu 79 to Asp 78 and Leu
79 (in RevM10) abolished the Rev nuclear export, whereas they did not abolish the
nuclear import of the activation domain. However a weak reduction of nuclear import
of the RevM10 NES with respect to the Rev wt NES was observed and this increased
in presence of the Arg 80 mutation.
In a recent study, where the toleration of diverse amino acid substitutions in the Rev
NES was investigated, the single mutational exchange of the arginine in the PPXXR
motif with the hydrophobic alanine reduced Rev function by 50% (Zhang and
Dayton, 1998). According to what is known so far, the impairment of Rev function
related to the Arg mutation, could depend also on inhibition of Rev nuclear import via
its activation domain.
However, the highly similar concentration of leucine residues in the PKI
(LALKLAGLDI) and Rev (LQLPPLERLTL) NES sequences (essential for the
nuclear export) and the absence of the PPXXR motif in PKI NES could also indicate,
that this motif itself is not important to confer nuclear import in Rev. Whereas the
alternating presence of hydrophobic leucine and hydrophilic residues (acidic, basic or
uncharged) in both NESs is the essential requirement to transform both domains in
target signal for the transport receptors.
It is interesting to note that until now no Rev mutants exist, which show only
disabled import activity. Since the arginine-rich NLS is located within the RNA
binding domain, mutants in this region of course exhibited impairment in nuclear entry
and in RNA binding, which resulted in a clear abrogation of Rev function (Kubota et
al., 1992; Malim et al., 1989). Even though the existence of two NLS in the Rev
protein is confirmed, it is not yet  known ,which cellular or viral element controls their
function.
Interestingly not all the cytoplasmic injected BSA-RevNES conjugated entered the
nucleus and furthermore the BSA-RevNES did not accumulate in the nucleoli  The
signal and the mechanism of entry of this additional Rev NLS might be different from
the Rev arginine-rich NLS, which has been shown to mediate also nucleolar
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localization of transfected fusion protein (Cochrane et al., 1990). However, since no
microinjection experiments with BSA-Rev NLS have been performed so far, it is
difficult compare the two NLSs directly.
Since the arginine-rich NLS is very basic, while the NES is very hydrophobic, these
two motifs target very likely different sites to achieve nuclear translocation. Despite
information on the identification of an additional NLS in the activation domain of
Rev, the import pathway through which this signal acts has not yet been investigated,
therefore only hypothesis on known pathways could be proposed and discussed.
It is known that nuclear import of proteins with classical lysine-rich NLS is conferred
by their NLS-dependent interaction with the importin α/importin β heterodimer
transport receptors. Arginine-rich NLSs, of both Tat and Rev (that are very similar to
each other) directly interact with importin β but not importin α in vitro. Importin β is
both necessary and sufficient for the nuclear import in vitro assays suggesting a
function independent of importin α (Truant and Cullen, 1999). Already Henderson
and Percipalle (Henderson and Percipalle, 1997) have reported that the Rev NLS can
bind directly to importin β and that this interaction is inhibited by added importin α,
thus suggesting that importin α and Rev compete for overlapping binding sites on
importin β. It is interesting to note that these authors also reported a Rev-importin α
interaction. However, since it was not dependent on a functional Rev NLS it was
therefore regarded to be non specific. Nevertheless, with the discovery of a nuclear
import activity in the Rev NES it could not be excluded that the activation domain
itself may also bind specifically to importin α. It may be that the nuclear translocation
of the Rev protein via its activation domain could be dependent on importin α.
However Efthymiadis and coworkers were not able to prove a direct binding
between the Rev and PKI NESs with the importin α/β-NLS-binding subunits using an
ELISA-based binding assay (Efthymiadis et al., 1998). They proposed, that exportins,
such as Crm1, which are known to mediate export of NES-containing proteins could
themselves facilitate nuclear import under certain conditions. However, in this study it
was shown that the Crm1-binding leptomycin B inhibited nuclear export but not
nuclear import of BSA-Rev NES conjugate. Moreover, the mutations of Leu 78 and
Glu 79 (RevM10) abolished the Rev nuclear export but not the nuclear import of the
NES. Since it is known that RevM10 in the yeast two-hybrid is not able to bind Crm1
(Neville et al., 1997) it is conceivable that other transport receptors different from
Crm1 may be involved in the binding of the Rev activation domain and mediate its
nuclear import.  
In summary, the Rev activation domain might be considered as a nucleocytoplasmic
shuttling domain containing a nucleocytoplasmic shuttling signal (NSS) rather than a
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“simple” NES. Several proteins involved in mRNA nuclear export are known to
contain NSSs, which are transport signals, that can direct both nuclear import and
nuclear export (Michael, 2000). Analysis of NSS has demonstrated, that subcellular
trafficking of mRNA-binding proteins occurs by a mechanism fundamentally different
from that of other shuttling proteins. Therefore, the import receptor recognizing the
Rev NSS could be one of those which are mediating the import of other NSS-
containing proteins. Until now only transportin 1, a distant relative of the importin β,
was discovered to mediate the import of two NSS-containing proteins hnRNP A1 and
Tap (Bonifaci et al., 1997; Pollard et al., 1996; Truant et al., 1999), whereas the import
receptor for the other proteins is still unknown (Michael, 2000).
In conclusion, these results demonstrate, how, for a small protein such as Rev, which
could in principle cross the nuclear pores free by passive diffusion, the
nucleocytoplasmic shuttling, which is essential for its key regulatory roles, is highly
controlled by different targeting signals and cellular transport mechanisms. Therefore,
HIV-1 Rev still represents an excellent system to study and increase the knowledge
on the signal-mediated transport across the nuclear envelope.
5.  Concluding Remarks
In this work a new Rev-interacting protein has been identified using the yeast two-
hybrid system. The protein was termed Risp (Rev-interacting shuttle protein), because
it shuttles between the nuclear and the cytoplasmic compartments.
The Risp gene is widely expressed in human cells and conserved among various
species, most probably as part of a larger gene. High identity (99%) with the C-
terminal part of a large brain cDNA clone for KIAA0592 protein (Nagase et al., 1998)
has been found, whereas no high sequence homology has been associated with any
protein with known function. However, a weak and partial homology appeared with
several RNA-/DNA-binding and shuttle proteins. This might indicate that Risp protein
- or the larger protein containing it - could be a member of a new family of
nucleocytoplasmic shuttle proteins with RNA-/DNA-binding function.
In HeLa cells Risp-GFP localizes in both nuclear and cytoplasmic compartments, but
clearly accumulates in the cytoplasm, indicating the presence of a strong nuclear
export signal (NES). The identification of Risp NES was confirmed by localization
analysis of different transfected segments of Risp and by cytoplasmic accumulation of
nuclear microinjected BSA-fusion protein containing a peptide from the C-terminal
part of Risp. The inhibition of the Crm1-mediated nuclear export, induced by the
presence of leptomycin B, showed that the nuclear export of Risp is Crm1-dependent.
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As it is rich in leucine and isoleucine residues, the Risp NES might be related with
other leucine-rich NESs. To determine if these hydrophobic amino acids are also
crucial for the nuclear export of Risp, the export activity of Risp NES mutant peptides
and Risp mutant protein with alterations in one or more of the leucine and isoleucine
positions has to be analyzed.
Risp has been shown to share a specific motif with other Rev-interacting proteins.
This consists of 12 amino acids [P (AELNR) (KHILST) (KCRST) T N (PD) F (GLQ)
(LST) (LIN) (EAGQS)] termed RIP motif. This is the first indication for the presence of
a specific and common motif shared between Rev-interacting factors, including Rev
itself. A region containing a sequence matching to the consensus motif was identified
in every Rev-interacting protein. Nevertheless, a particular group of cellular proteins,
mostly involved in the Rev/RRE nuclear export, showed to be highly specific versus
the motif. No correlation was found between the motif and the Rev-binding ability, in
fact the region of Risp harboring the RIP motif was neither essential nor sufficient for
the Rev-binding in the yeast two hybrid system.
Therefore, the role and the relevance of the consensus motif present in Risp and in the
other Rev-interacting factors should be in detail investigated in future studies. For
example mutational analysis and deletions of the domain in the Risp protein will be
established to analyze whether the function of Rev could be modified.
Although, it is not yet clear which is the minimal sequence part required for the Risp-
Rev interaction, we can assume that the Risp-binding region in Rev should be
located in a region overlapping the basic domain deputed to RNA binding/NLS (34-
50aa) and the second multimerization region (52-60aa). In the basic domain already
other Rev-interacting proteins such as B23, p32, and importin β are supposed to bind
Rev, whereas other proteins involved directly and indirectly to the Rev nuclear
export, such as Crm1, eIF-5A, hRab/rip, are known to bind Rev in its activation
domain (Table 2.3 and Fig. 5.1).
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Fig. 5.1 Rev and cellular interacting factors. It is known that Rev is composed of
several domains harboring distinct binding sites for cellular proteins. Here an updated scheme
of the primary Rev structure is proposed. The leucine-rich activation domain in the C-terminus
(aa 73-84) contains a nucleocytoplasmic shuttling signal (NSS) mediating the Rev nuclear
export and nuclear import. In the nucleus, Rev NSS binds directly together with RanGTP to the
export receptor Crm1 to form a stable complex Rev/Crm1/RanGTP able to dock and translocate
the nuclear pore complex. Several nucleoporins (hRip/Rab, yRip1p1/Nup42, Nup98, Nup153,
Nup214, NLP-1) and eIF-5A, identified as Rev NES-interacting proteins, are involved to
mediate the nuclear export of Rev/Crm1/RanGTP complex. The interacting import protein (?)
mediating the Rev import via the NSS domain is not yet discovered. The arginine-rich stretch
located toward the N-terminus (aa 34-50) serves as a RNA-binding domain as well as a
nuclear/nucleolar localization signal (NLS/NOS). This is, in turn, closely flanked on both sides
by residues that mediate Rev multimerization (aa 12-29 and 52-60). Importin β and p32, have
been proposed to bind directly with the Rev basic domain. In the cytoplasm, the import receptor
importin β recognizes the REV NLS and thus mediates the Rev nuclear entry. The interaction of
Rev with the protein p32, normally associated with the cellular splicing factor SF2/ASF, may
participate in the removal of splicing factors from intron-containing RNAs and permit a nuclear
accumulation of RNAs substrate for Rev-mediated nuclear export. A binding between the
nucleolar phosphoprotein B23 and Rev has been also observed. However, the accumulation of
both proteins in the nucleolus may reflect the ability of the interaction, while no B23 role in
supporting Rev function has been demonstrated. Finally, in this study, we showed the presence
of a new Rev-interacting protein, Risp, that binds Rev in its RNA-binding and the II
multimerization domain.
Activation domain
Nucleocytoplasmic shuttling signal (NSS)
RNA-binding domain & 
Nuclear/nucleolar localization   
(NLS/NOS)
Oligomerization I Oligomerization II
eIF-5A
B23
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Preliminary experiments suggested that Risp, as a Rev-interacting protein, is able to
inhibit Rev-trans-activation, while Risp does not interfere with Tat in a Tat-trans-
activation assay. In fact, the over-expression of Risp-GFP was able to reduce the
production of the Rev-dependent structural viral protein p24gag up to 70% and
fairly specifically the SLIIB-CAT expression in a Tat-Rev/SLIIB-binding assay.
Therefore, it is possible that the binding of Risp to Rev in its RNA-binding and
multimerization domain may compete with the binding of Rev to its SLIIB RNA
target and to other Rev molecules inhibiting thereby Rev function.
Since Risp most probably is only a part of a larger protein, it is also important to
isolate its full-length cDNA and repeat the Rev-trans-activation studies. Currently,
Chris Bickel, in the group of Dr. Brack-Werner, is trying to enlarge to the 5’ end of
the full-length cDNA. It will be of high interest to determine whether the original
protein containing Risp is able to interfere with the Rev function and thus to limit
HIV-1 replication.
Moreover, since both Risp and Rev are using the same export receptor Crm1, an
additional role of Risp could also be proposed at the level of the nucleocytoplasmic
translocation of Rev. The direct binding of Risp to Crm1 could compete with the
Rev-Crm1binding and therefore reduce Rev nuclear export. On the other hand, Risp
bound to Rev in its RNA-binding and multimerization domain may accelerate the
nuclear export of Rev, providing also its NES, and therefore facilitating the
association with Crm1and RanGTP to form an active export complex in the absence
of HIV-1 RNA.
Of course, most of the implications reported here are still speculative, requiring future
experimental work to obtain a better understanding of the function(s) of Risp and its
interactions with Rev.
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Fig. 5.2 Possible interference on the Rev functions by Risp. The interaction of
Risp with Rev in its RNA-binding and multimerization domain may compete with the binding
of Rev to the unspliced and single spliced mRNAs and to other Rev molecules. The binding of
Risp to the export receptor Crm1 may result in competition with the Crm1-Rev binding at the
level of the nucleocytoplasmic translocation. Therefore, the transport out of the nucleus and the
following translation of the viral mRNAs responsible for the production of the viral enzymes
and structural proteins might be inhibited by the presence of Risp.
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Summary
The aim of this study was to characterize the role of Rev-interacting cellular proteins in
controlling the function of Rev in the host cell. The HIV-1 protein Rev plays an essential role in
the temporal regulation of the virus gene expression by stimulating the expression of viral
structural proteins. Rev enhances the nucleocytoplasmic transport and the translation of unspliced
and single spliced viral mRNAs by binding with high affinity to a specific target element on the
HIV-RNA. It was assumed that interaction with cellular factors is essential for Rev function. At
the onset of this study, only a few potential cofactors were known with no clearly defined
functional relevance. So we decided to search for new Rev-interacting factors using the yeast
two-hybrid system.
In this work a new Rev-interacting protein has been identified, by screening a Jurkat T cell cDNA
library. The protein was termed Risp (Rev-interacting shuttle protein), because it shuttles
between the nuclear and the cytoplasmic compartments.
The Risp gene is widely expressed in human cells and conserved among various species, most
probably as part of a larger gene. High amino acid homology (99%) with the C-terminal part of a
large brain cDNA clone for KIAA0592 protein has been found, whereas no obvious homology to
proteins with known function was observed. However, a weak and partial similarity appeared
with several RNA-/DNA-binding and shuttle proteins. This might indicate that the Risp protein -
or the larger protein containing it - could be a member of a new family of nucleocytoplasmic
shuttle proteins with RNA-/DNA-binding function.
Next, the intracellular localization and shuttling of Risp was investigated. In HeLa cells Risp-
GFP localized in both nuclear and cytoplasmic compartments, but clearly accumulated in the
cytoplasm, indicating the presence of a strong nuclear export signal (NES). The identification of
a NES sequence was confirmed by deletion analysis of Risp and by nuclear microinjection of
BSA-fusion proteins conjugated to peptides from the C-terminal part of Risp.
Treatment with leptomycin B, a drug which has been shown to specifically block Crm1
(exportin) mediated export, resulted in nuclear accumulation of Risp-GFP, showing that the
nuclear export of Risp, like that of Rev, is Crm1-dependent.
Using bioinformatic tools able to detect weak homologies with high specificity, sequence
comparisons between Risp and all currently known Rev interacting factors were performed. This
analysis for the first time revealed a common motif shared between Rev and Rev-interacting
cellular factors, termed RIP. The region of Risp harboring the RIP motif was neither essential nor
sufficient for the Rev-binding in the yeast two hybrid system, suggesting no direct correlation
between RIP and the Rev-binding ability.
Preliminary experiments suggested, that Risp, as a Rev-interacting protein, is able to inhibit Rev-
trans-activation, while Risp does not interfere with Tat in a Tat-trans-activation assay. The over-
expression of Risp-GFP reduced the production of the Rev-dependent structural viral protein
p24gag up to 70%.
In addition a previously unrecognized sequence motif in the activation domain of Rev with
intrinsic nuclear import activity was found and tested in transfection and microinjection assays.
This motif (“PPXXR”) is conserved in various RNA-binding proteins and was proposed to
mediate nuclear translocation of the cellular functional homologue of HIV-1 Rev Sam68.
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